

CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: U52190TG2016PTC111232

H.No 8-2-269/S/43, Plot No.43, 2nd Floor, Sagar Co-operative Housing Society Ltd, Road No.2

Banjara Hills, Hyderabad, Khairatabad, Telangana, India, 500034

Balance Sheet As At 31.12.2025

Particulars	Note No	As at 31.12.2025	As at 31.03.2025
		Amount (₹)	Amount (₹)
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	1	9,69,00,000	9,69,00,00
(b) Reserves and Surplus	2	383,32,874	91,78,37
(C) Money Received against Share Warrants		-	-
(2) Share Application Money Pending Allotment			
		-	-
(3) Non-Current Liabilities			
(a) Long-Term Borrowings	3	-	-
(b) Deferred tax liabilities (Net)		4,31,376	2,50,11
(C) Other Long Term Liabilities		-	-
(d) Long-term provisions		-	-
(4) Current Liabilities			
(a) Short Term Borrowings	4	1,02,86,296	1,10,81,85
(b) Trade payables:-	5	3,57,76,885	1,69,69,10
(A) total outstanding dues of micro enterprises and small enterprises; and		-	-
(B) total outstanding dues of creditors other than micro enterprises and small enterprises		-	-
(C) Other Current Liabilities	6	30,000	40,00
(D) Short-Term Provisions	7	98,61,959	62,12,84
Total of Equity and Liabilities		19,16,19,390	14,06,32,28
II.Assets			
(1) Non-Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	8	4,18,03,011	1,58,67,96
(ii) Intangible Assets		-	-
(iii) Capital work-inprogress		-	2,85,84,50
(iv) Intangible assets under development		-	-
(b) Non-current investments	9	-	-
(c) Deferred tax assets (net)	10	-	-
(d) Long-term loans and advances	11	-	-
(e) Other non-current assets	12	-	-
(i) Priliminary Expenses		-	-
(2) Current Assets			
(a) Current Investments	13	-	-
(b) Inventories	14	4,50,50,023	2,51,57,94
(c) Trade receivables	15	8,97,40,398	5,70,02,72
(d) Cash and Cash Equivalents	16	13,95,820	2,31,46
(e) Short-term loans and advances	17	58,85,584	75,00,00
(f) Other Current Assets	18	77,44,554	62,87,69
Total of Assets		19,16,19,390	14,06,32,28

Other Notes on account and Significant Accounting Policies

1

The Notes on account referred to above form an integral part of Balance Sheet.

As per our report of even date attached.

For M VENAKTESWAR & ASSOCIATES

Chartered Accountants

FRN : 026251S

m.v. Reddy

CA M Venkateswar Reddy

Proprietor

Membership No. 271992

UDIN:26271992PSGBPR3260

For and on behalf of the Board of Directors

CHEMGENIX LABORATORIES PRIVATE LIMITED

Hyderabad

DURGA KISHORE FEBBANIDI

Director

DIN: 11045613

M L L U RAMAKRISHNA REDDY

Director

DIN: 09151234

CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: U52190TG2016PTC111232

H.No 8-2-269/S/43, Plot No.43, 2nd Floor, Sagar Co-operative Housing Society Ltd, Road No.2

Banjara Hills, Hyderabad, Khairatabad, Telangana, India, 500034

Profit And Loss A/c For the Period Ended 31.12.2025

Particulars	Note No	For the Period Ended	For the Year Ended
		31.12.2025	31.03.2025
		Amount (₹)	Amount (₹)
I. Revenue from operations	19	32,43,60,882	23,72,41,947
II. Other Income	20	-	-
III. Total Income (I + II)		32,43,60,882	23,72,41,947
IV. Expenses:			
Cost of materials consumed	21	27,47,66,104	21,75,81,649
Purchases of Stock-in-Trade	22		
Changes in inventories of finished goods	23		
Work-in-progress and Stock-in-Trade	24		
Finance Cost		9,88,240	15,40,368
Employee Benefit Expense	25	31,44,740	32,64,321
Depreciation and Amortization Expense (as per annexure "A" & "B")		26,49,451	11,07,951
Other Expenses	26	33,64,510	34,47,196
IV. Total Expenses		28,49,13,045	22,69,41,484
V. Profit Before Exceptional and Extraordinary Items and Tax (III - IV)		3,94,47,838	1,03,00,463
VI. Exceptional Items			
VII. Profit Before Extraordinary Items and Tax (V - VI)		3,94,47,838	1,03,00,463
VIII. Extraordinary Items		-	-
IX. Profit Before Tax (VII - VIII)		3,94,47,838	1,03,00,463
X. Tax Expense:			
(1) Current Tax		98,61,959	23,32,304
(2) Deferred Tax Liability/ (Asset)		4,31,376	2,50,112
XI. Profit(Loss) from the Period from Continuing Operations (IX-X)		2,91,54,503	77,18,048
XII. Profit/(Loss) from Discontinuing Operations		-	-
XIII. Tax Expense of Discontinuing Operations		-	-
XIV. Profit/(Loss) from Discontinuing Operations (XII - XIII)		-	-
XV. Profit/(Loss) for the Period (XI + XIV)		2,91,54,503	77,18,048
XVI. Earning per Equity Share:			
-Basic/Diluted on Share of '10/- each	27	3.01	0.80

Other Notes on account and Significant Accounting Policies 1

The Notes on account referred to above form an integral part of Balance Sheet.
As per our report of even date attached.


For M VENAKTESWAR & ASSOCIATES
Chartered Accountants
FRN : 026251S

CA M Venkateswar Reddy
Proprietor
Membership No. 271992
UDIN:26271992PSGBPR3260



For and on behalf of the Board of Directors
CHEMGENIX LABORATORIES PRIVATE LIMITED

DURGA
KISHOR
Director
DIN: 11045613



ALLU
RAMAKRISHNA
Director
DIN: 09151234

Place: Hyderabad
Date: 09-01-2026

CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: U52190TG2016PTC111232

**H.No 8-2-269/S/43, Plot No.43, 2nd Floor, Sagar Co-operative Housing Society Ltd, Road No.2
Banjara Hills, Hyderabad, Khairatabad, Telangana, India, 500034**

1 SIGNIFICANT ACCOUNTING POLICIES

A. Basis of preparation of Financial Statement

The financial statements are prepared under the historical cost convention, in accordance with the generally accepted accounting principles in India and the provisions of the Companies Act, 2013.

B. Use of Estimates

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognised in the period in which the results are known/ materialised.

C. Own Fixed Assets

Fixed Assets are stated at cost net of recoverable taxes and, less accumulated depreciation, if any.

D. Impairment of Assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the Profit and Loss Account in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed if there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use.

E. Investments

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term Investments are stated at acquisition / amortised cost. A provision for diminution in the value of long term investments is made only if such a decline is other than temporary in the opinion of the management.

F. Borrowing Cost

Borrowing costs are recognised as expense in the year in which they are incurred.

G. Revenue Recognition

Revenue is recognised only when it can be reliably measured and it is reasonable to expect ultimate collection.

H. Inventories

Inventories are valued at Cost or NRV whichever is lower.



CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: U52190TG2016PTC111232

**H.No 8-2-269/S/43, Plot No.43, 2nd Floor, Sagar Co-operative Housing Society Ltd, Road No.2
Banjara Hills, Hyderabad, Khairatabad, Telangana, India, 500034**

I. Taxes on Income and Deferred Tax

Provision for Income Tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of Current Tax and Deferred Tax at the applicable enacted or substantively enacted rates. Current Tax represents the amount of Income Tax payable/recoverable in respect of the taxable income/ loss for the reporting period. Deferred Tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods. The Deferred Tax Asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, Deferred Tax Assets are recognised only if there is virtual certainty of realisation of assets.

J. Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognised when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent assets are neither recognised nor disclosed in the Financial Statements.

K. Earning per Share

In determining Earning per Share, the Company considers the net profit after tax and includes the post tax effect of any extraordinary/ exceptional item. The number of shares used in computing Basic Earning per Share is the weighted average number of shares outstanding during the period. The number of shares used in computing Diluted Earning per Share comprises the weighted average shares considered for deriving Basic Earnings per Share and also the weighted average number of shares that could have been issued on the conversion of all dilutive potential Equity Shares unless the results would be anti - dilutive. Dilutive potential Equity Shares are deemed converted as of the beginning of the period, unless issued at a later date.

The Notes on account referred to above form an integral part of Balance Sheet.
As per our report of even date attached.

For M VENAKTESWAR & ASSOCIATES

Chartered Accountants
FRN : 026251S

M.V. Reddy

CA M Venkateswar Reddy

Proprietor

Membership No. 271992

Place: Hyderabad

Date: 09-01-2026

UDIN:26271992PSGBPR3260



For and on behalf of the Board of Directors

CHEMGENIX LABORATORIES PRIVATE LIMITED



Durga Kishore Pebbani
DURGA KISHORE PEBBANI

Director

DIN: 11045613

Allu Ramakrishna Reddy

ALLU RAMAKRISHNA REDDY

Director

DIN: 09151234

NOTES TO ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2025

Note No.	Particulars	As at 31.12.2025	As at 31.03.2025
		Amount (₹)	Amount (₹)
1	Share Capital		
	Equity Share Capital		
	Authorised Share Capital	1,20,00,000	1,19,00,000
	Equity Shares of Rs 10/- each	1,20,00,000	1,19,00,000
	Issued, Subscribed & Paid up		
Equity Shares of Rs 10/- each	9,69,00,000	1,19,00,000	
		9,69,00,000	1,19,00,000
	Total of Share Capital	9,69,00,000	1,19,00,000

Addition Information

(i) Reconciliation of Shares Outstanding

Note No.		As at 31.12.2025	As at 31.03.2025
		No. Of Shares	No. Of Shares
	Share outstanding at the beginning of the year	96,90,000	11,90,000
	Add: Share Issued		85,00,000
	Less: Share Bought Back		
	Share outstanding at the end of the year	96,90,000	96,90,000

(ii) Details of shares held by shareholders holding more than 5% shares

Note No.	Shares held at the end of the year				As at 31.12.2025	As at 31.03.2025	
		Name	Category	No. of Shares	% of total shares	% Change during the year	No. Of Shares
1	Y Madhusudan Reddy	Promoter	238000	0.00%	20.00%	-	-
2	K Karunakar Reddy	Promoter	969000	10.00%	0.00%	9,69,000	9,69,000
3	K Shankar Reddy	Promoter	1938000	20.00%	5.00%	19,38,000	19,38,000
4	M. Prasanth	Promoter	242250	2.50%	7.50%	2,42,250	2,42,250
5	Daka Srinivasareddy	Public	242250	2.50%	7.50%	2,42,250	2,42,250
6	A Ramakrishna Reddy	Promoter	969000	10.00%	0.00%	9,69,000	9,69,000
7	V. Prasanna Lakshmi	Promoter	89250	0.00%	7.50%	-	-
8	V. Pravalika	Promoter	1453500	15.00%	7.50%	14,53,500	14,53,500
9	J. Avinash Reddy	Promoter	969000	10.00%	10.00%	9,69,000	9,69,000
10	Shaik Shams	Promoter	1938000	20.00%	20.00%	19,38,000	19,38,000
11	Geethika Kolfi	Public	484500	5.00%	5.00%	4,84,500	4,84,500
12	A Mohan Rao	Promoter	484500	5.00%	5.00%	4,84,500	4,84,500
	TOTAL			100.00%		96,90,000	96,90,000

(iii) There are no shares reserved for issue under options and contracts/commitments for the sale of shares/disinvestment.

(iv) There are no shares which have been issued for other than cash, by way of bonus issue or which have been bought back in the preceding 5 years

(v) There are no such securities which are convertible into equity/preference shares

(vi) There are no unpaid calls or forfeited shares.

Note No.	Particulars	As at 31.12.2025	As at 31.03.2025
		Amount (₹)	Amount (₹)
2	Reserves & Surplus		
	(a) Capital Reserves:		
	(b) Capital Redemption Reserve;		
	(c) Securities Premium		
	(d) Debenture Redemption Reserve;		
	(e) Revaluation Reserve;		
	(f) Share Options Outstanding Account.		
(g) Other Reserves - (specify the nature and purpose of each reserve and the amount in respect thereof).			
(h) Surplus/ Profit & Loss Account			
Opening balance	91,78,371.32	14,60,323.71	
Add/Less: Transfer from P&L a/c	291,54,563	77,18,048	
Closing balance	383,32,874	91,78,371	
	Total of Reserves & Surplus	383,32,874	91,78,371



Note No.	Particulars	As at 31.12.2025		As at 31.03.2025			
		Amount (₹)		Amount (₹)			
3	<p>Long-Term Borrowings</p> <p>(i) Long-term borrowings shall be classified as:</p> <p>(a) Bonds/debentures;</p> <p>(b) Term loans:</p> <p>(A) from banks.</p> <p>(B) from other parties.</p> <p>(c) Deferred payment liabilities;</p> <p>(d) Deposits</p> <p>(e) Loans and advances from related parties;</p> <p>(f) Long term maturities of finance lease obligations;</p> <p>(g) Other loans and advances (specify nature).</p> <p>(ii) Borrowings shall further be sub-classified as secured and unsecured. Nature of security shall be specified separately in each case.</p> <p>(iii) Where loans have been guaranteed by directors or others, the aggregate amount of such loans under each head shall be disclosed.</p> <p>(iv) Bonds/debentures</p> <p>(v) Particulars of any redeemed bonds/debentures which the company has power to reissue shall be disclosed.</p> <p>(vi) Terms of repayment of term loans and other loans shall be stated.</p> <p>(vii) Period and amount of continuing default as on the balance sheet date in repayment of loans and interest, shall be specified separately in each case.</p>						
	Total of Long-Term Borrowings						
4	<p>Other Short-term Liabilities</p> <p>Other Long-term Liabilities shall be classified as:</p> <p>(a) From Banks and Financial Institutions;</p> <p>(b) Others.</p>	1,02,86,296	1,10,81,854.28				
	Total of Other Long-term Liabilities				1,10,81,854.28		
5	<p>Trade Payables</p> <p>(i)MSME</p> <p>(ii)Others</p> <p>(iii) Disputed dues – MSME;</p> <p>(iv) Disputed dues - Others</p> <p>Total of Trade Payables</p>	Less than 1 year	1-2 years	2-3 years	More than 3 year	As at 31.12.2025 Amount (₹)	As at 31.03.2025 Amount (₹)
		1,69,69,106				3,57,76,885	1,69,69,106
	Total of Trade Payables					3,57,76,885	1,69,69,106
6	<p>Other Current Liabilities</p> <p>(a) Current maturities of finance lease obligations;</p> <p>(b) Interest accrued but not due on borrowings;</p> <p>(c) Interest accrued and due on borrowings;</p> <p>(d) Income received in advance;</p> <p>(e) Unpaid dividends;</p> <p>(f) Unpaid matured deposits and interest accrued thereon;</p> <p>(g) Unpaid matured debentures and interest accrued thereon;</p> <p>(h) Audit Fee Payable</p> <p>(i) Other payables</p> <p>Total of Other Current Liabilities</p>					30,000	40,000.00
	Total of Other Current Liabilities					30000.00	40,000



7	Short-term provisions (a) Provision for employee benefits (b) Others (Provision for Income Tax) (c) Statutory Remittances due (d) Others	17,14,520 98,61,959 - -	38,80,540 23,32,304 - -															
	Total of Short-term provisions	1,15,76,479	,62,12,844															
8	Fixed Assets Tangible (as per annexure "A") Opening Balance Add: Additions Less: Disposals Less: Depreciation Closing Balance	158,67,962 2,85,84,500 - 26,49,451 4,18,03,011	57,54,713 1,12,21,200.00 - 11,07,951 1,58,67,962															
	Total of Fixed Assets	4,18,03,011	1,58,67,962															
9	Non-current investments (a) Investment property; (b) Investments in Equity Instruments; (c) Investments in preference shares; (d) Investments in Government or trust securities; (e) Investments in debentures or bonds; (f) Investments in Mutual Funds; (g) Investments in partnership firms; (h) Other non-current investments (Security deposits to Building Owners)																	
	Total of Non-current investments																	
Note No.	Particulars	As at 31.12.2025	As at 31.03.2025 Amount (₹ in)															
10	Deferred tax Asset Property, Plant and Equipment	0.00	-															
	Total of Deferred tax Asset	-	-															
11	Long-term loans and advances (i) Long-term loans and advances shall be classified as: (a) Capital Advances; (b) Loans and advances to related parties (giving details thereof): a) repayable on demand b) without specifying any terms or period of repayment <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 40%;">Type of Borrower</th> <th style="width: 30%;">Amount of loan or advance in the nature of loan outstanding</th> <th style="width: 30%;">% of the total Loans and Advances in the nature of loans</th> </tr> </thead> <tbody> <tr> <td>Promoters</td> <td></td> <td></td> </tr> <tr> <td>Directors</td> <td></td> <td></td> </tr> <tr> <td>KMPs</td> <td></td> <td></td> </tr> <tr> <td>Related Parties</td> <td></td> <td></td> </tr> </tbody> </table> (c) Other loans and advances (specify nature) (ii) The above shall also be separately sub-classified as: (a) Secured, considered good; (b) Unsecured, considered good; (c) Doubtful. (iii) Allowance for bad and doubtful loans and advances shall be disclosed under the relevant heads separately.	Type of Borrower	Amount of loan or advance in the nature of loan outstanding	% of the total Loans and Advances in the nature of loans	Promoters			Directors			KMPs			Related Parties				
Type of Borrower	Amount of loan or advance in the nature of loan outstanding	% of the total Loans and Advances in the nature of loans																
Promoters																		
Directors																		
KMPs																		
Related Parties																		
	Total of Long-term loans and advances																	
12	Other non-current assets Other non-current assets shall be classified as: (i) Long-term Trade Receivables (including trade receivables on deferred credit terms): (ia) Security Deposits (ii) Others (specify nature); (iii) Long term Trade Receivables, shall be sub-classified as: (iv) For trade receivables outstanding, following ageing schedule shall be given:																	
	Total of Short-term provisions																	



13	Current Investments (a) Investment property; (b) Investments in Equity Instruments; (c) Investments in Preference Shares; (d) Investments in Government or trust securities; (e) Investments in debentures or bonds; (f) Investments in Mutual Funds; (g) Investments in partnership firms; (h) Other investments (specify nature)						
Total Other Non-Current Assets							
14	Inventories (a) Raw materials; (b) Work-in-progress; (c) Finished goods; (d) Stock-in-trade (in respect of goods acquired for trading); (e) Stores and spares; (f) Loose tools; (g) Others (specify nature). Total of Inventories	4,50,50,023	2,51,57,946			4,50,50,023	2,51,57,946
15	Trade Receivables (i) Undisputed Trade receivables – considered good (ii) Undisputed Trade Receivables – considered doubtful (iii) Disputed Trade Receivables considered good (iv) Disputed Trade Receivables considered doubtful Total of Trade Receivables	Less than 1	1-2 years	2-3 years	More than 3 year	Amount (₹)	Amount (₹)
		5,70,02,720				8,97,40,398	5,70,02,720
						8,97,40,398	5,70,02,720
16	Cash & Cash Equivalents (i) Cash and cash equivalents shall be classified as: (a) Balances with banks; (b) Cheques, drafts on hand; (c) Cash on hand; (d) Others (specify nature). (ii) Earmarked balances with banks (for example, for unpaid dividend) shall be separately stated (iii) Balances with banks to the extent held as margin money or security against the borrowings, guarantees, other commitments shall be disclosed separately. (iv) Repatriation restrictions, if any, in respect of cash and bank balances shall be separately stated. (v) Bank deposits with more than twelve months maturity shall be disclosed separately.	1206,050	29,143			1,89,770	202,325
						13,95,820	2,31,468
	Total of Cash & Cash Equivalents					13,95,820	2,31,468
17	Short-term loans and advances (i) Short-term loans and advances shall be classified as: (a) Loans and advances to related parties (giving details thereof); (b) Others (specify nature). (ii) The above shall also be sub-classified as: (a) Secured, considered good; (b) Unsecured, considered good; (c) Doubtful. (iii) Allowance for bad and doubtful loans and advances shall be disclosed under the relevant heads separately.	45,88,140	75,00,000				
						45,88,140	75,00,000
	Total of Short-term loans and advances					45,88,140	75,00,000
18	Other Current Assets Preliminary Expenses to the extent not written off Advance Tax & TDS Receivables GST Input MAT Receivable Advance to Suppliers Deferred Tax					12,47,880	10,81,000
						60,30,674	47,40,692
						4,86,000	4,66,000.00
						77,44,554	62,87,692
	Total of Other Current Assets					77,44,554	62,87,692



Note No.	Particulars	For the Period ended 31.12.2025	Year ended 31.03.2025	As at 31.03.2024
		Amount (Rs.)	Amount (Rs.)	Amount (Rs.)
19	Revenue from Operation			
	(a) Sale of products			
		32,43,60,882	23,72,41,947	23,89,69,410
		32,43,60,882	23,72,41,947	23,89,69,410
	Total Revenue from Operation	32,43,60,882	23,72,41,947	23,89,69,410

Note No.	Particulars	For the Period ended 31.12.2025	Year ended 31.03.2025	As at 31.03.2024
		Amount (Rs.)	Amount (Rs.)	Amount (Rs.)
20	Other Income			
	Other Income			
	Total Other Income		-	-

Note No.	Particulars	For the Period ended 31.12.2025	Year ended 31.03.2025	As at 31.03.2024
		Amount (Rs.)	Amount (Rs.)	Amount (Rs.)
21	Cost of Raw materials consumed			
	Opening	2,51,57,946	1,78,79,120	-
	Purchases	29,46,58,181	22,48,60,474	24,33,23,849
	Closing	4,50,50,023	2,51,57,946	1,78,79,060
	Total Cost of materials consumed	27,47,66,104	21,75,81,649	22,54,44,789

Note No.	Particulars	For the Period ended 31.12.2025	Year ended 31.03.2025	As at 31.03.2024
		Amount (Rs.)	Amount (₹)	Amount (₹)
22	Purchase of Stock -in Trade			
	Total Purchase of Stock -in Trade			-

Note No.	Particulars	For the Period ended 31.12.2025	Year ended 31.03.2025	As at 31.03.2024
		Amount (Rs.)	Amount (₹)	Amount (₹)
23	Changes in inventories of Finished goods			
	Finished Goods			
	Opening Stock			
	Closing Stock			
	Total Changes in inventories of Finished goods			-

Note No.	Particulars	For the Period ended 31.12.2025	Year ended 31.03.2025	As at 31.03.2024
		Amount (Rs.)	Amount (₹)	Amount (₹)
24	Work-in Progress and Stock-in-Trade			
	Packing Material			
	Opening Stock			
	Closing Stock			
	Raw Material			
	Opening Stock			
	Closing Stock			
	Fuel			
	Opening Stock			
	Closing Stock			
	Total Changes in inventories of Stock-in-Trade-Increase			-



Note No.	Particulars	For the Period ended 31.12.2025	Year ended 31.03.2025	As at 31.03.2024
		Amount (Rs.)	Amount (₹)	Amount (₹)
25	Employee Benefit Expenses			
	Salaries and Wages	3144740	32,64,321	37,37,999
	Staff Welfare			
	Total Employee Benefit Expenses	31,44,740	32,64,321	37,37,999
				-
	Finance Cost			
	Interest Expenses	889540	12,65,104	24,42,829
	Bank Charges	98700	2,75,264	7,034
	Total Finance Cost	9,88,240	15,40,368	24,49,863
26	Other Expenses			
	Professional & Consultancy Fees		-	50,000
	Printing and Stationary	16400	1,156	2,511
	Audit Fee	30000	40,000	30,000
	Insurance	68100	90,785	82,042
	Repairs & Maintenance	24600	10,312	5,18,880
	Safety and Security Expenses		-	18,000
	General and Travelling Expenses	1124210	-	9,74,100
	Power and Fuel	54780	64,041	10,000
	GST Penalties		-	48,993
	Preliminary Expenses		-	4,35,813
	Loan Renewal Charges		-	51,500
	Rent Rates And taxes	1980000	31,52,790	
	Consultancy Charges	66420	88,112	
	Total Other Expenses	33,64,510	34,47,196	22,21,839



Annexure "A" to Note-12: FIXED ASSETS- Property, Plant and Equipment

Sl No.	Particulars	SLM %	Gross Block				Depreciation			Net Block	
			As on 01-04-2025	Additions	Deletions	As on 31-12-2025	Accumulated Depreciation	Depreciation for the Year	Total Depreciation	Balance as on 01.04.2024	Balance as on 31.12.2025
1	PLANT & MACHINERY	13.91%	158,67,962	2,85,84,500		444,52,462		26,49,451	26,49,451	418,03,011	1,58,67,962
	Total		158,67,962	2,85,84,500		4,44,52,462		26,49,451	26,49,451	418,03,011	1,58,67,962





M Venkateswar & Associates

Chartered Accountants

Mob : 9493458535, 9666048094

E-mail : venkica92@gmail.com

mvenkateswarandassociates@gmail

INDEPENDENT AUDITORS' REPORT

TO
THE MEMBERS OF
CHEMGENIX LABORATORIES PRIVATE LIMITED.
HYDERABAD

Report on the Audit of the Financial Statements

Opinion

We have audited the Financial Statements of CHEMGENIX LABORATORIES PRIVATE LIMITED ("the Company"), which comprise the balance sheet as at 31st March 2025, and the statement of profit and loss, and statement of cash flows for the period ended, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information [hereinafter referred to as "the Financial Statements"].

in our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, its Profits, (*changes in equity*) and its cash flows for the period ended on that date.

Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

"Information Other than the Financial Statements and Auditor's Report Thereon"

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report, but does not include the Financial Statements and our auditor's report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially



misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Key Audit Matters

Key Audit Matters are those matter that, in our professional judgement, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. During the year under consideration, we have no Key Audit Matters to report.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the financial position and financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the



operating effectiveness of such controls

- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in

- (i) Planning the scope of our audit work and in evaluating the results of our work; and
- (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure A statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
 - (c) The Balance Sheet, the Statement of Profit and Loss, (the Statement of Changes in Equity) & Cash Flow statements dealt with by this Report are in agreement with the books of account.



- (d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the Directors as on March 31, 2025 taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2025 from being appointed as a Director in terms of Section 164(2) of the Act.
- (f) According to information and explanations given to us together with our audit examination, reporting with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls we give in Annexure B to the extent applicable.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv.
 - (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (c) Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- v. No Dividend has been declared or paid during the year by the Company, hence provisions of section 123 of the Companies Act, 2013, are not applicable..



- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2025 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software's. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

for M Venkateswar and Associates

Chartered Accountants

FRN No. 026251S



M. V. Reddy

M Venkateswar Reddy
(Proprietor)

M No. 271992

Place: Hyderabad
Date: 09/09/2025

UDIN: 25271992BMODGI6131

Annexure – A to the Independent Auditor’s Report of even date to the Members of M/s CHEMGENIX LABORATORIES PRIVATE LIMITED, on the Financial Statements for the Year ended March 31, 2025

Based on the audit procedures performed for the purpose of reporting a true and fair view on the Financial Statements of the Company and taking into consideration the information and explanations given to us and the Books of Accounts and other records examined by us in the normal course of Audit, and to the best of our knowledge and belief, we report that:

- 1)
 - a. The Company has maintained proper records showing full particulars, including quantitative details and situation of Fixed Assets,
 - b. The Company has a regular program of physical verification of its Fixed Assets under which Fixed Assets are verified in a phased manner over a period for which we have received the certificate of confirmation from the Management.
 - c. The Title Deeds of all the Immovable Properties (which are included under the head ('Property, Plant and Equipment')) are held in the name of the Company.
 - d. The Company has not revalued any of its Property, Plant and Equipment's during the year.
 - e. As per the information given to us there are no proceedings initiated or pending against the Company for holding any Benami Property under the Benami Transactions (Prohibition) Act, 1988 and Rules made there under.
- 2)
 - a. In our opinion and according to the information and explanation given to us, the Management has conducted physical verification of Inventory at reasonable intervals during the year, and no material discrepancies were noticed on the aforesaid verification, for which we have received the certificate of confirmation from the Management.
 - b. The Company has availed Financial Assistance from Bank or Financial Institutions.
- 3) The Company has not granted any Loans, secured or unsecured, to any Companies, Firms, Limited Liability Partnerships or other parties.
- 4) In our opinion, the Company has complied with the provisions of Section 186 in respect of the Investments and Loans. Further, in our opinion, the Company has not entered into any transaction covered under Section 185 and Section 186 of the Act in respect of Guarantees and Security.
- 5) In our opinion, the Company has not accepted any Deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- 6) As informed to us that the provisions of Section 148 are not applicable to the Company.
- 7)
 - (a) In our opinion, the Company has been regular in depositing undisputed statutory dues, including Goods and Services Tax, Income Tax, Sales Tax, Duty of Custom, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service Tax, Income Tax, Sales Tax, duty of Custom, duty of Excise, Cess and other material statutory dues in arrears as at March 31, 2025 for a period of more than six months from the date they become payable. However as per the information provided by the management, Provident Fund and Employees' State Insurance is not applicable to the Company for the current year.
 - (b) There is no Dues outstanding in respect of Income Tax, Sales Tax, Service Tax, Duty of Customs on account of disputes, whereas the Company has intimations and Outstanding demands under Income Tax Act, 1961.



- (c) According to the information and explanations given to us, the dues in respect of Sales Tax, Income Tax, Custom Duties, Wealth Tax, Excise Duty and Cess that have been deposited with the appropriate authorities except in cases where there is a dispute.
- 8) All the transactions recorded in the books of account have been disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961). There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as Income during the year in the Tax Assessments under the Income Tax Act, 1961 (43 of 1961).
- 9) According to the records of the Company examined by us and as per the information and explanations given to us, we hereby report that:
- The Company has not defaulted in repayment of Loans or Borrowings to any Bank during the Year under review. The Company has No Outstanding Debentures during the year.
 - The Company is not declared Willful Defaulter by any Bank or Financial Institution or other Lender.
 - The Company has raised Term Loan from any Bank or Financial Institution during the current year.
 - To the extent of our check, no funds raised by the Company for short-term has been utilized for long term purposes.
 - The Company has not taken any funds from any entity or person on account of or to meet the obligations of its Subsidiaries, Associates or Joint Ventures.
 - The Company has not raised loans during the Year on the Pledge of Securities held in its Subsidiaries, Joint Ventures or Associate Companies.
- 10) The Company has not raised the funds by way of Initial Public Offer in the month June, 2023.
- 11)
- According to the information and explanations given to us, no material fraud by the Company or by its officers or employees has been noticed or reported during the course of Audit.
 - No Report under sub-section (12) of section 143 of the Companies Act has been filed by the Auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - No Whistle Blowers Complaints were received during the year under review. As represented to us by the Management, no Whistle Blowers Complaints were received during the year under review.
- 12) In our opinion, the Company is not a Nidhi Company, and accordingly, provisions of Clause 3(xii) of the Order are not applicable.
- 13) In our opinion, the Company is in compliance with Sections 177 and 188 of the Companies Act, 2013, with respect to applicable transactions with related parties, and the requisite details have been disclosed in the Financial Statements.
- 14) As per the information provided to us, the Company does not have an adequate Internal Audit System.
- 15) In our opinion, the Company has not entered in any non-cash transactions with the Directors or persons connected with them covered under Section 192 of the Act. Accordingly, the provisions of Clause 3(xv) of the order are not applicable.
- 16)
- According to the information and explanation given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934 and the Company has not conducted any NBFC Company during the year.
 - The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.
- 17) The Company has not incurred cash losses in the Financial Year and in the immediately preceding Financial Year.
- 18) There has been no resignation of Statutory Auditors during the Financial year 2023-24.



- 19) On the basis of the Financial Ratios, ageing and expected dates of realisation of Financial Assets and payment of Financial Liabilities, other information accompanying the Financial Statements, the Auditor's knowledge of the Board of Directors and the Management's plans, the Auditor is of the opinion that no material uncertainty exists as on the date of the Audit Report and that the Company is capable of meeting its Liabilities existing at the Date of Balance Sheet, as and when they fall due within a period of one year from the Balance Sheet Date. We however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- 20) The Company is not liable to contribute under Section 135 of the Companies Act, 2013. Accordingly, the provisions of Clause 3(xx) of the order are not applicable.
- 21) In our opinion and according to the information and explanations given to us, Company does not have any subsidiaries; associates and joint venture Therefore this clause is not applicable

for M Venkateswar and Associates
Chartered Accountants
FRN No. 026251S

Place : Hyderabad
Date : 09/09/2025

UDIN: 25271992BMODGI6131



M.V. Reddy

M Venkateswar Reddy
(Proprietor)
M No. 271992

ANNEXURE - B TO THE AUDITORS' REPORT

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **CHEMGENIX LABORATORIES PRIVATE LIMITED**. ("The Company") as of 31 March, 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit



preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and Directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place : Hyderabad
Date : 09/09/2025

UDIN: 25271992BMODGI6131

for M Venkateswar and Associates
Chartered Accountants
FRN No. 026251S



M.V.R.Reddy

M Venkateswar Reddy
(Proprietor)
M No. 271992

CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: U52190TG2016PTC111232

H.No 8-2-269/S/43, Plot No.43, 2nd Floor, Sagar Co-operative Housing Society Ltd, Road No.2

Banjara Hills, Hyderabad, Khairatabad, Telangana, India, 500034

Balance Sheet As At 31.03.2025

Particulars	Note No	As at 31.03.2025	As at 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
<u>I. EQUITY AND LIABILITIES</u>			
<u>(1) Shareholder's Funds</u>			
(a) Share Capital	1	969.00	119.00
(b) Reserves and Surplus	2	91.78	14.60
(C) Money Received against Share Warrants		-	-
<u>(2) Share Application Money Pending Allotment</u>			
		-	-
<u>(3) Non-Current Liabilities</u>			
(a) Long-Term Borrowings	3	-	135.94
(b) Deferred tax liabilities (Net)		2.50	
(C) Other Long Term Liabilities			-
(d) Long-term provisions		-	-
<u>(4) Current Liabilities</u>			
(a) Short Term Borrowings	4	110.82	
(b) Trade payables:-	5	169.69	282.36
(A) total outstanding dues of micro enterprises and small enterprises; and		-	-
(B) total outstanding dues of creditors other than micro enterprises and small enterprises		-	-
(C) Other Current Liabilities	6	0.40	5.68
(D) Short-Term Provisions	7	62.13	52.26
Total of Equity and Liabilities		1,406.32	609.84
<u>II. Assets</u>			
<u>(1) Non-Current Assets</u>			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	8	158.68	57.55
(ii) Intangible Assets		-	-
(iii) Capital work-inprogress		285.85	-
(b) Non-current investments		-	-
(c) Deferred tax assets (net)	9	-	4.66
<u>(2) Current Assets</u>			
(a) Current Investments		-	-
(b) Inventories	10	251.58	178.79
(c) Trade receivables	11	570.03	274.55
(d) Cash and Cash Equivalents	12	2.31	3.23
(e) Short-term loans and advances	13	75.00	75.00
(f) Other Current Assets	14	62.88	16.05
Total of Assets		1,406.32	609.84

Other Notes on account and Significant Accounting Policies

1

The Notes on account referred to above form an integral part of Balance Sheet.

As per our report of even date attached.

For M VENAKTESWAR & ASSOCIATES

Chartered Accountants

FRN : 026251S

M.V. Reddy



CA M Venkateswar Reddy

Proprietor

Membership No. 271992

UDIN:25271992BMODGI6131

For and on behalf of the Board of Directors

CHEMGENIX LABORATORIES PRIVATE LIMITED

Durga Kishore



DURGA KISHORE PERRANI ALINI RAMAKRISHNA REDDY

Director

DIN: 11045613

Director

DIN: 09151234

Place: Hyderabad

Date: 09-09-2025

CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: U52190TG2016PTC111232

H.No 8-2-269/S/43, Plot No.43, 2nd Floor, Sagar Co-operative Housing Society Ltd, Road No.2

Banjara Hills, Hyderabad, Khairatabad, Telangana, India, 500034

Profit And Loss A/c For the Year Ended 31.03.2025

Particulars	Note No	Year ended 31.03.2025	Year ended 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
I. Revenue from operations	15	2,372.42	2,389.69
II. Other Income		-	-
III. Total Income (I +II)		2,372.42	2,389.69
IV. Expenses:			
Cost of materials consumed	16	2,175.82	2,254.45
Purchases of Stock-in-Trade			
Changes in inventories of finished goods			
Work-in-progress and Stock-in-Trade			
Finance Cost	17	15.40	24.50
Employee Benefit Expense	18	32.64	37.38
Depreciation and Amortization Expense (as per annexure "A" & "B")		11.08	23.40
Other Expenses	19	34.47	22.22
IV. Total Expenses		2,269.41	2,361.94
V. Profit Before Exceptional and Extraordinary Items and Tax (III - IV)		103	27.75
VI. Exceptional Items			
VII. Profit Before Extraordinary Items and Tax (V - VI)		103	27.75
VIII. Extraordinary Items		-	-
IX. Profit Before Tax (VII - VIII)		103	27.75
X. Tax Expense:			
(1) Current Tax		23.32	8.50
(2) Deferred Tax Liability/ (Asset)		2.50	-0.21
XI. Profit(Loss) from the Period from Continuing Operations (IX-X)		77.18	21.35
XII. Profit/(Loss) from Discontinuing Operations		-	-
XIII. Tax Expense of Discounting Operations		-	-
XIV. Profit/(Loss) from Discontinuing Operations (XII - XIII)		-	-
XV. Profit/(Loss) for the Period (XI + XIV)		77.18	21.35
XVI. Earning per Equity Share:			
-Basic/Diluted on Share of '10/- each	20	0.80	1.79

Other Notes on account and Significant Accounting Policies 1

The Notes on account referred to above form an integral part of Balance Sheet.
As per our report of even date attached.

For M VENAKTESWAR & ASSOCIATES

Chartered Accountants

FRN : 026251S

M. Venkateswar Reddy

CA M Venkateswar Reddy
Proprietor
Membership No. 271992
UDIN:25271992BMODGI6131



For and on behalf of the Board of Directors

CHEMGENIX LABORATORIES PRIVATE LIMITED

Durga Kishore Pebbani

DURGA KISHORE PEBBANIDI
Director
DIN: 11045613



A. Ramakrishna Reddy

A. RAMAKRISHNA REDDY
Director
DIN: 09151234

Place: Hyderabad

Date: 09-09-2025

Note: any item of income or expense exceeding 1% of revenue from operation or Rs. 1,00,000/- whichever is higher should be disclosed separately and should not be clubbed.

CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: US2190TG2016PTC111232

H.No 8-2-269/S/43, Plot No.43, 2nd Floor, Sagar Co-operative Housing Society Ltd, Road No.2

Banjara Hills, Hyderabad, Khairatabad, Telangana, India, 500034

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2025

Particulars	As at	As at
	31-Mar-2025	31-Mar-2024
	Audited	Audited
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	103.00	27.75
Adjustment For		
Depreciation	11.08	23.40
Foreign Exchange		
Gain or Loss on Sale of Fixed Assets		
Gain or Loss on Sale of Investment		
Finance Cost	15.40	24.50
Dividend Income		
Other adjustment of Non-Cash Item		
Other adjustment to reconcile Profit		
	26.48	47.90
Adjustment For working Capital Change		
Adjustment for Increase/Decrease in Inventories	-72,78,885.57	-178.79
Adjustment for Increase/Decrease in Trade Receivables	-295.48	18.88
Adjustment for Increase/Decrease in Other Current Assets	-46.82	21.34
Adjustment for Increase/Decrease in Other Non Current Assets	-	-
Adjustment for Increase/Decrease in Short Term Borrowings	110.82	-
Adjustment for Increase/Decrease in Long term Loans and Advances	-135.94	-30.56
Adjustment for Increase/Decrease in Short Term Loans and advances	-	-
Adjustment for Increase/Decrease in Trade Payables	(112.67)	132.81
Adjustment for Increase/Decrease in Other Current Liabilities	(5.28)	1.96
Adjustment for Provisions	9.87	-6.53
Total Adjustment For Working Capital (B)	(475.49)	-40.90
Total Adjustment to reconcile Profit (A+B)	(449.01)	7.00
Net Cash Flow from (Used in) Operations	(346.01)	34.75
Dividend Received		
Interest Received	-	-
Interest Paid		
Income Tax Paid / Refund	18.66	(8.5)
Net Cash Flow from (used in) operation before Extra-ordinary Items	-364.67	26.25
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from Operating Activities	-364.67	26.25
Cash Flows from Investing Activities		
Proceeds from Fixed Assets		-
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets	-398.06	
Purchase of Investments or Equity Instruments		
Interest Received	0.00	-
Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash Flow from loosing Control of Subsidiaries		
Cash Payment for acquiring Control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow / Outflow of Cash		
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	(398.06)	-
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (Used in) in Investing Activities	(398.06)	-



Abhy



Cash Flows from Financial Activities		
Proceeds from Issue of Shares	8.50	-
Proceeds from Issuing shares for security premium	0	-
Proceeds from Issue of Debenture / Bonds / Notes		
Redemption of Preference Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Borrowing	0	
Repayment of Borrowing	-	-
Dividend Paid		
Interest Paid	(15.4)	(24.5)
Income Tax Paid / Refund		
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	-834.60	(25)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from (Used in) in Financial Activities	-834.60	(25)
Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	71.87	1.75
Effect of Exchange Rate change on Cash and Cash Equivalents		
Net Increase (Decrease) in Cash and Cash Equivalents	71.87	1.75
Cash and Cash Equivalents at beginning of period	3.23	1.48
Cash and Cash Equivalents at end of period	75.10	3.23

Other Notes on account and Significant Accounting Policies

The Notes on account referred to above form an integral part of Balance Sheet.
As per our report of even date attached.

For M VENAKTESWAR & ASSOCIATES

Chartered Accountants

FRN : 026251S

CA M Venkateswar Reddy
Proprietor
Membership No. 271992
UDIN:25271992BMODG16131

Place: Hyderabad

Date: 09-09-2025

For and on behalf of the Board of Directors

CHEMGENIX LABORATORIES PRIVATE LIMITED

DURGA KISHORE PRABHU, IDILLU RAMAKRISHNA REDDY
Director Director
DIN: 11045613 DIN: 09151234

Notes on Financial Statements for the Financial year ended on March 31, 2025

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

1. General information

Chemgenix Laboratories Private Limited ('the Company') is engaged in the business of manufacturing and selling pharmaceutical products.

The Company is a private limited Company incorporated under Companies Act, 2013 and domiciled in India bearing CIN No: U52190TG2016PTC111232 and has its registered office at H.No 8-2-269/S/43, Plot No.43, 2nd Floor, Sagar Co-operative Housing Society Ltd, Road No.2, Banjara Hills, Hyderabad, Khairatabad, Telangana, India, 500034.

2. Significant Accounting policies

(a) Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). These financial statements have been prepared to comply in all material respects with the Accounting Standards notified by Companies (Accounting Standards) Rules, 2006, (as amended) and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared under the historical cost convention on an accrual basis and going concern basis. The accounting policies have been consistently applied by the Company are consistent with those used in the previous year.

(a) Use of estimates

The preparation of Financial Statements in conformity with the Generally Accepted Accounting Principles requires the Management to make estimates, judgements, and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period.

Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcome requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(b) Functional and Presentation Currency

The Financial Statements are prepared in Indian Rupees ("INR") which is the Company's Functional Currency for its Operations. All Financial Information presented in INR has been rounded to the nearest 'Lakhs' with two decimal places, unless stated otherwise.

(c) Recognition of Revenue and Expenditure


Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria is ensured before revenue is recognized.

Income from services

Revenue from services contracts priced on time and material basis are recognized when services are rendered and related costs are incurred. The Company collects Goods and Services Tax on behalf of the government and therefore it is not an economic benefit flowing to the Company. Hence, it is excluded from revenue.

(d) Sale of goods

Revenue is measured at the transaction price of the consideration received or receivable. Revenue from Sale of products is recognized when the control on the Goods have been transferred to the Customer. The Performance Obligation in case of sale of product is satisfied at a point in time i.e., when the material is shipped to the customer or on delivery to the customer, as may be specified in the Contract.



(e) Property, Plant and Equipment (PPE)

i. Recognition and measurement

Property, Plant and Equipment are stated at Cost comprising of Purchase Price and any initial directly attributable cost of bringing the Asset to its working condition for its intended use less Accumulated Depreciation and Impairment Loss, if any

(a) Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

(b) Depreciation

Depreciation on fixed assets is provided on Written Down Value method (WDV) as per Useful life of Asset and in the manner prescribed in Schedule II of the Companies Act, 2013.

(f) Intangible assets

Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortisation/depletion. All costs, including financing costs till commencement of commercial production, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets are capitalized.

The Company has elected to continue with the carrying value of all its intangible assets as recognized in the financial statements as at the date of transition, measured as per the previous GAAP and use that as the deemed cost as at the transition date.

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific to which it relates.

(g) Impairment of non-financial assets

Assets that have a definite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Management periodically assesses using, external and internal sources, whether there is an indication that an asset may be impaired.

The recoverable amount is higher of the asset's net selling price or value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss for an asset is reversed if, and only if, the reversal can be related objectively to an event occurring after the impairment loss was recognized. The carrying amount of an asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

(h) Borrowing cost

Borrowing costs attributable to the acquisition/construction of qualifying assets are capitalized and form part of the cost of the qualifying assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue as an expense.

(i) Income Tax

Provision for income tax is made for both current and deferred taxes. Provision for current income tax is made on the current tax rates based on the assessable income. The Company provides deferred tax based on the tax effect of timing differences resulting from the recognition of items in the financial statements and in estimating its current tax provision. Deferred tax assets are recognized where there is certainty that there will be sufficient future taxable income available against which such deferred tax assets can be realized.



(j) Inventories

Inventories are measured at lower of cost and net realisable value after providing for obsolescence, if any. Cost of inventories comprises of cost of purchase, cost of conversion and other cost including manufacturing overheads incurred in bringing them to their respective present location and condition. Cost of raw materials, work-in-progress, packing materials, trading and other products are determined on first-in-first-out basis.

(k) Research and development

Revenue expenditure on Research and Development is charged to Profit and Loss Account as incurred. Capital expenditure on assets acquired for Research and Development is added to Property, Plant and Equipment (PPE).

(l) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets Classification

The Company shall classify financial assets as subsequently measured at amortised cost and fair value through profit and loss (FVTPL) on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date i.e., the date that the Company commits to purchase or sell the asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

(m) Cash and cash equivalents

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term deposits with banks with an original maturity of three months or less.

(o) Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost. Gains and losses are recognised in profit and loss when the liabilities are derecognized. This category generally applies to interest-bearing loans and borrowings.

(n) Foreign currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are retranslated using the exchange rate prevailing at the reporting date. Non-monetary items, which are measured in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency are translated using the exchange rate at the date when such value was determined.

Treatment of exchange differences

Exchange differences arising on settlement/restatement of foreign currency monetary assets and liabilities of the Company are recognized as income or expense in the statement of profit and loss.



(q) Leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the Statement of Profit and Loss on a Straight – line basis over the lease term.

(r) Employee benefits

All Employee Benefits payable for rendering the service such as Salaries, Wages etc. and the expected cost of ex-gratia are recognised in the period in which the employee renders the related service. A Liability is recognised for the amount expected to be paid when there is a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

(s) Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognised when the Company has a Present Obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Contingent Liability is disclosed in case of a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognised in Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Entity. Contingent Assets are not recognised in Financial Statements and are disclosed in the Notes when it is virtually certain that economic benefits will inflow to the Company.

(t) Earnings per share (EPS)

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.

20. Earnings Per Share (EPS):

Basic EPS and Diluted EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the Company by the weighted average number of Equity shares outstanding during the year.

(` in Lakhs)

Particulars	As at March 31, 2025	As at 31st March, 2024
Profit attributable to equity holders	77.18	21.35
Weighted average number of shares outstanding during the year	96,90,000	11,90,000
Nominal Value of Equity Shares (in Rs.)	10	10
Earning Per Share Basic and Diluted (in Rs.)	0.80	1.79

21. As at March 31, 2025, the Company has certain dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows:

	Year ended March 31, 2025	Year ended 31st March, 2024



a) The principal amount remaining unpaid to any supplier at the end of the year	0	0
b) Interest due remaining unpaid to any supplier at the end of the year	0	0
c) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during the year	0	0
d) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006	0	0
e) The amount of interest accrued and remaining unpaid at the end of each accounting year	0	0
f) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprises, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act, 2006	0	0

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006" is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company. There are no overdue principal amounts / interest payable amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the year or for any earlier years and accordingly there is no interest paid or outstanding interest in this regard in respect of payment made during the year or on balance brought forward from previous year.

22. Capital commitment and contingent liabilities

a) Capital commitment

There are no capital commitment outstanding as at reporting date (as at March 31, 2024: NIL)

b) Contingent Liabilities and Commitments

There are no contingent liabilities

23. OTHER STATUTORY INFORMATION:


- (i) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (ii) The Company has not granted Loans or Advances in the nature of loans to promoters, Directors, KMPs and the related parties.
- (iii) The Company does not have any transactions with companies which are struck off.

24. The Company has considered the business segment as the primary reporting segment on the basis that the risk and returns of the Company is primarily determined by the nature of products and services. Consequently, the geographical segment has been considered as a secondary segment.

The business segment have been identified on the basis of the nature of products and services, the risks and returns, internal organization and management structure and the internal performance reporting systems. The business segment comprises of manufacturing and selling of pharmaceutical products.



M.V. Reddy



Geographical segment is considered based on sales within India and outside India.

25. Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.

In terms of our attached report of even date
For M VENAKTESWAR & ASSOCIATES

CHARTERED ACCOUNTANTS
FRN : 026251S

CA M VENKATESWAR REDDY

m.v.reddy.



(PROPRIETOR)
MEMBERSHIP NO: 271992

For CHEMGENIX LABORATORIES PRIVATE LIMITED

bsw
DURGA
KISHORE
PEBBANIDI(DI
N:11045613)



[Signature]
RALLU
RAMAKRISH
NA REDDY
(DIN:091512
34)

Place : Hyderabad
Date : 09/09/2025

NOTES TO ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2025

Note No.	Particulars	As at 31.03.2025	As at 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
1	Share Capital		
	Equity Share Capital		
	Authorised Share Capital	120.00	119.00
	Equity Shares of Rs. 10/- each	120.00	119.00
	Issued Subscribed & Paid up		
Equity Shares of Rs. 10/- each	969.00	119.00	
		969.00	119.00
	Total of Share Capital	969.00	119.00

Addition Information

(i) **Reconciliation of Shares Outstanding**

Note No.	Particulars	As at 31.03.2025	As at 31.03.2024
		No. Of Shares	No. Of Shares
	Share outstanding at the beginning of the year	11,90,000.00	11,90,000.00
	Add: Share Issued	85,00,000.00	-
	Less: Share Bought Back	-	-
	Share outstanding at the end of the year	96,90,000.00	11,90,000.00

(ii) **Details of shares held by shareholders holding more than 5% shares**

Note No.	Shares held at the end of the year					As at 31.03.2025	As at 31.03.2024
	Name	Category	No. of Shares	% of total shares	% Change during the year	No. Of Shares	No. Of Shares
1	Y Madhusudhan Reddy	Promoter	238000	0.00%	20.00%	-	2,38,000
2	K Karunakar Reddy	Promoter	969000	10.00%	0.00%	9,69,000	1,19,000
3	K Shankar Reddy	Promoter	1938000	20.00%	5.00%	19,38,000	2,97,500
4	M. Praneeth	Promoter	242250	2.50%	7.50%	2,42,250	1,19,000
5	Daka Srinivasareddy	Public	242250	2.50%	7.50%	2,42,250	1,19,000
6	A Ramakrishna Reddy	Promoter	969000	10.00%	0.00%	9,69,000	1,19,000
7	V.Prasanna Lakshmi	Promoter	89250	0.00%	7.50%	-	89,250
8	V.Pravallika	Promoter	1453500	15.00%	7.50%	14,53,500	89250
9	J. Avinash Reddy	Promoter	969000	10.00%	10.00%	9,69,000	
10	Shaik Sharaz	Promoter	1938000	20.00%	20.00%	19,38,000	
11	Geethika Kolli	Public	484500	5.00%	5.00%	4,84,500	
12	A Mohan Rao	Promoter	484500	5.00%	5.00%	4,84,500	
	TOTAL			100.00%		96,90,000	11,90,000

(iii) There are no shares reserved for issue under options and contracts/commitments for the sale of shares/disinvestment.

(iv) There are no shares which have been issued for other than cash, by way of bonus issue or which have been bought back in the preceding 5 years

(v) There are no such securities which are convertible into equity/preference shares

(vi) There are no unpaid calls or forfeited shares.

Note No.	Particulars	As at 31.03.2025	As at 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
2	Reserves & Surplus		
	(a) Capital Reserves;		
	(b) Capital Redemption Reserve;		
	(c) Securities Premium		
	(d) Debenture Redemption Reserve;		
	(e) Revaluation Reserve;		
(f) Share Options Outstanding Account;			
(g) Other Reserves-(specify the nature and purpose of each reserve and the amount in respect thereof).			
(h) Surplus/ Profit & Loss Account			
Opening balance	14.60	(6.75)	
Add/Less: Transfer from P&L a/c	77.18	21.35	
Closing balance	91.78	14.60	
	Total of Reserves & Surplus	91.78	14.60



bku



Note No.	Particulars	As at 31.03.2025	As at 31.03.2024				
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)				
3	Long-Term Borrowings (i) Long-term borrowings shall be classified as: (a) Bonds/debentures; (b) Term loans: (A) from banks. (B) from other parties. (c) Deferred payment liabilities; (d) Deposits (e) Loans and advances from related parties; (f) Long term maturities of finance lease obligations; (g) Other loans and advances (specify nature). (ii) Borrowings shall further be sub-classified as secured and unsecured. Nature of security shall be specified separately in each case. (iii) Where loans have been guaranteed by directors or others, the aggregate amount of such loans under each head shall be disclosed. (iv) Bonds/debentures (v) Particulars of any redeemed bonds/debentures which the company has power to reissue shall be disclosed. (vi) Terms of repayment of term loans and other loans shall be stated. (vii) Period and amount of continuing default as on the balance sheet date in repayment of loans and interest, shall be specified separately in each case.		104.11 31.82				
		-	135.94				
	Total of Long-Term Borrowings	-	135.94				
Note No.	Particulars	As at 31.03.2025	As at 31.03.2024				
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)				
4	Other Short-term Liabilities Other Long-term Liabilities shall be classified as: (a) From Banks and Financial Institutions; (b) Others.	110.82					
		110.82	-				
	Total of Other Long-term Liabilities		-				
5	Trade Payables	Less than 1 year	1-2 years	2-3 years	More than 3 year	As at 31.03.2025	As at 31.03.2024
						Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
	(i)MSME						-
	(ii)Others					169.69	282.36
	(iii) Disputed dues - MSME						-
	(iv) Disputed dues - Others						-
	Total of Trade Payables					169.69	282.36
6	Other Current Liabilities (a) Current maturities of finance lease obligations; (b) Interest accrued but not due on borrowings; (c) Interest accrued and due on borrowings; (d) Income received in advance; (e) Unpaid dividends; (f) Unpaid matured deposits and interest accrued thereon; (g) Unpaid matured debentures and interest accrued thereon; (h) Audit Fee Payable (i) Other payables					0.40 -	5.68
	Total of Other Current Liabilities					0.40	5.68
7	Short-term provisions (a) Provision for employee benefits (b) Others (Provision for Income Tax). (c) Statutory Remittances due. (d) Others					38.81 23.32 -	21.00 8.50 22.76
	Total of Short-term provisions					62.13	52.26



8	Fixed Assets						
	Tangible (as per annexure "A")						
	Opening Balance		57.55			80.95	
	Add: Additions		112.21				
	Less: Disposals						
	Less: Depreciation		11.08			23.40	
	Closing Balance		158.68			57.55	
	Total of Fixed Assets		158.68			57.55	
Note No.	Particulars		As at 31.03.2025		As at 31.03.2024		
			Amount (₹ in Lakhs)		Amount (₹ in Lakhs)		
9	Deferred tax Asset						
	Property, Plant and Equipment		0.00			0.466	
	Total of Deferred tax Asset		-			0.466	
10	Inventories						
	(a) Raw materials;						
	(b) Work-in-progress;						
	(c) Finished goods;						
	(d) Stock-in-trade (in respect of goods acquired for trading);						
	(e) Stores and spares;						
	(f) Loose tools;						
	(g) Others (specify nature).						
	Total of Inventories		251.58			178.79	
11	Trade Receivables						
		Less than 1					
		1-2 years					
		2-3 years					
		More than 3 year					
	(i) Undisputed Trade receivables – considered good		570.03			274.55	
	(ii) Undisputed Trade Receivables – considered doubtful						
	(iii) Disputed Trade Receivables considered good						
	(iv) Disputed Trade Receivables considered doubtful						
	Total of Trade Receivables		570.03			274.55	
12	Cash & Cash Equivalents						
	(i) Cash and cash equivalents shall be classified as:						
		(a) Balances with banks;		0.29			3.16
		(b) Cheques, drafts on hand;					
		(c) Cash on hand;		2.02			0.07
	(d) Others (specify nature).						
	(ii) Earmarked balances with banks (for example, for unpaid dividend) shall be separately stated						
	(iii) Balances with banks to the extent held as margin money or security against the borrowings, guarantees, other commitments shall be disclosed separately.						
	(iv) Repatriation restrictions, if any, in respect of cash and bank balances shall be separately stated.						
	(v) Bank deposits with more than twelve months maturity shall be disclosed separately.						
	Total of Cash & Cash Equivalents		2.31			3.23	
13	Short-term loans and advances						
	(i) Short-term loans and advances shall be classified as:						
		(a) Loans and advances to related parties (giving details thereof);					
		(b) Others (specify nature).					
		(ii) The above shall also be sub-classified as:					
	(a) Secured, considered good;						
	(b) Unsecured, considered good;						
	(c) Doubtful.						
	Total of Short-term loans and advances		75.00			75.00	
14	Other Current Assets						
	Preliminary Expenses to the extent not written off			-			1.99
	Advance Tax & TDS Receivables			-			1.99
	GST Input			10.81			10.81
	MAT Receivable			-			0.04
	Advance to Suppliers			47.41			1.21
	Deferred Tax			4.66			
		Total off Other Current Assets		62.88			16.05



Note No.	Particulars	As at 31.03.2025	As at 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
15	Revenue from Operation		
	(a) Sale of products	2,372.42	2,389.69
	Total Revenue from Operation	2,372.42	2,389.69

Note No.	Particulars	As at 31.03.2025	As at 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
16	Cost of Raw materials consumed		
	Opening	178.79	-
	Purchases	2,248.60	2,433.24
	Closing	251.58	178.79
	Total Cost of materials consumed	2,175.82	2,254.45

Note No.	Particulars	As at 31.03.2025	As at 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
17	Employee Benefit Expenses		
	Salaries and Wages	32.64	37.38
	Staff Welfare		
	Total Employee Benefit Expenses	32.64	37.38

Note No.	Particulars	As at 31.03.2025	As at 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
18	Finance Cost		
	Interest Expenses	12.65	24.43
	Bank Charges	2.75	0.07
	Total Finance Cost	15.40	24.45

Note No.	Particulars	As at 31.03.2025	As at 31.03.2024
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
19	Other Expenses		
	Professional & Consultancy Fees	-	0.50
	Printing and Stationary	0.11	0.25
	Audit Fee	0.40	0.30
	Insurance	0.91	0.82
	Repairs & Maintenance	0.10	5.19
	Safety and Security Expenses	-	0.18
	General Expenses	-	9.74
	Power and Fuel	0.64	0.10
	GST Penalties	-	0.49
	Preliminary Expenses	-	4.36
	Loan Renewal Charges	-	0.52
	Rent Rates And taxes	31.53	
	Consultancy Charges	0.88	
	Total Other Expenses	34.47	22.22

m.v.p.d.s.



ANNUAL AUDIT AND FINANCIAL REPORTS

F.Y. 2023 - 2024

CHEMGENIX LABORATORIES PRIVATE LIMITED

CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: U52190TG2016PTC111232

6-3-109FLAT NO.201,SECOND FLOOR,SIRI RESIDENCY PLOT NO 63 PHASE-V,KPHB COLONY

KUKATPALLY, Hyderabad, HYDERABAD, Telangana, India, 500072

Balance Sheet As At 31.03.2024

Particulars	Note No	As at 31.03.2024	As at 31.03.2023
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	1	119.00	119.00
(b) Reserves and Surplus	2	14.60	(6.75)
(C) Money Received against Share Warrants		-	-
(2) Share Application Money Pending Allotment			
		-	-
(3) Non-Current Liabilities			
(a) Long-Term Borrowings	3	135.94	166.50
(b) Deferred tax liabilities (Net)		-	-
(C) Other Long Term Liabilities	4	-	-
(d) Long-term provisions		-	-
(4) Current Liabilities			
(a) Short Term Borrowings		-	-
(b) Trade payables:-	5	282.36	149.55
(A) total outstanding dues of micro enterprises and small enterprises; and		-	-
(B) total outstanding dues of creditors other than micro enterprises and small enterprises		-	-
(C) Other Current Liabilities	6	5.68	3.72
(D) Short-Term Provisions	7	52.26	58.79
Total of Equity and Liabilities		609.84	490.81
II.Assets			
(1) Non-Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	8	57.55	80.95
(ii) Intangible Assets		-	-
(iii) Capital work-inprogress		-	-
(iv) Intangible assets under development		-	-
(b) Non-current investments	9	-	-
(c) Deferred tax assets (net)	10	4.66	2.55
(d) Long-term loans and advances	11	-	-
(e) Other non-current assets	12	-	-
(i) Priliminery Expenses		-	-
(2) Current Assets			
(a) Current Investments	13	-	-
(b) Inventories	14	178.79	-
(c) Trade receivables	15	274.55	293.43
(d) Cash and Cash Equivalents	16	3.23	1.48
(e) Short-term loans and advances	17	75.00	75.00
(f) Other Current Assets	18	16.06	37.39
Total of Assets		609.84	490.81

Other Notes on account and Significant Accounting Policies

1


The Notes on account referred to above form an integral part of Balance Sheet.
As per our report of even date attached.

Place: Hyderabad
Date: 01-09-24

For M VENAKTESWAR & ASSOCIATES
Chartered Accountants
FRN : 026251S

M Venkateswar Reddy


CA M Venkateswar Reddy
Proprietor
Membership No. 271992



For and on behalf of the Board of Directors
CHEMGENIX LABORATORIES PRIVATE LIMITED

Madhur

MADHUSUDHAN YADAMAKANTI REDDY
Director
DIN: 02874260




AKU RAMAKRISHNA REDDY
Director
DIN: 09151234

Notes

i) no. of share to be issued ii) premium at which shares will be issued iii) period before which share will be issued

Particulars	As at 31.03.2024	As at 31.03.2023					
	Amount (₹ in Lakhs)	Amount (₹)					
1 Share Capital							
Equity Share Capital							
Authorised Share Capital	119.00	119.00					
Equity Shares of Rs. 10/- each	119.00	119.00					
Issued Subscribed & Paid up							
Equity Shares of Rs. 10/- each	119.00	119.00					
	119.00	119.00					
Total of Share Capital	119.00	119.00					
Addition Information							
(i) Reconciliation of Shares Outstanding							
Note No.	Particulars	As at 31.03.2024	As at 31.03.2023				
		No. Of Shares	No. Of Shares				
	Share outstanding at the beginning of the year	1190000	1190000				
	Add: Share Issued						
	Less: Share Bought Back						
	Share outstanding at the end of the year	1190000	1190000				
(ii) Details of shares held by shareholders holding more than 5% shares							
Note No.	Shares held at the end of the year	As at 31.03.2024	As at 31.03.2023				
	Name	Category	No. of Shares	% of total shares	% Change during the year	No. Of Shares	No. Of Shares
1	Nitin Panchagnula	Promoter	330000		27.73%		330000
2	B.Premalatha	Promoter	860000		72.27%		860000
3	Y Madhusudhan Reddy	Promoter	238000	20.00%		238000	
4	K Karunakar Reddy	Promoter	119000	10.00%		119000	
5	K Shankar Reddy	Promoter	297500	25.00%		297500	
6	M. Praneeth	Promoter	119000	10.00%		119000	
7	Daka Srinivasareddy	Promoter	119000	10.00%		119000	
8	A Ramakrishna Reddy	Promoter	119000	10.00%		119000	
9	V.Prasanna Lakshmi	Promoter	89250	7.50%		89250	
10	V.Pravallika	Promoter	89250	7.50%		89250	
(iii) There are no shares reserved for issue under options and contracts/commitments for the sale of shares/disinvestment.							
(iv) There are no shares which have been issued for other than cash, by way of bonus issue or which have been bought back in the preceding 5 years							
(v) There are no such securities which are convertible into equity/preference shares							
(vi) There are no unpaid calls or forfeited shares.							
Note No.	Particulars	As at 31.03.2024	As at 31.03.2023				
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)				
2 Reserves & Surplus							
	(a) Capital Reserves;						
	(b) Capital Redemption Reserve;						
	(c) Securities Premium						
	(d) Debenture Redemption Reserve;						
	(e) Revaluation Reserve;						
	(f) Share Options Outstanding Account;						
	(g) Other Reserves—(specify the nature and purpose of each reserve and the amount in respect thereof);						
	(h) Surplus/ Profit & Loss Account						
	Opening balance	(6.75)	-9.47				
	Add/Less: Transfer from P&L a/c	21.35	2.72				
	Closing balance	14.60	-6.75				
	Total of Reserves & Surplus	14.60	-6.75				



Handwritten signature/initials

CHEMGENIX LABORATORIES PRIVATE LIMITED

CIN: U52190TG2016PTC111232

6-3-109FLAT NO.201,SECOND FLOOR,SIRI RESIDENCY PLOT NO 63 PHASE-V,KPHB COLONY
KUKATPALLY, Hyderabad, HYDERABAD, Telangana, India, 500072

Profit And Loss A/c For the Year Ended 31.03.2024

Particulars	Note No	As at 31.03.2024	As at 31.03.2023
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
I. Revenue from operations	19	2,389.69	873.18
II. Other Income	20	-	-
III. Total Income (I +II)		2,389.69	873.18
IV. Expenses:			
Cost of materials consumed	21	2,254.45	634.09
Purchases of Stock-in-Trade	22		
Changes in inventories of finished goods	23		
Work-in-progress and Stock-in-Trade	24		
Employee Benefit Expense	25	37.38	49.30
Depreciation and Amortization Expense (as per annexure "A" & "B")		23.40	24.29
Other Expenses	26	46.72	158.82
IV. Total Expenses		2,361.94	866.51
V. Profit Before Exceptional and Extraordinary Items and Tax (III - IV)		27.75	6.68
VI. Exceptional Items		-	-
VII. Profit Before Extraordinary Items and Tax (V - VI)		27.75	6.68
VIII. Extraordinary Items		-	-
IX. Profit Before Tax (VII - VIII)		27.75	6.68
X. Tax Expense:			
(1) Current Tax		8.50	5.60
(2) Deferred Tax Asset		(2.10)	(1.64)
XI. Profit(Loss) from the Period from Continuing Operations (IX-X)		21.35	2.72
XII. Profit/(Loss) from Discontinuing Operations		-	-
XIII. Tax Expense of Discounting Operations		-	-
XIV. Profit/(Loss) from Discontinuing Operations (XII - XIII)		-	-
XV. Profit/(Loss) for the Period (XI + XIV)		21.35	2.72
XVI. Earning per Equity Share:			
-Basic/Diluted on Share of '10/- each	27	1.79	0.23

Other Notes on account and Significant Accounting Policies

1

The Notes on account referred to above form an integral part of Balance Sheet.
As per our report of even date attached.

Place: Hyderabad
Date: 01-09-2024

For M VENAKTESWAR & ASSOCIATES
Chartered Accountants
FRN : 026251S

For and on behalf of the Board of Directors
CHEMGENIX LABORATORIES PRIVATE LIMITED




M Venkateswar Reddy

CA M Venkateswar Reddy
Proprietor
Membership No. 271992

Madhushan

MADHUSUDHAN YADAMAKANTI REDDY
Director
DIN: 02874260



Alu Ramakrishna Reddy

ALU RAMAKRISHNA REDDY
Director
DIN: 09151234



Note: any item of income or expense exceeding 1% of revenue from operation or Rs. 1,00,000/- whichever is higher should be disclosed separately and should not be clubbed.

Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
3	<p>Long-Term Borrowings</p> <p>(i) Long-term borrowings shall be classified as:</p> <p>(a) Bonds/debentures;</p> <p>(b) Term loans:</p> <p>(A) from banks.</p> <p>(B) from other parties.</p> <p>(c) Deferred payment liabilities;</p> <p>(d) Deposits</p> <p>(e) Loans and advances from related parties;</p> <p>(f) Long term maturities of finance lease obligations;</p> <p>(g) Other loans and advances (specify nature).</p> <p>(ii) Borrowings shall further be sub-classified as secured and unsecured. Nature of security shall be specified separately in each case.</p> <p>(iii) Where loans have been guaranteed by directors or others, the aggregate amount of such loans under each head shall be disclosed.</p> <p>(iv) Bonds/debentures</p> <p>(v) Particulars of any redeemed bonds/debentures which the company has power to reissue shall be disclosed.</p> <p>(vi) Terms of repayment of term loans and other loans shall be stated.</p> <p>(vii) Period and amount of continuing default as on the balance sheet date in repayment of loans and interest, shall be specified separately in each case.</p>	<p>104.11</p> <p>31.82</p>	166.50
		135.94	166.50
	Total of Long-Term Borrowings	135.94	166.50
Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
4	<p>Other Long-term Liabilities</p> <p>Other Long-term Liabilities shall be classified as:</p> <p>(a) Trade payables;</p> <p>(b) Others.</p>		
		-	0.00
	Total of Other Long-term Liabilities	-	0.00




Madhuri

1,5	Trade Payables	Less than 1 year	1-2 years	2-3 years	More than 3 year	As at 31.03.2024	As at 31.03.2023													
						Amount (₹ in Lakhs)	Amount (₹ in Lakhs)													
	(i)MSME (ii)Others (iii) Disputed dues – MSME (iv) Disputed dues - Others Total of Trade Payables	282.36				- 282.36 - - 282.36	149.55													
6	Other Current Liabilities (a) Current maturities of finance lease obligations; (b) Interest accrued but not due on borrowings; (c) Interest accrued and due on borrowings; (d) Income received in advance; (e) Unpaid dividends; (f) Unpaid matured deposits and interest accrued thereon; (g) Unpaid matured debentures and interest accrued thereon; (h) Audit Fee Payable (i) Other payables Total of Other Current Liabilities					5.68 5.68	3.72 3.72													
7	Short-term provisions (a) Provision for employee benefits (b) Others (Provision for Income Tax). (c) Statutory Remittances due. (d) Others Total of Short-term provisions					21.00 8.50 22.76 52.26	15.00 11.45 32.34 58.79													
8	Fixed Assets Tangible (as per annexure "A") Opening Balance Add: Additions Less: Disposals Less: Depreciation Closing Balance Total of Fixed Assets					80.95 23.40 57.55 57.55	105.24 24.29 80.95 80.95													
9	Non-current investments (a) Investment property; (b) Investments in Equity Instruments; (c) Investments in preference shares; (d) Investments in Government or trust securities; (e) Investments in debentures or bonds; (f) Investments in Mutual Funds; (g) Investments in partnership firms; (h) Other non-current investments (Security deposits to Building Owners). Total of Non-current investments					-	0.00													
Note No.	Particulars					As at 31.03.2024 Amount (₹ in Lakhs)	As at 31.03.2023 Amount (₹ in Lakhs)													
10	Deferred tax Asset Property, Plant and Equipment Total of Deferred tax Asset					4.66 4.66	2.55 2.55													
11	Long-term loans and advances (i) Long-term loans and advances shall be classified as: (a) Capital Advances; (b) Loans and advances to related parties (giving details thereof); a) repayable on demand b) without specifying any terms or period of repayment <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:40%;">Type of Borrower</th> <th style="width:30%;">Amount of loan or advance in the nature of loan outstanding</th> <th style="width:30%;">% of the total Loans and Advances in the nature of loans</th> </tr> </thead> <tbody> <tr> <td>Promoters</td> <td></td> <td></td> </tr> <tr> <td>Directors</td> <td></td> <td></td> </tr> <tr> <td>KMPs</td> <td></td> <td></td> </tr> <tr> <td>Related Parties</td> <td></td> <td></td> </tr> </tbody> </table> (c) Other loans and advances (specify nature). (ii) The above shall also be separately sub-classified as: (a) Secured, considered good; (b) Unsecured, considered good; (c) Doubtful. (iii) Allowance for doubtful loans and advances shall be disclosed under the relevant heads separately. Total of Long-term loans and advances	Type of Borrower	Amount of loan or advance in the nature of loan outstanding	% of the total Loans and Advances in the nature of loans	Promoters			Directors			KMPs			Related Parties						
Type of Borrower	Amount of loan or advance in the nature of loan outstanding	% of the total Loans and Advances in the nature of loans																		
Promoters																				
Directors																				
KMPs																				
Related Parties																				



Handwritten signatures and initials at the bottom of the page.

12	Other non-current assets Other non-current assets shall be classified as: (i) Long-term Trade Receivables (including trade receivables on deferred credit terms); (ia) Security Deposits (ii) Others (specify nature); (iii) Long term Trade Receivables, shall be sub-classified as: (iv) For trade receivables outstanding, following ageing schedule shall be given:						
Total of Short-term provisions					-	0.00	
13	Current Investments (a) Investment property; (a) Investments in Equity Instruments; (b) Investment in Preference Shares; (c) Investments in Government or trust securities; (d) Investments in debentures or bonds; (e) Investments in Mutual Funds; (f) Investments in partnership firms; (g) Other investments (specify nature).						
Total Other Non-Current Assets					-	0.00	
14	Inventories (a) Raw materials; (b) Work-in-progress; (c) Finished goods; (d) Stock-in-trade (in respect of goods acquired for trading); (e) Stores and spares; (f) Loose tools; (g) Others (specify nature).				178.79		
Total of Inventories				178.79	0.00		
15	Trade Receivables	Less than 1	1-2 years	2-3 years	More than 3 year	Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
	(i) Undisputed Trade receivables – considered good	1,149.80				274.55	293.43
	(ii) Undisputed Trade Receivables – considered doubtful						
	(iii) Disputed Trade Receivables considered good						
	(iv) Disputed Trade Receivables considered doubtful						
Total of Trade Receivables						274.55	293.43
16	Cash & Cash Equivalents (i) Cash and cash equivalents shall be classified as: (a) Balances with banks; (b) Cheques, drafts on hand; (c) Cash on hand; (d) Others (specify nature). (ii) Earmarked balances with banks (for example, for unpaid dividend) shall be separately stated (iii) Balances with banks to the extent held as margin money or security against the borrowings, guarantees, other commitments shall be disclosed separately. (iv) Repatriation restrictions, if any, in respect of cash and bank balances shall be separately stated. (v) Bank deposits with more than twelve months maturity shall be disclosed separately.				3.16		
				0.07		1.48	
Total of Cash & Cash Equivalents				3.23		1.48	
17	Short-term loans and advances (i) Short-term loans and advances shall be classified as: (a) Loans and advances to related parties (giving details thereof); (b) Others (specify nature). (ii) The above shall also be sub-classified as: (a) Secured, considered good; (b) Unsecured, considered good; (c) Doubtful. (iii) Allowance for bad and doubtful loans and advances shall be disclosed under the relevant heads separately.				75.00		75.00
Total of Short-term Loans and advances				75.00		75.00	0.00
				75.00		75.00	
				75.00		75.00	



M. V. Kateswar

M. V. Kateswar

18 Other Current Assets			
Preliminary Expenses to the extent not written off		1.99	4.36
Advance Tax & TDS Receivables		1.99	3.89
GST Input		10.81	3.29
MAT Receivable		0.04	0.04
Advance to Suppliers		1.21	25.82
		16.06	37.39
Total off Other Current Assets		16.06	37.39



Madhuri



AWA

Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (Rs. In Lakhs)	Amount (Rs. In Lakhs)
19	Revenue from Operation		
	(a) Sale of products		-
		2,389.69	873.18
		2,389.69	873.18
	(b) Sale of services;		
		-	-
	Total Revenue from Operation	2,389.69	873.18


Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (Rs. In Lakhs)	Amount (Rs. In Lakhs)
20	Other Income		
	Other Income		
	Total Other Income	-	-

Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (Rs. In Lakhs)	Amount (Rs. In Lakhs)
21	Cost of Raw materials consumed		
	Opening	-	1.86
	Purchases	2,433.24	632.23
	Closing	178.79	-
	Total Cost of materials consumed	2,254.45	634.09

Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
22	Purchase of Stock -in Trade		
	Total Purchase of Stock -in Trade	-	-



Mahesh





Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
23	Changes in inventories of Finished goods		
	Finished Goods		
	Opening Stock		
	Closing Stock	-	-
	Total Changes in inventories of Finished goods	-	-


Note No.	Particulars	As at 31.03.2024	As at 31.03.2023	
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)	
24	Work-in Progress and Stock-in-Trade			
	Packing Material			
	Opening Stock			
	Closing Stock	-	-	
	Raw Material			
	Opening Stock			
	Closing Stock	-	-	
	Fuel			
	Opening Stock			
	Closing Stock	-	-	
		Total Changes in inventories of Stock-in-Trade-Increase	-	-

Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
25	Employee Benefit Expenses		
	Salaries and Wages	37.38	49.30
	Staff Welfare		
	Total Employee Benefit Expenses	37.38	49.30



Mdhu.  

Note No.	Particulars	As at 31.03.2024	As at 31.03.2023
		Amount (₹ in Lakhs)	Amount (₹ in Lakhs)
26	Other Expenses		
	Business Development		8.57
	Friight And Forwarding Charges		0.29
	Telephone Postage		0.25
	Professional & Consultancy Fees	0.50	0.50
	Printing and Stationary	0.03	0.44
	Audit Fee	0.30	0.30
	Insurance	0.82	1.22
	Repairs & Maintenance	5.19	5.17
	Safety and Security Expenses	0.18	0.79
	General Expenses	9.74	8.51
	Power and Fuel	0.10	0.80
	GST Penalties	0.49	0.27
	Bank Charges	0.07	0.64
	Preliminary Expenses	4.36	4.36
	Loan Renewal Charges	0.52	
	Interest Expenses	24.43	24.77
	Rent Rates And taxes		31.15
	Travelling Conveyance		0.66
	Commission Paid		21.22
	Import Related Expenses		0.08
	Testing Charges		1.20
	Construction Expenses		27.55
	CGTMS Fee		0.27
	Consultancy Charges		19.45
	ROC Rates & Taxes		0.36
	Total Other Expenses	46.72	158.82



Annexure "A" to Note-8: FIXED ASSETS- Property, Plant and Equipment

SI No.	Particulars	SLM %	Gross Block				Depreciation			Net Block	
			As on 01-04-2023	Additions	Deletions	As on 31-03-2024	Accumulated Depreciation	Depreciation for the Year	Total Depreciation	Balance as on 01.04.2023 (A)	Balance as on 31.03.2024
	FURNITURES & FIXTURES	25.88%	0.06			0.06	-	0.06	0.06	0	-
	PLANT & MACHINERY	13.91%	80.89			80.89	86.90	23.34	110.24	81	57.55
	Total		80.95				86.90	23.40	110.30	80.95	57.55

Annexure "B" to Note-8: FIXED ASSETS- INTANGIBLE

SI No.	Particulars	Balance as on 01.04.2021 (A)	Cost				Depreciation			Net Block	
			Purchase	Put to Use	Residual Value @ 5% (B)	Real Value (A-B)	Accumulated Depreciation	Depreciation for the Year	Total Depreciation	Balance as on 01.04.2021 (A)	Balance as on 31.03.2022
	Total	-					-	-	-	-	-

Annexure "A" to Note-8: FIXED ASSETS- Property, Plant and Equipment As per IT Act

SI No.	Particulars	WDV	Gross Block				Depreciation			Net Block	
			As on 01-04-2023	Additions	Deletions	As on 31-03-2024	Accumulated Depreciation	Depreciation for the Year	Total Depreciation	Balance as on 01.04.2023 (A)	Balance as on 31.03.2024
	FURNITURES & FIXTURES	10.00%	2.89			2.89	-	0.03	0.03	3.21	2.86
	PLANT & MACHINERY	15.00%	99.76			99.76	-	14.96	14.96	117.37	84.80
	Computers	40.00%	0.78			0.78	-	0.31	0.31	0.13	0.47
	Total		103.43				-	15.30	15.30	120.71	88.13

Annexure "B" to Note-8: FIXED ASSETS- INTANGIBLE

SI No.	Particulars	Balance as on 01.04.2021 (A)	Cost				Depreciation			Net Block	
			Purchase	Put to Use	Residual Value @ 5% (B)	Real Value (A-B)	Accumulated Depreciation	Depreciation for the Year	Total Depreciation	Balance as on 01.04.2021 (A)	Balance as on 31.03.2022
	Total	-					-	-	-	-	-



Handwritten signature/initials in blue ink.

Handwritten signature/initials in blue ink.

1 SIGNIFICANT ACCOUNTING POLICIES

A. Basis of preparation of Financial Statement

The financial statements are prepared under the historical cost convention, in accordance with the generally accepted accounting principles in India and the provisions of the Companies Act, 2013.

B. Use of Estimates

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognised in the period in which the results are known/ materialised.

C. Own Fixed Assets

Fixed Assets are stated at cost net of recoverable taxes and, less accumulated depreciation, if any.

D. Impairment of Assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the Profit and Loss Account in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed if there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use.

E. Investments

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term Investments are stated at acquisition / amortised cost. A provision for diminution in the value of long term investments is made only if such a decline is other than temporary in the opinion of the management.

F. Borrowing Cost


Borrowing costs are recognised as expense in the year in which they are incurred.

G. Revenue Recognition

Revenue is recognised only when it can be reliably measured and it is reasonable to expect ultimate collection.

H. Inventories

Inventories are valued at Cost or NRV whichever is lower.



I. Taxes on Income and Deferred Tax

Provision for Income Tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of Current Tax and Deferred Tax at the applicable enacted or substantively enacted rates. Current Tax represents the amount of Income Tax payable/ recoverable in respect of the taxable income/ loss for the reporting period. Deferred Tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods. The Deferred Tax Asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, Deferred Tax Assets are recognised only if there is virtual certainty of realisation of assets.

J. Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognised when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent assets are neither recognised nor disclosed in the Financial Statements.


K. Earning per Share

In determining Earning per Share, the Company considers the net profit after tax and includes the post tax effect of any extraordinary/ exceptional item. The number of shares used in computing Basic Earning per Share is the weighted average number of shares outstanding during the period. The number of shares used in computing Diluted Earning per Share comprises the weighted average shares considered for deriving Basic Earnings per Share and also the weighted average number of shares that could have been issued on the conversion of all dilutive potential Equity Shares unless the results would be anti - dilutive. Dilutive potential Equity Shares are deemed converted as of the beginning of the period, unless issued at a later date.

The Notes on account referred to above form an integral part of Balance Sheet.
As per our report of even date attached.


For M VENAKTESWAR & ASSOCIATES
Chartered Accountants
FRN : 026251S

M Venkateswar Reddy
CA M Venkateswar Reddy
Proprietor
Membership No. 271992
Place: Hyderabad
Date: 01-09-24



For and on behalf of the Board of Directors
CHEMGENIX LABORATORIES PRIVATE LIMITED

Madhur
MADHUSUDHAN YADAMAKANDI
Director
DIN: 02874260



AA
ALLU RAMAKRISHNA REDDY
Director
DIN: 09151234

2	Auditor Remuneration :		
	Particulars	2023-24	2022-23
	Audit Fees	30000	30000
	Fee For Other Services		
3	Balances lying as debtors, creditors, loans & advances are subject to confirmation to be received from parties.		
4	The previous year's figures have been reworked, regrouped, rearranged and reclassified wherever necessary.		

5 Related Party Disclosures

(i) **Key Management Personnel**

(ii) **Relatives of Key Management Personnel**

(iii) **Enterprises where Key Management Personal have significant influence**

Disclosures in Respect of Material Related Parties Transaction During the Year:


Sl.No	Name	Nature of Transaction	Opening Balance (₹) (CR)	Debit(₹)	Credit(₹)	Closing Balance(₹) (CR)
1		Nil	Nil	Nil	Nil	

Note No.	Particulars	RS In Lakhs	
		As at 31.03.2024	As at 31.03.2023
27	Earning per share		
	a) Profit attributable to Equity Share Holders (Rs) (used as numerator for calculation of EPS)	21.35	2.72
	b) Weighted Average number of Equity Shares outstanding during the year	1,190,000	1,190,000
	c) Basic and Diluted Earnings per share of Rs. 10/- each (a/b)	1.79	0.23

For M VENAKTESWAR & ASSOCIATES

Chartered Accountants

FRN : 026251S

M. Venkateswar Reddy


CA M Venkateswar Reddy
 Proprietor
 Membership No. 271992

Place: Hyderabad

Date: 01-09-24

For and on behalf of the Board of Directors

CHEMGENIX LABORATORIES PRIVATE LIMITED

Madh

 MADHUSUDHAN YADAMAKANTI REDDY ALLU RAMAKRISHNA REDDY
 Director Director
 DIN: 02874260 DIN: 09151234

CHEMGENIX LABORATORIES PRIVATE LIMITED

Registered Office: Flat No. 201, Second Floor, Siri Residency, Plot No. 63, Phase-V, KPHB Colony,
Kukatpally Hyderabad – 500072; Ph No. +91 9989210087
CIN: U52190TG2016PTC111232; Email id: premalatha@chemgenix.co.in


NOTICE OF ANNUAL GENERAL MEETING


Notice is hereby given that the Annual General Meeting of the members of **CHEMGENIX LABORATORIES PRIVATE LIMITED** will be held on Saturday the 30th day of September, 2023 at 10.00 A.M. at the registered office of the Company to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the audited financial statements of the Company for the financial year ended 31st March 2023 and the reports of the auditors and the directors thereon.

By Order of the Board
FOR CHEMGENIX LABORATORIES PRIVATE LIMITED


(NITIN PANCHAGNULA)
DIRECTOR
DIN: 07122387


(PREMALATHA BHASKARA)
DIRECTOR
DIN: 07553855

Place: Hyderabad
Date : 27.09.2023

NOTES

1. A member entitled to attend and vote is entitled to appoint a proxy to attend and vote instead of himself/herself and the proxy need not be a member of the Company.
2. The Ministry of Corporate Affairs has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the companies and has issued circulars stating that service of notice/documents including Annual Report can be sent by e-mail to its members.
3. At the meeting held on September 30, 2022 the members approved appointment of M/s. Utkala Meher & Co., Chartered Accountants as Statutory Auditors of the Company to hold office for a period of five years from the conclusion of that AGM till the conclusion of the AGM to be held for the financial year 2026-27. The requirement to place the matter relating to appointment of auditors for ratification by Members at every AGM has been done away by the Companies (Amendment) Act, 2017 with effect from May 7, 2018. Accordingly, no resolution is being proposed for ratification of appointment of statutory auditors.

BOARD'S REPORT

To
The Members of
CHEMGENIX LABORATORIES PRIVATE LIMITED
Hyderabad

Your directors take the pleasure in presenting the Annual report on the affairs of the Company for the financial year 2022-23 together with the audited financial statements and the report of the Auditors thereon.

FINANCIAL HIGHLIGHTS:

(Amount in Rs. 00s)

PARTICULARS	YEAR ENDED MARCH 31, 2023	YEAR ENDED MARCH 31, 2022
Revenue from Operations	8,73,182.77	22,48,884.94
Other Income	-	-
Total Income	8,73,182.77	22,48,884.94
Cost of Material Consumed	6,34,089.28	20,31,238.91
Purchase of Stock in Trade	-	-
Changes in Inventories	-	-
Employee Benefit Cost	49,304.84	42,929.87
Finance Cost	25,409.63	16,815.60
Depreciation and Amortization	24,293.34	24,843.88
Administrative and other expenses	1,33,410.76	1,06,208.96
Total Expenses	8,66,507.85	22,22,037.22
Profit/(Loss) – Before Tax	6,674.94	26,846.87
Current Tax	5,595.42	5,852.20
Deferred Tax	(1,641.85)	(958.95)
Profit/(Loss) – After Tax	2,721.35	21,953.62

BUSINESS OPERATIONS (Rs. In 00s)

During the year under review the company has made a turnover of Rs. 8,73,182.77/- as compared to previous year turnover of Rs. 22,48,884.94/- and incurred expenditure of Rs. 8,66,507.85/- as compared to previous year expenditure of Rs. 22,22,037.22/- resulting in net profit of Rs. 2,721.35/- as previous year net profit of Rs. 21,953.62/-. The Company expects good business in the upcoming years.

DIVIDEND:

Your directors have not recommended any dividend for the financial year.

RESERVES:

During the year under review, the company has not transferred any amount to reserves.

MATERIAL CHANGES AND COMMITMENTS

There are no such changes which occurred or commitments made, affecting the financial position of the Company between the end of the financial year and the date of this report.

DEPOSITS:

During the year under review your Company has not accepted any deposit within the meaning of Sections 73 and 74 of the Companies Act, 2013 read together with the Companies (Acceptance of Deposits) Rules, 2014.

CHANGE IN THE NATURE OF BUSINESS

There are no such changes occurred in the nature of business during the financial year under review.

DIRECTORS' RESPONSIBILITY STATEMENT:

As per Section 134(3)(c) of the Companies Act, 2013 the Board of Directors makes the following statement:

- (a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures.
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit of the company for that period.
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities.
- (d) the directors had prepared the annual accounts on a going concern basis and
- (e) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

BOARD MEETINGS:

The Board of directors met 04 (Four) times on 06.06.2022; 30.09.2022; 15.12.2022 and 15.03.2023 during the financial year. The necessary quorum was present for all the meetings. The maximum interval between any two meetings did not exceed 120 days.

Details of attendance of directors at the Board Meetings during the year are provided below:

Name of the Director	Designation	No. of Board Meetings			% of attendance
		Held	Entitled	Attended	
Nitin Panchagnula	Director	4	4	4	100
Premalatha Bhaskara	Director	4	4	4	100

CHANGES IN SHARE CAPITAL:

During the year under review the company has undertaken the following transaction:

Increase in share capital	Issue of Shares	Bonus Issue	Sweat Equity	ESOP's
Nil	Nil	Nil	Nil	Nil

DIRECTORS / KEY MANAGERIAL PERSONNEL:

DIRECTORS / KEY MANAGERIAL PERSONNEL:

During the year under review, there were no changes in the Composition of Board.

PARTUCLARS OF CONTRACTS / ARRANGEMENTS MADE WITH RELATED PARTIES:

The Company has not entered into any contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013.

AUDITORS:

At the meeting held on September 30, 2022 the members approved appointment of M/s. Utkala Meher & Co., Chartered Accountants as Statutory Auditors of the Company to hold office for a period of five years from the conclusion of that AGM till the conclusion of the AGM to be held for the financial year 2026-27. The requirement to place the matter relating to appointment of auditors for ratification by Members at every AGM has been done away by the Companies (Amendment) Act, 2017 with effect from May 7, 2018. Accordingly, no resolution is being proposed for ratification of appointment of statutory auditors.

QUALIFICATIONS IN AUDIT REPORT:

- a. The statutory auditor in his report: **As mentioned below:**

Remark	Reply
Emphasis of Matter: We draw attention to various expenses in the course of our audit, we encountered a situation where requested documentations for the verification of expenses, specifically related to commission and professional fees, was not provided by client.	Management hereby like to inform the person who was looking after the accounts of the company has resigned due to which management was not in a position to provide the documents. Management hereby assure that the company is in process of appointing new accounts head.

- b. By the company secretary in practice in the secretarial audit report if secretarial audit has been conducted: **N.A**

FRAUDS REPORTED BY AUDITORS:

During the year, there were no frauds reported by the Auditors falling under purview of Section 143 of the Companies Act, 2013.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The company has not entered into any transaction falling under the provisions of section 186 of the Companies Act, 2013 and rules made there under with respect to Loans, Guarantees and Investments as such the relevant information is not applicable.

DETAILS AND FINANCIAL PERFORMANCE OF SUBSIDIARIES / ASSOCIATE COMPANIES / JOINT VENTURES

There are no subsidiary / associate / joint venture companies associated with the Company as such the information required is not applicable.

RISK MANAGEMENT POLICY:

The Risk Management framework of your company which ensures regular review by management to proactively identify the emerging risks, to do risk evaluation and risk prioritization along with development of risk mitigation plans and action taken. The various risks, including the risks associated with the economy, regulation, competition, foreign exchange, interest rate etc., are documented, monitored and managed efficiently.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, ADAPTATION AND INNOVATION:

The particulars prescribed under the provision of Section 134(3)(m) of the Companies Act, 2013 read with rules made there under is not Applicable. However the Company is making continuous efforts to keep the employees informed of all emerging technologies and developments which are relevant to Business of the Company.

FOREIGN EXCHANGE EARNING AND OUTGO:

Foreign Exchange earnings : Nil
Foreign Out go : Nil

SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS:

There are no significant and material orders passed by the regulators or courts or tribunals impacting the going concern and Company's operation in future.

DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Company is well equipped with adequate internal financial controls. The Company has a continuous monitoring mechanism which enables the organisation to maintain with the same standard of the control systems and helps them in managing any default on timely basis because of strong reporting mechanisms followed by the company.

EXTRACT OF ANNUAL RETURN:

As required pursuant to Section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014, an extract of annual return in Form MGT 9 as a part of this Annual Report is enclosed herewith.

MAINTENANCE OF COST RECORDS:

The particulars prescribed under the Section 148 (1) of the Companies Act, 2013 read with rules made there under is not Applicable.

SECRETARIAL AUDITORS:

As per Section 204 of the Companies Act, 2013 read with the Rules made thereunder, Secretarial audit is not applicable to the Company and hence, the Company has not appointed any Secretarial Auditors.

SECRETARIAL STANDARDS

The Company complies with all applicable secretarial standards.

CORPORATE SOCIAL RESPONSIBILITY:

The provisions of Section 135 of the Companies Act, 2013 are not applicable to the Company for the year

TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND:



The Company did not have any funds lying unpaid or unclaimed for a period of seven years for transfer of Investor Education and Protection Fund (IEPF)

INFORMATION REQUIRED UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013

Your Company has always believed in providing an environment that is free from discrimination and harassment including sexual harassment for every individual working in the premises. During the year, no complaints were received pertaining to sexual harassment.

ACKNOWLEDGEMENTS:

Your Directors wish to place on record their sincere appreciation and acknowledge with gratitude the support and consideration extended by the Bankers, Shareholders and employees and look forward for their continued support and cooperation.

By Order of the Board
For Chem Genix Laboratories Pvt. Ltd. For Chem Genix Laboratories Pvt. Ltd.
 
(NITIN PANCHAGNULA) (PREMALATHA BHASKARA)
DIRECTOR DIRECTOR
DIN: 07122387 DIN: 07553855

Place: Hyderabad
Date : 27.09.2023

upto Rs. 1 Lakh									
Individual Shareholders holding nominal share capital in excess of Rs. 1 Lakh	-	-	-	-	-	-	-	-	-
Others (Specify)	-	-	-	-	-	-	-	-	-
SUB TOTAL B2	-	-	-	-	-	-	-	-	-
TOTAL PUBLIC SHAREHOLDING(B 1+B2)	-	-	-	-	-	-	-	-	-
C. Shares held by Custodian for GDRs & ADRs	-	-	-	-	-	-	-	-	-
GRAND TOTAL (A+B+C)	-	1,19,000	1,19,000	100	-	1,19,000	1,19,000	100	-

b) Shareholding of Promoters

SL NO	SHAREHOLDER'S NAME	SHAREHOLDING AT THE BEGINNING OF THE YEAR			SHAREHOLDING AT THE END OF THE YEAR			% CHANGE IN SHAREHOLDING DURING THE YEAR
		NO OF SHARES	% OF TOTAL SHARES OF THE COMPANY	% OF SHARES PLEDGED / ENCUMBERED TO TOTAL SHARES	NO OF SHARES	% OF TOTAL SHARES OF THE COMPANY	% OF SHARES PLEDGED / ENCUMBERED TO TOTAL SHARES	
1.	Nitin Panchagnula	32,999	27.73	-	32,999	27.73	-	-
2.	Premalatha Bhaskara	86,001	72.27	-	86,001	72.27	-	-

c) Change in Promoters Shareholding (Please Specify if there is no change): NO CHANGE

SL. NO.	SHAREHOLDER'S NAME	SHAREHOLDING AT THE BEGINNING OF THE YEAR		SHAREHOLDING AT THE END OF THE YEAR	
1.		NO OF SHARES	% OF TOTAL SHARES OF THE COMPANY	NO OF SHARES	% OF TOTAL SHARES OF THE COMPANY
	At the beginning of the year				
	Date wise Increase / Decrease in Promoters Shareholding specifying the reasons for increase /				

decrease (e.g. Allotment / Transfer/ Bonus / Sweat equity etc)				
--	--	--	--	--

d. Shareholding Pattern of Top ten Shareholders (Other than Directors, Promoters and Holders of GDRs & ADR's) - **NOT APPLICABLE**

SL. NO.	FOR EACH OF THE TOP 10 SHAREHOLDERS	SHAREHOLDING AT THE BEGINNING OF THE YEAR		CUMULATIVE SHAREHOLDING DURING THE YEAR		
		NO OF SHARES	% OF TOTAL SHARES OF THE COMPANY	NO OF SHARES	OF	% OF TOTAL SHARES OF THE COMPANY
1.						
	At the beginning of the year					
	Date wise Increase / Decrease in Promoters Shareholding specifying the reasons for increase / decrease (e.g. Allotment / Transfer/ Bonus / Sweat equity etc)					
	At the end of the year or on date of separation, if separated during the year					

e. Shareholding of Directors and Key Managerial Personnel:

S.NO	NAME OF THE DIRECTOR	SHAREHOLDING AT THE BEGINNING OF THE YEAR		CHANGE IN SHAREHOLDING	SHAREHOLDING AT THE END OF THE YEAR	
		No of Shares	% of total Shares		No of Shares	% of total Shares
1.	Nitin Panchagnula	32,999	27.73	-	32,999	27.73
2.	Premalatha Bhaskara	86,001	72.27	-	86,001	72.27

V. INDEBTEDNESS (Rs. In 00s)

	SECURED LOANS EXCLUDING DEPOSITS	UNSECURED LOANS	DEPOSITS	TOTAL INDEBTEDNESS
Indebtedness at the beginning of the financial year				
Principal Amount	1,73,543.27	55,114.08	-	2,28,657.35
Interest due but not paid	-	-	-	-
Interest accrued but not due	-	-	-	-
Total	1,73,543.27	55,114.08	-	2,28,657.35

Change in Indebtedness during the year				
Addition	-	-	-	-
Reduction	7,039.98	55,114.08	-	62,154.06
Indebtedness at the end of the financial year				
Principal Amount	1,66,503.29	-	-	1,66,503.29
Interest due but not paid	-	-	-	-
Interest accrued but not due	-	-	-	-
Total	1,66,503.29	-	-	1,66,503.29

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

A. Remuneration to Managing Director, Whole time directors and / or Manager :

SL. NO	PARTICULARS OF REMUNERATION	NAME OF THE MD / ED /WTD / MANAGER		TOTAL AMOUNT
		Nitin Panchagnula	Premalatha Bhaskara	
1.	Gross Salary			
	a) Salary as per provisions contained in Section 17(1) of the Income Tax Act, 1961	12,00,000	12,00,000	24,00,000
	b) Value of perquisites u/s 17(2) of Income Tax Act, 1961	-	-	-
	c) Profits in lieu of salary u/s 17(3) of Income Tax Act, 1961	-	-	-
2.	Stock Option	-	-	-
3.	Sweat Equity	-	-	-
4.	Commission - as % of profit - Others (Specify)	-	-	-
5.	Others (Pls Specify)	-	-	-
	Total A			
	Ceiling as per Act	Not Applicable		

B. REMUNERATION TO OTHER DIRECTORS: NOT APPLICABLE

SL. NO	PARTICULARS OF REMUNERATION	NAME OF THE DIRECTOR	TOTAL AMOUNT
1.	INDEPENDENT DIRECTORS		
	a) Fee for attending Board / Committee meetings		
	b) Commission		
	c) Others, Pls Specify		
	TOTAL - I		

2.	OTHER NON-EXECUTIVE DIRECTORS		
	a) Fee for attending Board / Committee meetings		
	b) Commission		
	c) Others, Pls Specify		
	Total 2		
	Total B (1+2)		
	Total Managerial Remuneration		
	Overall Ceiling as per Act		

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/WTD/MANAGER: NOT APPLICABLE

SL. NO.	PARTICULARS OF REMUNERATION	KEY MANAGERIAL PERSONNEL			
		CEO	CFO	COMPANY SECRETARY	TOTAL
1.	Gross Salary				
	a) Salary as per provisions contained in Section 17(1) of the Income Tax Act, 1961				
	b) Value of perquisites u/s 17(2) of Income Tax Act, 1961				
	c) Profits in lieu of salary u/s 17(3) of Income Tax Act, 1961				
2.	Stock Option				
3.	Sweat Equity				
4.	Commission - as % of profit - Others (Specify)				
5.	Others (Pls Specify)				
	Total				


VII. PENALTIES / PUNISHMENT / COMPOUNDING OF OFFENCES: NIL

TYPE	SECTION OF THE COMPANIES ACT	BRIEF DESCRIPTION	DETAILS OF PENALTY / PUNISHMENT / COMPOUNDING FEE IMPOSED	AUTHORITY [RD/NCLT/COURT]	APPEAL MADE, IF ANY
A. COMPANY					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
B. DIRECTORS					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-


C. OTHER OFFICERS IN DEFAULT

Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-


By Order of the Board
FOR CHEMGENIX LABORATORIES PRIVATE LIMITED



(NITIN PANCHAGNULA)
DIRECTOR
DIN: 07122387



(PREMALATHA BHASKARA)
DIRECTOR
DIN: 07553855



INDEPENDENT AUDITOR'S REPORT

To the Members of **CHEMGENIX LABORATORIES PRIVATE LIMITED**
Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **CHEMGENIX LABORATORIES PRIVATE LIMITED** ("the Company"), which comprise the balance sheet as at March 31 2023, the Statement of Profit and Loss for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013, as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, its profit and its cash flows for the year ended on that date.

Basis for Opinion


We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Other Information

The Company's Management and Board of Directors is responsible for the other information. The other information comprises the information included in the Director report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether such other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



Responsibility of Management for the Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Companies (Accounting Standards) Rules, 2021 specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.



Independent Auditor's Report on the Financial Statements for the year ended on March 31, 2023

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Emphasis of Matter

We draw attention to various expenses in the course of our audit, we encountered a situation where requested documentation for the verification of expenses, specifically related to commissions and professional fees, was not provided by the client. As a result, we were unable to fully verify the nature and appropriateness of these expenses. It is important to note that the absence of these documents may impact the completeness and accuracy of the financial information presented in this report


Report on Other Legal and Regulatory Requirements

1. This report does not include a statement on matters specified in paragraph 3 and 4 of the Companies (Auditor's Report) Order, 2020 ("the Order"), as amended, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, since in my opinion and according to the information and explanations given to me, the said order is not applicable to the Company.
2. A. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;



Independent Auditor's Report on the Financial Statements for the year ended on March 31, 2023

- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid financial statements comply with the Companies (Accounting Standards) Rules, 2021 specified under section 133 of the Act;
 - (e) On the basis of the written representations received from the directors as on March 31, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164 (2) of the Act;
 - (f) Reporting on the adequacy with respect to the internal financial controls over financial reporting of the company and the operating effectiveness of such controls are not applicable to the company.
- B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company did not have any pending litigations on its financial position in its financial statements
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company;
 - iv. a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on



Independent Auditor's Report on the Financial Statements for the year ended on March 31, 2023

behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

c) Based on such audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

v. No dividend has been declared or paid by the company for the financial year 2022-23.

vi. As provision to rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable for the company only w.e.f April 1, 2023, reporting under this clause is not applicable

C. The provisions of section 197 read with Schedule V of the Act are not applicable to the Company for the year ended March 31, 2023;

For Utkala Meher & Co.
(Chartered Accountant)
FRN: 018556S


CA Utkala Meher
Proprietor
(M.No. 243246)



UDIN: 23243246BGYHNR6468

Place : Hyderabad
Date : 27-Sep-2023



CHEMGENIX LABORATORIES PRIVATE LIMITED
CIN : U52190TG2016PTC111232
BALANCE SHEET AS AT 31/03/2023

in ₹ Hundreds

Particulars	Note	31/03/2023	31/03/2022
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	2.1	119000	119000
Reserves and surplus	2.2	-6753.35	-9474.7
Money received against share warrants		-	-
Share application money pending allotment		112246.65	109525.3
Non-current liabilities			
Long-term borrowings	2.3	166503.29	228657.35
Deferred tax liabilities (Net)	2.4	-	-
Other Long term liabilities		-	-
Long-term provisions		-	-
Current liabilities			
Short-term borrowings		-	-
Trade payables	2.5	-	-
Total outstanding dues of micro enterprises and sma		-	-
Total outstanding dues of creditors other than micro e		149551.83	1381926.24
Other current liabilities	2.6	18717	101502.14
Short-term provisions	2.7	43787.31	33009.56
TOTAL		212056.14	1516437.94
ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible Assets			
Property, Plant and Equipment	2.8	80946.61	105239.95
Intangible assets		-	-
Capital work-in-progress		-	-
Intangible assets under development		-	-
Non-current investments		80946.61	105239.95
Deferred tax assets (net)	2.9	2553.93	912.08
Long-term loans and advances		-	-
Other non-current assets		-	-
Current assets			
Current investments		-	-
Inventories	3	-	1856.2
Trade receivables	3.1	293431.1	1657390.24
Cash and cash equivalents	3.2	1479.91	1453.23
Short-term loans and advances	3.3	75000	57129.82
Other current assets	3.4	37394.53	30594.85
TOTAL		407305.54	1748424.34
TOTAL		490806.08	1854576.37

In terms of our attached report of even date

For UTKALA MEHER & CO.

CHARTERED ACCOUNTANTS

FRN : 0018556S



Utkala Meher

Proprietor

M.No. 243246

UDIN: 23243246BGYHNR6468

Place : HYDERABAD

Date : 27-SEP-2023

For CHEMGENIX LABORATORIES PRIVATE LIMITED

For ChemGenix Laboratories Pvt. Ltd.

For ChemGenix Laboratories Pvt. Ltd.

Nitin Panchagnula

Director

Din: 07122387

P. Premalatha

Director

Din: 07553855

Director

CHEMGENIX LABORATORIES PRIVATE LIMITED
CIN : U52190TG2016PTC111232
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31/03/2023

in ₹ Hundreds except earning per share

Particulars	Note	31/03/2023	31/03/2022
Revenue from operations	3.5	873182.77	2248884.09
Other income		-	-
Total Revenue		873182.77	2248884.09
Expenses			
Cost of materials consumed	3.6	634089.28	2031238.91
Purchases of Stock-in-Trade	3.7	-	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade		-	-
Employee benefits expense	3.8	49304.84	42929.87
Finance costs	3.9	25409.63	16815.6
Depreciation and amortization expense	4	24293.34	24843.88
Other expenses	4.1	133410.76	106208.96
Total expenses		866507.85	2222037.22
Profit before exceptional, extraordinary and prior period items and tax		6674.92	26846.87
Exceptional items		-	-
Profit before extraordinary and prior period items and tax		6674.92	26846.87
Extraordinary items		-	-
Profit before prior period items and tax		6674.92	26846.87
Prior Period Items		-	-
Profit before tax		6674.92	26846.87
Tax expense:	4.2		
Current tax		5595.42	5852.2
Deferred tax		-1641.85	-958.95
Profit/(loss) for the period from continuing operations		2721.35	21953.62
Profit/(loss) from discontinuing operations		-	-
Tax expense of discontinuing operations		-	-
Profit/(loss) from Discontinuing operations (after tax)		-	-
Profit/(loss) for the period		2721.35	21953.62
Earnings per equity share:			
Basic		-	-
Diluted		-	-

In terms of our attached report of even date

For UTKALA MEHER & CO.

CHARTERED ACCOUNTANTS

FRN : 0018556S

Utkala Meher

Proprietor

M.No. 243246

UDIN: 23243246BGYHNR6468

Place : HYDERABAD

Date : 27-SEP-2023



For CHEMGENIX LABORATORIES PRIVATE LIMITED

For ChemGenix Laboratories Pvt. Ltd.

For ChemGenix Laboratories Pvt. Ltd.

Nitin Panchagnuta

Director

Din: 07122387

P. Premalatha

Director

Din: 07553855

Director

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2023

Share Capital

Particulars	in ₹ Hundreds	
	31/03/2023	31/03/2022
Authorised		
1190000 (1190000) Equity Shares of Rs. 10/- Par Value	119000	119000
Issued		
1190000 (1190000) Equity Shares of Rs. 10/- Par Value	119000	119000
Subscribed		
1190000 (1190000) Equity Shares of Rs. 10/- Par Value	119000	119000
Paidup		
1190000 (1190000) Equity Shares of Rs. 10/- Par Value Fully Paidup	119000	119000

2.2 Reserve and Surplus

Particulars	in ₹ Hundreds	
	31/03/2023	31/03/2022
Profit and Loss Opening	-9474.7	-31428.32
Amount Transferred From Statement of P&L	2721.35	21953.62
	-6753.35	-9474.7
	-6753.35	-9474.7

2.3 Long Term Borrowings

Particulars	in ₹ Hundreds	
	31/03/2023	31/03/2022
Term Loan		
Banks	166503.29	158770.41
Others	0	14772.86
Loan and Advances From Related Parties	0	55114.08
	166503.29	228657.35

2.4 Deferred Taxes

Particulars	in ₹ Hundreds	
	31/03/2023	31/03/2022
Deferred Tax Assets		
Property, Plant and Equipment	2553.93	912.08
	2553.93	912.08

2.5 Trade Payables

as at 31/03/2023 in ₹ Hundreds

Particulars	Periods from due date of payment				Not Due	Total
	less than 1 year	1-2 years	2-3 years	more than 3 years		
(i) MSME	0	0	0	0	0	0
(ii) Others	149551.83	0	0	0	0	149551.83
(iii) Disputed dues - MSME	0	0	0	0	0	0
(iv) Disputed dues - Others	0	0	0	0	0	0

as at 31/03/2022 in ₹ Hundreds

Particulars	Periods from due date of payment				Not Due	Total
	less than 1 year	1-2 years	2-3 years	more than 3 years		
(i) MSME	0	0	0	0	0	0
(ii) Others	1381926.2	0	0	0	0	1381926.2
(iii) Disputed dues - MSME	0	0	0	0	0	0
(iv) Disputed dues - Others	0	0	0	0	0	0

For ChemGenix Laboratories Pvt. Ltd.

[Signature]

Director

For ChemGenix Laboratories Pvt. Ltd.

[Signature]

Director



2.6 Other Current Liabilities

in ₹ Hundreds

Particulars	31/03/2023	31/03/2022
Other payables		
Employee Related	15000	23111.2
Other Current Liabilities	3717	78390.94
	18717	101502.14

2.7 Short Term Provisions

in ₹ Hundreds

Particulars	31/03/2023	31/03/2022
Tax Provision		
Current Tax	11447.62	5852.2
Statutory Liabilities	0	2667.37
Others	32339.69	24489.99
	43787.31	33009.56

For ChemGenix Laboratories Pvt. Ltd.

[Handwritten Signature]

Director
For ChemGenix Laboratories Pvt. Ltd.

[Handwritten Signature]

Director



2.8 Tangible assets											in ₹ Hundreds					
Particulars	Gross				Depreciation					Impairment			Net			
	Opening	Addition	Deduction	Closing	Opening	During Period	Deduction	Other Adj.	Closing	Opening	During Period	Reversal	Closing	Closing	Opening	
Plant and Machinery	167783.11			167783.11	63558.72	23338.63			88897.35					80885.76	104224.39	
Equipments																
Office Equipments	1510.7			1510.7	1510.7				1510.7							
Computer Equipments	723.5			723.5	723.5				723.5							
Furniture and Fixtures	3688.97			3688.97	2673.41	954.71			3628.12					60.85	1015.56	
Grand Total	173706.28	0	0	173706.28	68466.33	24293.34	0	0	92759.67	0	0	0	0	80946.61	105239.95	
Previous Year	129960.33	123.5	0	130083.83	0	24843.88	0	0	24843.88	0	0	0	0	106239.95	129960.33	

For ChemGenix Laboratories Pvt. Ltd.

Director

For ChemGenix Laboratories Pvt. Ltd.

Preves

Director




3.0 Inventories				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
Finished Goods		0		1856.2	
		0		1856.2	
3.1 Trade receivables				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
Trade Receivable					
Secured, considered good		293431.1		1657390.24	
		293431.1		1657390.24	
Ageing Schedule as at 31/03/2023					
Particulars	Outstanding for following periods from due date of payment				Total
	More than 6 months - 1 yr	1-2 years	2-3 years	More than 3 ye	
Ageing Schedule as at 31/03/2022					
Particulars	Outstanding for following periods from due date of payment				Total
	More than 6 months - 1 yr	1-2 years	2-3 years	More than 3 ye	
3.2 Cash and cash equivalents				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
Cash in Hand		0		43.23	
Balances With Banks					
		1479.91		1453.23	
3.3 Short-term loans and advances				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
Loans and advances to others		75000		57129.82	
		75000		57129.82	
3.4 Other current assets				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
TCS/TDS Receivables		3885.58		1467.81	
GST Input Tax Credit		3285.03		20410.77	
Preliminary Expenses to the extent not written off		4358.13		8716.27	
Advance To Supply		25821.57		0	
MAT Receivable		44.22		0	
		37394.53		30594.85	
3.5 Revenue from operations				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
Sale of Products		873182.77		2199210.59	
Sale of Services		0		49673.5	
		873182.77		2248884.09	
3.6 Cost of materials consumed				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
Raw Material					
Opening		1856.2		43472.63	
Purchase		632233.08		1989622.48	
Closing		0		1856.2	
		634089.28		2031238.91	
		634089.28		2031238.91	
Details of Raw Material				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
stock		634089.28		2031238.91	
		634089.28		2031238.91	
3.7 Purchases of Stock-in-Trade				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
		0		0	
3.8 Employee benefits expense				in ₹ Hundreds	
Particulars		31/03/2023		31/03/2022	
Salary, Wages & Bonus		49304.84		42929.87	

For ChemGenix Laboratories Pvt. Ltd.

For ChemGenix Laboratories Pvt. Ltd.

Director



	49304.84	42929.87
3.9 Finance costs		
	in ₹ Hundreds	
Particulars	31/03/2023	31/03/2022
Interest Expenses		
Interest Expenses	24402.66	10685.62
Bank Charges	638.43	1744.54
Finance Charges		
Other Finance Charges	368.54	4385.44
	25409.63	16815.6
4.0 Depreciation and amortisation expense		
	in ₹ Hundreds	
Particulars	31/03/2023	31/03/2022
Depreciation & Amortisation		
Depreciation Tangible Assets	24293.34	24043.88
	24293.34	24843.88

4.1 Other expenses		
	in ₹ Hundreds	
Particulars	31/03/2023	31/03/2022
Manufacturing Service Costs Expenses		
Power and Fuel	798.76	2006.51
Repairs Maintenance Charges Of Plant and Machinery	4492.55	0
Repairs Maintenance Charges Of Other Assets	678.9	517.82
Freight And Forwarding Charges	281.89	383.41
Administrative and General Expenses		
Telephone Postage	250.66	0
Printing Stationery	436.63	56.64
Rent Rates And taxes	31149.38	27951
Auditors Remuneration	300	0
Travelling Conveyance	657	572.56
Insurance Expenses	1220.38	420.65
Safety and Security Expenses	781.54	1620.79
Selling Distribution Expenses		
Commission Paid	21224.8	20000
Other Expenses		
Import Related Expenses	80	4751.71
Testing Charges	1197.8	491.07
Construction Expenses	27548.95	15507.74
CGTMS Fee	273.06	1195.09
Consultancy Charges	19446.11	25530.86
GST/TDS Late Fee and Interest	270.95	274.97
Professional Charges	500	500
ROC Rates & Taxes	360.06	70
Preliminary Expenses	4358.14	4358.14
General Expenses	8508.34	0
Business Development	8574.86	0
	133410.76	106208.96

4.2 Tax expense		
	in ₹ Hundreds	
Particulars	31/03/2023	31/03/2022
Current tax	5595.42	5852.2
Deferred tax	-1641.85	-858.95
	3953.57	4893.25

In terms of our attached report of even date

For UTKALA MEHER & CO.

CHARTERED ACCOUNTANTS
FRN : 0018556S

Utkala Meher

Proprietor

M.No. 243246

UDIN: 23243246BGYHNR6468-D

Place : HYDERABAD

Date : 27-SEP-2023



For ChemGenix Laboratories Pvt. Ltd.

For CHEMGENIX LABORATORIES PRIVATE LIMITED

For ChemGenix Laboratories Pvt. Ltd.

Nitin Panchagnula

Director

Din: 07122387

Director

P. Premalatha

Director

Din: 07553855

Director

Statement showing Yearly Figures

Particulars	2021-2022	2022-2023
CURRENT ASSETS	17,48,42,434.00	4,07,30,554.00
CURRENT LIABILITIES	15,16,43,794.00	2,12,05,614.00
LONG TERM DEBT	2,28,65,735.00	1,66,50,329.00
SHAREHOLDER'S FUND	1,09,52,530.00	1,12,24,665.00
TRADE PAYABLE	13,81,92,624.00	1,49,55,183.00
TRADE RECEIVABLE	16,57,39,024.00	2,93,43,110.00
EQUITY SHARE CAPITAL PLUS RESERVES	1,09,52,530.00	1,12,24,665.00
NET PROFIT AFTER TAX	21,95,362.00	2,72,135.00
CREDIT SALES	22,48,88,409.00	8,73,18,277.00
CREDIT PURCHASES	19,89,62,248.00	6,32,23,308.00
REVENUE FROM OPERATION	22,48,88,409.00	8,73,18,277.00
EARNINGS BEFORE INTEREST, TAX & PRIOR PERIOD ITEM	39,27,703.00	31,71,601.00
COST OF SALES	20,31,23,891.00	6,34,08,928.00
AVERAGE STOCK	22,66,441.50	92,810.00
WORKING CAPITAL	2,31,98,640.00	1,95,24,940.00

Statement showing Yearly Ratios

Particulars	Numerator	Denominator	2021-2022	2022-2023	Variance
Current Ratio	Current Assets	Current Liabilities	1.15	1.92	66.96%
Debt-Equity Ratio	Long term Debt	Shareholder's Funds	2.09	1.48	-29.19%
Debt Service Coverage Ratio	Earnings available for debt service	Debt Service	-	-	-
Return on Equity Ratio	Net Earnings	Shareholder Equity	0.20	0.02	-90.00%
Inventory Turnover Ratio	Cost of Sales	Average Stock Carried or Inventory	89.62	683.21	662.34%
Trade Receivables Turnover Ratio	Credit Sales	Accounts Receivable	1.36	2.98	119.12%
Trade payables Turnover Ratio	Credit Purchases	Accounts Payable	1.44	4.23	193.75%
Net Capital Turnover Ratio	Sales or Cost of Sales	Net Working Capital	9.69	4.47	-53.87%
Net Profit Ratio (%)	Net Operating Profit	Sales	0.98%	0.31%	-0.67%
Return on Capital Employed	Earning Before Interest and Tax	Capital Employed	0.36	0.28	-22.22%
Return on Investment (%)	Net Profit after interest, taxes and preference dividends	Equity capital plus reserves	20.04%	2.42%	-17.62%

CHEMGENIX LABORATORIES PRIVATE LIMITED
FLAT NO.201, SIRI RESIDENCY, PLOT NO 63 PHASE-V, KPHB, KUKATPALLY, HYDERABAD, TELANGANA - 500072

ACCOUNTING POLICIES & NOTES ON ACCOUNTS AS AT 31ST MARCH, 2022:

I. SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Preparation of Financial Statements:

The financial statements have been prepared under the historical cost basis, as a going concern. The company follows accrual system of accounting and is in accordance with the Generally Accepted Accounting Principles (GAAP) in compliance with the provision of the Companies Act, 2013 and the accounting standards as specified in the Companies (Accounting Standards) Rules, 2006 read with Rule 7(1) of the companies (Accounts) Rules, 2014 issued by the Ministry of Corporate Affairs in respect of Section 133 of Companies Act, 2013.

(b) Use of Accounting Estimates

The preparation of financial statements in conformity with Indian GAAP which requires management to make estimates and assumptions that affect the reported number of assets and liabilities and disclosures relating to contingent liabilities as at the reporting date of the financial statements and operational results during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.

(c) Fixed Assets:

The Fixed Assets shall be stated at cost of acquisition and subsequent improvements thereto including taxes, duties, freight and other incidental expenses related to acquisitions and installations.

(d) Depreciation:

Depreciation on fixed assets shall be provided on straightly line method in pro-rata basis at the rates prescribed in Schedule XIV of the Companies Act 1956 as amended from time to time.

(e) Deferred tax liability and deferred tax assets are recognized for the tax effect at present tax rates on the difference between taxable income and accounting income which are not permanent in nature subject to the consideration of prudence in the case of deferred tax assets.

(f) Loans & Advances and Debtors are subject to confirmation and reconciliation.

(g) Based on the information available with the Company, there are no dues outstanding in respect of Micro, Small and Medium enterprises at the balance sheet date. The above disclosure has been determined to the extent such parties have been identified on the basis of information available with the Company. This has been relied upon by the auditors.

(h) Deffered Tax assets has been apportioned to p&l as no future benefit expceted as a result of section 115BAA

(i) The land development expenses has been accumulated and chrged to p&l proportionately.

(j) Cost of Inventories includes all purchase costs, service costs, conversion costs and all other costs which is incurred

(k) Other Statutory Information

(i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder.

(ii) The Company does not have balances outstanding with nature of transaction with struck off companies as per section 248 of the Companies Act, 2013.

(iii) The Company has not advanced or loaned or invested funds to any other persons or entities, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) Provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(iv) The Company has not received any fund from any persons or entities, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) Provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(v) The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income-tax Act, 1961.

(vi) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

- (vi) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
(vii) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

As per our report of even date attached
For Utkala Meher & Co.
Chartered Accountants
FRN: 018556S

Utkala Meher

Utkala Meher
Proprietor
M.No. 243246
UDIN: 23243246BGYHNR6468



For and on behalf of the Board of Directors of
CHEMGENIX LABORATORIES PRIVATE LIMITED

Nitin Panchagnula
Director
Din: 07122387

B.Premalatha
Director
Din: 07553855

Place : HYDERABAD
Date : 27/09/2023

For ChemGenix Laboratories Pvt. Ltd.

Premalatha

Director

For ChemGenix Laboratories Pvt. Ltd.

Nitin Panchagnula

Director

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED 31ST DECEMBER, 2025
(Rs. in Lakhs)

	PARTICULARS	31-Dec-2025	31-Mar-2025
		Unaudited	Audited
I	Income		
(a)	Revenue from Operations	2,105.50	1,480.99
(b)	Other Income	-	46.85
	Total Revenue	2,105.50	1,527.84
II	Expenses		
(a)	Cost of Materials Consumed	1,919.34	1,347.23
(b)	Purchase of Stock in Trade	-	-
(c)	Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	-	-
(d)	Employee Benefit Expenses	37.29	29.50
(e)	Finance Cost	6.88	84.51
(f)	Depreciation and Amortisation Expenses	17.93	10.44
(g)	Other Expenses	30.17	25.57
	Total Expenses	2,011.62	1,497.26
III	Profit / (Loss) Before Exceptional Items and Tax	93.88	30.58
	Exceptional Items	-	-
	Profit / (Loss) Before Tax	93.88	30.58
IV	Tax Expense:		
	(1) Current Tax	24.04	6.95
	(2) Deferred Tax	0.37	1.28
	Profit / (Loss) for the Period from Continuing Operations	69.47	22.35
	Profit / (Loss) from Discontinued Operations	-	-
	Tax Expense of Discontinued Operations	-	-
	Profit / (Loss) from Discontinued Operations (After Tax)	-	-
V	Profit / (Loss) for the Period	69.47	22.35
	Other Comprehensive Income		
	A (i) Items that will not be reclassified to Profit or Loss		
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss		
	B (i) Items that will be reclassified to Profit or Loss		
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss		
	Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period)		
VI	Earnings Per Equity Share - Basic and Diluted (In Rs.)	0.50	0.16



Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com



Date: February 11, 2026

Place: Hyderabad


For Vilin Bio Med Limited



Madhusudhan Yadamakanti Reddy

Managing Director

DIN: 02874260



Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills
Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com

BALANCE SHEET AS AT 31ST DECEMBER, 2025

(Rs. in Lakhs)

Particulars		As at	As at
		31-Dec-2025	31-Mar-2025
		(Unaudited)	(Audited)
I	EQUITY AND LIABILITIES		
(A)	Shareholder's Funds		
(a)	Share Capital	1,395.00	1,395.00
(b)	Reserves and Surplus	980.82	911.35
(c)	Money received against Share Warrants	-	-
		2,375.82	2,306.35
(B)	Non-Current Liabilities		
(a)	Long-Term Borrowings	-	-
(b)	Other Long-Term Liabilities	9.81	9.44
(c)	Deferred Tax Liabilities (Net)	-	-
(d)	Other Non-Current Liabilities	-	-
		9.81	9.44
(C)	Current Liabilities		
(a)	Short Term Borrowings	32.43	257.33
(b)	Trade Payables		
	- Total Outstanding due to MSMEs	-	-
	- Total Outstanding dues other than MSMEs	63.40	138.85
(c)	Other Current Liabilities	7.88	3.00
(d)	Short Term Provisions	38.33	57.83
		142.05	457.00
	Total Equity and Liabilities	2,527.68	2,772.79
II	ASSETS		
(A)	Non-Current Assets		
(a)	Property, Plant and Equipment and Intangible Assets		
(i)	Property, Plant and Equipment	296.26	128.46
(ii)	Capital work-in-progress	0.50	156.84
(iii)	Intangible Assets	-	-
(b)	Non - Current Investments	-	-
(c)	Deferred Tax Assets (Net)	-	-
(d)	Long Term Loans and Advances	3.17	505.84
(e)	Other Non-Current Assets	662.66	725.59
		962.59	1,516.73

 Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills
 Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbio.com




(B)	Current Assets			
(a)	Inventories		432.99	441.18
(b)	Trade Receivables		892.75	630.57
(c)	Cash and Cash Equivalents		147.16	5.61
(d)	Short Term Loans and Advances		63.26	70.37
(e)	Other Current Assets		28.96	108.33
			1,565.09	1,256.06
	Total Assets		2,527.68	2,772.79

Date: February 11, 2026
Place: Hyderabad

For Vilin Bio Med Limited



Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260



Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills
Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com

CASH FLOW STATEMENT FOR THE PERIOD ENDED 31ST DECEMBER, 2025

Particulars	(Figures in Lakhs)	
	As at 31-Dec-2025	As at 31-Mar-2025
	Unaudited	Audited
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	93.88	30.58
Adjustment For		
Depreciation	17.93	10.44
Foreign Exchange		
Gain or Loss on Sale of Fixed Assets		
Gain or Loss on Sale of Investment		
Finance Cost	6.88	84.51
Dividend Income		
Other adjustment of Non-Cash Item		
Other adjustment to reconcile Profit		
	24.82	94.95
Adjustment for Working Capital Change		
Adjustment for Increase/Decrease in Inventories	8.19	5.57
Adjustment for Increase/Decrease in Trade Receivables	(262.18)	(62.16)
Adjustment for Increase/Decrease in Other Current Assets	79.38	15.53
Adjustment for Increase/Decrease in Other Non-Current Assets	62.93	48.91
Adjustment for Increase/Decrease in Short Term Borrowings	(224.89)	(404.79)
Adjustment for Increase/Decrease in Long Term Loans and Advances	502.68	(39.78)
Adjustment for Increase/Decrease in Short Term Loans and Advances	7.11	47.23
Adjustment for Increase/Decrease in Trade Payables	(75.45)	(56.49)
Adjustment for Increase/Decrease in Other Current Liabilities	4.89	(8.89)
Adjustment for Provisions	(19.50)	(0.18)
Total Adjustment for Working Capital (B)	83.16	(455.07)
Total Adjustment to reconcile Profit (A+B)	107.97	(360.12)
Net Cash Flow from (Used in) Operations	201.86	(329.54)
Dividend Received		
Interest Received	-	(46.56)
Interest Paid		
Income Tax Paid / Refund	(24.04)	(6.95)
Net Cash Flow from (used in) operation before Extra-ordinary Items	177.82	(383.04)

 Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills
 Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667


Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbio.com



Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from Operating Activities	177.82	(383.04)
Cash Flows from Investing Activities		
Proceeds from Fixed Assets	156.34	
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets	185.73	157.47
Purchase of Investments or Equity Instruments		
Interest Received	-	46.56
Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash Flow from losing Control of Subsidiaries		
Cash Payment for acquiring Control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow / Outflow of Cash		
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	(29.39)	(110.91)
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (Used in) in Investing Activities	(29.39)	(110.91)
Cash Flows from Financial Activities		
Proceeds from Issue of Shares		
Proceeds from Issuing shares for security premium		
Proceeds from Issue of Debenture / Bonds / Notes		
Redemption of Preference Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Borrowing		
Repayment of Borrowing	-	20.87
Dividend Paid		
Interest Paid	6.88	84.51
Income Tax Paid / Refund		
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	(6.88)	(105.38)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from (Used in) in Financial Activities	(6.88)	(105.38)
Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	141.54	(599.33)

Registered Office: Plot No. 43, H. No. 8-2-269/S/43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667


Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbio.com




Effect of Exchange Rate change on Cash and Cash Equivalents		
Net Increase (Decrease) in Cash and Cash Equivalents	141.54	(599.33)
Cash and Cash Equivalents at beginning of period	5.61	604.94
Cash and Cash Equivalents at end of period	147.15	5.61

Date: February 11, 2026
Place: Hyderabad

For Vilm Bio Med Limited



Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260



August 6, 2025

To
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block- G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Notice of 19th Annual General Meeting and Annual Report for the Financial Year 2024-2025

Dear Sir / Madam,

This is with reference to the provisions of Regulations 30, 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the 19th Annual General Meeting ('AGM') of the Company scheduled to be held on Saturday, August 30, 2025 at 3:00 P.M. IST through Video Conferencing / Other Audio Visual Means, in accordance, with the relevant Circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India from time to time.

1. Pursuant to the said Circulars, Notice of the 19th AGM and Annual Report including for the Financial Year 2024-2025 will be sent through electronic mode to all the Members of the Company whose email addresses are registered with the Company/Registrar and Share Transfer Agent/Depository Participant(s).
2. The Company has provided the facility to its Members to cast their vote by electronic means (through Remote E-Voting and E-Voting at the AGM) on all the Resolutions set out in the AGM Notice, who are holding Equity Shares as on the Cut-Off Date i.e., Saturday, August 23, 2025. The Remote E-Voting will commence on Wednesday, August 27, 2025 (9:00 A.M. IST) and ends on Friday, August 29, 2025 (5:00 P.M. IST). Detailed instructions for registering e-mail address(s) and E-Voting/ attendance at the AGM are given in the AGM Notice.
3. The AGM Notice and Annual Report for the Financial Year 2024-2025 are enclosed herewith.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260

Vilin Bio Med Limited
19th Annual Report
2024-2025

INDEX

SI No	Particulars	Page Nos.
I	Corporate Information	3
II	Notice of the 19th Annual General Meeting	4 – 21
III	Board's Report	22 – 30
IV	Annexures	31 – 39
V	Independent Auditor's Report	40 – 48
VI	Standalone Financial Statements	49 – 66

BOARD OF DIRECTORS

Mr. Madhusudhan Yadamakanti Reddy
Ms. Prasanna Lakshmi Venna
Mr. Viswa Prasad Sadhanala
Mr. Sasikanth Paritala
Mr. Veeraiah Chowdary Kolla
Mr. Girish Muktevi
Mr. Veerareddy Vallapureddy
Ms. Aruna Madishetti
Mr. Anuj Bajpai
Ms. Padmaja Kalyani Sadhanala

Managing Director (w.e.f. 03.10.2024)
Whole-Time Director (w.e.f. 10.01.2025)
Director (w.e.f. 10.01.2025)
Independent Director (w.e.f. 23.01.2025)
Independent Director (w.e.f. 23.01.2025)
Independent Director (w.e.f. 23.01.2025)
Independent Director (till 23.01.2025)
Independent Director (till 10.01.2025)
Whole-Time Director (till 10.01.2025)
Non-Executive Director (till 29.05.2024)

KEY MANAGERIAL PERSONNEL

Mr. Hari Prasad Avula
Mr. Chilam Srikanth
Mr. Dhruv Viswanath Todi
Mr. Anand Lohia

Chief Financial Officer (w.e.f. 10.01.2025)
Chief Financial Officer (till 10.01.2025)
Company Secretary (w.e.f. 10.01.2025)
Company Secretary (till 04.09.2024)

REGISTERED OFFICE:

H. No. 8-2-269/S/43, Plot No. 43
Sagar Co-operative Housing Society
Road No. 2, Banjara Hills
Khairatabad, Hyderabad
Telangana – 500034
E-mail: cs@vilinbiomed.co.in
Web: www.vilinbiomed.co.in
Tel No.: 040-7961 8843

MANUFACTURING UNIT:

Unit-II, Khasra No. 85,
Madhopur Village, Roorkee
Haridwar
Uttarakhand

STATUTORY AUDITORS

M/s PPKG & Co
Chartered Accountants

SECRETARIAL AUDITORS

M/s Kashinath Sahu & Co
Practicing Company Secretaries

REGISTRAR & SHARE TRANSFER AGENTS (RTA)

M/s Bigshare Services Private Limited
#306, 3rd Floor, Right Wing, Amrutha Ville
Somajiguda, Rajbhavan Road
Hyderabad – 500082, Telangana
E-mail: bsshyd@bigshareonline.com
Web: www.bigshareonline.com

LISTING

Listed on NSE SME Board
(EMERGE Platform)

BANKERS TO THE COMPANY

Punjab National Bank
ICICI Bank

NOTICE

Notice is hereby given that the Nineteenth Annual General Meeting of the Members of M/s Vilin Bio Med Limited ("the Company") will be held on Saturday, August 30, 2025 at 3:00 P.M. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact following business mentioned below:

Ordinary Business

- 1. To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended March 31, 2025 together with the Report of the Directors and Auditors thereon and in this regard, to give assent or dissent to the following Resolution as an Ordinary Resolution:**

"RESOLVED THAT the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2025 including the Audited Balance Sheet as at March 31, 2025 the Statement of Profit and Loss for the year ended on that date and the Reports of the Board of Directors and Auditors thereon, be and are hereby received, considered and adopted."

Special Business

- 2. Appointment of Mr. Sasikanth Paritala (DIN: 08407277) as an Independent Director of the Company**

To consider and, if thought fit, to pass with or without modification, the following Resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Section 149, 150 and 152, Schedule-IV and other applicable provisions, if any, of the Companies Act, 2013 (the "Act") and the Rules made thereunder and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) (including any statutory modification(s) or re-enactment thereof for the time being in force), the provisions of the Articles of Association of the Company and based on the recommendations of the Nomination and Remuneration Committee and the Board of Directors of the Company, approval of the Members be and is hereby accorded for appointment of Mr. Sasikanth Paritala (DIN: 08407277) who was appointed as an Additional Director in the capacity of Non-Executive Independent Director of the Company by the Board of Directors with effect from January 23, 2025, and who has submitted a declaration that he meets the criteria of independence under Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations and is eligible for appointment under the provisions of the Act, the Rules made thereunder and the Listing Regulations, and in respect of whom the Company has received a Notice in writing under Section 160(1) of the Act proposing his candidature for the office of a Director, as an Independent Director, not liable to retire by rotation, to hold office for a term of five consecutive years i.e., from January 23, 2025 up to January 22, 2030."

"RESOLVED FURTHER THAT the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution."

- 3. Appointment of Mr. Veeraiah Chowdary Kolla (DIN: 09741691) as an Independent Director of the Company**

To consider and, if thought fit, to pass with or without modification, the following Resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Section 149, 150 and 152, Schedule-IV and other applicable provisions, if any, of the Companies Act, 2013 (the "Act") and the Rules made thereunder and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) (including any statutory modification(s) or re-enactment thereof for the time being in force), the provisions of the Articles of Association of the Company and based on the recommendations of the Nomination and Remuneration Committee and the Board of Directors of the Company, approval of the Members be and is hereby accorded for appointment of Mr. Veeraiah Chowdary Kolla (DIN: 09741691) who was appointed as an Additional Director in the capacity of Non-Executive Independent Director of the Company by the Board of Directors with effect from January 23, 2025, and who has submitted a declaration that he meets the criteria of independence under Section

149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations and is eligible for appointment under the provisions of the Act, the Rules made thereunder and the Listing Regulations, and in respect of whom the Company has received a Notice in writing under Section 160(1) of the Act proposing his candidature for the office of a Director, as an Independent Director, not liable to retire by rotation, to hold office for a term of five consecutive years i.e., from January 23, 2025 up to January 22, 2030.”

“**RESOLVED FURTHER THAT** the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution.”

4. Appointment of Mr. Girish Muktevi (DIN: 10709464) as an Independent Director of the Company

To consider and, if thought fit, to pass with or without modification, the following Resolution as Special Resolution:

“**RESOLVED THAT** pursuant to the provisions of Section 149, 150 and 152, Schedule-IV and other applicable provisions, if any, of the Companies Act, 2013 (the “Act”) and the Rules made thereunder and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) (including any statutory modification(s) or re-enactment thereof for the time being in force), the provisions of the Articles of Association of the Company and based on the recommendations of the Nomination and Remuneration Committee and the Board of Directors of the Company, approval of the Members be and is hereby accorded for appointment of Mr. Girish Muktevi (DIN: 10709464) who was appointed as an Additional Director in the capacity of Non-Executive Independent Director of the Company by the Board of Directors with effect from January 23, 2025, and who has submitted a declaration that he meets the criteria of independence under Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations and is eligible for appointment under the provisions of the Act, the Rules made thereunder and the Listing Regulations, and in respect of whom the Company has received a Notice in writing under Section 160(1) of the Act proposing his candidature for the office of a Director, as an Independent Director, not liable to retire by rotation, to hold office for a term of five consecutive years i.e., from January 23, 2025 up to January 22, 2030.”

“**RESOLVED FURTHER THAT** the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution.”

5. Appointment of Mr. Madhusudhan Yadamakanti Reddy (DIN: 10862263) as Managing Director of the Company

To consider and, if thought fit, to pass with or without modification, the following Resolution as Special Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 198 and 203 read with Schedule-V and all other applicable provisions of the Companies Act, 2013 (Act) and relevant Rules framed thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) or any statutory modification(s) or reenactment(s) thereof, the Articles of Association of the Company and pursuant to the recommendation and approval respectively of the Nomination and Remuneration Committee and the Board of Directors of the Company, Consent of the Shareholders of the Company be and is hereby accorded to the appointment of Mr. Madhusudhan Yadamakanti Reddy (DIN: 10862263), as Managing Director of the Company for a term of five consecutive years, effective from October 3, 2024 on terms and conditions of appointment and remuneration as set out in the Explanatory Statement annexed hereto, which shall be deemed to form part hereof, with liberty to the Board to vary the terms and conditions of the said appointment including remuneration, as may be mutually agreed, from time to time, without being required to seek further approval of the Members of the Company or otherwise to the end intent that they shall be deemed to have given their approval thereto expressly by the authority of this Resolution.”

“**RESOLVED FURTHER THAT** the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution.”

6. Appointment of Ms. Prasanna Lakshmi Venna (DIN: 10862263) as Whole-Time Director of the Company

To consider and, if thought fit, to pass with or without modification, the following Resolution as Special Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203 read with Schedule-V and all other applicable provisions of the Companies Act, 2013 (Act) and relevant Rules framed thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) or any statutory modification(s) or reenactment(s) thereof, the Articles of Association of the Company and pursuant to the recommendation and approval respectively of the Nomination and Remuneration Committee and the Board of Directors of the Company, Consent of the Shareholders of the Company be and is hereby accorded to the appointment of Ms. Prasanna Lakshmi Venna (DIN: 10862263), as Whole-Time Director of the Company for a term of five consecutive years, effective from January 23, 2025 on terms and conditions of appointment and remuneration as set out in the Explanatory Statement annexed hereto, which shall be deemed to form part hereof, with liberty to the Board to vary the terms and conditions of the said appointment including remuneration, as may be mutually agreed, from time to time, without being required to seek further approval of the Members of the Company or otherwise to the end intent that they shall be deemed to have given their approval thereto expressly by the authority of this Resolution.”

“RESOLVED FURTHER THAT the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution.”

7. Appointment of Mr. Viswa Prasad Sadhanala (DIN: 08068933) as Director of the Company

To consider and, if thought fit, to pass with or without modification, the following Resolution as Special Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203 read with Schedule-V and all other applicable provisions of the Companies Act, 2013 (Act) and relevant Rules framed thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) or any statutory modification(s) or reenactment(s) thereof, the Articles of Association of the Company and pursuant to the recommendation and approval respectively of the Nomination and Remuneration Committee and the Board of Directors of the Company, Consent of the Shareholders of the Company be and is hereby accorded to the appointment of Mr. Viswa Prasad Sadhanala (DIN: 08068933), as Director of the Company, liable to retire by rotation, on terms and conditions of appointment and remuneration as set out in the Explanatory Statement annexed hereto, which shall be deemed to form part hereof, with liberty to the Board to vary the terms and conditions of the said appointment including remuneration, as may be mutually agreed, from time to time, without being required to seek further approval of the Members of the Company or otherwise to the end intent that they shall be deemed to have given their approval thereto expressly by the authority of this Resolution.”

“RESOLVED FURTHER THAT the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution.”

8. Appointment of M/s Kashinath Sahu & Co, Practicing Company Secretaries as the Secretarial Auditors of the Company

To consider, and if thought fit, to pass the following Resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 179 and 204, and any other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, (including any statutory modification(s) or re-enactment thereof) and in terms of Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, as amended from time to time, M/s Kashinath Sahu & Co, be and are hereby appointed as Secretarial Auditors of the Company for a term of five (5) consecutive years, commencing from Financial Year 2025-2026 till Financial Year 2029-2030, on such remuneration and on such terms and conditions as may be decided by the Board of Directors in consultation with

the Secretarial Auditors of the Company and to avail any other services, certificates, or reports as may be permissible under the applicable laws.”

“**RESOLVED FURTHER THAT** the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution.”

**By Order of the Board of Directors
For Vilin Bio Med Limited**

**Date: August 6, 2025
Place: Registered Office
8-2-269/S/43, Plot No. 43
Sagar Co-operative Housing Society
Road No. 2, Banjara Hills
Khairatabad, Hyderabad
Telangana – 500034**

**Sd/-
Dhruv V Todi
Company Secretary**

NOTES:

1. The details as required under Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') entered with the Stock Exchanges and Secretarial Standard on General Meeting (SS-2) in respect of the Directors seeking appointment / re-appointment at this Annual General Meeting is annexed.
2. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 is annexed.
3. Pursuant to the General Circular Nos. 14/2020, 20/2020, 10/2022 and 09/2023, the latest being 09/2024 dated September 19, 2024 read with other Circulars issued by the Ministry of Corporate Affairs (MCA) and in line with the Circulars issued by the Securities and Exchange Board of India (SEBI) from time to time, (hereinafter collectively referred to as "the Circulars"), the Company is convening the Annual General Meeting ('the Meeting' or 'AGM') through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') without the physical presence of the Members. The deemed venue for the AGM will be the Registered Office of the Company.

In line with the MCA and SEBI Circulars and the latest SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024, the Notice of the AGM along with the Annual Report 2024-2025 is being sent by electronic mode to those Members whose e-mail addresses are registered with the Company/Depository Participants. In compliance of Section 20 of the Companies Act, 2013 and further to the aforesaid MCA Circulars and SEBI Circulars, Notice of the 19th Annual General Meeting along with the Annual Report 2024-2025 is being sent only through electronic mode to the Members whose email addresses are registered with the Company/Depositories. Members may note that the Notice and the Annual Report 2024-2025 will also be available on the Company's Website: <http://www.vilinbiomed.co.in/> and Website of the Stock Exchange i.e., National Stock Exchange Limited: <https://www.nseindia.com>, and on the Website of CDSL: <https://www.evotingindia.com>

4. Green Initiative: To support the Green Initiative, Members who have not registered their e-mail address are requested to register their e-mail address to receive all communications including Annual Report, Notices, Circulars etc. from the Company electronically.
5. A Member entitled to attend and vote at the AGM is entitled to appoint a Proxy to attend and vote on his / her behalf and the Proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars and SEBI Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of Proxies by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
6. Members of the Company under the category of Institutional Investors are encouraged to attend and vote at the AGM through VC/OAVM. Corporate Members intending to authorize their Representatives to participate and vote at the AGM are requested to upload a copy of the Board Resolution/Authorisation Letter on the E-Voting Portal or send to the Company at cs@vilinbiomed.co.in.
7. Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the Quorum under Section 103 of the Act. As per Regulation 40 of the SEBI Listing Regulations, as amended, Securities of Listed Entities can be transferred only in Dematerialised form with effect from April 1 2019, except in case of transmission or transposition of Securities. In view of this, Members holding Shares in Physical Form are requested to consider converting their holdings to Dematerialised form. Members can contact M/s Bigshare Services Private Limited, Registrar and Share Transfer Agents of the Company, ("RTA" or "Registrar") situated at 306, Right Wing, 3rd Floor, Amrutha Ville, Somajiguda, Raj Bhavan Road, Hyderabad – 500082, E-mail: bsshyd@bigshareonline.com and website of the Registrar: www.bigshareonline.com for assistance in this regard.
8. Members are requested to intimate changes, if any, pertaining to their Name, Postal Address, E-mail Address, Telephone/Mobile Numbers, Permanent Account Number, Mandates, Nominations, Power of Attorney, Bank Details viz., Name of the Bank, Branch Details, Bank Account Number, MICR Code, IFSC Code etc., to their Depository Participants ("DPs") in case the Shares are held in Electronic Form and Registrar/RTA in case the Shares are held in Physical Form.
 - a. Registration of E-mail for Shareholders holding Physical Shares: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with the Registrar, by referring to their website: www.bigshareonline.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile

Number and E-mail and also upload the image of Share Certificate in PDF or JPEG format. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification. For Permanent Registration for Demat Shareholders: It is clarified that for permanent registration of E-mail address, Members are requested to register their E-mail address, in respect of Demat holdings with the respective Depository Participant (DP) by follow the procedure as prescribed by the Depository Participant.

- b. For Temporary Registration for Demat Shareholders: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with the Registrar, by referring to their website: www.bigshareonline.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail.
 - c. Registration of Bank Details for Physical Shareholders: Members holding Shares in Physical Form and who have not registered their Bank details can get the same registered with the Registrar, by clicking the www.bigshareonline.com and follow the registration process as guided therein. Members are requested to provide details such as Name, Folio Number, Share Certificate Number, PAN, E-mail, along with the copy of the Cheque Leaf with the First named Member as mentioned on the Cheque Leaf containing Bank Name and Branch, Type of Account, Bank Account Number, MICR Details and IFSC code in PDF or JPEG format. It is very important that the Member should submit the request letter duly signed. The Registrar will verify the documents upload and will only take on records for all valid cases. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification.
9. The Register of Members and Share Transfer Books of the Company will remain closed from August 23, 2025 to August 30, 2025 (both days inclusive).
 10. Nomination: Pursuant to Section 72 of the Companies Act, 2013, Members holding Shares in Physical Form are advised to file Nomination in the prescribed Form SH-13 with the Company's Share Transfer Agent. In respect of the Shares held in Dematerialised form, Members may please contact their respective Depository Participant.
 11. Consolidation of Physical Share Certificates: Members holding Shares in Physical Form, in identical order of Names, in more than One Folio are requested to send to the Company or Registrar, the details of such Folios together with the Share Certificates for consolidating their holdings in One Folio. A Consolidated Share Certificate will be issued to such Members after making requisite changes.
 12. In compliance with the provisions of Section 108 of the Act read with Rule 20 of Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI Listing Regulations, the Company has provided a facility to its Members to cast their vote electronically, through E-Voting Services provided by Central Depository Services (India) Limited ("CDSL") on all the Resolutions set forth in this Notice. Members who have cast their Votes by Remote E-Voting prior to the AGM may also participate in the AGM through VC but shall not be entitled to cast their Vote on such Resolutions again. The manner and process of E-Voting remotely by Members is provided in the instructions for E-Voting which forms part of this Notice.
 13. A Person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date for dispatch of Notice and Annual Report i.e. July 28, 2025 will only be entitled for receipt of Annual Report.
 14. The Voting Rights of the Shareholders for Voting through Remote E-Voting at the AGM shall be in proportion to their share of the Paid-up Equity Shares of the Company as on Saturday, August 23, 2025 (**Cut-off Date**). A Person whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date, only shall be entitled to avail the facility of Remote E-Voting or of Voting at the AGM and who is not a Member as on the Cut-off Date shall treat this Notice for information purposes only.
 15. The Remote E-Voting Period will commence on **Wednesday, August 27, 2025 (IST 9:00 A.M.) and will end on Friday, August 29, 2025 (IST 5:00 P.M.)**. During this period, Members of the Company holding Shares in Dematerialised form, as on the Cut-off Date i.e., on **Saturday, August 23, 2025 ('Cut-off Date')** shall be entitled to cast their vote by Remote E-Voting. Once the Vote on a Resolution is cast by the Member, the Member shall not be allowed to change it subsequently.

16. The facility for Voting during the AGM will also be made available. Members present in the AGM through VC and who have not cast their Vote on the Resolutions through Remote E-Voting and are otherwise not barred from doing so, shall be eligible to Vote through E-Voting system during the AGM.
17. Any person who becomes a Member of the Company after sending the Notice and holding Shares as on the Cut-Off Date **(August 23, 2025)** may obtain the login and password by sending a request at helpdesk.evoting@cdslindia.com. However, if a Member is already registered with CDSL for Remote E-Voting then he/she can use his/her existing User-id and Password for casting the Vote.
18. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through Remote E-Voting.
19. Members seeking any information with regard to the accounts or any matter to be placed at the AGM, are requested to write to the Company mentioning their Name, Demat Account Number/Folio Number, E-mail, Mobile Number at cs@vilinbiomed.co.in on or before **Monday, August 25, 2025**. The same will be replied by the Company suitably.
20. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through Remote E-Voting.
21. The Board of Directors has appointed Mr. Kashinath Sahu, Practicing Company Secretary, Hyderabad as the Scrutinizer to scrutinize the Remote E-Voting Process and Voting during the AGM, in a fair and transparent manner.
22. The Scrutinizer shall immediately, after the conclusion of E-Voting at the AGM, first count the Votes Cast during the AGM, thereafter, unblock the Votes Cast through Remote E-Voting and make, not later than 2 working dates of conclusion of the AGM, a consolidated Scrutinizer's Report of the Total Votes Cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same. The Results declared along with the Scrutinizer's Report shall be placed on the Website of the Company and on the Website of CDSL immediately. The results will also be communicated to NSE Limited, where the Shares of the Company are listed.
23. To prevent fraudulent transactions, Members are advised to exercise Due Diligence and notify the Company of any change in address or Demise of any Member as soon as possible. Members are also advised not to leave their Demat account(s) dormant for long. Periodic Statement of Holdings should be obtained from the concerned DPs and Holdings should be verified from time to time.
24. **Instructions for attending the AGM through VC / OAVM:**
 - a. Shareholder will be provided with a facility to attend the AGM through VC/OAVM through the CDSL E-Voting system. Shareholders may access the same at <https://www.evotingindia.com> under Shareholders / Members login by using the Remote E-Voting credentials. The link for VC/OAVM will be available in Shareholder / Members login where the EVSN of the Company is displayed.
 - b. Members may join the Meeting through Laptops, Smartphones, Tablets and I-Pads for better experience. Further, Members will be required to use the Internet with a good speed to avoid any disturbance during the Meeting. Please note that participants connecting from Mobile Devices or Tablets or through Laptops connecting via mobile hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any glitches.
 - c. Shareholders who would like to express their views / ask questions during the Meeting may register themselves as a speaker by sending their request in advance before **Monday, August 25, 2025 (5:00 P.M.)** from their registered E-mail address mentioning their names, DP-ID and ClientID / Folio Number, PAN and Mobile Number at cs@vilinbiomed.co.in. Only those Members who have pre-registered themselves as a speaker will be allowed to express their views / ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.
 - d. Members are encouraged to submit their questions in advance with regard to the Financial Statements or any other matter to be placed at the 19th Annual General Meeting, from their registered E-mail address, mentioning their Name, DP-ID and Client-ID Number / Folio Number and Mobile Number, to reach the Company's E-mail address at cs@vilinbiomed.co.in before Monday, August 25, 2025 (5:00 P.M.). Such questions by the Members shall be suitably replied by the Company.
 - e. Those Shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the Meeting. If any votes are cast by the Shareholders through the E-Voting

available during the AGM and if the same Shareholders have not participated in the Meeting through VC / OAVM facility, then the votes cast by such Shareholders shall be considered as invalid, as the facility of E-Voting during the Meeting is available only to the Shareholders attending the Meeting.

25. Subject to the receipt of Requisite number of Votes, the Resolutions forming part of the AGM Notice shall be deemed to be passed on the date of the AGM. Voting through Electronic Means: Pursuant to Section 108 of the Companies Act, 2013 and Rule 20 read with the Companies (Management and Administration) Rules, 2014 read with amendments or re-enactments made thereunder and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is pleased to provide the facility to exercise Members' Right to Vote at the 19th Annual General Meeting (AGM) by electronic means and the business may be transacted through E-Voting Services provided by Central Depository Services (India) Limited (CDSL). The Members attending the Meeting, who have not already cast their vote through Remote E-Voting shall be able to exercise their Voting Rights at the Meeting. The Members who have already cast their vote through Remote E-Voting may attend the Meeting but shall not be entitled to cast their vote again at the AGM.
26. The instructions for Shareholders for Voting Electronically are as under:
- (i) **The Remote E-Voting Period commences on Wednesday, August 27, 2025 (9:00 A.M.) and closes on Friday, August 29, 2025 (5:00 P.M.)** During this period, the Shareholders of the Company, holding Shares in Dematerialized Form, as on the Cut-off Date (Record Date), Saturday, August 23, 2025 may cast their vote electronically. The E-Voting Module shall be disabled by CDSL for Voting thereafter.
 - (ii) Shareholders who have already voted prior to the Meeting Date would not be entitled to Vote at the Meeting.

Login method for E-Voting and Joining Virtual Meetings for Individual Shareholders holding Securities in Demat Mode:

Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/ CIR/P/2020/242 dated 9th December, 2020 on "E-Voting Facility provided by Listed Companies", Individual Shareholders holding Securities in Demat mode are allowed to cast their vote through their Demat Account maintained with the Depositories and Depository Participants. Shareholders are advised to update their Mobile Number and E-mail in their Demat Accounts in order to access the E-Voting Facility. Pursuant to the above said SEBI Circular, Login method for E-Voting and joining Virtual Meetings for Individual Shareholders holding Securities in Demat mode CDSL/NSDL is given below:

Type of Shareholders	Login Method
Individual Shareholders holding Securities in Demat Mode with CDSL Depository	<ol style="list-style-type: none"> 1. Users who have opted for CDSL EASI/EASIEST facility, can login through their existing User-id and Password. Option will be made available to reach the E-Voting page without any further authentication. The URL for login to EASI/EASIEST is https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System MYEASI. 2. After successful login to the EASI/EASIEST User will be able to see the E-Voting option for eligible Companies where the E-Voting is in progress as per the information provided by Company. On clicking the E-Voting option, the User will be able to see E-Voting page of the E-Voting Service Provider for casting your Vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting. Additionally, there are also links provided to access the system of all E-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME so that the User can visit the E-Voting Service Providers website directly. 3. If the user is not registered for EASI/ EASIEST, option to register is available at CDSL website www.cdslindia.com To login click on login & New System MYEASI Tab and then click on registration option. 4. Alternatively, the User can directly access E-Voting Page by providing Demat Account Number and PAN on E-Voting link available on www.cdslindia.com homepage. The system will authenticate the User by sending OTP on the Registered Mobile and E-mail as recorded in the Demat Account. After successful authentication, the User will be able to see the E-Voting option where the E-Voting is in progress and also able to directly access the system of all the E-Voting Service Providers.
Individual Shareholders holding Securities in Demat Mode with NSDL Depository	<ol style="list-style-type: none"> 1. If you are already registered for NSDL 'IDeAS' facility, please visit the E-services website of NSDL. Open web browser by typing the following URL: https://eservices.nsd.com either on a Personal Computer or on a Mobile. Once the Homepage of E-services is launched Click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' Section. A new screen will open. You will have to enter your User-id and Password. After successful authentication, you will be able to see E-Voting Services. Click on "Access to E-Voting" under E-Voting Services and you will be able to see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be re-directed to E-Voting Service Provider website for casting your vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.

	<ol style="list-style-type: none"> 2. If the User is not registered for IDeAS E-services, option to register is available at https://eservices.nsdl.com/ Select "Register Online for IDeAS" Portal or Click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the E-Voting website of NSDL. Open web browser by typing the following URL: https://www.eVoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the homepage of E-Voting system is launched, click on the icon "Login" which is available under 'Shareholder / Member' Section. A new screen will open. You will have to enter your User-id (i.e. your sixteen-digit Demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository Site wherein you can see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your Vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.
Individual Shareholders holding Securities in Demat Mode Login through their Depository Participants (DP)	You can also login using the login credentials of your Demat account through your Depository Participant registered with NSDL / CDSL for E-Voting facility. After successful login, you will be able to see E-Voting option. Once you click on E-Voting option, you will be redirected to the NSDL / CDSL Depository site after successful authentication, wherein you can see E-Voting feature. Click on Company Name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your vote during the remote E- Voting period or joining Virtual Meeting and Voting during the Meeting

Important note: Members who are unable to retrieve User-id/ Password are advised to use Forgot User-id and Forgot Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding Securities in Demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding the Securities in Demat Mode with CDSL	Members facing any technical issue in login can contact the CDSL Helpdesk by sending request at the following e-mail: helpdesk.evoting@cdslindia.com or Contact at Toll Free No. 1800 22 5533
Individual Shareholders holding the Securities in Demat Mode with NSDL	Members facing any technical issue in login can contact the NSDL Helpdesk by sending a request at evoting@nsdl.co.in or Call at Toll Free No. 1800 10 20990 and 1800 22 4430

Access through CDSL E-Voting system in case of Shareholders holding Shares in Physical Mode and Non-Individual Shareholders in Demat Mode

- i. The Shareholders should log on to the E-Voting Website: www.evotingindia.com
- ii. Click on "SHAREHOLDERS" Module.
- iii. Now enter your User-id
 - i. For CDSL: 16 Digits Beneficiary ID
 - ii. For NSDL: 8 Character DP-ID followed by 8 Digits Client-ID
 - iii. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- iv. Next enter the 'Image Verification' as displayed and Click on Login.
- v. If you are holding Shares in Demat form and had logged on to www.evotingindia.com and had voted on an earlier E-Voting of any Company, then your existing password is to be used.
- vi. If you are a first-time user follow the steps given below:

For Physical Shareholders and other than Individual Shareholders holding Shares in Demat Form

PAN	Enter your 10-digit alpha–numeric PAN issued by Income Tax Department (Applicable for both Demat Shareholders as well as Physical Shareholders) Shareholders who have not updated their PAN with the Company/ Depository Participant are requested to use the sequence number sent by Company /RTA or contact Company/RTA
Dividend Bank Details or Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your Demat Account or in the Company Records in order to login. If both the details are not recorded with the Depository or Company, please enter the Member-id /Folio Number in the 'Dividend Bank Details' field.

- vii. After entering these details appropriately, click on 'SUBMIT' tab.
- viii. Shareholders holding Shares in Physical Form will then directly reach the Company selection screen. However, Shareholders holding Shares in Demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the 'New Password' field. Kindly note that this password is to be also used by the Demat Holders for Voting for Resolutions of any other Company on which they are eligible to vote, provided that the Company opts for E-Voting through CDSL Platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- ix. For Shareholders holding shares in Physical Form, the details can be used only for E-Voting on the Resolutions contained in this Notice.
- x. Click on the EVSN of the relevant Company (**Vilin Bio Med Limited**) on which you choose to vote.
- xi. On the Voting Page, you will see 'RESOLUTION DESCRIPTION' and against the same the option 'YES/NO' for Voting. Select the option 'YES' or 'NO' as desired. The option 'YES' implies that you assent to the Resolution and option 'NO' implies that you dissent to the Resolution.
- xii. Click on the 'RESOLUTIONS FILE LINK' if you wish to view the entire Resolution details.
- xiii. After selecting the Resolution, you have decided to vote on, click on 'SUBMIT'. A Confirmation Box will be displayed. If you wish to confirm your vote, click on 'OK', else to change your vote, click on 'CANCEL' and accordingly modify your vote.
- xiv. Once you 'CONFIRM' your vote on the Resolution, you will not be allowed to modify your Vote.
- xv. You can also take a print of the votes cast by clicking on 'Click here to Print' option on the Voting Page.
- xvi. If a Demat Account Holder has forgotten the login password, then enter the User-id and the 'Image Verification Code' and click on Forgot Password and enter the details as prompted by the system.

xvii. Additional Facility for Non – Individual Shareholders and Custodians – For Remote Voting:

- Non – Individual Shareholders (i.e. Other than Individuals, HUF, NRI etc.) and Custodians are required to log on to the website: www.evotingindia.com and register themselves in the 'CORPORATES' Module.
- A Scanned copy of the Registration Form bearing the Stamp and Sign of the Entity should be mailed to helpdesk.evoting@cdslindia.com
- After receiving the login details, a Compliance User should be created using the Admin login and Password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The List of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- It is mandatory that a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, should be uploaded in PDF format in the system for the Scrutinizer to verify the same.
- Alternatively Non–Individual Shareholders are required to send the relevant Board Resolution/Authority Letter etc. together with the Attested Specimen Signature of the Duly Authorized Signatory who are authorized to vote, to the Scrutinizer and to the Company at the E-mail address: cs@vilinearbiomed.co.in if they have voted from individual tab and not uploaded same in the CDSL E-Voting System for the Scrutinizer to verify the same.

If you have any queries or issues regarding E-Voting from the CDSL E-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022–23058738 and 022–23058542/43

All grievances connected with the facility for Voting by electronic means may be addressed to Shri Rakesh Dalvi, Senior Manager, Central Depository Services (India) Limited (CDSL), Wing–A, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai, Maharashtra – 400013 or send an e-mail to helpdesk.evoting@cdslindia.com or call on 022–23058542/43

**By Order of the Board of Directors
For Vilin Bio Med Limited**

**Date: August 6, 2025
Place: Registered Office
8-2-269/S/43, Plot No. 43
Sagar Co-operative Housing Society
Road No. 2, Banjara Hills
Khairatabad, Hyderabad
Telangana – 500034**

**Sd/-
Dhruv V Todi
Company Secretary**

EXPLANATORY STATEMENT

The following Explanatory Statement pursuant to Section 102(1) of the Companies Act 2013, sets out all material facts relating to items of Special Business mentioned in the accompanying AGM Notice.

Item No. 2

Mr. Sasikanth Paritala (DIN: 08407277) was appointed as an Additional Director with effect from January 23, 2025 by the Board of Directors on the recommendation of the Nomination and Remuneration Committee and in accordance with the provisions of the Section 161 of the Companies Act, 2013. The Company has received Notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Sasikanth Paritala (DIN: 08407277) as an Independent Director of the Company. Mr. Sasikanth Paritala is a Graduate in Engineering and Technology from JNTUH University having more than eight years' experience in the field of Engineering, it would be beneficial to the Company to have him on the Board of Directors of the Company.

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint him as Independent Director for the first term of 5 (five) years pursuant to the provisions of Sections 149, 150, 152 read with Schedule-IV and other applicable provisions of the Companies Act, 2013 (the Act) on the Company Board and the Company will be benefited out of his expertise and can contribute the strategic guidance in the Financial matters of the Company.

None of the Directors of the Company is in any way concerned or interested in the said Resolution except the appointee himself is concerned in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 2 of the Notice of the AGM.

Disclosure under Secretarial Standard-2, issued by the Institute of Company Secretaries of India is detailed in the Annexure – A to the Notice.

Item No. 3

Mr. Veeraiah Chowdary Kolla (DIN: 09741691) was appointed as an Additional Director with effect from January 23, 2025 by the Board of Directors on the recommendation of the Nomination and Remuneration Committee and in accordance with the provisions of the Section 161 of the Companies Act, 2013. The Company has received Notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Veeraiah Chowdary Kolla (DIN: 09741691) as an Independent Director of the Company. Mr. Veeraiah Chowdary Kolla is a Graduate in Engineering and Technology from Kakatiya University having more than twenty-five years' experience in the field of Engineering, it would be beneficial to the Company to have him on the Board of Directors of the Company.

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint him as Independent Director for the first term of 5 (five) years pursuant to the provisions of Sections 149, 150, 152 read with Schedule-IV and other applicable provisions of the Companies Act, 2013 (the Act) on the Company Board and the Company will be benefited out of his expertise and can contribute the strategic guidance in the Financial matters of the Company.

None of the Directors of the Company is in any way concerned or interested in the said Resolution except the appointee himself is concerned in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 3 of the Notice of the AGM.

Disclosure under Secretarial Standard-2, issued by the Institute of Company Secretaries of India is detailed in the Annexure – A to the Notice.

Item No. 4

Mr. Girish Muktevi (DIN: 10709464) was appointed as an Additional Director with effect from January 23, 2025 by the Board of Directors on the recommendation of the Nomination and Remuneration Committee and in accordance with the provisions of the Section 161 of the Companies Act, 2013. The Company has received Notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Girish Muktevi (DIN: 10704964) as an Independent Director of the Company. Mr. Girish Muktevi is a Graduate in Finance and Marketing from Acharya

Nagarjuna University having experience with more than seven years in the field of Finance and Marketing, it would be beneficial to the Company to have him on the Board of Directors of the Company.

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint him as Independent Director for the first term of 5 (five) years pursuant to the provisions of Sections 149, 150, 152 read with Schedule-IV and other applicable provisions of the Companies Act, 2013 (the Act) on the Company Board and the Company will be benefited out of his expertise and can contribute the strategic guidance in the Financial matters of the Company.

None of the Directors of the Company is in any way concerned or interested in the said Resolution except the appointee himself is concerned in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 4 of the Notice of the AGM.

Disclosure under Secretarial Standard-2, issued by the Institute of Company Secretaries of India is detailed in the Annexure – A to the Notice.

Item No. 5

Mr. Madhusudhan Yadamakanti Reddy (DIN: 02874260) was appointed as an Additional Director with effect from October 3, 2024 and was subsequently appointed as Managing Director by the Board of Directors on recommendation of the Nomination and Remuneration Committee. The Company has received Notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Madhusudhan Yadamakanti Reddy (DIN: 02874260) as Managing Director of the Company. Mr. Madhusudhan Yadamakanti Reddy (DIN: 02874260) is an MBA Graduate from the Indian Institute of Management and a Technocrat having more than twenty-three years' experience in Pharma Industry, it would be beneficial to the Company to have him on the Board of Directors of the Company.

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint him as Managing Director for the first term of 5 (five) years pursuant to the provisions of Sections 196, 197, 198, 203 read with Schedule-V and other applicable provisions of the Companies Act, 2013 (the Act) on the Company Board and the Company will be benefited out of his expertise and can contribute the strategic guidance in growth of the Company. The Board of Directors on the basis of Nomination and Remuneration Committee has also approved the remuneration of Mr. Madhusudhan Yadamakanti Reddy at monthly remuneration of Rs.1,00,000/- (Rupees One Lakh Only) for the aforesaid period.

None of the Directors of the Company is in any way concerned or interested in the said Resolution except the appointee himself is concerned in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 5 of the Notice of the AGM.

Disclosure under Secretarial Standard-2, issued by the Institute of Company Secretaries of India is detailed in the Annexure – A to the Notice.

Item No. 6

Ms. Prasanna Lakshmi Venna (DIN: 10862263) was appointed as an Additional Director with effect from January 10, 2025 and was appointed as Whole-Time Director by the Board of Directors on recommendation of the Nomination and Remuneration Committee in the Board Meeting held on July 4, 2025. The Company has received Notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Ms. Prasanna Lakshmi Venna (DIN: 10862263) as Whole-Time Director of the Company. She is an MBA Graduate and having five years of experience in the field of Strategic Planning, Finance and Business Development, it would be beneficial to the Company to have her on the Board of Directors of the Company.

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint her as Whole-Time Director for the first term of 5 (five) years pursuant to the provisions of Sections 196, 197, 198, 203 read with Schedule-V and other applicable provisions of the Companies Act, 2013 (the Act) on the Company Board and the Company will be benefited out of her expertise and can contribute the strategic guidance in growth of the Company. The Board of Directors on the basis of Nomination and Remuneration Committee has also approved the remuneration of Ms. Prasanna Lakshmi Venna at monthly remuneration of Rs.50,000/- (Rupees Fifty Thousand Only) for the aforesaid period.

None of the Directors of the Company is in any way concerned or interested in the said Resolution except the appointee himself is concerned in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 6 of the Notice of the AGM.

Disclosure under Secretarial Standard-2, issued by the Institute of Company Secretaries of India is detailed in the Annexure – A to the Notice.

Item No. 7

Mr. Viswa Prasad Sadhanala (DIN: 08068933) was appointed as an Additional Director with effect from January 10, 2025 and was appointed as Whole-Time Director by the Board of Directors on recommendation of the Nomination and Remuneration Committee in the Board Meeting held on July 4, 2025. The Company has received Notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Mr. Viswa Prasad Sadhanala (DIN: 08068933) as Whole-Time Director of the Company. He is a Commerce and Law Graduate twenty years of experience in General Administration and Legal Matters; it would be beneficial to the Company to have her on the Board of Directors of the Company.

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint him as Whole-Time Director, liable to retire by rotation, pursuant to the provisions of Sections 196, 197, 198, 203 read with Schedule-V and other applicable provisions of the Companies Act, 2013 (the Act) on the Company Board and the Company will be benefited out of his expertise and can contribute the strategic guidance in growth of the Company. The Board of Directors on the basis of Nomination and Remuneration Committee has also approved the remuneration of Mr. Viswa Prasad Sadhanala at monthly remuneration of Rs.50,000/- (Rupees Fifty Thousand Only) for the aforesaid period.

None of the Directors of the Company is in any way concerned or interested in the said Resolution except the appointee himself is concerned in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 7 of the Notice of the AGM.

Disclosure under Secretarial Standard-2, issued by the Institute of Company Secretaries of India is detailed in the Annexure – A to the Notice.

Item No. 8

In accordance with the provisions of Section 204 and other applicable provisions of the Companies Act, 2013, read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) (“the Act”), every Listed Company and certain other prescribed categories of companies are required to annex a Secretarial Audit Report, issued by a Practicing Company Secretary, to their Board’s Report, prepared under Section 134(3) of the Act. Furthermore, pursuant to recent amendments to Regulation 24A of the SEBI Listing Regulations, every Listed Entity is required to conduct a Secretarial Audit and annex the Secretarial Audit Report to its Annual Report. Additionally, a Listed Entity must appoint a Secretarial Audit firm for a maximum of two terms of five consecutive years, with Shareholders approval to be obtained at the Annual General Meeting. Accordingly, based on the recommendation of the Audit Committee, the Board of Directors has approved the appointment of M/s Kashinath Sahu & Co, Practicing Company Secretaries, as the Secretarial Auditors of the Company for a period of five years, commencing from April 1, 2025, to March 31, 2030. The appointment is subject to Shareholders’ approval at the Annual General Meeting.

M/s Kashinath Sahu & Co is a Peer Reviewed Firm and a well-established firm of Practicing Company Secretaries, registered with the Institute of Company Secretaries of India. The Firm delivers comprehensive Consulting and Advisory Services in Corporate Law. Their expertise encompasses a wide spectrum, including Corporate Secretarial Services, Secretarial Audit, SEBI Compliances, Initial Public Offerings, FEMA, Mergers and Amalgamations. The terms and conditions of appointment include a tenure of five years, from April 1, 2025, to March 31, 2030. The fixed remuneration for the Secretarial Audit for the year 2025-26 is set at Rs.1,50,000/- (Rupees One Lakh Fifty Thousand only), plus applicable taxes and other out-of-pocket costs incurred in connection with the audit. They have provided consent to act as the Secretarial Auditors of the Company and has confirmed that the proposed appointment, if made, will be in compliance with the provisions of the Act and the SEBI Listing Regulations.

None of the Directors of the Company is in any way concerned or interested in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 8 of the Notice of the AGM.

ANNEXURE – A

Details of Director seeking appointment at the 19th Annual General Meeting to be held on August 30, 2025 pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 for General Meetings (SS-2) are as mentioned below:

Name	Madhusudan Yadamakanti Reddy	Prasanna Lakshmi Venna	Viswa Prasad Sadhanala	Sasikanth Paritala	Veeraiah Chowdary Kolla	Girish Muktevi
DIN	02874260	10862263	08068933	08407277	09741691	10709464
Date of Birth	14.02.1978	11.12.1998	26.08.1965	11.08.1993	08.05.1973	23.02.1992
Date of First Appointment	03.10.2024	10.01.2025	10.01.2025	23.01.2025	23.01.2025	23.01.2025
Designation	Managing Director	Whole-Time Director	Whole-Time Director	Non-Executive Director	Non-Executive Director	Non-Executive Director
Qualification	MBA	MBA	B.Com; LLB	B.E.	B.E.	MBA
Brief Resume, Nature of Expertise and skill set in specific functional areas	He is a MBA (IIM) and is a Techno-Commercial professional and has twenty-three years' experience in the Pharma Industry	She is a MBA Graduate having five years of experience in the field of Strategic Planning, Finance and Business Development	He is a Graduate in Commerce and Law having twenty years of experience in General Administration and Legal Matters	He is a Graduate in Engineering Having experience of more than eight years in Engineering.	He is a Graduate in Engineering and has experience of more than twenty-five years in Engineering	He is a Graduate and has experience of more than seven years in Finance and Marketing
Shareholding in the Company	Nil	Nil	18,48,140 (13%)	Nil	Nil	Nil
Relationship with other Directors / KMP's	Not related to any Director / KMP	Not related to any Director / KMP	Not related to any Director / KMP	Not related to any Director / KMP	Not related to any Director / KMP	Not related to any Director / KMP
Number of Meetings of the Board attended during the year	5	1	1	NA	NA	NA
Directorships holding in other Companies / LLP *	Nil	Nil	Nil	Nil	Nil	Nil
Directorships holding in Listed Companies *	Nil	Nil	Nil	Nil	Nil	Nil
Membership/Chairmanship of Committees of other Companies #	Nil	Nil	Nil	Nil	Nil	Nil
Remuneration (including Sitting Fees, if any) last drawn	Nil	Nil	Nil	Nil	Nil	Nil
Terms and conditions of Appointment	To be appointed as Managing Director of the Company for five years	To be appointed as Whole-Time Director of the Company for five years	To be appointed as Whole-Time Director of the Company, liable to retire by rotation	To be appointed as Independent Director of the Company for first term of five years	To be appointed as Independent Director of the Company for first term of five years	To be appointed as Independent Director of the Company for first term of five years

*Note: *excludes Directorships held in Private Limited Companies which are not Subsidiaries or Holding Companies of Public Limited Companies, Unlimited Companies, Foreign Companies and Companies formed under Section 8 of the Companies Act, 2013.*

includes Chairmanship / Membership of the Audit Committee and Stakeholders Relationship Committee of only Public Limited Companies, whether Listed or not.

**By Order of the Board of Directors
For Vilin Bio Med Limited**

**Date: August 6, 2025
Place: Hyderabad**

**Sd/-
Dhruv V Todi
Company Secretary**

ANNEXURE – B**Statement containing Additional Information as required under Schedule-V to the Companies Act, 2013
(as amended)**

SI No	Particulars			
I	General Information			
1	Nature of Industry: Vilin Bio Med Limited (the Company) is engaged in Manufacturing and Trading of Pharmaceutical Products.			
2	Date or Expected Date of Commercial Production: 2006			
3	In case of new companies, Expected Date of Commencement of Activities as per Project approved by the Financial Institutions appearing in the Prospectus: Not Applicable			
4	Financial Performance based on given indicators			
	(Rs. in Lakhs)			
	Particulars	2024-2025	2023-2024	2022-2023
	Revenue from Operations	1,527.84	1,612.92	1,233.74
	Profit / (Loss) Before Tax	30.58	22.52	178.17
	Tax Expenses	8.23	6.28	53.67
	Net Profit / (Loss)	22.35	16.24	124.50
	Earnings Per Share	0.16	0.12	1.25
5	Foreign Investments or Collaborations, if any: Not Applicable			

SI No	Particulars			
II	Information about the Appointees			
	Particulars	Madhusudan Yadamakanti Reddy	Prasanna Lakshmi Venna	Viswa Prasad Sadhanala
	Background Details	Please refer to Annexure – A above		
	Past Remuneration			
	Recognition or Awards	Please refer to the Explanatory Statement above		
	Job Profile			
	Remuneration Proposed			
	Comparative Remuneration Profile with respect to Industry, Size of the Company, Profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin): The proposed remuneration of Mr. Madhusudhan Yadamakanti Reddy, Managing Director; Ms. Prasanna Lakshmi Venna, Whole-Time Director and Mr. Viswa Prasad Sadhanala, Whole-Time Director, is comparable to that drawn in the similar capacity in the Industry and is commensurate with the size of the Company and nature of its businesses. The proposed remuneration of Mr. Madhusudhan Yadamakanti Reddy, Managing Director; Ms. Prasanna Lakshmi Venna, Whole-Time Director and Mr. Viswa Prasad Sadhanala, Whole-Time Director is determined by the Board, based on the recommendations of the Nomination and Remuneration Committee which peruses Industry Benchmarks in general, remuneration prevalent in the Industry, profile and responsibilities of the aforesaid Managing/Whole-Time Directors and other relevant factors			
	Pecuniary Relationship directly or indirectly relationship with the Directors and Managerial Personnel, of the Company: The said Directors do not have any pecuniary relationship with the Directors / Managerial Personnels and inter-se among themselves. Their Relatives, to the extent of their Shareholding, if any, in the Company, may deemed to be interested in the proposed Resolutions.			

III	Other Information	
1	Reason of loss or Inadequate Profits	Not Applicable, as the Company has posted Net Profit of Rs.22.35 Lakhs for the Financial Year 2024-25
2	Steps taken or proposed to be taken for improvement	Not Applicable
3	Expected increase in productivity and profits in measurable term	The Company is seeking approval in terms of Part II of Schedule-V as a matter of abundant caution so that the Remuneration, as per the details provided in the Explanatory Statement, can be paid to the Managing Director and the Whole-Time Directors as Minimum Remuneration.
IV	Disclosures	
	Please refer to the Explanatory Statement above, given pursuant to the provisions of Section 102 of the Companies Act, 2013 for the details of proposed Remuneration	

**By Order of the Board of Directors
For Vilin Bio Med Limited**

**Date: August 6, 2025
Place: Hyderabad**

**Sd/-
Dhruv V Todi
Company Secretary**

DIRECTORS' REPORT

Dear Members,

The Directors have pleasure in presenting the 19th Annual Report of the Company, together with the Audited Accounts for the Financial Year ended March 31, 2025.

Financial Highlights

Particulars	(Rs. in Lakhs)	
	2024-2025	2023-2024
Sales	1,480.99	1,580.49
Other Income	46.85	32.43
Total Income	1,527.84	1,612.92
Total Expenses	1,497.26	1,590.40
Profit / (Loss) Before Tax	30.58	22.52
Current Tax	6.95	5.11
Deferred Tax	1.28	1.16
Profit / (Loss) After Tax	22.35	16.24

State of Company Affairs

The Company's Revenues stood at Rs.1,480.99 Lakhs as compared to the previous year Rs.1,580.49 Lakhs. During the year under review, Profit After Tax (PAT) stood at Rs.22.35 Lakhs, as compared to the previous year of Rs.16.24 Lakhs. Your Directors are exploring more business opportunities and growth and profitability of the Company in the years ahead.

Dividend

The Board of Directors has not recommended any Dividend on the Equity Shares of the Company for the Financial Year ended March 31, 2025.

Transfer to Reserves

The Board of Directors has not proposed to transfer any amount to the General Reserve.

Changes in Share Capital

During the year under review, there was no change in the Share Capital of the Company. The Authorised Share Capital of the Company is Rs.15,00,00,000 (divided into 1,50,00,000 Equity Shares of Rs. 10/- each) and the Paid-up Share Capital is Rs.13,95,00,000/- (divided into 1,39,50,000 Equity Shares of Rs.10/- each). The Company got listed on the NSE SME Board on June 30, 2023.

Material Changes and Commitments affecting the Financial Position of the Company which have occurred between March 31, 2025 and August 6, 2025 (Date of the Report)

During the period under review, the Company has regularised the accounts in respect of the Cash Credit Facility and Term Loan availed.

Nature of Business

The Company is into the manufacturing of Pharmaceuticals Products and there has been no change in the nature of Business of the Company during the year.

Public Deposits

During the year under review, the Company has not accepted any deposit pursuant to the provisions of Sections 73 and 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

Annual Return

A copy of the Annual Return for the Financial Year 2024-2025 pursuant to the Sub-Section (3) of Section 92 of the Companies Act, 2013 read with Rule 11(1) of the Companies (Management and Administration) Rules, 2014 and forming part of this Report is placed on the website of the Company as per provisions of Section 134(3)(a) and is available at the following link: <http://www.vilinbiomed.co.in/>

Director's Responsibility Statement

In terms of Section 134 (5) of the Companies Act, 2013, the Directors would like to state that:

- i) In the preparation of the Annual Accounts, the applicable Accounting Standards have been followed.
- ii) The Directors have selected such Accounting Policies and applied them consistently and made judgements and estimates that were prudent so as to give a true and fair view of the State of Affairs of the Company at the end of the Financial Year and of the Profit or Loss of the Company for the Year under review.
- iii) The Directors have taken proper and sufficient care for the maintenance of adequate Accounting Records in accordance with the provisions of this Act for safeguarding the Assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) The Directors have prepared the Annual Accounts on a Going Concern basis.
- v) The Directors had laid down Internal Financial Controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively.
- vi) The Directors had devised proper system to ensure compliance with the provisions of all the applicable laws and that such system was adequate and operating effectively.

Directors and Key Managerial Personnel

- a. **Composition of Board of Directors of the Company:** As on March 31, 2025 the Board constituted of the following Directors:

SI No	Name of Director	DIN	Designation
1	Mr. Y Madhusudhan Reddy	02874260	Managing Director
2	Ms. Prasanna Lakshmi Venna	10862263	Whole-Time Director
3	Mr. Viswa Prasad Sadhanala	08068933	Director
4	Mr. Sasikanth Paritala	08407277	Independent Director
5	Mr. Girish Muktevi	10709464	Independent Director
6	Mr. K Veeraiah Chowdary	09741691	Independent Director

- b. **Changes in the KMP:**

SI No	Name of Director / KMP	Nature of Change	Date of Change
1	Mr. Hari Prasad Avula – Chief Financial Officer	Appointment	10/01/2025
2	Mr. Chilam Srikanth – Chief Financial Officer	Resignation	10/01/2025
3	Mr. Dhruv Viswanath Todi – Company Secretary	Appointment	10/01/2025
4	Mr. Anand Lohia – Company Secretary	Resignation	04/09/2024

c. Number of Meetings of the Board and Director's Attendance

During the year ended March 31, 2025, Nine (9) Board Meetings were held in accordance with the provisions of the Companies Act, 2013 and in compliance with the Secretarial Standards of the Institute of Company Secretaries of India.

SI No	Date of the Meeting	Number of Directors entitled to attend the Meeting	Number of Directors who attended the Meeting
1	May 4, 2024	5	5
2	May 29, 2024	5	5
3	August 22, 2024	4	4
4	October 3, 2024	5	5
5	October 30, 2024	5	5
6	September 4, 2024	5	5
7	December 26, 2024	5	5
8	January 10, 2025	5	5
9	January 23, 2025	6	6

The following General Meetings were held during the year under review:

SI No	Date of the Meeting	Meeting
1	September 23, 2024	18th Annual General Meeting held through VC/OAVM

Formal Annual Evaluation

As per Section 149 of the Companies Act, 2013 the Independent Directors of the Company had a Meeting, without the attendance of Non-Independent Directors. In the Meeting, the following issues were taken up:

- Review of the performance of the Board as a whole;
- Review of the performance of the Chairperson of the Company, taking into account the views of Executive Directors and Non – Executive Directors;
- Assessing the Quality, Quantity and timelines of flow of information between the Company's Management and the Board, that is necessary for the Board to perform their duties effectively and reasonably.

The Meeting also reviewed and evaluated the performance of Non – Independent Directors.

The Meeting also reviewed and evaluated the performance the Board as whole in terms of the following aspects:

- Preparedness for Board and Committee Meetings
- Attendance at the Board and Committee Meetings
- Guidance on Corporate Strategy, Risk Policy and Corporate Performance
- Ensuring a transparent Board Nomination process with the diversity of experience, knowledge, and perspective in the Board.
- Ensuring the integrity of the Company's Accounting and Financial Reporting Systems, including the Independent Audit, and that appropriate systems of control are in place, in particular, systems for Financial and Operational Control and Compliance with the law and relevant Standards.

Declaration from Independent Directors on Annual Basis

The Company has received declarations from Mr. Sasikanth Paritala, Mr. Girish Muktevi and Mr. K Veeraiah Chowdary, Independent Directors of the Company, to the effect that they are meeting the criteria of Independence, as provided in Sub-Section (6) of Section 149 of the Companies Act, 2013 and of Sub-Rule (1) and Sub-Rule (2) of Rule 6 of Companies (Appointment and Qualifications of Directors) Rules, 2014. In the opinion of the Board, the Independent Directors possess the requisite integrity, expertise and experience (including the proficiency) of the Independent Directors.

Statutory Auditors

M/s PPKG & Co, Chartered Accountants (FRN: 009655S) have been appointed as the Statutory Auditors of the Company for a term of five consecutive years till the conclusion of 22nd Annual General Meeting. The said Auditors have carried out the Statutory Audit for the Financial Year 2024-2025. The Auditors Report for the Financial Year 2024-2025 does not contain any qualifications, reservations or adverse remarks.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

Pursuant to provisions of Section 134 of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 the details of Conservation of Energy, Technology Absorption is attached herewith as "Annexure – A."

Foreign Exchange Earnings and Outgo: During the period under review, there was no Foreign Exchange Earnings or Outflow.

Secretarial Audit

Pursuant to provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the Company had appointed Mr. Kashinath Sahu, Company Secretary in Whole-time Practice to undertake the Secretarial Audit of the Company. The Secretarial Audit Report is annexed herewith as "Annexure – B."

During the year under review, there were no qualifications, reservations or adverse remarks reported by Secretarial Auditor under Section 204 of the Companies Act, 2013 in the course of the performance of his duties as Secretarial Auditor.

Management Discussion and Analysis

Pursuant to Regulation 34(2)(e) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Report on Management Discussion and Analysis, is herewith annexed as "Annexure – C."

Internal Control Systems and their Adequacy

The Company has an in-house Internal Control System, commensurate with the size, scale and complexity of its operations. The Scope and Authority of the Internal Audit Function is defined in the Internal Audit Manual. To maintain its objectivity and independence, the Internal Audit Function reports to the Chairman of the Audit Committee of the Board and to the Chairman and Management.

The Internal Audit Department monitors and evaluates the efficacy and adequacy of Internal Control System in the Company, its compliance with Operating Systems, Accounting Procedures and Policies at all levels of the Company.

Based on the report of Internal Audit Function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant Audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

Audit Committee

The Audit Committee was constituted in accordance with the provisions of the Companies Act, 2013 and Regulation 18 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the following as Members of the Committee.

The Audit Committee comprises:

Name of Director	Status in Committee	Nature of Directorship
Mr. Girish Muktevi	Chairman	Non-Executive Independent Director
Mr. K. Veeraiah Chowdary	Member	Non-Executive Independent Director
Mr. Y Madhusudhan Reddy	Member	Managing Director

The Company Secretary of the Company acts as the Secretary of the Audit Committee.

The terms of reference of our Audit Committee, in accordance with Section 177 of the Companies Act, 2013 and Regulation 18 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Audit Committee Meetings and Attendance

During the year ended March 31, 2025, four Audit Committee Meetings were held. The maximum time gap between any of the two meetings was not more than four months.

Date of the Meeting	Committee Strength	Number of Directors Present
May 4, 2024	3	3
August 22, 2024	3	3
October 30, 2024	3	3
January 10, 2025	3	3

Nomination and Remuneration Committee

The Nomination and Remuneration Committee was constituted in accordance with the provisions of the Companies Act, 2013 and Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Nomination and Remuneration Committee include the following:

Name of Director	Status in Committee	Nature of Directorship
Mr. K. Veeraiah Chowdary	Chairman	Non-Executive Independent Director
Mr. Sasikanth Paritala	Member	Non-Executive Independent Director
Mr. Girish Muktevi	Member	Non-Executive Independent Director

The scope, functions and the terms of reference of the Nomination and Remuneration Committee is in accordance with the Section 178 of the Companies Act, 2013 read with Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nomination and Remuneration Committee Meetings and Attendance

The Nomination and Remuneration Committee has met six times during the year under review.

Date of the Meeting	Committee Strength	Number of Directors Present
May 4, 2024	3	3
August 22, 2024	3	3
October 3, 2024	3	3
December 26, 2024	3	3
January 10, 2025	3	3
January 23, 2025	3	3

Stakeholders Relationship Committee

The Stakeholders Relationship Committee was constituted in accordance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations. The Stakeholders Relationship Committee include the following:

Name of Director	Status in Committee	Nature of Directorship
Mr. K. Veeraiah Chowdary	Chairman	Non-Executive Independent Director
Mr. Sasikanth Paritala	Member	Non-Executive Independent Director
Mr. Y Madhusudhan Reddy	Member	Managing Director

The Company Secretary of the Company acts as the Secretary of the Stakeholders Relationship Committee.

Stakeholders Relationship Committee Meetings and Attendance

The Stakeholders Relationship Committee has met once during the year under review.

Date of the Meeting	Committee Strength	Number of Directors Present
August 22, 2024	3	3

Risk Management Committee

Regulation 21 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to forming of Risk Management Committee is not applicable to the Company during the Financial Year under review.

Corporate Governance and Shareholders Information

Pursuant to Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the provisions of filing Corporate Governance Report with the Stock Exchange is not applicable, as the Equity Shares of the Company are listed on the SME Platform of the National Stock Exchange.

Particulars of Loans, Guarantees or Investments under Section 186 of the Companies Act, 2013

The Company has not given any Loans nor provided Guarantee nor made any Investments during the Financial Year 2024-2025, which is beyond the limits as per Section 186 of the Companies Act, 2013.

Contracts or Arrangements with Related Parties under Section 188 (1) of the Companies Act, 2013

All the Contracts / Arrangements / Transactions entered by the Company, during the year under review, with Related Parties were in the ordinary course of business and at Arm's Length Basis. The particulars of such contracts or arrangements with Related Parties, pursuant to the provisions of Section 134(3)(h) and Rule 8 of the Companies (Accounts) Rules, 2014, in the prescribed Form AOC-2 is enclosed as "Annexure – D" to this Report.

All the Related Party Transactions were placed before the Audit Committee and also before the Board for their respective approval. Omnibus approval of the Audit Committee is obtained as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the transactions which can be foreseen and are repetitive in nature. The Company has developed a Policy on Related Party Transactions including the latest amendments thereof for the purpose of identification and monitoring of such transactions.

Policy on Preservation of the Documents

The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 ("Regulations") on Preservation of the Documents of the following type:

- (a) documents whose preservation shall be permanent in nature;
- (b) documents with preservation period of not less than eight years after completion of the relevant transactions

Vigil Mechanism

The Vigil Mechanism/Whistle Blower Policy has been adopted to provide appropriate Avenues to the employees to bring to the attention of the management, the concerns about any unethical behaviour by using the mechanism provided in the Policy. In cases related to financial irregularities, including fraud or suspected fraud, the employees may directly approach the Chairman of the Audit Committee of the Company. No Director or employee has been denied access to the Audit Committee. The web link for the policy is as follows: <http://www.vilinbiomed.co.in/>

Policy on criteria for determining Materiality of Events

The Company has adopted a Policy in accordance with the requirements of the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations). The Policy is authorising the Key Managerial Personnels of the Company for the purpose of determining materiality of an event or information of the Company and to ensure that such information is adequately disseminated in pursuance with the Regulations and to provide an overall Governance Framework for such determination of Materiality.

Policy on Directors' Appointment, Remuneration and Other Details

The Company's Remuneration Policy is directed towards the rewarding of performance based on review of achievements periodically. The Remuneration Policy is in consonance with the existing Industry practice. The Company's Shareholders may refer the Company's website for the Remuneration Policy of the Company on the appointment and remuneration of Directors including criteria for determining qualifications, positive attributes, independence of a Director; and other matters provided under Sub-Section (3) of Section 178.

Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concerns Status and Company's Operations in future

The Company has not received any Significant or Material Orders passed by any Regulatory Authority, Court or Tribunal which shall impact the going concern status and Company's operations in future.

Details of Subsidiary Companies, Associates and Joint Venture Companies

The Company does not have any Subsidiary, Associate or Joint Ventures during the period under review.

Industrial Relations

Employee relations during the period under review continued to be healthy, cordial and harmonious at all levels and your Company is committed to maintain good relations with the employees. It has taken various steps to improve productivity across the organization.

Business Risk Management

Business Risk Evaluation and Management is an ongoing process within the Organisation. The Company has a robust Risk Management Framework to identify, monitor and minimize risks as also identify business opportunities. At present, the Company has not identified any element of risk which may threaten the existence of the Company.

Transfer of Amounts to Investor Education and Protection Fund

Your Company does not have any Unpaid or Unclaimed amounts lying for a period of seven years. Therefore, there were no Funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

Particulars of Employees

In terms of Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company does not have any Employee who is employed throughout the Financial Year and in receipt of Remuneration of Rs.120 Lakhs or more, or Employees who are employed for part of the year and in receipt of Rs.8.50 Lakhs or more per month.

Corporate Social Responsibility

The Provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility are not applicable to our Company

Maintenance of Cost Records

The Provisions relating to maintenance of Cost Records under Section 148 of Companies Act, 2013 are not applicable to the Company.

Insider Trading Regulations

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992, as amended from time to time, the Code of Conduct for Prevention of Insider Trading and the Code for Corporate Disclosures ("Code"), as approved by the Board from time to time, are in force by the Company. The objective of this Code is to protect the interest of

Shareholders at large, to prevent misuse of any Unpublished Price Sensitive Information (UPSI) and to prevent any Insider Trading activity by dealing in Securities of the Company by its Directors, Designated Persons and Employees. The Company adopts Trading Window Closure, to prevent its Directors, Officers, Designated Persons and Employees from trading in the Securities of Vilin Bio Med Limited at the time, when there is Unpublished Price Sensitive Information.

Obligation of Company under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

In order to prevent Sexual Harassment of Women at Workplace as per the "Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013" has been notified. Under the said Act, every Company is required to set up Internal Complaints Committee (ICC) to look into complaints relating to sexual harassment at workplace of any women employee. As required under law, the Committee has been constituted for reporting and conducting inquiry into the complaints made by the victim on the harassments at the workplace. During the year under review, no complaint of harassment at the workplace was received by the Committee.

Acknowledgement

Your Directors take this opportunity to place on record the valuable co-operation and continuous support extended by its valued Business Associates, Auditors, Supplier, Customers, Banks, Government Authorities and the Shareholders for their continuously reposed confidence in the Company and look forward to having the same support in all its future endeavors.

Your Directors also wish to place on record their sincere appreciation for significant contribution made by the Employees at all the levels through their dedication, hard work and commitment, thereby enabling the Company to boost its performance during the year under report.

Date: August 6, 2025

Place: Hyderabad

By Order of the Board of Directors

**Sd/-
Y Madhusudhan Reddy
Managing Director
(DIN: 02874260)**

**Sd/-
Prasanna Lakshmi Venna
Whole-Time Director
(DIN: 10862263)**

A. Conservation of Energy, Power and Fuel Consumption

Particulars	Current Year (2024-2025)	Previous Year (2022-2023)
1. Electricity (Purchased) Units		
Total Amount (Rs.)	10,56,000	12,04,000
Rate Per Unit (Rs.)	5.69	5.58
2. Electricity (Generated) Units		
Total Amount (Rs.)	--	--
Rate Per Unit (Rs.)	--	--
3. Total Units Consumed	1,85,589	2,15,770

a) Company ensures that the Manufacturing Operations are conducted in the manner whereby optimum utilization and maximum possible savings of energy is achieved.

b) No specific investment has been made in reduction in energy consumption.

c) As the impact of measures taken for conservation and optimum utilization of energy are not quantitative, its impact on cost cannot be stated accurately.

B. Technology Absorption

The Company's products are manufactured by using In-house Know-how and no outside technology is being used for manufacturing activities. Therefore, no technology absorption is required. The Company constantly strives for maintenance and improvement in quality of its products and entire activities are directed to achieve the aforesaid goal.

C. Foreign Exchange Earnings and Outgo

Particulars	Current Year	Previous Year
Earnings	-	-
Outgo	-	-

Date: August 6, 2025

Place: Hyderabad

For Vilin Bio Med Limited

Sd/-
Y Madhusudhan Reddy
Managing Director
(DIN: 02874260)

Sd/-
Prasanna Lakshmi Venna
Whole-Time Director
(DIN: 10862263)

FORM MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025

(Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014)

To

The Members

Vilin Bio Med Limited

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Vilin Bio Med Limited** having CIN: **L24230TG2005PLC046689** and having Registered Office at # 8-2-269/S/43, Plot No. 43, Second Floor, Sagar Co-operative Housing Society, Road No. 2, Banjara Hills, Khairatabad, Hyderabad – 500034, Telangana (hereinafter called “the Company”). The Secretarial Audit was conducted in accordance with the guidance note issued by the Institute of Company Secretaries of India and in a manner that provided us a reasonable basis for evaluating the statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Minute Books, Forms and Returns filed and other records maintained by the Company and also the information, confirmations, clarifications provided by its Officers and Authorised Representatives during the conduct of Secretarial Audit, we hereby report that in our opinion, the Company has, during the audit period covering the Financial Year ended on March 31, 2025 complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the Books, Minute Books, Forms and Returns filed and other records maintained by the Company for the Financial Year ended on March 31, 2025, according to the provisions of:

- I. The Companies Act, 2013 (the Act) and the Rules made there under;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
- III. The Depositories Act, 1996 and the Regulations and Byelaws framed there under;
- IV. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings **(Not applicable to the Company during the period of Audit)**
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"):
 - (a) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and Securities Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers (Amendment) Regulations, 2013;
 - (b) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **(Not applicable to the Company during the period of Audit)**
 - (d) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **(Not applicable to the Company during the period of Audit)**
 - (e) Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; **(Not applicable to the Company during the period of Audit)**

- (f) Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **(Not applicable to the Company during the period of Audit)**
- (g) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **(Not applicable to the Company during the period of Audit);**
- (h) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; **(Not applicable to the Company during the period of Audit)**
- (i) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **(Not applicable to the Company during the period of Audit)** and
- (j) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018; **(Not applicable to the Company during the period of Audit)**

VI. Other Laws specifically applicable to the Company as per the representations made by the Management include:

- a) Drugs and Cosmetics Act, 1940;
- b) Narcotic Drugs and Psychotropic Substances Act, 1985;
- c) Pharmacy Act, 1948;
- d) Hazardous Waste Management Rules, 2016;
- e) National Pharmaceutical Policy, 2012
- f) The Factories Act, 1948;
- g) Environment Protection Act, 1996;
- h) Employees State Insurance Act, 1948;
- i) Employees Provident Fund and Miscellaneous Provisions Act, 1952;
- j) The Industrial Disputes Act, 1947;
- k) The Payment of Wages Act, 1936;
- l) The Minimum Wages Act, 1948;
- m) The Payment of Bonus Act, 1965;
- n) The Payment of Gratuity Act, 1972.
- o) The Maternity Benefit Act, 1961.

We have relied on the representations made by the Company, its officers for systems and mechanism framed by the Company for compliances under other Acts, Laws and Regulations applicable to the Company as mentioned above.

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by the Institute of Company Secretaries of India and notified under the Companies Act, 2013;
- (ii) Listing Agreements entered by the Company with the Stock Exchange(s);

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Key Managerial Persons. The changes in the composition of the Board of Directors and Committees that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, Agenda and detailed notes on Agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the Meeting.

Majority decisions are carried through while the dissenting Member's views, if any, are captured and recorded as part of the Minutes.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable Laws, Rules, Regulations and Guidelines. We further report that the compliance by the Company of the applicable Financial Laws like Direct and Indirect Tax Laws and maintenance of Financial Records and Books of Accounts has not been reviewed in this Audit since the same have been subject to review by the Statutory Auditors and other designated professionals.

**For Kashinath Sahu & Co
Practicing Company Secretaries**

**Date: August 2, 2025
Place: Hyderabad**

**Sd/-
CS Kashinath Sahu
FCS: 4790, CP: 4807
UDIN: F004790G000916789
Peer Review No.: 2957/2023**

This Report is to be read with our letter of even date, which is annexed as **Annexure** and forms an integral part of this Report.

Annexure to the Secretarial Audit Report

**To
The Members
Vilin Bio Med Limited**

Our Report of even date is to be read along with this letter:

- Maintenance of Secretarial Records is the responsibility of the Management of M/s Vilin Bio Med Limited ("the Company"). Our responsibility is to express an opinion on these Secretarial Records based on our Audit.
- We have followed the Audit Practices and Processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records. The verification was done on to ensure that correct facts are reflected in the Secretarial Records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.
- We have not verified the correctness and appropriateness of Financial Records and Books of Accounts of the Company.
- Wherever required, we have obtained the Management representation about the compliance of Laws, Rules and Regulations and happening of events etc.
- The compliance of the provisions of Corporate and other applicable Laws, Rules, Regulations, Standards is the responsibility of the Management. Our examination was limited to the verification of procedures on test basis.
- The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Practicing Company Secretaries**

**Date: August 2, 2025
Place: Hyderabad**

**Sd/-
CS Kashinath Sahu
FCS: 4790, CP: 4807
UDIN: F004790G000916789
Peer Review No.: 2957/2023**

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis present the Industry overview, opportunities and threats, the Company's initiatives and overall strategy of becoming a market-driven service provider with various offerings. The Company is optimistic about capturing a substantial share of the global and domestic market amid the threats faced due to the liberalisation and increased competition from well-established companies from India and abroad.

Global Economic Outlook

The Global Pharmaceutical Industry witnessed a transformative phase in past year, driven by Scientific breakthroughs, Demographic Shifts, Evolving Patient-needs and Rapid Digitalisation. Amidst evolving Global Health demands and Economic pressures, the Industry strengthened its foundation for long-term growth while adapting to structural changes across regions and therapeutic segments. In 2024, Global Medicine spending continued its upward trajectory, reflecting a growing demand for chronic care, specialty treatments and innovative therapies. Total Pharmaceutical spending remains on course to exceed US\$ 2.3 Trillion by 2028, supported by a projected CAGR of 5–8%. While volume growth plateaued in 2023, it is expected to grow at an average rate of 2.3% through 2028, driven by emerging markets such as China, India, Southeast Asia and Latin America. These regions are poised to drive the next phase of global demand, in contrast to mature markets such as North America, Western Europe and Japan, where per capita consumption levels are already high and future growth is expected to moderate. Digital transformation has advanced across the pharmaceutical value chain in last few years. Companies are adopting data-driven tools to optimise clinical trials, enhance patient targeting and strengthen supply chains. AI-enabled drug discovery, real-world evidence platforms and integrated digital health solutions are redefining how pharmaceutical organisations engage with patients and deliver care outcomes. Operational agility has also improved, supported by advancements in modular manufacturing and predictive analytics.

Despite lower manufacturer net sales due to confidential rebates and pricing pressures, last few years have seen robust spending across key regions, driven by the launch of new brands and the expansion of innovative treatment options. Developed economies, while mature in terms of volume, have continued to invest in high-value therapeutics, contributing to a more diverse and innovation-led portfolio mix. Global disparities in per capita consumption have persisted through last few years. High-income countries like Japan and Western Europe have recorded usage levels more than twice that of lower-income regions. While consumption is gradually rising in Africa and the Middle East, challenges in infrastructure, affordability and access continue to limit growth. These persistent gaps underscore the critical need for inclusive access strategies.

As cost pressures mount, particularly in developed economies, payers are recalibrating reimbursement models to ensure value-based outcomes. Efforts to moderate spending include greater emphasis on generics and biosimilars, performance-linked pricing mechanisms and cost-sharing arrangements with patients. Striking the balance between affordability and innovation remains a core priority for healthcare systems worldwide.

Indian Economy

India's Pharmaceutical Market is projected to see strong growth, with medicine spending expected to reach US\$ 38-42 Billion by 2028, with a CAGR of 7–10% from 2024 to 2028. This growth is driven by a combination of expanding access, growing demand for treatments across both acute and chronic conditions, and continued reliance on affordable generic medicines. In 2023, acute therapies such as anti-infectives and vitamins/minerals recorded notable volume increases, indicating a recovery in demand patterns. At the same time, chronic therapy areas like cardiac and respiratory treatments have sustained robust performance, supported by the rising burden of non-communicable diseases and improved diagnosis rates. India's cost-sensitive market continues to favour high-volume, lower-cost products, with generics dominating the therapeutic landscape. However, ongoing investments in domestic manufacturing, greater healthcare outreach, and increasing Insurance coverage are expected to further support growth across therapy areas. The growth is driven by several factors, including the increasing prevalence of chronic diseases, the rising demand for generic and biosimilar drugs and advancements in drug manufacturing technologies. Additionally, the expansion of healthcare infrastructure in developing economies and the adoption of advanced technologies like Artificial Intelligence (AI) and Machine Learning (ML) in development and manufacturing are contributing to the market's expansion.

The following are the Growth Drivers of the Indian Pharmaceutical Market.

- A. Government Support and Incentives various Government Schemes and Incentives, such as the Production Linked Incentive (PLI) Scheme, bolster the Pharmaceutical Industry, encouraging Investment and Growth.
- B. Expertise in Low-Cost Manufacturing: India's proficiency in Cost-effective end-to-end manufacturing processes enables competitive pricing of Pharmaceutical Products.
- C. Improving Affordability: Rising Per Capita Incomes contribute to the improved affordability of Healthcare and Pharmaceuticals, making them more accessible to a broader segment of the population

We sell our products in bulk to Pharmaceuticals Manufacturers, Marketers and Traders, who in turn provide the channel for sales to customers. Our products are primarily used by other Pharmaceutical Companies and Traders, who ultimately will market it to the Distributors and Retail Customers. We do not sell our products under any brand name.

Opportunities, Threats and Outlook

Vilin Bio Med Limited will be able to place itself in strong position by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization. The Company is looking at different opportunities in untapped markets and across a value chain. It plans for alliances with business associates in the Indian market, giving a huge boost to the selective products that it already deals in. We are fully conscious of our responsibility toward our customers. Our efforts are directed toward the fulfillment of customer satisfaction through the quality of products. As the consolidation of this industry gains momentum, the need to develop a dedicated team of skilled manpower assumes urgency and importance.

Health, Safety, Security and Environment is always looked at with its due seriousness along with our business activities and all employees are adequately trained for taking up their individual job accountability. Vilin's operations are well resourced, and they comply with the stringent and new norms of Health, Safety, Security and Environment.

Safety Audits are carried out regularly by government approved consultants for the regular operations. Environmental Audits and hazard-studies were also carried out and the Statutory Reports of our compliances are submitted to regulators periodically for their review and inputs. Efforts are made at all levels to conserve energy and resources.

The Company maintains a system of well-established Policies and Procedures for Internal Control of Operations and Activities. The Company has strong and adequate Internal Control System suitable to its size and nature of business.

FORM NO. AOC-2

(Pursuant to Clause (h) of Sub-Section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of Contracts/Arrangements entered into by the Company with Related Parties referred to in Sub-Section (1) of Section 188 of the Companies Act, 2013 including certain Arm's Length Transactions under third proviso thereto.

1. Details of Contracts or Arrangements or transactions not at Arm's Length Basis:

Sl No	Name(s) of the Related Party and nature of relationship	Nature of Contracts/ Arrangements/ Transactions	Duration of the Contracts/ Arrangements/ Transactions	Salient terms of the Contracts or Arrangements or Transactions including the Value, if any	Justification for entering into such Contracts or Arrangements or Transactions	Date(s) of approval by the Board	Amount paid as advances, if any	Date on which the Special Resolution was passed in General Meeting as required under first proviso to Section 188
There were no Contracts or Arrangements or Transactions entered into during the year ended March 31, 2025 which were not at Arm's Length Basis.								

2. Details of Material Contracts or Arrangement or Transactions at Arm's Length Basis:

Sl No	Name of the Related Party and nature of relationship	Nature of Contracts/ Arrangements/ Transactions	Duration of Contracts/ Arrangements/ Transactions	Salient terms of the Contracts or Arrangements or Transactions including the Value; if any;	Date of approval by the Board/ Shareholders, if any	Amount incurred in (Rs. in Lakhs)
1	Redizen Lifesciences Private Limited	Trade Receivables	Regular	In the ordinary course of business	May 17, 2025	220.88
2	Spectrogen Pharmachem Limited	Advance to Customers	Regular	In the ordinary course of business	May 17, 2025	249.43
3	Blue Nile Capital Advisory Limited	Inter Corporate Loan	Regular	As per the Agreement	May 17, 2025	504.43

Date: August 6, 2025

Place: Hyderabad

For Vilin Bio Med Limited

Sd/-

**Y Madhusudhan Reddy
Managing Director
(DIN: 02874260)**

Sd/-

**Prasanna Lakshmi Venna
Whole-Time Director
(DIN: 10862263)**

CERTIFICATE OF COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE

To
The Members
Vilin Bio Med Limited

We have examined compliance of conditions of Corporate Governance by Vilin Bio Med Limited (“the Company”), for the year ended on March 31, 2025, as stipulated in Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) for the period April 1, 2024 to March 31, 2025.

The compliance of conditions of Corporate Governance is the responsibility of Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the Financial Statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us by the Directors, Officers and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the abovementioned Listing Regulations.

We further state that, such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For Kashinath Sahu & Co
Practicing Company Secretaries

Date: August 2, 2025
Place: Hyderabad

Sd/-
CS Kashinath Sahu
FCS: 4790, CP: 4807
UDIN: F004790G000916965
Peer Review No.: 2957/2023

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule-V Para-C Clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To
The Members
Vilin Bio Med Limited

We have examined the relevant Registers, Records, Forms, Returns and Disclosures received from the Directors of Vilin Bio Med Limited (CIN: L24230TG2005PLC046689), having its Registered Office at # 8-2-269/S/43, Plot No. 43, Second Floor, Sagar Co-operative Housing Society, Road No. 2, Banjara Hills, Khairatabad, Hyderabad – 500034, Telangana (hereinafter called “the Company”), for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule-V, Para-C, Sub Clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in as considered necessary and explanations furnished to us by the Company and its Officers. We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on March 31, 2025 have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

SI No	Name of Director	DIN	Designation
1	Mr. Sasikanth Paritala	08407277	Non-Executive Independent Director
2	Mr. Veeraiah Chowdary Kolla	09741691	Non-Executive Independent Director
3	Mr. Girish Muktevi	10709464	Non-Executive Independent Director
4	Mr. Viswa Prasad Sadhanala	08068933	Director
5	Ms. Prasanna Lakshmi Venna	10862263	Whole-Time Director
6	Mr. Madhusudhan Y Reddy	02874260	Managing Director

Ensuring the eligibility for the appointment/continuity of every Director on the Board is the responsibility of the Management of the Company. Our responsibility is only to express an opinion, as per our verification. This Certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Practicing Company Secretaries**

Date: August 2, 2025

Place: Hyderabad

**Sd/-
CS Kashinath Sahu
FCS: 4790, CP: 4807
UDIN: F004790G000917031
Peer Review No.: 2957/2023**

INDEPENDENT AUDITORS' REPORT

To
The Members of
Vilin Bio Med Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the Financial Statements of **Vilin Bio Med Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2025, and the Statement of Profit and Loss, and Statement of Cash Flows for the period ended on that date, and notes to the Financial Statements, including a summary of Significant Accounting Policies and Explanatory Information [hereinafter referred to as "the Financial Statements"].

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the Accounting Principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, its Profits, (*changes in equity*) and its Cash Flows for the period ended on that date.

Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* Section of our Report. We are independent of the Company, in accordance with the *Code of Ethics* issued by Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the Audit Evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the Other Information. The Other Information comprises the information included in the Director's Report, but does not include the Financial Statements and our Auditor's Report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Key Audit Matters

Key Audit Matters are those matter that, in our professional judgement, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our Audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these Financial Statements that give a true and fair view of the financial position and financial performance, (*changes in equity*) and Cash Flows of the Company in accordance with the Accounting Principles generally accepted in India, including the accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the Assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate Accounting Policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate Internal Financial Controls, that were operating effectively for ensuring the accuracy and completeness of the Accounting Records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as 'going concern', disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's Financial Reporting Process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain Audit Evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of Internal Controls.
- b. Obtain an understanding of Internal Controls relevant to the Audit in order to design Audit Procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Company has adequate Internal Financial Controls system in place and the operating effectiveness of such controls
- c. Evaluate the appropriateness of Accounting Policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- d. Conclude on the appropriateness of Management's use of the going concern basis of accounting and, based on the Audit Evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as 'going concern'. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the Audit Evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in

- (i) Planning the scope of our audit work and in evaluating the results of our work; and
- (ii) to evaluate the effect of any identified misstatements in the Financial Statements

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our Auditor's Report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-Section (11) of Section 143 of the Companies Act, 2013, we give in the Annexure A statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our Audit.
 - b. In our opinion, proper Books of Accounts as required by law, have been kept by the Company, so far, as it appears from our examination of those Books.
 - c. The Balance Sheet, Statement of Profit and Loss, (Statement of Changes in Equity) and Cash Flow statements dealt with by this Report are in agreement with the Books of Account.
 - d. In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e. On the basis of the written representations received from the Directors as on March 31, 2025 taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2025 from being appointed as a Director in terms of Section 164(2) of the Act.
 - f. According to information and explanations given to us together with our Audit Examination, reporting with respect to the adequacy of the Internal Financial Controls over Financial Reporting of the Company and the operating effectiveness of such controls we give in Annexure – B to the extent applicable.
 - g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv.
 - i. The Management has represented that, to the best of its knowledge and belief, other than as disclosed in the Notes to the Accounts, no funds have been advanced or loaned or invested (either from Borrowed Funds or Share Premium or any other sources or kind of funds) by the Company to or in any other person(s) or Entity(ies), including Foreign Entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - ii. The Management has represented, that, to the best of its knowledge and belief, other than as disclosed in the Notes to the Accounts, no funds have been received by the Company from any person(s) or Entity(ies), including Foreign Entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - iii. Based on such Audit Procedures that the Auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material misstatement.
 - v. No Dividend has been declared or paid during the year by the Company, hence provisions of Section 123 of the Companies Act, 2013, are not applicable.

- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its Books of Accounts for the Financial Year ended March 31, 2025 which has a feature of recording Audit Trail (Edit Log) facility and the same has operated throughout the year, for all relevant transactions recorded in the software's. Further, during the course of our Audit, we did not come across any instance of the Audit Trail feature being tampered with.

**For PPKG & Co
Chartered Accountants
Firm Registration No.: 0009655S**

**Date: May 17, 2025
Place: Hyderabad**

**Sd/-
Girdhari Lal Toshniwal
(Partner)
M. No. 205140
UDIN: 25205140BMOPC13781**

Annexure – A to the Independent Auditor’s Report of Even Date to the Members of M/s Vilin Bio Med Limited, on the Financial Statements for the Year ended March 31, 2025

Based on the Audit Procedures performed for the purpose of reporting a true and fair view on the Financial Statements of the Company and taking into consideration the information and explanations given to us and the Books of Accounts and other records examined by us in the normal course of Audit, and to the best of our knowledge and belief, we report that:

- 1)
 - a. The Company has maintained proper records showing full particulars, including quantitative details and situation of Fixed Assets,
 - b. The Company has a regular program of physical verification of its Fixed Assets under which Fixed Assets are verified in a phased manner over a period for which we have received the certificate of confirmation from the Management.
 - c. The Title Deeds of all the Immovable Properties (which are included under the head (‘Property, Plant and Equipment’) are held in the name of the Company.
 - d. The Company has not revalued any of its Property, Plant and Equipment’s during the year.
 - e. As per the information given to us there are no proceedings initiated or pending against the Company for holding any Benami Property under the Benami Transactions (Prohibition) Act, 1988 and Rules made there under.
- 2)
 - a. In our opinion and according to the information and explanation given to us, the Management has conducted physical verification of Inventory at reasonable intervals during the year, and no material discrepancies were noticed on the aforesaid verification, for which we have received the certificate of confirmation from the Management.
 - b. The Company has availed Financial Assistance from Bank or Financial Institutions.
- 3) The Company has not granted any Loans, secured or unsecured, to any Companies, Firms, Limited Liability Partnerships or other parties.
- 4) In our opinion, the Company has complied with the provisions of Section 186 in respect of the Investments and Loans. Further, in our opinion, the Company has not entered into any transaction covered under Section 185 and Section 186 of the Act in respect of Guarantees and Security.
- 5) In our opinion, the Company has not accepted any Deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- 6) As informed to us that the provisions of Section 148 are not applicable to the Company.
- 7)
 - (a) In our opinion, the Company has been regular in depositing undisputed statutory dues, including Goods and Services Tax, Income Tax, Sales Tax, Duty of Custom, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service Tax, Income Tax, Sales Tax, duty of Custom, duty of Excise, Cess and other material statutory dues in arrears as at March 31, 2025 for a period of more than six months from the date they become payable. However as per the information provided by the management, Provident Fund and Employees’ State Insurance is not applicable to the Company for the current year.
 - (b) There is no Dues outstanding in respect of Income Tax, Sales Tax, Service Tax, Duty of Customs on account of disputes, whereas the Company has intimations and Outstanding demands under Income Tax Act,1961.
 - (c) According to the information and explanations given to us, the dues in respect of Sales Tax, Income Tax, Custom Duties, Wealth Tax, Excise Duty and Cess that have been deposited with the appropriate authorities except in cases where there is a dispute.

- 8) All the transactions recorded in the Books of Accounts have been disclosed as Income, during the year, in the Tax Assessments under the Income Tax Act, 1961 (43 of 1961). There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as Income during the year in the Tax Assessments under the Income Tax Act, 1961 (43 of 1961).
- 9) According to the records of the Company examined by us and as per the information and explanations given to us, we hereby report that:
- a. The Company has not defaulted in repayment of Loans or Borrowings to any Bank during the year under review.
 - b. The Company is not declared Willful Defaulter by any Bank or Financial Institution or other Lender.
 - c. The Company has not raised Term Loan from any Bank or Financial Institution during the current year.
 - d. To the extent of our check, no funds raised by the Company for short-term has been utilised for long term purposes.
 - e. The Company has not taken any funds from any entity or person on account of or to meet the obligations of its Subsidiaries, Associates or Joint Ventures.
 - f. The Company has not raised loans on the Pledge of Securities
- 10)
- a. According to information and explanation given to us and on the basis of our examination of the records of the Company, the Company has not raised any money by way of Initial Public Offer or Further Public Offer (including Debt Instruments) during the year and hence, reporting under Clause 3(x)(a) of the Order is not applicable to the Company.
 - b. During the year, the Company has not made any Preferential Allotment or Private Placement of Shares or Convertible Debentures (fully or partly or optionally) and hence, reporting under Clause 3(x)(b) of the Order is not applicable to the Company.
- 11)
- a. According to the information and explanations given to us, no material fraud by the Company or by its officers or employees has been noticed or reported during the course of Audit.
 - b. No Report under sub-Section (12) of Section 143 of the Companies Act has been filed by the Auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - c. No Whistle Blowers Complaints were received during the year under review. As represented to us by the Management, no Whistle Blowers Complaints were received during the year under review.
- 12) In our opinion, the Company is not a Nidhi Company, and accordingly, provisions of Clause 3(xii) of the Order are not applicable.
- 13) In our opinion, the Company is in compliance with Sections 177 and 188 of the Companies Act, 2013, with respect to applicable transactions with the Related Parties, and the requisite details have been disclosed in the Financial Statements.
- 14) As per the information provided to us, the Company does not have an adequate Internal Audit System.
- 15) In our opinion, the Company has not entered in any non-cash transactions with the Directors or persons connected with them covered under Section 192 of the Act. Accordingly, the provisions of Clause 3(xv) of the order are not applicable.
- 16)
- a. According to the information and explanation given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934 and the Company has not conducted any NBFC Company during the year.
 - b. The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.
- 17) The Company has not incurred cash losses in the Financial Year and in the immediately preceding Financial Year.
- 18) There has been no resignation of Statutory Auditors during the Financial Year 2023-24.

- 19) On the basis of the Financial Ratios, ageing and expected dates of realisation of Financial Assets and payment of Financial Liabilities, other information accompanying the Financial Statements, the Auditor's knowledge of the Board of Directors and the Management's plans, the Auditor is of the opinion that no material uncertainty exists as on the date of the Audit Report and that the Company is capable of meeting its Liabilities existing at the Date of Balance Sheet, as and when they fall due within a period of one year from the Balance Sheet Date. We however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the Audit Report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the Balance Sheet date, will get discharged by the Company as and when they fall due.
- 20) The Company is not liable to contribute under Section 135 of the Companies Act, 2013. Accordingly, the provisions of Clause 3(xx) of the Order are not applicable.
- 21) In our opinion and according to the information and explanations given to us, Company does not have any Subsidiaries, Associates and Joint Ventures. Therefore, this Clause is not applicable.

Date: May 17, 2025
Place: Hyderabad

For PPKG & Co
Chartered Accountants
Firm Registration No.: 0009655S

Sd/-
Girdhari Lal Toshniwal
(Partner)
M. No. 205140
UDIN: 25205140BMOPC13781

ANNEXURE – B TO THE AUDITORS' REPORT

Report on Internal Financial Controls under Clause (i) of Sub-Section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the Internal Financial Controls over Financial Reporting of **Vilin Bio Med Limited** ('the Company') as of March 31, 2025 in conjunction with our Audit of the Financial Statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining Internal Financial Controls based on the Internal Control over Financial Reporting criteria established by the Company, considering the essential components of Internal Controls stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate Internal Financial Controls, that were operating effectively for ensuring orderly and efficient conduct of its business, including adherence to Company's Policies, the safeguarding of its Assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's Internal Financial Controls over Financial Reporting based on our Audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting ("Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of Internal Financial Controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India.

Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate Internal Financial Controls over Financial Reporting was established and maintained and if such controls operated effectively in all material respects.

Our Audit involves performing procedures to obtain Audit Evidence about the adequacy of the Internal Financial Controls system over Financial Reporting and their operating effectiveness. Our Audit of Internal Financial Controls over Financial Reporting included obtaining an understanding of Internal Financial Controls over Financial Reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error.

We believe that the Audit Evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's Internal Financial Controls system over Financial Reporting.

Meaning of Internal Financial Controls over Financial Reporting

A Company's Internal Financial Controls over Financial Reporting is a process designed to provide reasonable assurance regarding the reliability of Financial Reporting and the preparation of Financial Statements for external purposes in accordance with Generally Accepted Accounting Principles. The Company's Internal Financial Controls over Financial Reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Financial Statements in accordance with Generally Accepted Accounting Principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of the Management and Directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's Assets that could have a material effect on the Financial Statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of Internal Financial Controls over Financial Reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the Internal Financial Controls over Financial Reporting to future periods are subject to the risk

that the Internal Financial Controls over Financial Reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate Internal Financial Controls System over Financial Reporting and such Internal Financial Controls over Financial Reporting were operating effectively as at March 31, 2025, based on the Internal Controls over Financial Reporting criteria established by the Company, considering the essential components of Internal Controls, as stated in the Guidance Note on Audit of "Internal Financial Controls Over Financial Reporting" issued by the Institute of Chartered Accountants of India.

Date: May 17, 2025
Place: Hyderabad

For PPKG & Co
Chartered Accountants
Firm Registration No.: 00096555

Sd/-
Girdhari Lal Toshniwal
(Partner)
M. No. 205140
UDIN: 25205140BMOPC13781

BALANCE SHEET AS AT MARCH 31, 2025

(Rupees in Lakhs)

Particulars	Note No.	As at 31-Mar-2025	As at 31-Mar-2024
EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	1	1,395.00	1,395.00
Reserves and Surplus	2	911.35	889.00
Money received against Share Warrants		-	-
		2,306.35	2,284.00
Share Application Money pending allotment		-	-
Non-Current Liabilities			
Long-Term Borrowings	3	-	20.87
Deferred Tax Liabilities (Net)	4	9.44	8.16
Other Long-Term Liabilities		-	-
Long-Term Provisions		-	-
		9.44	29.02
Current Liabilities			
Short-Term Borrowings	5	257.33	662.12
Trade Payables	6		
Total Outstanding Dues of Micro Enterprises and Small Enterprises		-	-
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises		138.85	195.34
Other Current Liabilities	7	3.00	11.89
Short-Term Provisions	8	57.83	58.01
		457.00	927.36
TOTAL		2,772.79	3,240.38
ASSETS			
Non-Current Assets			
Property, Plant and Equipment and Intangible Assets			
Property, Plant and Equipment	9	128.46	138.27
Intangible Assets		-	-
Capital Work-in-Progress	10	156.84	-
Intangible Assets under Development		-	-
		285.30	138.27
Non-Current Investments		-	-
Deferred Tax Assets (Net)		-	-
Long-Term Loans and Advances	11	505.84	466.06
Other Non-Current Assets	12	725.59	774.50
		1,516.73	1,378.83
Current Assets			
Current Investments		-	-
Inventories	13	441.18	446.75
Trade Receivables	14	630.57	568.41
Cash and Cash Equivalents	15	5.61	604.94
Short-Term Loans and Advances	16	70.37	117.59
Other Current Assets	17	108.33	123.87
		1,256.06	1,861.55
Accounting Policies and Notes on Accounts	28		
TOTAL		2,772.79	3,240.38

In terms of our attached Report of Even Date
FOR PPKG AND CO
Chartered Accountants
FRN: 00096555

Sd/-
Girdhari Lal Toshniwal
(Partner)
M. No.: 205140
UDIN: 25205140BMOPDJ4623
Date: May 17, 2025
Place: Hyderabad

FOR VILIN BIO MED LIMITED

Sd/- Madhusudhan Yadamakanti Reddy	Sd/- Prasanna Lakshmi Venna	Sd/- Hari Prasad Avula	Sd/- Dhruv V Todi
(Managing Director)	(Whole- Time Director)	(Chief Financial Officer)	(Company Secretary)

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025

(Rupees in Lakhs except Share Data)

Particulars	Note No.	For the year ended 31-Mar-2025	For the Year ended 31-Mar-2024
Revenue from Operations	18	1,480.99	1,580.49
Other Income	19	46.85	32.43
Total Income		1,527.84	1,612.92
Expenses			
Cost of Materials Consumed	20	1,347.23	1,279.55
Purchases of Stock-in-Trade		-	-
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	21	-	21.06
Employee Benefits Expenses	22	29.50	80.38
Finance Costs	23	84.51	78.58
Depreciation and Amortization Expenses	24	10.44	13.01
Other Expenses	25	25.57	117.83
Total Expenses		1,497.26	1,590.40
Profit before Exceptional and Extraordinary Items and Tax Exceptional Items		30.58 -	22.52 -
Profit before Extraordinary Items and Tax Extraordinary Items		30.58 -	22.52 -
Profit before Tax		30.58	22.52
Tax Expense:	26		
Current Tax		6.95	5.11
Deferred Tax		1.28	1.16
Profit / (Loss) for the period from Continuing Operations		22.35	16.24
Profit / (Loss) from Discontinuing Operations		-	-
Tax expense of Discontinuing Operations		-	-
Profit / (Loss) from Discontinuing Operations (After Tax)		-	-
Profit / (Loss) for the Period		22.35	16.24
Earnings Per Equity Share:	27		
Basic		0.16	0.12
Diluted		0.16	0.12

In terms of our attached Report of Even Date
FOR PPKG AND CO
Chartered Accountants
FRN: 00096555

FOR VILIN BIO MED LIMITED

Sd/-
Girdhari Lal Toshniwal
(Partner)
M. No.: 205140
UDIN: 25205140BMOPDJ4623
Date: May 17, 2025
Place: Hyderabad

Sd/- Madhusudhan Yadamakanti Reddy	Sd/- Prasanna Lakshmi Venna	Sd/- Hari Prasad Avula	Sd/- Dhruv V Todi
(Managing Director)	(Whole-Time Director)	(Chief Financial Officer)	(Company Secretary)

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2025

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Cash Flows from Operating Activities		
Net Profit Before Tax and Extra Ordinary Items	30.58	22.53
Adjustment For		
Depreciation	10.44	13.01
Foreign Exchange		
Gain or loss on Sale of Fixed Assets		
Gain or loss on Sale of Investments		
Finance Cost	84.51	78.58
Dividend Income		
Other adjustment of Non-Cash Item		
Other adjustment to reconcile Profit		
Total Adjustment to Profit/Loss (A)	94.95	91.59
Adjustment For Working Capital Change		
Adjustment for Increase/Decrease in Inventories	5.57	-358.87
Adjustment for Increase/Decrease in Trade Receivables	-62.16	-8.36
Adjustment for Increase/Decrease in Other Current Assets	64.44	-100.06
Adjustment for Increase/Decrease in Trade Payable	-56.49	76.40
Adjustment for Increase/Decrease in Other Current Liabilities	-1.45	-431.47
Adjustment for Provisions	-0.18	3.68
Total Adjustment for Working Capital (B)	-50.28	-818.68
Total Adjustment to reconcile Profit (A+B)	44.67	-727.09
Net Cash Flow from (used in) Operations	75.25	-704.56
Dividend Received		
Interest Received	-46.56	-32.43
Interest Paid		
Income Tax Paid/Refund	-6.95	-5.11
Net Cash Flow from (used in) Operations before Extra-Ordinary Items	21.75	-742.10
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from Operating Activities	21.75	-742.10
Cash Flows from Investing Activities		
Proceeds From fixed Assets		
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets	157.47	0.13
Purchase of Investments or Equity Instruments		
Interest Received	46.56	32.43
Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash flow from losing control of Subsidiaries		
Cash Payment for acquiring control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow/Outflow of Cash		
Net Cash Flow from (used in) in Investing Activities before Extra-Ordinary Items	-110.91	32.30
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (used in) in Investing Activities	-110.91	32.30
Cash Flows from Financial Activities		
Proceeds from Issuing Shares	0.00	1,200.00
Proceeds from Issuing Debenture/Bonds/Notes		
Redemption of Preference Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Borrowings		
Repayment of Borrowings	425.66	234.37

Dividend Paid		
Interest Paid	84.51	78.58
Income Tax Paid/Refund		
Net Cash Flow from (used in) in Financial Activities before Extra-Ordinary Items	-510.17	887.05
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (used in) in Financial Activities	-510.17	887.05
Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	-599.33	177.25
Effect of Exchange Rate change on Cash and Cash Equivalents		
Net increase (decrease) in Cash and Cash Equivalents	-599.33	177.25
Cash and Cash Equivalents at beginning of period	604.94	3.45
Cash and Cash Equivalents at end of period	5.61	180.70

In terms of our attached Report of Even Date
FOR PPKG AND CO
Chartered Accountants
FRN: 00096555

FOR VILIN BIO MED LIMITED

Sd/-
Girdhari Lal Toshniwal
(Partner)
M. No.: 205140
UDIN: 25205140BMOPDJ4623
Date: May 17, 2025
Place: Hyderabad

Sd/- Madhusudhan Yadamakanti Reddy	Sd/- Prasanna Lakshmi Venna	Sd/- Hari Prasad Avula	Sd/- Dhruv V Todi
(Managing Director)	(Whole-Time Director)	(Chief Financial Officer)	(Company Secretary)

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2025

NOTE NO. 1: SHARE CAPITAL

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Authorised		
1,50,00,000 Equity Shares of Rs.10/- Par Value	1,500.00	1,500.00
	1,500.00	1,500.00
Issued		
1,39,50,000 Equity Shares of Rs.10/- Par Value	1,395.00	1,395.00
	1,395.00	1,395.00
Subscribed		
1,39,50,000 Equity Shares of Rs.10/- Par Value	1,395.00	1,395.00
	1,395.00	1,395.00
Paid-up		
1,39,50,000 Equity Shares of Rs.10/- Par Value Fully Paid-up	1,395.00	1,395.00
	1,395.00	1,395.00

Shareholding more than 5%

Particulars	As at 31-Mar-2025		As at 31-Mar-2024	
	Number of Shares	% Holding	Number of Shares	% Holding
- Sadhanala Venkata Rao	45,73,705	32.79	45,89,705	32.90
- Srinivasa Reddy Devireddy	19,68,795	14.11	20,12,795	14.43
- Viswa Prasad Sadhanala	18,48,140	13.25	18,76,140	13.45

NOTE NO. 2: RESERVE AND SURPLUS

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Capital Reserve - Opening	22.56	22.56
Addition	0.00	0.00
Deduction	0.00	0.00
	22.56	22.56
Securities Premium Opening	800.00	0.00
Additions	0.00	800.00
	800.00	800.00
Profit and Loss Opening	66.44	50.20
Amount Transferred From Statement of P&L	22.35	16.24
Amount Transferred From Sundries		
Others	0.00	0.00
	0.00	0.00
	88.80	66.44
	911.35	889.00

NOTE NO. 3: LONG TERM BORROWINGS

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Term Loan		
Banks	0.00	20.87
	0.00	20.87

NOTE NO. 4: DEFERRED TAXES

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Deferred Tax Liabilities		
Other	9.44	8.16
	9.44	8.16

NOTE NO. 5: SHORT TERM BORROWINGS

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Other Loans and Advances	257.33	662.12
	257.33	662.12

NOTE NO. 6: TRADE PAYABLES**As at 31-Mar-2025**

(Rupees in Lakhs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) MSME	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Others	39.79	0.00	99.05	0.00	0.00	138.85
(iii) Disputed dues – MSME	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed dues – Others	0.00	0.00	0.00	0.00	0.00	0.00

As at 31-Mar-2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) MSME	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Others	195.34	114.69	0.00	0.00	0.00	195.34
(iii) Disputed dues – MSME	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed dues – Others	0.00	0.00	0.00	0.00	0.00	0.00

NOTE NO. 7: OTHER CURRENT LIABILITIES

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Other Payables		
Other Current Liabilities	3.00	11.89
	3.00	11.89

NOTE NO. 8: SHORT TERM PROVISIONS

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Tax Provision		
- Current Tax	56.89	56.94
Others	0.94	1.07
	57.83	58.01

NOTE NO. 9: PROPERTY, PLANT AND EQUIPMENT

(Rupees in Lakhs)

Particulars	Gross					Depreciation					Impairment				Net	
	Opening as at 01-Apr-2024	Addition	Deductions	Revaluation	Closing as at 31-Mar-2025	Opening as at 01-Apr-2024	During Period	Deductions	Other Adjustment	Closing as at 31-Mar-2025	Opening as at 01-Apr-2024	During Period	Reversal	Closing as at 31-Mar-2025	Closing as at 31-Mar-2025	Closing as at 31-Mar-2024
Land																
Free Hold Land																
LAND	21.15				21.15										21.15	21.15
Total	21.15				21.15										21.15	21.15
Building																
Office Building																
BUILDING	43.68				43.68	36.86	0.67			37.53					6.15	6.82
BUILDING	129.76				129.76	105.91	2.46			108.37					21.39	23.85
BUILDING	37.44				37.44	31.50	0.47			31.97					5.47	5.94
BUILDING	34.10				34.10	29.10	0.41			29.51					4.59	5.00
BUILDING	22.36				22.36	16.54	0.61			17.15					5.20	5.81
BUILDING	19.15				19.15	13.81	0.56			14.37					4.79	5.34
BUILDING	39.86				39.86	27.13	1.30			28.43					11.43	12.73
BUILDING	22.65				22.65	12.20	1.03			13.23					9.42	10.46
Total	348.99				348.99	273.05	7.51			280.56					68.43	75.94
Plant and Machinery																
PLANT AND MACHINERY-1	3.93				3.93	3.45	0.10			3.55					0.38	0.47
PLANT AND MACHINERY-1	21.27				21.27	19.93	0.28			20.20					1.06	1.34
PLANT AND MACHINERY-1	57.18				57.18	54.32				54.32					2.86	2.86
PLANT AND MACHINERY-1	95.46				95.46	90.68				90.68					4.77	4.77
PLANT AND MACHINERY-1	88.16				88.16	83.75				83.75					4.41	4.41
PLANT AND MACHINERY-1	0.86				0.86	0.69	0.03			0.72					0.13	0.16
PLANT AND MACHINERY-1	0.35				0.35	0.25	0.02			0.27					0.08	0.10
PLANT AND MACHINERY-1	0.73				0.73	0.51	0.04			0.55					0.18	0.22
PLANT AND MACHINERY-1	0.34				0.34	0.24	0.02			0.26					0.08	0.10
PLANT AND	0.65				0.65	0.45	0.04			0.48					0.17	0.20

MACHINERY-1																	
PLANT AND MACHINERY-1	0.34				0.34	0.24	0.02			0.26						0.09	0.10
PLANT AND MACHINERY-1	0.20				0.20	0.17	0.01			0.18						0.02	0.03
PLANT AND MACHINERY-1	4.16				4.16	3.62	0.11			3.73						0.43	0.54
PLANT AND MACHINERY-1	0.53				0.53	0.49	0.01			0.50						0.03	0.04
PLANT AND MACHINERY-1	0.40				0.40	0.36	0.01			0.37						0.03	0.04
PLANT AND MACHINERY-1	0.39				0.39	0.37	0.00			0.37						0.02	0.02
PLANT AND MACHINERY-1	0.18				0.18	0.17				0.17						0.01	0.01
PLANT AND MACHINERY-1	1.14				1.14	1.08				1.08						0.06	0.06
PLANT AND MACHINERY-1	2.85				2.85	0.28	0.16			0.45						2.40	2.57
PLANT AND MACHINERY-1	3.61				3.61	2.95	0.13			3.08						0.52	0.66
PLANT AND MACHINERY-1	8.00				8.00	6.15	0.37			6.51						1.49	1.85
PLANT AND MACHINERY-1	0.70				0.70	0.53	0.03			0.56						0.14	0.17
PLANT AND MACHINERY-1	0.92				0.92	0.70	0.04			0.74						0.17	0.22
PLANT AND MACHINERY-1	12.83				12.83	9.84	0.59			10.43						2.40	2.99
PLANT AND MACHINERY-1	201.15				201.15	188.76				188.76						12.39	12.39
PLANT AND MACHINERY-1	22.48				22.48	20.25	0.48			20.73						1.75	2.23
PLANT AND MACHINERY-1	1.96				1.96	1.81	0.03			1.85						0.11	0.15
PLANT AND MACHINERY-1	0.63				0.63	0.50	0.03			0.52						0.11	0.13
PLANT AND MACHINERY-1	0.51				0.51	0.41	0.02			0.43						0.08	0.10
PLANT AND MACHINERY-1	0.38				0.38	0.30	0.02			0.32						0.06	0.08
GENERATOR			0.28		0.28		0.03			0.03						0.25	
PLANT AND MACHINERY			0.35		0.35		0.06			0.06						0.29	

Total	532.29	0.63			532.92	493.28	2.66			495.94				36.98	39.01	
Equipments																
Office Equipments																
OFFICE EQUIPMENT	2.93				2.93	2.78				2.78				0.15	0.15	
OFFICE EQUIPMENT	0.44				0.44	0.42				0.42				0.02	0.02	
OFFICE EQUIPMENT	0.29				0.29	0.28				0.28				0.01	0.01	
Total	3.67				3.67	3.48				3.48				0.19	0.19	
Computer Equipments																
COMPUTER	4.61				4.61	4.44				4.44				0.17	0.17	
Total	4.61				4.61	4.44				4.44				0.17	0.17	
Other Equipments																
PRINTER	0.11				0.11	0.07	0.02			0.09				0.01	0.04	
Total	0.11				0.11	0.07	0.02			0.09				0.01	0.04	
Furniture and Fixtures																
FURNITURE	3.51				3.51	3.32				3.32				0.19	0.19	
FURNITURE	6.55				6.55	6.05	0.15			6.21				0.34	0.49	
FURNITURE	2.82				2.82	2.66	0.02			2.68				0.14	0.16	
FURNITURE	2.46				2.46	2.33				2.33				0.12	0.12	
FURNITURE	0.48				0.48	0.43	0.01			0.44				0.03	0.05	
FURNITURE	0.15				0.15	0.13	0.01			0.13				0.02	0.03	
FURNITURE	0.13				0.13	0.01	0.04			0.05				0.08	0.12	
Total	16.09				16.09	14.93	0.23			15.16				0.93	1.16	
Vehicles																
Motor Vehicles																
VEHICLE	0.45				0.45	0.43				0.43				0.02	0.02	
VEHICLE	0.48				0.48	0.44	0.01			0.45				0.03	0.04	
VEHICLE	10.77				10.77	10.23				10.23				0.54	0.54	
Total	11.71				11.71	11.10	0.01			11.11				0.59	0.60	
Grand Total	938.62	0.63	0.00	0.00	939.25	800.35	10.44	0.00	0.00	810.79	0.00	0.00	0.00	0.00	128.46	138.27
Previous	938.49	0.13	0.00	0.00	938.62	787.34	13.01	0.00	0.00	800.35	0.00	0.00	0.00	0.00	138.27	151.15

NOTE NO. 10: CAPITAL WORK-IN-PROGRESS

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Other Capital Work in Progress	156.84	0.00
	156.84	0.00

NOTE NO. 11: LONG-TERM LOANS AND ADVANCES

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Loans and advances to related parties	504.42	274.14
Loans and advances to others	1.42	191.92
	505.84	466.06

NOTE NO. 12: OTHER NON-CURRENT ASSETS

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Trade Receivable		
Secured, Considered Good		
Exceeding Six Months	725.59	774.50
	725.59	774.50

NOTE NO. 13: INVENTORIES

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Raw Material	73.99	74.03
Finished Goods	292.39	297.91
Others		
- Packing Material	74.80	74.80
	441.18	446.75

NOTE NO. 14: TRADE RECEIVABLES

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Trade Receivable		
Secured, considered good		
Within Six Months	629.67	567.50
Exceeding Six Months	0.90	0.90
	630.57	568.41

NOTE NO. 15: CASH AND CASH EQUIVALENTS

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Cash in Hand	5.58	4.83
Balances with Banks	0.03	600.11
	5.61	604.94

NOTE NO. 16: SHORT-TERM LOANS AND ADVANCES

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Security Deposits	6.35	6.35
Loans and Advances to others	64.02	111.24
	70.37	117.59

NOTE NO. 17: OTHER CURRENT ASSETS

(Rupees in Lakhs)

Particulars	As at 31-Mar-2025	As at 31-Mar-2024
Other Current Assets	108.33	123.87
	108.33	123.87

NOTE NO. 18: REVENUE FROM OPERATIONS

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Sale of Products	1,480.99	1,580.49
	1,480.99	1,580.49

NOTE NO. 19: OTHER INCOME

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Interest Income	46.85	32.43
	46.85	32.43

NOTE NO. 20: COST OF MATERIALS CONSUMED

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Raw Material		
Opening	446.75	66.82
Purchase	1,341.66	1,659.48
Closing	441.18	446.75
	1,347.23	1,279.55
	1,347.23	1,279.55

Details of Raw Material

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Raw Material	1,347.23	1,279.55
	1,347.23	1,279.55

NOTE NO. 21: CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Opening		
	0.00	21.06
Closing		
	0.00	0.00
Increase/Decrease		
	0.00	21.06

Details of Changes in Inventory

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
- Finished Goods	0.00	21.06
	0.00	21.06

NOTE NO. 22: EMPLOYEE BENEFITS EXPENSES

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Salary, Wages and Bonus	28.36	79.07
Staff Welfare Expenses	1.14	1.31
	29.50	80.38

NOTE NO. 23: FINANCE COSTS

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Interest Expenses		
- Interest Expenses	82.40	75.22
- Bank Charges	2.11	2.82
Finance Charges		
- Other Finance Charges	0.00	0.54
	84.51	78.58

NOTE NO. 24: DEPRECIATION AND AMORTISATION EXPENSES

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Depreciation	10.44	13.01
	10.44	13.01

NOTE NO. 25: OTHER EXPENSES

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Administrative and General Expenses		
- Telephone Postage	0.15	0.61
- Printing Stationery	0.42	0.65
- Rent Rates and Taxes	0.00	0.75
- Auditors Remuneration	0.75	1.25
- Repairs Maintenance Expenses	1.73	2.46
- Legal and Professional Charges	4.67	0.81
- Insurance Expenses	0.00	0.58
- Safety and Security Expenses	0.82	5.54
- Registration and Filing Fees	0.35	0.00
- Other Administrative and General Expenses	13.38	25.33
Selling Distribution Expenses		
- Advertising Promotional Expenses	0.00	0.29
Write off Assets and Liabilities		
- Other Write Offs	0.00	73.66
Other Expenses	3.31	5.90
	25.57	117.83

NOTE NO. 26: TAX EXPENSES

(Rupees in Lakhs)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Current Tax	6.95	5.11
Deferred Tax	1.28	1.16
	8.23	6.27

NOTE NO. 27: EARNINGS PER EQUITY SHARE

(In Rupees)

Particulars	For the year ended 31-Mar-2025	For the year ended 31-Mar-2024
Earnings Per Equity Share		
- Basic	0.16	0.12
- Diluted	0.16	0.12
Number of Shares used in computing EPS		
- Basic	1,39,50,000	1,39,50,000
- Diluted	1,39,50,000	1,39,50,000

NOTES ON FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025

1. General Information

Vilin Bio Med Limited ('the Company') is engaged in business of Manufacturing and Trading of Pharmaceutical Products. The Company is Public Limited Company incorporated under the Companies Act, 2013 and bearing CIN: L24230TG2005PLC046689 and has its Registered Office at # 8-2-269/S/43, Plot No. 43, Second Floor, Sagar Co-operative Housing Society Limited, Road No. 2, Banjara Hills, Hyderabad, Telangana – 500034. The Company is listed on the SME Platform of the National Stock Exchange ('NSE EMERGE')

2. Significant Accounting Policies

Basis of Preparation

The Financial Statements of the Company have been prepared in accordance with Generally Accepted Accounting Principles in India (Indian GAAP). These Financial Statements have been prepared to comply in all material respects with the Accounting Standards notified by Companies (Accounting Standards) Rules, 2006, (as amended) and the relevant provisions of the Companies Act, 2013. The Financial Statements have been prepared under the historical cost convention on an accrual basis and going concern basis. The Accounting Policies have been consistently applied by the Company are consistent with those used in the previous year.

Use of Estimates

The preparation of Financial Statements in conformity with Generally Accepted Accounting Principles requires the Management to make estimates, judgements, and assumptions that affect the reported amounts of Revenue, Expenses, Assets and Liabilities and the disclosure of Contingent Liabilities, at the end of the Reporting Period.

Although these estimates are based on the Management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcome requiring a material adjustment to the Carrying Amounts of Assets or Liabilities in future periods.

Functional and Presentation Currency: The Financial Statements are prepared in Indian Rupees ("INR") which is the Company's Functional Currency for its Operations. All Financial Information presented in INR has been rounded to the nearest 'Lakhs' with two decimal places, unless stated otherwise.

Recognition of Revenue and Expenditure: Revenue is recognized to the extent that it is probable that the Economic Benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria is ensured before revenue is recognized.

Income from Services: Revenue from Service Contracts priced on time and material basis are recognized when services are rendered and related costs are incurred. The Company collects Goods and Services Tax on behalf of the Government and therefore it is not an Economic Benefit flowing to the Company. Hence, it is excluded from Revenue.

Sale of Goods: Revenue is measured at the Transaction Price of the consideration received or receivable. Revenue from Sale of Products is recognized when the control on the goods, have been transferred to the Customer. The performance obligation in case of Sale of product is satisfied at a point in time i.e., when the material is shipped to the customer or on delivery to the customer, as may be specified in the Contract.

Interest Income: Interest Income is recognized on a time proportion basis taking into account the amount outstanding and the effective interest rate method. Interest Income is included under the head "Other Income" in Statement of Profit and Loss.

Property, Plant and Equipment (PPE):

a. **Recognition and Measurement:** Property, Plant and Equipment are stated at Cost comprising of Purchase Price and any initial directly attributable cost of bringing the Asset to its working condition for its intended use less Accumulated Depreciation and Impairment Loss, if any.

b. **Subsequent Expenditure:** Subsequent Expenditure is capitalised only if it is probable that the Future Economic Benefits associated with the expenditure will flow to the Company.

c. **Depreciation:** Depreciation on Fixed Assets is provided on Written Down Value method (WDV) as per Useful Life of Asset and in the manner prescribed in Schedule-II of the Companies Act, 2013.

d. **Intangible Assets:** Intangible Assets are stated at the Historical Cost of Acquisition, Net of Recoverable Taxes less Accumulated Amortisation/Depletion. All Costs, including Financing Costs till commencement of Commercial Production, Net Charges on Foreign Exchange Contracts and adjustments arising from Exchange Rate variations attributable to the Intangible Assets are capitalized. The Company has elected to continue with the Carrying Value of all its Intangible Assets as recognized in the financial Statements as at the date of transition, measured as per the previous GAAP and use that as the deemed cost as at the transition

date. Subsequent Expenditure is capitalized only when it increases the Future Economic Benefits embodied in the specific to which it relates.

e. Impairment of Non-Financial Assets: Assets that have a definite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Management periodically assesses using, external and internal sources, whether there is an indication that an asset may be impaired. The Recoverable Amount is higher of the Asset's Net Selling Price or Value in use, which means the Present Value of Future Cash flows expected to arise from the continuing use of the Asset and its eventual disposal. An Impairment Loss for an Asset is reversed if, and only if, the reversal can be related objectively to an event occurring after the impairment loss was recognized. The Carrying Amount of an Asset is increased to its Revised Recoverable Amount, provided that this amount does not exceed the Carrying Amount that would have been determined (Net of any Accumulated Amortisation or Depreciation) had no impairment loss been recognized for the asset in prior years.

f. Borrowing Cost: Borrowing Costs attributable to the Acquisition/Construction of Qualifying Assets are capitalised and form part of the Cost of the Qualifying Assets. A Qualifying Asset is an Asset that necessarily takes a substantial period of time to get ready for its intended use. All other Borrowing Costs are charged to Revenue as an Expense.

g. Income Tax: Provision for Income Tax is made for both Current and Deferred Taxes. Provision for Current Income Tax is made on the Current Tax Rates based on the Assessable Income. The Company provides Deferred Tax based on the Tax effect of timing differences resulting from the recognition of items in the Financial Statements and in estimating its Current Tax Provision. Deferred Tax Assets are recognised where there is certainty that there will be sufficient Future Taxable Income available against which such Deferred Tax Assets can be realised.

h. Inventories: Inventories are measured at lower of Cost and Net Realisable Value after providing for obsolescence, if any. Cost of comprises of Cost of Purchases, Cost of Conversion and other cost including Manufacturing Overheads incurred in bringing them to their respective present location and condition. Cost of Raw Materials, Work-in-Progress, Packing Materials, Trading and other products are determined on first-in-first-out basis.

i. Research and Development: Revenue Expenditure on Research and Development is charged to Profit and Loss Account as incurred. Capital Expenditure on Assets acquired for Research and Development is added to Property, Plant and Equipment.

j. Financial Instruments: A Financial Instrument is any Contract that gives rise to a Financial Asset of one Entity and a Financial Liability or Equity Instrument of another Entity.

k. Financial Assets Classification: The Company shall classify Financial Assets as subsequently measured at Amortised Cost and Fair Value through Profit and Loss (FVTPL) on the basis of its business model for managing the Financial Assets and the Contractual Cash flow characteristics of the Financial Asset.

l. Initial Recognition and Measurement: All Financial Assets are recognised initially at Fair Value plus, in the case of Financial Assets not recorded at Fair Value through Profit or Loss (FVTPL), Transaction Costs that are attributable to the acquisition of the Financial Asset. Purchases or Sales of Financial Assets that require delivery of Assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date i.e., the date that the Company commits to purchase or sell the Asset. However, Trade Receivables that do not contain a significant Financing Component are measured at Transaction Price.

m. Cash and Cash Equivalents: Cash and Cash Equivalents for the purposes of Cash Flow Statement comprise Cash at Bank and in hand and Short-Term Deposits with Banks with an original maturity of three months or less.

n. Loans and Borrowings: After initial recognition, Interest-bearing Loans and Borrowings are subsequently measured at an Amortised Cost. Gains and Losses are recognised in Profit and Loss when the liabilities are derecognized. This category generally applies to Interest-bearing Loans and Borrowings.

o. Foreign Currency Transactions:

Initial Recognition: Foreign Currency Transactions are recorded in the Reporting Currency by applying to the Foreign Currency amount the Exchange Rate between the Reporting Currency and the Foreign Currency at the date of the transaction.

Conversion: Foreign Currency monetary items are retranslated using the Exchange Rate prevailing at the Reporting Date. Non-monetary items, which are measured in terms of historical cost denominated in the Foreign Currency, are reported using the Exchange Rate at the date of the transaction. Non-Monetary items, which are measured at Fair Value or other similar valuation denominated in a Foreign Currency are translated using the Exchange Rate at the date when such value was determined.

Treatment of Exchange Differences: Exchange differences arising on settlement/restatement of Foreign Currency Monetary Assets and Liabilities of the Company are recognised as Income or Expense in the Statement of Profit and Loss.

p. Leases: Leases where the Lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as Operating Leases. Operating Lease payments are recognized as an expense in the Statement of Profit and Loss on a Straight – line basis over the Lease Term.

q. Employee Benefits: All Employee Benefits payable for rendering the service such as Salaries, Wages etc. and the expected cost of ex-gratia are recognised in the period in which the employee renders the related service. A Liability is recognised for the amount expected to be paid when there is a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

r. Provisions, Contingent Liabilities and Contingent Assets: Provisions are recognised when the Company has a Present Obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying Economic Benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Contingent Liability is disclosed in case of a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognised in Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Entity. Contingent Assets are not recognised in Financial Statements and are disclosed in the Notes when it is virtually certain that economic benefits will inflow to the Company.

s. Earnings Per Share (EPS): Basic EPS is computed using the Weighted Average Number of Equity Shares outstanding during the period. Diluted EPS is computed using the Weighted Average Number of Equity and Dilutive Equity Equivalent Shares outstanding during the period except where the results would be anti-dilutive.

3. Related Party Disclosure as required by Accounting Standard (AS) 18

(Rupees in Lakhs)

Party Name	Relationship	Nature of Transactions	For the year ended March 31, 2025	For the year ended March 31, 2024
Viswa Prasad Sadhanala	Director	Advances	24.00	25.00
Spectrogen International Private Limited	Enterprises – KMP having significant influence/owned by major Shareholder	Advance from Customers	249.43	449.37
Redizen Lifesciences Private Limited	Enterprises – KMP having significant influence/owned by major Shareholder	Trade Receivable	220.88	220.88
Blue Nile Capital Advisory Limited	Enterprises – KMP having significant influence/owned by major Shareholder	Current Assets	504.43	274.14

Capital Management: The Company's Policy is to maintain strong capital base to maintain Investor, Creditor and Market confidence and to sustain future development of the business. The Management monitors the Return on Capital as well as the level of Dividends to Equity Shareholders. The Company monitors Capital using a ratio of 'Net Debt' to 'Equity'. For this purpose, Net Debt is defined as Total Debt, comprising Loans and Borrowings less Cash and Cash Equivalents and Current Investments. The Company's Net Debt to Equity Ratio is as follows:

(Rupees in Lakhs)

Particulars	As at March 31, 2025	As at March 31, 2024
Current Borrowings	257.32	682.99
Gross Debt	257.32	682.99
Less - Cash and Cash Equivalents	5.61	604.94
Less - Current Investments	-	-
Net Debt	251.71	78.05
Total Equity	2306.35	2284.00
Net Debt to Equity Ratio*	0.11	0.034
Since Net Debt to Equity Ratio result is negative, the same is shown as Nil.		

1. Earnings Per Share (EPS): Basic EPS and Diluted EPS amounts are calculated by dividing the Profit for the year attributable to the Equity Holders of the Company by the Weighted Average Number of Equity Shares outstanding during the year.

Particulars	As at March 31, 2025	As at March 31, 2024
Profit attributable to Equity Holders (Rs. in Lakhs)	22.35	16.24
Weighted Average Number of Shares outstanding during the year	1,39,50,000	1,39,50,000
Nominal Value of Equity Shares (In Rs.)	10	10
Earnings Per Share Basic and Diluted (In Rs.)	0.16	0.12

2. As at March 31, 2025 the Company has certain dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows:

	As at March 31, 2025	As at March 31, 2024
(a) Principal Amount remaining unpaid to any supplier at the end of year	-	-
(b) Interest due remaining unpaid to any supplier at the end of the year	-	-
(c) The amount of Interest paid by the buyer in terms of Section 16 of the MSMED Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during the year	-	-
(d) The amount of Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the Interest specified under the MSMED Act, 2006	-	-
(e) The amount of Interest accrued and remaining unpaid at the end of each year	-	-
(f) The amount of further Interest remaining due and payable even in the succeeding years, until such date when the Interest dues above are actually paid to the Small Enterprises, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act, 2006	-	-

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006" is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company. There are no overdue Principal amounts / Interest Payable amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the year or for any earlier years and accordingly, there is no Interest Paid or Outstanding Interest in this regard in respect of payment made during the year or on balance brought forward from previous years.

3. Trade Receivables Ageing Schedule:

(Rupees in Lakhs)

Particulars	As at March 31, 2025					
	Less than 6 Months	6 months - 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Undisputed Trade Receivables - Considered Good	629.67	-	0.90	-	-	630.57
(ii) Undisputed Trade Receivables - which have Significant Increase In Credit Risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
(v) Disputed Trade Receivables - which have Significant Increase In Credit Risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
Total Debtors	629.67	-	0.90	-	-	630.57

(Rupees in Lakhs)

Particulars	As at March 31, 2024					Total
	Less than 6 Months	6 months – 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade Receivables - Considered Good	477.28	91.13	-	-	-	568.41
(ii) Undisputed Trade Receivables - which have Significant Increase in Credit Risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
(v) Disputed Trade Receivables - which have Significant Increase In Credit Risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
Total Debtors	568.41	-	-	-	-	568.41
Less: Provision for Doubtful Debts	-	-	-	-	-	-
Net Debtors	568.41	-	-	-	-	568.41

4. Trade Payables Ageing Schedule:

(Rupees in Lakhs)

Particulars	As at March 31, 2025					Total
	Less than one year	1-2 years	2-3 years	More than 3 years		
(i) MSME	-	-	-	-	-	
(ii) Others	39.79	99.05	-	-	138.84	
(iii) Disputed Dues – MSME	-	-	-	-	-	
(iv) Disputed Dues – Others	-	-	-	-	-	
Total	39.79	99.05	-	-	138.84	

(Rupees in Lakhs)

Particulars	As at March 31, 2024					Total
	Less than one year	1-2 years	2-3 years	More than 3 years		
(i) MSME	-	-	-	-	-	
(ii) Others	80.65	114.69	-	-	195.34	
(iii) Disputed Dues – MSME	-	-	-	-	-	
(iv) Disputed Dues – Others	-	-	-	-	-	
Total	80.65	114.69	-	-	195.34	

5. Capital Commitment and Contingent Liabilities

- a) **Capital Commitment:** There are no Capital Commitments outstanding as at Reporting Date (As at March 31, 2025: Nil)
- b) **Contingent Liabilities and Commitments:** There are no Contingent Liabilities

6. Other Statutory Information:

- The Company has not been declared Wilful Defaulter by any Bank or Financial Institution or Government or any authority.
- The Company has not granted Loans or Advances in the nature of loans to Promoters, Directors, KMPs and the Related Parties.
- The Company does not have any transactions with Companies which are struck off.
- The Company has considered the business segment as the primary reporting segment on the basis that the risk and returns of the Company is primarily determined by the nature of products and services. Consequently, the geographical segment

has been considered as a secondary segment.

5. The Business Segment has been identified on the basis of the nature of products and services, risks and returns, Management Structure and Internal Performance Reporting Systems. The Business Segment comprises of Manufacturing and Selling of Pharmaceutical Products. Geographical segment is considered based on sales within India and outside India.
6. Previous Year's figures have been regrouped/reclassified wherever necessary to correspond with the Current Year's classification/disclosure.

In terms of our attached Report of Even Date
FOR PPKG AND CO
Chartered Accountants
FRN: 00096555

FOR VILIN BIO MED LIMITED

Sd/-
Girdhari Lal Toshniwal
(Partner)
M. No.: 205140
UDIN: 25205140BMOPDJ4623
Date: May 17, 2025
Place: Hyderabad

Sd/- Madhusudhan Yadamakanti Reddy	Sd/- Prasanna Lakshmi Venna	Sd/- Hari Prasad Avula	Sd/- Dhruv V Todi
(Managing Director)	(Whole-Time Director)	(Chief Financial Officer)	(Company Secretary)

VILIN BIO MED LIMITED



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

August 23, 2024

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

Subject: Submission of Annual Report for The Financial Year 2023-24

Ref: i). Disclosure under Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

ii). NSE Symbol- VILINBIO ISIN: INE0L4V01013

Dear Sir/Madam,

In terms of Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit a copy of the Annual Report of the Company for the Financial Year 2023-24, including Notice of 18th Annual General Meeting (“AGM”) of the members of the Company, scheduled to be held on Saturday, September 21, 2024 at 11.30 A.M. (“IST”) Video Conferencing /Other Audio-Visual Means (“VC/OAVM”).

Kindly take the same on record.

Thanking You

Yours Faithfully

For Vilin Bio Med Limited

Viswa Prasad Sadhanala
Director

Encl.: As above

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in

Vilin Bio Med Limited
18th Annual Report
2023-2024

INDEX

SI No	Particulars	Page Nos.
I	Corporate Information	03
II	Notice of the 18th Annual General Meeting	04-14
III	Board's Report	15-22
IV	Annexures	23-32
V	Independent Auditor's Report	33-41
VI	Standalone Financial Statements	42-66

BOARD OF DIRECTORS:

Mr. Veerareddy Vallapureddy
Ms. Aruna Madishetti
Mr. Viswa Prasad Sadhanala
Mr. Anuj Bajpai

Independent Director
Independent Director
Managing Director
Whole-Time Director

KEY MANAGERIAL PERSONNEL:

Mr. Chilam Srikanth
Mr. Anand Lohia

Chief Financial Officer
Company Secretary & Compliance Officer

REGISTERED OFFICE:

Sy. No. 115/GF/J, Hanumanji Colony
Brig Sayeed Road, Bowenpally
Secunderabad-500009 Telangana
E-mail: cs@vilinebiomed.co.in
Website: www.vilinebiomed.co.in
Tel No.: 040-7961 8843

MANUFACTURING UNIT:

Unit-II, Khasra No. 85, Madhopur Village, Roorkee
Haridwar, Uttarakhand

STATUTORY AUDITORS:

M/s PPKG & Co
Chartered Accountants

SECRETARIAL AUDITORS:

M/s Kashinath Sahu & Co
Company Secretaries

REGISTRAR & SHARE TRANSFER AGENTS (RTA):

M/s Bigshare Services Private Limited
#306, 3rd Floor, Right Wing, Amrutha Ville
Somajiguda, Rajbhavan Road
Hyderabad – 500082, Telangana
E-mail: bsshyd@bigshareonline.com
Website: www.bigshareonline.com

LISTING:

Listed on NSE SME Board
(EMERGE Platform)

BANKER TO THE COMPANY:

Punjab National Bank
ICICI Bank

NOTICE

Notice is hereby given that the Eighteenth Annual General Meeting of the Members of M/s Vilin Bio Med Limited ("the Company") will be held on Saturday, September 21, 2024 at 11:30 A.M. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact following business mentioned below:

Ordinary Business:

1. To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended March 31, 2024, together with the Report of the Directors and Auditors thereon and in this regard, to give assent or dissent to the following Resolution as an Ordinary Resolution:

"**RESOLVED THAT** the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2024 including the Audited Balance Sheet as at March 31, 2024, the Statement of Profit and Loss for the year ended on that date and the Reports of the Board of Directors and Auditors thereon, be and are hereby received, considered and adopted."

Special Business

2. Regularization of the Appointment of Ms. Aruna Madishetti (DIN: 10746293), Additional Director as an Independent Director.

To consider and, if thought fit, to pass with or without modification, the following resolution as Special Resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 149, 150, 152 read with Schedule – IV and other applicable provisions of the Companies Act, 2013 ('the Act') and the Companies (Appointment and Qualifications of Directors) Rules, 2014, (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and as amended from time to time, of Ms. Aruna Madishetti (DIN: 10746293), who was appointed as an Additional Director- Independent of the Company with effect from August 22, 2024 by the board of directors on the recommendation of the Nomination and Remuneration Committee and who holds office up to the date of this Annual General Meeting of the Company in terms of Section 161(1) of the Act and in respect of whom the Company has received a notice in writing from a member under Section 160(1) of the Act proposing his candidature for the office of Director of the Company and also a written declaration in conformity with SEBI (LODR) Regulations, 2015, be and is hereby appointed as Director of the Company under Independent Category of the company, not liable to retire by rotation, for a First Term of five (5) consecutive years commencing from August 22, 2024 up to August 21, 2029

"RESOLVED FURTHER THAT the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution."

**By Order of the Board
For Vilin Bio Med Limited**

**Date: August 22, 2024
Place: Hyderabad**

**Sd/-
Anand Lohia
Company Secretary**

NOTES:

1. The details as required under Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') entered with the Stock Exchanges and Secretarial Standard on General Meeting (SS-2) in respect of the Directors seeking appointment / re-appointment at this Annual General Meeting is annexed.
2. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 is annexed.
3. In continuation to the MCA General Circular No. 10/2022 dated December 28, 2022 and General Circular No. 09/2023 dated September 25, 2023 has decided to allow the Companies to conduct their AGMs on or before September 30, 2024, in accordance with the requirements laid down in paragraphs 3 and 4 of the General Circular No. 20/ 2020 dated May 5, 2020. As per the said General Circular dated May 5, 2020, in view of the prevailing situation, owing to the difficulties involved in dispatching of physical copies of the Financial Statements (including Board's Report, Auditor's Report or other documents required to be attached therewith), such statements along with Notice of the Meeting shall be sent only by e-mail to the Members and to all other persons so entitled. With this facility, the Companies are allowed to conduct their AGM through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Hence, in compliance with the MCA Circulars and SEBI Circulars, the 18th Annual General Meeting of the Company is being held through VC / OAVM on Saturday, September 21, 2024 at 11:00 A.M. (IST).

In compliance of Section 20 of the Companies Act, 2013 and further to the aforesaid MCA Circulars and SEBI Circulars, Notice of the 18th Annual General Meeting along with the Annual Report 2023-2024 is being sent only through electronic mode to the Members whose e-mail addresses are registered with the Company/Depositories. Members may note that the Notice and the Annual Report 2023-2024 will also be available on the Company's Website: <http://www.vilinbiomed.co.in/> and Website of the Stock Exchange i.e., National Stock Exchange Limited: <https://www.nseindia.com>, and on the Website of CDSL: <https://www.eVotingindia.com>

4. Green Initiative: To support the Green Initiative, Members who have not registered their e-mail address are requested to register their e-mail address for receiving all the communications including Annual Report, Notices, Circulars etc. from the Company electronically.
5. A Member entitled to attend and vote at the AGM is entitled to appoint a Proxy to attend and vote on his / her behalf and the Proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars and SEBI Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of Proxies by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
6. Members of the Company under the category of Institutional Investors are encouraged to attend and vote at the AGM through VC/OAVM. Corporate Members intending to authorize their Representatives to participate and vote at the AGM are requested to upload a copy of the Board Resolution/Authorization Letter on the E-Voting Portal or send to the Company at cs@vilinbiomed.co.in.
7. Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the Quorum under Section 103 of the Act. As per Regulation 40 of the SEBI Listing Regulations, as amended, Securities of Listed Entities can be transferred only in Dematerialised form with effect from April 1 2019, except in case of transmission or transposition of Securities. In view of this, Members holding Shares in Physical Form are requested to consider converting their holdings to Dematerialised form. Members can contact M/s Bigshare Services Private Limited, Registrar and Share Transfer Agents of the Company, ("RTA" or "Registrar") situated at 306, Right Wing, 3rd Floor, Amrutha Ville, Somajiguda, Rajbhavan Road, Hyderabad – 500082, E-mail: bsshyd@bigshareonline.com and website of the Registrar: www.bigshareonline.com for assistance in this regard.
8. Members are requested to intimate changes, if any, pertaining to their Name, Postal Address, E-mail Address, Telephone/Mobile Numbers, Permanent Account Number, Mandates, Nominations, Power of Attorney, Bank Details viz., Name of the Bank, Branch Details, Bank Account Number, MICR Code, IFSC Code etc., to their Depository Participants ("DPs") in case the Shares are held in Electronic Form and Registrar/RTA in case the Shares are held in Physical Form.
 - a. Registration of E-mail for Shareholders holding Physical Shares: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with

- the Registrar, by referring to their website: www.bigshareonline.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail and also upload the image of Share Certificate in PDF or JPEG format. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification. For Permanent Registration for Demat Shareholders: It is clarified that for permanent registration of E-mail address, Members are requested to register their E-mail address, in respect of Demat holdings with the respective Depository Participant (DP) by follow the procedure as prescribed by the Depository Participant.
- b. For Temporary Registration for Demat Shareholders: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with the Registrar, by referring to their website: www.bigshareonline.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail.
- c. Registration of Bank Details for Physical Shareholders: Members holding Shares in Physical Form and who have not registered their Bank details can get the same registered with the Registrar, by clicking the www.bigshareonline.com and follow the registration process as guided therein. Members are requested to provide details such as Name, Folio Number, Share Certificate Number, PAN, E-mail, along with the copy of the Cheque Leaf with the First named Member as mentioned on the Cheque Leaf containing Bank Name and Branch, Type of Account, Bank Account Number, MICR Details and IFSC code in PDF or JPEG format. It is very important that the Member should submit the request letter duly signed. The Registrar will verify the documents upload and will only take on records for all valid cases. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification.
9. The Register of Members and Share Transfer Books of the Company will remain closed from September 18, 2024 to September 21, 2024 (both days inclusive).
10. Nomination: Pursuant to Section 72 of the Companies Act, 2013, Members holding Shares in Physical Form are advised to file Nomination in the prescribed Form SH-13 with the Company's Share Transfer Agent. In respect of the Shares held in Dematerialised form, Members may please contact their respective Depository Participant.
11. Consolidation of Physical Share Certificates: Members holding Shares in Physical Form, in identical order of Names, in more than One Folio are requested to send to the Company or Registrar, the details of such Folios together with the Share Certificates for consolidating their holdings in One Folio. A Consolidated Share Certificate will be issued to such Members after making requisite changes.
12. In compliance with the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI Listing Regulations, the Company has provided a facility to its Members to cast their vote electronically, through the E-Voting services provided by Central Depository Services (India) Limited ("CDSL") on all the Resolutions set forth in this Notice. Members who have cast their Votes by Remote E-Voting prior to the AGM may also participate in the AGM through VC but shall not be entitled to cast their Vote on such Resolutions again. The manner and process of E-Voting remotely by Members is provided in the instructions for E-Voting which forms part of this Notice.
13. A Person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date for dispatch of Notice and Annual Report i.e., August 23, 2024 will only be entitled for receipt of Annual Report.
14. The Voting Rights of the Shareholders for Voting through Remote E-Voting at the AGM shall be in proportion to their share of the Paid-up Equity Shares of the Company as on Saturday, 14th September, 2024 (**Cut-off Date**). A Person whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date, only shall be entitled to avail the facility of Remote E-Voting or of Voting at the AGM and who is not a Member as on the Cut-off Date shall treat this Notice for information purposes only.

15. The Remote E-Voting Period will commence on **Wednesday, 18th September, 2024 (IST 9:00 A.M.) and will end on Friday, 20th September, 2024 (IST 5:00 P.M.)**. During this period, Members of the Company holding Shares in Dematerialised form, as on the Cut-off Date i.e., on Saturday, 14th September, 2024 ('Cut-off Date') shall be entitled to cast their vote by Remote E-Voting. Once the Vote on a Resolution is cast by the Member, the Member shall not be allowed to change it subsequently.
16. The facility for Voting during the AGM will also be made available. Members present in the AGM through VC and who have not cast their Vote on the Resolutions through Remote E-Voting and are otherwise not barred from doing so, shall be eligible to Vote through E-Voting system during the AGM.
17. Any person who becomes a Member of the Company after sending the Notice and holding Shares as on the **Cut-off Date (Saturday, 14th September, 2024)** may obtain the Login-id and Password by sending a request at helpdesk.eVoting@cdslindia.com However, if a Member is already registered with CDSL for Remote E-Voting then he/she can use his/her existing User-id and Password for casting the Vote.
18. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through Remote E-Voting.
19. Members seeking any information with regard to the accounts or any matter to be placed at the AGM, are requested to write to the Company mentioning their Name, Demat Account Number/Folio Number, E-mail, Mobile Number at cs@vilinearbiomed.co.in on or before **Monday, 16th September, 2024**. The same will be replied by the Company suitably.
20. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through Remote E-Voting.
21. The Board of Directors has appointed Mr. Kashinath Sahu, Practicing Company Secretary, Hyderabad as the Scrutinizer to scrutinize the Remote E-Voting Process and Voting during the AGM, in a fair and transparent manner.
22. The Scrutinizer shall immediately, after the conclusion of E-Voting at the AGM, first count the Votes Cast during the AGM, thereafter, unblock the Votes Cast through Remote E-Voting and make, not later than 2 working dates of conclusion of the AGM, a consolidated Scrutinizer's Report of the Total Votes Cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same. The Results declared along with the Scrutinizer's Report shall be placed on the Website of the Company and on the Website of CDSL immediately. The results will also be communicated to NSE Limited, where the Shares of the Company are listed.
23. To prevent fraudulent transactions, Members are advised to exercise Due Diligence and notify the Company of any change in address or Demise of any Member as soon as possible. Members are also advised not to leave their Demat account(s) dormant for long. Periodic Statement of Holdings should be obtained from the concerned DPs and Holdings should be verified from time to time.
24. **Instructions for attending the AGM through VC / OAVM:**
 - a. Shareholder will be provided with a facility to attend the AGM through VC/OAVM through the CDSL E-Voting system. Shareholders may access the same at <https://www.eVotingindia.com> under Shareholders / Members login by using the Remote E-Voting credentials. The link for VC/OAVM will be available in Shareholder / Members login where the EVSN of the Company is displayed.
 - b. Members may join the Meeting through Laptops, Smartphones, Tablets and I-Pads for better experience. Further, Members will be required to use the Internet with a good speed to avoid any disturbance during the Meeting. Please note that participants connecting from Mobile Devices or Tablets or through Laptops connecting via mobile hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any glitches.
 - c. Shareholders who would like to express their views / ask questions during the Meeting may register themselves as a speaker by sending their request in advance before **Monday, 16th September, 2024 (5:00 P.M.)** from their registered E-mail address mentioning their names, DP-ID and ClientID / Folio Number, PAN and Mobile Number at cs@vilinearbiomed.co.in. Only those Members who have pre-registered themselves as a speaker will be allowed to express their views / ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

- d. Members are encouraged to submit their questions in advance with regard to the Financial Statements or any other matter to be placed at the 18th Annual General Meeting, from their registered E-mail address, mentioning their Name, DP-ID and Client-ID Number / Folio Number and Mobile Number, to reach the Company's E-mail address at cs@vilinebiomed.co.in before **Monday, 16th September, 2024 (5:00 P.M.)**. Such questions by the Members shall be suitably replied by the Company.
 - e. Those Shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the Meeting. If any votes are cast by the Shareholders through the E-Voting available during the AGM and if the same Shareholders have not participated in the Meeting through VC / OAVM facility, then the votes cast by such Shareholders shall be considered as invalid, as the facility of E-Voting during the Meeting is available only to the Shareholders attending the Meeting.
25. Subject to the receipt of Requisite number of Votes, the Resolutions forming part of the AGM Notice shall be deemed to be passed on the date of the AGM. Voting through Electronic Means: Pursuant to Section 108 of the Companies Act, 2013 and Rule 20 read with the Companies (Management and Administration) Rules, 2014 read with amendments or re-enactments made thereunder and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is pleased to provide the facility to exercise Members' Right to Vote at the 18th Annual General Meeting (AGM) by electronic means and the business may be transacted through E-Voting Services provided by Central Depository Services (India) Limited (CDSL). The Members attending the Meeting, who have not already cast their vote through Remote E-Voting shall be able to exercise their Voting Rights at the Meeting. The Members who have already cast their vote through Remote E-Voting may attend the Meeting but shall not be entitled to cast their vote again at the AGM.
26. The instructions for Shareholders for Voting Electronically are as under:
- (i) **The Voting Period commences on Wednesday, 18th September, 2024 (9:00 A.M.) and closes on Friday, 20th September, 2024 (5:00 P.M.)** During this period, the Shareholders of the Company, holding Shares in Dematerialized Form, as on the Cut-off Date (Record Date), Saturday, 14th September, 2024 may cast their vote electronically. The E-Voting Module shall be disabled by CDSL for Voting thereafter.
 - (ii) Shareholders who have already voted prior to the Meeting Date would not be entitled to Vote at the Meeting.

Login method for E-Voting and Joining Virtual Meetings for Individual Shareholders holding Securities in Demat Mode:

Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/ CIR/P/2020/242 dated 9th December 2020 on "E-Voting Facility provided by Listed Companies", Individual Shareholders holding Securities in Demat mode are allowed to cast their vote through their Demat Account maintained with the Depositories and Depository Participants. Shareholders are advised to update their Mobile Number and E-mail in their Demat Accounts in order to access the E-Voting Facility. Pursuant to the above said SEBI Circular, Login method for E-Voting and joining Virtual Meetings for Individual Shareholders holding Securities in Demat mode CDSL/NSDL is given below:

Type of Shareholders	Login Method
<p>Individual Shareholders Holding Securities in Demat Mode with CDSL Depository</p>	<ol style="list-style-type: none"> 1. Users who have opted for CDSL EASI / EASIEST facility, can login through their existing User-id and Password. Option will be made available to reach E-Voting page without any further authentication. The URL for Users to login to EASI / EASIEST are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System MYEASI. 2. After successful login to the EASI/EASIEST User will be able to see the E-Voting option for eligible Companies where the E-Voting is in progress as per the information provided by Company. On clicking the E-Voting option, the User will be able to see E-Voting page of the E-Voting Service Provider for casting your Vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting. Additionally, there are also links provided to access the system of all E-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME so that the User can visit the E-Voting Service Providers website directly. 3. If the user is not registered for EASI/ EASIEST, option to register is available at CDSL website www.cdslindia.com To login click on login & New System MYEASI Tab and then click on registration option. 4. Alternatively, the User can directly access E-Voting Page by providing Demat Account Number and PAN on E-Voting link available on www.cdslindia.com homepage. The system will authenticate the User by sending OTP on the Registered Mobile and E-mail as recorded in the Demat Account. After successful authentication, the User will be able to see the E-Voting option where the E-Voting is in progress and also able to directly access the system of all the E-Voting Service Providers.
<p>Individual Shareholders Holding Securities in Demat Mode with NSDL Depository</p>	<ol style="list-style-type: none"> 1. If you are already registered for NSDL 'IDeAS' facility, please visit the E-services website of NSDL. Open web browser by typing the following URL: https://eservices.nsd.com either on a Personal Computer or on a Mobile. Once the Homepage of E-services is launched Click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' Section. A new screen will open. You will have to enter your User-id and Password. After successful authentication, you will be able to see E-Voting Services. Click on "Access to E-Voting" under E-Voting Services and you will be able to see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be re-directed to E-Voting Service Provider website for casting your vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.

	<ol style="list-style-type: none"> 2. If the User is not registered for IDEAS E-services, option to register is available at https://eservices.nsdl.com/ Select "Register Online for IDEAS" Portal or Click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the E-Voting website of NSDL. Open web browser by typing the following URL: https://www.eVoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the homepage of E-Voting system is launched, click on the icon "Login" which is available under 'Shareholder / Member' section. A new screen will open. You will have to enter your User-id (i.e. your sixteen-digit Demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository Site wherein you can see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your Vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.
<p>Individual Shareholders Holding Securities in Demat Mode Login through their Depository Participants (DP)</p>	<p>You can also login using the login credentials of your Demat account through your Depository Participant registered with NSDL/CDSL for E-Voting facility. After Successful login, you will be able to see E-Voting option. Once you click on E-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see E-Voting feature. Click on Company Name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your vote during the remote E- Voting period or joining Virtual Meeting and Voting during the Meeting</p>

Important note: Members who are unable to retrieve User-id/ Password are advised to use Forgot User-id and Forgot Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding Securities in Demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
<p>Individual Shareholders holding the Securities in Demat Mode with CDSL</p>	<p>Members facing any technical issue in login can contact CDSL Helpdesk by sending request at the following E-Mail: helpdesk.evoting@cdslindia.com or Contact at Toll Free No. 1800 22 5533</p>
<p>Individual Shareholders holding the Securities in Demat Mode with NSDL</p>	<p>Members facing any technical issue in login can contact NSDL Helpdesk by sending a request at evoting@nsdl.co.in or Call at Toll Free No. 1800 10 20990 and 1800 22 4430</p>

Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode

- i. The Shareholders should log on to the E-Voting Website: www.evotingindia.com
- ii. Click on "SHAREHOLDERS" Module.
- iii. Now enter your User-id
 - i. For CDSL: 16 Digits Beneficiary ID
 - ii. For NSDL: 8 Character DP-ID followed by 8 Digits Client-ID
 - iii. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- iv. Next enter the 'Image Verification' as displayed and Click on Login.
- v. If you are holding Shares in Demat form and had logged on to www.evotingindia.com and had voted on an earlier E-Voting of any Company, then your existing password is to be used.
- vi. If you are a first-time user follow the steps given below:

For Physical Shareholders and other than Individual Shareholders holding Shares in Demat Form

PAN	Enter your 10-digit alpha-numeric PAN issued by Income Tax Department (Applicable for both Demat Shareholders as well as Physical Shareholders) Shareholders who have not updated their PAN with the Company/ Depository Participant are requested to use the sequence number sent by Company /RTA or contact Company/RTA
Dividend Bank Details or Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your Demat Account or in the Company Records in order to login. If both the details are not recorded with the Depository or Company, please enter the Member-id /Folio Number in the 'Dividend Bank Details' field.

- vii. After entering these details appropriately, click on 'SUBMIT' tab.
- viii. Shareholders holding Shares in Physical Form will then directly reach the Company selection screen. However, Shareholders holding Shares in Demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the 'New Password' field. Kindly note that this password is to be also used by the Demat Holders for Voting for Resolutions of any other Company on which they are eligible to vote, provided that the Company opts for E-Voting through CDSL Platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- ix. For Shareholders holding shares in Physical Form, the details can be used only for E-Voting on the Resolutions contained in this Notice.
- x. Click on the EVSN of the relevant Company (**Vilin Bio Med Limited**) on which you choose to vote.
- xi. On the Voting Page, you will see 'RESOLUTION DESCRIPTION' and against the same the option 'YES/NO' for Voting. Select the option 'YES' or 'NO' as desired. The option 'YES' implies that you assent to the Resolution and option 'NO' implies that you dissent to the Resolution.
- xii. Click on the 'RESOLUTIONS FILE LINK' if you wish to view the entire Resolution details.
- xiii. After selecting the Resolution, you have decided to vote on, click on 'SUBMIT'. A Confirmation Box will be displayed. If you wish to confirm your vote, click on 'OK', else to change your vote, click on 'CANCEL' and accordingly modify your vote.
- xiv. Once you 'CONFIRM' your vote on the resolution, you will not be allowed to modify your Vote.
- xv. You can also take a print of the votes cast by clicking on 'Click here to Print' option on the Voting Page.

xvi. If a Demat Account Holder has forgotten the login password then enter the User-id and the 'Image Verification Code' and click on Forgot Password and enter the details as prompted by the system.

xvii. Additional Facility for Non – Individual Shareholders and Custodians – For Remote Voting:

- Non – Individual Shareholders (i.e. Other than Individuals, HUF, NRI etc.) and Custodians are required to log on to the website: www.evotingindia.com and register themselves in the 'CORPORATES' Module.
- A Scanned copy of the Registration Form bearing the Stamp and Sign of the Entity should be mailed to helpdesk.evoting@cdslindia.com
- After receiving the login details, a Compliance User should be created using the Admin login and Password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The List of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- It is mandatory that a Scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the Scrutinizer to verify the same.
- Alternatively Non-Individual Shareholders are required to send the relevant Board Resolution/Authority Letter etc. together with the Attested Specimen Signature of the Duly Authorized Signatory who are authorized to vote, to the Scrutinizer and to the Company at the E-mail address: cs@vilinebiomed.co.in if they have voted from individual tab and not uploaded same in the CDSL E-Voting System for the Scrutinizer to verify the same.

If you have any queries or issues regarding E-Voting from the CDSL E-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022-23058738 and 022-23058542/43

All grievances connected with the facility for Voting by electronic means may be addressed to Shri Rakesh Dalvi, Sr Manager, Central Depository Services (India) Limited (CDSL), Wing-A, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai-400013 or send an E-mail to helpdesk.evoting@cdslindia.com or call on 022-23058542/43

**By Order of the Board
For Vilin Bio Med Limited**

**Date: August 22, 2024
Place: Hyderabad**

**Sd/-
Anand Lohia
Company Secretary**

Explanatory Statement

The following Statement sets out all the material facts relating to Special Business in Item No. 2 pursuant to provisions of Section 102(1) of the Companies Act, 2013 mentioned in the accompanying Notice:

Ms. Aruna Madishetti (DIN: 10746293) was appointed as an Additional Director with effect from August, 22, 2024 by the Board of Directors on the recommendation of the Nomination and Remuneration Committee and in accordance with the provisions of the Section 161 of the Companies Act, 2013 and the said Director holds office until the conclusion of 18th Annual General Meeting. The Company has received Notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Ms. Aruna Madishetti (DIN: 10746293), as Director of the Company. Ms. Aruna Madishetti, MBA in Finance possess the required skills, knowledge in Finance & Accounts and it would be beneficial to the Company if she is on the Board of Directors of the Company

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint him as Independent Director for the First Term for a period of 5 (five) years pursuant to the provisions of Sections 149, 150, 152 read with Schedule-IV and other applicable provisions of the Companies Act, 2013 (the Act) on the Company Board and the Company will be benefited out of her expertise and can contribute the strategic guidance in the Financial matters of the Company.

None of the Directors of the Company is in any way concerned or interested in the said Resolution except Ms. Aruna Madishetti is concerned in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 2 of the Notice of the AGM

The Board recommends the Resolution for approval of the Members as a Special Resolution as set out in the Item No. 2 of the Notice.

Disclosure under Secretarial Standard - 2, issued by the Institute of Company Secretaries of India is detailed in the Annexure – A to the Notice.

ANNEXURE - A

Details of Director seeking appointment at the 18th Annual General Meeting to be held on September 21, 2024 pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 for General Meetings (SS-2) are as mentioned below:

Name	Ms. Aruna Madishetti
DIN	10746293
Date of Birth	2nd May, 1988
Date of First Appointment to the Board	22nd August, 2024
Designation	Non-Executive Director
Qualification	MBA Finance; B. Com
Brief Resume, Nature of Expertise and skill set in specific functional areas	Ms. Aruna Madishetti has been appointed as Non-Executive Director of our Company. She has a rich experience of ten years in Finance, Accounting and Management.
Shareholding (as on the date of this Notice) in the Company either directly or in form of beneficial interest for any other person	Nil
Relationship with other Directors / KMP's	None of the Directors / KMP's are related
Number of Meetings of the Board attended during the year	Nil
Directorships held in other Companies (excluding Foreign Companies)	Nil
Listed Companies from which the person has resigned from the Directorship in the past three years	Nil
Membership/ Chairmanship of Committees of other Companies	Nil
Remuneration (including Sitting Fees, if any) last drawn	Nil
Terms and conditions of Appointment	As per the Resolution No. 3 of the Notice read with the Explanatory Statement, Ms. Aruna Madishetti is proposed to be appointed as an Independent Director of the Company

**By Order of the Board
For Vilin Bio Med Limited**

**Date: August 22, 2024
Place: Hyderabad**

**Sd/-
Anand Lohia
Company Secretary**

BOARD'S REPORT

Dear Members,

The Directors have pleasure in presenting the 18th Annual Report of the Company, together with the Audited Accounts for the Financial Year ended 31st March, 2024

Financial Highlights

Particulars	(Rs. in Lakhs)	
	2023-2024	2022-2023
Sales	1,580.49	1,231.30
Other Income	32.43	2.44
Total Income	1,612.92	1,233.74
Total Expenses	1,590.41	1,055.58
Profit / (Loss) Before Tax	22.52	178.16
Current Tax	5.11	52.83
Deferred Tax	1.16	0.84
Profit / (Loss) After Tax	16.24	124.50

State of Company Affairs

The Company's Revenues stood at Rs.1,580.49 Lakhs During the year under review, PAT at Rs.16.24 Lakhs as against the corresponding Previous Year, there was Revenue of Rs.1,231.30 Lakhs and the PAT was Rs.124.50 Lakhs. Your directors are exploring more business opportunities and growth and profitability of the Company, in the years ahead.

Dividend

The Board of Directors has not recommended any Dividend on the Equity Shares of the Company for the Financial Year ended 31st March, 2024.

Transfer to Reserves

The Board of Directors has not proposed to transfer any amount to the General Reserve.

Changes in Share Capital

The Authorized Share Capital of the Company was increased to Rs.15,00,00,000 (divided into 1,50,00,000 Equity Shares of Rs. 10/- each) and the Paid-up Share Capital has increased from Rs.9,95,00,000/- to Rs.13,95,00,000/- (divided into 1,39,50,000 Equity Shares of Rs.10/- each), in respect of the Initial Public Offering wherein the Company had issued and allotted 40,00,000 Equity Shares of Face Value Rs.10/- each issued at Rs.30/- in the Initial Public Offer of the Company.

The Company got listed on the NSE SME Board on June 30, 2023.

Material Changes and Commitments affecting the Financial Position of the Company which have occurred between 31st March, 2024 and 22nd August, 2024 (Date of the Report)

During the period under review, the Company had defaulted in the repayment of Cash Credit Facility availed and the bank has classified the account as NPA. The Management has made representation to the bank for the erroneously classification of the Account as NPA, which was made on technical grounds. The Board is discussing to pay the overdue and regularize the account.

Nature of Business

The Company is into the manufacturing of Pharmaceuticals Products and there has been no change in the nature of Business of the Company during the year.

Public Deposits

During the year under review, the Company has not accepted any deposit pursuant to the provisions of Sections 73 and 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

Annual Return

A copy of the Annual Return for the Financial Year 2023-2024 pursuant to the Sub-Section (3) of Section 92 of the Companies Act, 2013 read with Rule 11(1) of the Companies (Management and Administration) Rules, 2014 and forming part of this Report is placed on the website of the Company as per provisions of Section 134(3)(a) and is available at the following link: <http://www.vilinbiomed.co.in/>

Director's Responsibility Statement

In terms of Section 134 (5) of the Companies Act, 2013, the Directors would like to state that:

- i) In the preparation of the Annual Accounts, the applicable Accounting Standards have been followed.
- ii) The Directors have selected such Accounting Policies and applied them consistently and made judgements and estimates that were prudent so as to give a true and fair view of the State of Affairs of the Company at the end of the Financial Year and of the Profit or Loss of the Company for the Year under review.
- iii) The Directors have taken proper and sufficient care for the maintenance of adequate Accounting Records in accordance with the provisions of this Act for safeguarding the Assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) The Directors have prepared the Annual Accounts on a Going Concern basis.
- v) The Directors had laid down Internal Financial Controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively.
- vi) The Directors had devised proper system to ensure compliance with the provisions of all the applicable laws and that such system was adequate and operating effectively.

Directors and Key Managerial Personnel

a. Composition of Board of Directors of the Company:

As on 31st March, 2024 the Board has the following Directors:

Sl No	Name of Director	DIN	Designation
1	Mr. Veerareddy Vallapureddy	08061781	Non-Executive Independent Director
2	Mr. Rakesh Kumar Chandak	09849680	Non-Executive Independent Director
3	Mr. Viswa Prasad Sadhanala	08068933	Managing Director
4	Mr. Anuj Bajpai	08939135	Whole-Time Director
5	Ms. Padmaja Kalyani Sadhanala	03096445	Non-Executive Non-Independent Director

b. Changes in the KMP:

During the year, Ms. Ashdeep Kaur has resigned from the position of Company Secretary and Compliance Officer of the Company on February 24, 2024.

c. Changes after the year under review:

From the closure of the Financial Year (31st March, 2024) till the date of the Boards' Report (22nd August, 2024), the following changes took place on the Board/KMP of the Company:

SI No	Name of Director / KMP	Nature of Change	Date of Change
1	Ms. Padmaja Kalyani Sadhanala (DIN: 03096445) Non-Executive Director	Resignation	29/05/2024
2	Mr. Rakesh Kumar (DIN: 09849680) Independent Director	Resignation	22/08/2024
3	Ms. Aruna Madishetti (DIN: 10746293) Non-Executive Independent Director	Appointment	22/08/2024
4	Mr. Anand Lohia Company Secretary and Compliance Officer	Appointment	04/05/2024

d. Number of Meetings of the Board and Director's Attendance

During the year ended 31st March, 2024 Five (5) Board Meetings were held in accordance with the provisions of the Companies Act, 2013 and in compliance with the Secretarial Standards of the Institute of Company Secretaries of India (ICSI).

SI No	Date of the Meeting	Number of Directors entitled to attend the meeting	Number of Directors who attended the meeting
1.	May 10, 2023	5	5
2.	July 19, 2023	5	5
3.	August 24, 2023	5	5
4.	November 10, 2023	5	5
5.	February 8, 2024	5	5

The following Annual/ Extra Ordinary General Meetings were held, During the year under review:

SI No	Date of the Meeting	Purpose of the Meeting
1.	September 23, 2023	17 th Annual General Meeting of the Company

Formal Annual Evaluation

As per Section 149 of the Companies Act, 2013 the Independent Directors of the Company had a Meeting on February 8, 2024 without attendance of Non – Independent Directors and Members of the Management. In the Meeting, the following issues were taken up:

- (a) Review of the performance of the Board as a whole;
- (b) Review of the performance of the Chairperson of the Company, taking into account the views of Executive Directors and Non – Executive Directors;
- (c) Assessing the Quality, Quantity and Timelines of flow of information between the Company Management and the Board, that is necessary for the Board to perform their duties effectively and reasonably.

The Meeting also reviewed and evaluated the performance of Non – Independent Directors.

The Meeting also reviewed and evaluated the performance the Board as whole in terms of the following aspects:

- Preparedness for Board / Committee Meetings
- Attendance at the Board / Committee Meetings

- Guidance on Corporate Strategy, Risk Policy, Corporate Performance and Overseeing Acquisitions and Disinvestments.
- Ensuring a Transparent Board Nomination Process with the diversity of Experience, Knowledge, Perspective in the Board.
- Ensuring the integrity of the Company's Accounting and Financial Reporting Systems, including the Independent Audit, and that appropriate systems of control are in place, in particular, systems for Financial and Operational Control and Compliance with the law and relevant Standards.

Declaration from Independent Directors on Annual Basis

The Company has received the declarations from Mr. Veerareddy Vallapureddy and Ms. Aruna Madishetti, Independent Directors of the Company to the effect that they are Meeting the criteria of Independence as provided in Sub-Section (6) of Section 149 of the Act and of Sub-Rule (1) and Sub-Rule (2) of the Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.

In the opinion of the Board, the Independent Directors possess the requisite integrity, expertise and experience (including the proficiency) of the independent Directors.

Statutory Auditors

M/s PPKG & Co, Chartered Accountants (FRN: 009655S) have been appointed as the Statutory Auditors of the Company for a term of five consecutive years till the conclusion of 22nd Annual General Meeting.

The said Auditors have carried out the Statutory Audit for the Financial Year 2023-2024. The Auditors Report for the Financial Year 2023-2024 does not contain any qualifications, reservations or adverse remark.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

Pursuant to provisions of Section 134 of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 the details of Conservation of Energy, Technology Absorption is attached herewith as "Annexure – A."

Foreign Exchange Earnings and Outgo: During the period under review, there was no Foreign Exchange Earnings or Outflow.

Secretarial Audit

Pursuant to provisions of Section 204 of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the Company had appointed Mr. Kashinath Sahu, Company Secretary in Practice to undertake the Secretarial Audit of the Company. The Secretarial Audit Report is annexed herewith as "Annexure – B."

During the year under review, there were no qualifications, reservations or adverse remarks reported by Secretarial Auditor under Section 204 of the Companies Act, 2013 in the course of the performance of his duties as Secretarial Auditor.

Management Discussion and Analysis

Pursuant to Regulation 34(2)(e) of the SEBI (LODR) Regulations, 2015, Report on Management Discussion and Analysis, is herewith annexed as "Annexure – C."

Internal Control Systems and their Adequacy

The Company has an in-house Internal Control System, commensurate with the size, scale and complexity of its operations. The Scope and Authority of the Internal Audit Function is defined in the Internal Audit Manual. To maintain its objectivity and independence, the Internal Audit Function reports to the Chairman of the Audit Committee of the Board and to the Chairman and Management.

The Internal Audit Department monitors and evaluates the efficacy and adequacy of Internal Control System in the Company, its compliance with Operating Systems, Accounting Procedures and Policies at all levels of the Company.

Based on the report of Internal Audit Function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant Audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

Audit Committee

The Audit Committee was constituted in accordance with the provisions of the Companies Act, 2013 and Regulation 18 of the SEBI (LODR) Regulations with the following as Members of the Committee.

The Audit Committee comprises:

Name of Director	Status in Committee	Nature of Directorship
Mr. Veerareddy Vallapureddy	Chairman	Non-Executive Independent Director
Ms. Aruna Madishetti	Member	Non-Executive Independent Director
Mr. Viswa Prasad Sadhanala	Member	Managing Director

The Company Secretary of the Company acts as the Secretary of the Audit Committee.

The terms of reference of our Audit Committee, in accordance with Section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI (LODR) Regulations.

Audit Committee Meetings and Attendance

Four Audit Committee Meetings were held during the year ended 31st March, 2024. The maximum time gap between any of the two meetings was not more than four months.

Date of the Meeting	Committee Strength	No. of Directors present
10.05.2023	3	3
24.08.2023	3	3
10.11.2023	3	3
08.02.2024	3	3

Nomination and Remuneration Committee

The Nomination and Remuneration Committee was constituted in accordance with the provisions of the Companies Act, 2013 and Regulation 19 of SEBI (LODR) Regulations. The Nomination and Remuneration Committee include the following:

Name of Director	Status in Committee	Nature of Directorship
Mr. Veerareddy Vallapureddy	Chairman	Non-Executive Independent Director
Ms. Aruna Madishetti	Member	Non-Executive Independent Director
Mr. Anuj Bajpai	Member	Whole-Time Director

The scope, functions and the terms of reference of the Nomination and Remuneration Committee is in accordance with the Section 178 of the Companies Act, 2013 read with Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nomination and Remuneration Committee Meetings and Attendance

The Nomination and Remuneration Committee has met once on 8th February 2024.

Date of the Meeting	Committee Strength	No. of Directors present
08.02.2024	3	3

Stakeholders Relationship Committee

The Stakeholders Relationship Committee was constituted in accordance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations. The Stakeholders Relationship Committee include the following:

Name of Director	Status in Committee	Nature of Directorship
Mr. Veerareddy Vallapureddy	Chairman	Non-Executive Independent Director
Ms. Aruna Madishetti	Member	Non-Executive Independent Director
Mr. Viswa Prasad Sadhanala	Member	Managing Director

The Company Secretary of the Company acts as the Secretary of the Stakeholders' Relationship Committee.

Stakeholders Relationship Committee Meetings and Attendance

The Stakeholders Relationship Committee has met once on 8th February 2024.

Date of the Meeting	Committee Strength	No. of Directors present
08.02.2024	3	3

Risk Management Committee

Regulation 21 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to forming of Risk Management Committee is not applicable to the Company during the Financial Year under review.

Corporate Governance and Shareholders Information

Pursuant to Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is not required to comply with the provisions of filing Corporate Governance Report to the Stock Exchange as it is not applicable to the Companies listed on the SME Platform.

Particulars of Loans, Guarantees or Investments under Section 186 of the Companies Act, 2013

The Company has not given any Loans nor provided Guarantee nor made any Investments during the Financial Year 2023-2024, which is beyond the limits as per Section 186 of the Companies Act, 2013.

Contracts or Arrangements with Related Parties under Section 188 (1) of the Companies Act, 2013

All the Contracts / Arrangements / Transactions entered by the Company, during the year under review, with Related Parties were in the ordinary course of business and at Arm's Length Basis. The particulars of such contracts or arrangements with Related Parties, pursuant to the provisions of Section 134(3)(h) and Rule 8 of the Companies (Accounts) Rules, 2014, in the prescribed Form AOC-2 is enclosed as "Annexure - D" to this Report.

All the Related Party Transactions were placed before the Audit Committee and also before the Board for their respective approval. Omnibus approval of the Audit Committee is obtained as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the transactions which can be foreseen and are repetitive in nature. The Company has developed a Policy on Related Party Transactions including the latest amendments thereof for the purpose of identification and monitoring of such transactions.

Policy on Preservation of the Documents

The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 ("Regulations") on Preservation of the Documents of the following type:

- documents whose preservation shall be permanent in nature;
- documents with preservation period of not less than eight years after completion of the relevant transactions

Vigil Mechanism

The Vigil Mechanism/Whistle Blower Policy has been adopted to provide appropriate Avenues to the employees to bring to the attention of the management, the concerns about any unethical behaviour by using the mechanism provided in the Policy. In cases related to financial irregularities, including fraud or suspected fraud, the employees may directly approach the Chairman of the Audit Committee of the Company. No Director or employee has been denied access to the Audit Committee. The web link for the policy is as follows: <http://www.vilinbiomed.co.in/>

Policy on criteria for determining Materiality of Events

The Company has adopted a Policy in accordance with the requirements of the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations). The Policy is authorizing the Key Managerial Personnels of the Company for the purpose of determining materiality of an event or information of the Company and to ensure that such information is adequately disseminated in pursuance with the Regulations and to provide an overall Governance Framework for such determination of Materiality.

Policy on Directors' Appointment, Remuneration & Other Details

The Company's Remuneration Policy is directed towards the rewarding of performance based on review of achievements periodically. The Remuneration Policy is in consonance with the existing Industry practice.

The Company's Shareholders may refer the Company's website for the Remuneration Policy of the Company on the appointment and remuneration of Directors including criteria for determining qualifications, positive attributes, independence of a Director; and other matters provided under Sub-Section (3) of Section 178.

Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concerns Status and Company's Operations in future

The Company has not received any Significant or Material Orders passed by any Regulatory Authority, Court or Tribunal which shall impact the Going Concern Status and Company's Operations in future.

Details of Subsidiary Companies, Associates and Joint Venture Companies

The Company does not have any Subsidiary, Associate or Joint Ventures during the period under review.

Industrial Relations

Employee relations during the period under review continued to be healthy, cordial and harmonious at all levels and your Company is committed to maintain good relations with the employees. It has taken various steps to improve productivity across the organization.

Business Risk Management

Business Risk Evaluation and Management is an ongoing process within the Organization. The Company has a robust Risk Management Framework to identify, monitor and minimize risks as also identify business opportunities. At present, the Company has not identified any element of risk which may threaten the existence of the Company.

Transfer of Amounts to Investor Education and Protection Fund

Your Company does not have any Unpaid or Unclaimed amounts lying for a period of seven years. Therefore, there were no Funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

Particulars of Employees

In terms of Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company does not have any Employee who is employed throughout the Financial Year and in receipt of Remuneration of Rs.120 Lakhs or more, or Employees who are employed for part of the year and in receipt of Rs.8.50 Lakhs or more per month.

Corporate Social Responsibility

The Provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility are not applicable to our Company

Maintenance of Cost Records

The Provisions relating to maintenance of Cost Records under Section 148 of Companies Act, 2013 are not applicable to the Company.

Insider Trading Regulations

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992 read with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Code of Conduct for prevention of Insider Trading and the Code for Corporate Disclosures ("Code"), as approved by the Board from time to time, are in force by the Company. The objective of this Code is to protect the interest of Shareholders at large, to prevent misuse of any price sensitive information and to prevent any Insider Trading activity by dealing in Shares of the Company by its Directors, Designated Employees and other Employees. The Company also adopts the concept of Trading Window Closure, to prevent its Directors, Officers, Designated Employees and other Employees from Trading in the Securities of Vilin Bio Med Limited at the time, when there is Unpublished Price Sensitive Information.

Obligation of Company under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

In order to prevent Sexual Harassment of Women at Workplace as per "The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013" has been notified. Under the said Act, every Company is required to set up an Internal Complaints Committee to look into complaints relating to sexual harassment at workplace of any women employee. As required under law, an Internal Compliance Committee has been constituted for reporting and conducting inquiry into the complaints made by the victim on the harassments at the workplace. During the year under review, no complaint of harassment at the workplace was received by the Committee.

Acknowledgement

Your directors take this opportunity to place on record the valuable co-operation and continuous support extended by its valued business associates, consultants, Auditors, Supplier, Customers, Banks / Financial Institutions, Government authorities and the shareholders for their continuously reposed confidence in the Company and look forward to having the same support in all its future endeavors.

Your directors also wish to place on record their sincere appreciation for significant contribution made by the employees at all the levels through their dedication, hard work and commitment, thereby enabling the Company to boost its performance during the year under report.

Date: 22nd August, 2024
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-
Anuj Bajpai
Whole-Time Director
(DIN: 08939135)

A. Conservation of Energy, Power and Fuel Consumption

Particulars	Current Year (2023-2024)	Previous Year (2022-2023)
1. Electricity (Purchased) Units		
Total Amount (Rs.)	12,04,000	13,64,000
Rate Per Unit (Rs.)	5.58	5.58
2. Electricity (Generated) Units		
Total Amount (Rs.)	--	--
Rate Per Unit (Rs.)	--	--
3. Total Units Consumed	215770	2,44,444

- a) Company ensures that the Manufacturing Operations are conducted in the manner whereby optimum utilization and maximum possible savings of energy is achieved.
- b) No specific investment has been made in reduction in energy consumption.
- c) As the impact of measures taken for conservation and optimum utilization of energy are not quantitative, its impact on cost cannot be stated accurately.

B. Technology Absorption

The Company's products are manufactured by using In-House Know-how and no outside technology is being used for manufacturing activities. Therefore, no technology absorption is required. The Company constantly strives for maintenance and improvement in quality of its products and entire activities are directed to achieve the aforesaid goal.

C. Foreign Exchange Earning and Outgo

Particulars	Current Year	Previous Year
Earnings	-	-
Outgo	-	-

Date: 22nd August, 2024
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-
Anuj Bajpai
Whole-Time Director
(DIN: 08939135)

FORM MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2024

(Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014)

To
The Members
Vilin Bio Med Limited

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Vilin Bio Med Limited** having CIN: **L24230TG2005PLC046689** and having Registered Office at Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally Hyderabad - 500009, Telangana (hereinafter called the Company). The Secretarial Audit was conducted in accordance with the guidance note issued by the Institute of Company Secretaries of India and in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other records maintained by the Company and also the information, confirmations, clarifications provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we hereby report that in our opinion, the Company has, during the audit period covering the Financial Year ended on 31st March, 2024 complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the Financial Year ended on 31st March, 2024, according to the provisions of:

- I. The Companies Act, 2013 (the Act) and the rules made there under;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- III. The Depositories Act, 1996 and the Regulations and Byelaws framed there under;
- IV. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings **(Not applicable to the Company during the period of Audit)**
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"):
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and The Securities Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers (Amendment) Regulations, 2013; **(Not applicable to the Company during the period of Audit)**
 - (b) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; **(Not applicable to the Company during the period of Audit);**
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **(Not applicable to the Company during the period of Audit)**
 - (d) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **(Not applicable to the Company during the period of Audit)**
 - (e) Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; **(Not applicable to the Company during the period of Audit)**
 - (f) Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **(Not applicable to the Company during the period of Audit)**

- (g) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; ***(Not applicable to the Company during the period of Audit)***;
- (h) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; ***(Not applicable to the Company during the period of Audit)***
- (i) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; ***(Not applicable to the Company during the period of Audit)*** and
- (j) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018; ***(Not applicable to the Company during the period of Audit)***

VI. Other Laws specifically applicable to the Company as per the representations made by the Management include:

- a) Drugs & Cosmetics Act, 1940;
- b) Narcotic Drugs and Psychotropic Substances Act, 1985;
- c) Pharmacy Act, 1948
- d) Hazardous Waste Management Rules, 2016;
- e) National pharmaceutical Policy, 2012
- f) The Factories Act, 1948;
- g) Environ Protection Act, 1996
- h) Employees State Insurance Act, 1948
- i) Employees Provident Fund and Miscellaneous Provisions Act, 1952
- j) The Industrial disputes act, 1947;
- k) The Payment of Wages Act, 1936;
- l) The Minimum Wages Act, 1948;
- m) The Payment of Bonus Act, 1965;
- n) The Payment of Gratuity act, 1972.
- o) The Maternity Benefit Act, 1961.

We have relied on the representations made by the Company, its officers for systems and mechanism framed by the Company for compliances under other Acts, Laws and Regulations applicable to the Company as mentioned above.

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by the Institute of Company Secretaries of India and notified under the Companies Act, 2013;
- (ii) The Listing Agreements entered by the Company with the Stock Exchange(s); ***(Not applicable to the Company during the period of Audit)***

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors/ Committees that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, Agenda and detailed notes on Agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the Meeting.

Majority decisions are carried through while the dissenting member's views, if any, are captured and recorded as part of the Minutes.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable Laws, Rules, Regulations and Guidelines.

We further report that the compliance by the Company of the applicable Financial Laws like Direct and Indirect Tax Laws and maintenance of Financial Records and Books of Accounts has not been reviewed in this Audit since the same have been subject to review by the Statutory Auditors and other designated professionals.

**For Kashinath Sahu & Co
Practicing Company Secretaries**

Date: 17th August, 2024

Place: Hyderabad

**SD/-
CS Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN: F004790F000996693
Peer Review No: 2957/2023**

This Report is to be read with our letter of even date, which is annexed as **Annexure – A** and forms an integral part of this Report.

Annexure – (i) to the Secretarial Audit Report

**To
The Members
Vilin Bio Med Limited**

Our report of even date is to be read along with this letter:

- Maintenance of Secretarial Records is the responsibility of the Management of M/s Vilin Bio Med Limited ("the Company"). Our responsibility is to express an opinion on these Secretarial Records based on our audit.
- We have followed the Audit Practices and Processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records. The verification was done on to ensure that correct facts are reflected in the Secretarial Records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.
- We have not verified the correctness and appropriateness of Financial Records and Books of Accounts of the Company.
- Wherever required, we have obtained the Management representation about the compliance of Laws, Rules and Regulations and happening of events etc.
- The compliance of the provisions of Corporate and other applicable Laws, Rules, Regulations, Standards is the responsibility of the Management. Our examination was limited to the verification of procedures on test basis.
- The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Practicing Company Secretaries**

**Date: 17th August, 2024
Place: Hyderabad**

**SD/-
CS Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN: F004790F000996693
Peer Review No: 2957/2023**

“ANNEXURE-C”

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis present the Industry overview, opportunities and threats, the Company's initiatives and overall strategy of becoming a market-driven service provider with various offerings. The Company is optimistic about capturing a substantial share of the global and domestic market amid the threats faced due to the liberalisation and increased competition from well-established companies from India and abroad.

Global Economic Outlook

The estimated value of the global (Contract Research Organization) CRO services market in revenue for 2023 is \$76.6 billion, with a projected growth to reach \$127.3 billion by 2028, representing a compound annual growth rate (CAGR) of 10.7% from 2023 to 2028. This growth is primarily attributed to factors such as the continuous expansion of pharmaceutical, biopharmaceutical, and medical device R&D pipelines, as well as technological advancements in the clinical trials process. Additionally, the increasing demand for novel clinical trial designs to support cell and gene therapies is expected to create growth opportunities for companies operating in this market.

The global pharmaceutical market is now estimated to be over USD 1.6 trillion and expected to grow at CAGR of about 6%

Though the pharmaceutical industry is developing at rapid pace, the pharmaceutical manufacturing companies are confronted with enormous challenges such as:

Cost & Pricing, New Medicines & Therapy dosages, changing regulatory landscape & growing digitization.

Indian pharma market is expected to grow to USD 130 Billion by 2030 thereby emerging as the 6 largest pharmaceutical market globally by absolute size. The growth of the pharmaceutical industry is globally driven by ageing population as well as about 1% increase in the global population at the same time

Indian Economy

India's GDP growth rate was 6.4% during FY 2023 due to a combination of factors such as expected global economic slowdown, strict monetary policies, and high oil prices. Despite these obstacles, India's growth rate remains higher than that of comparable economies, primarily due to strong domestic consumption and lower dependence on global demand.

The Indian pharmaceutical industry has been experiencing steady growth with a focus on generic medicines. It is expected that spending on pharmaceuticals in India will continue to increase, with a CAGR of 7.5–10.5% between 2023-27 to reach US\$ 35-39 Billion annually. The industry's continued focus on generics is a key factor to its growth, as they are typically priced lower than branded medicines. The industry's low-cost structure and its ability to produce large quantities of medicines have also made it a key player in the global pharmaceutical market.

India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 Active Pharma Ingredients (API) producers that make for around 8% of the worldwide API market.

Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with a potential to steer the industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the "pharmacy of the world" due to the low cost and high quality of its medicines.

Manufacturing

Our Sales Strategy is to sell our products in bulk to **Pharmaceuticals Manufacturers, Marketers and Traders**, who in turn provide the channel for sales to customers. Our products are primarily used by other pharmaceutical companies and traders, who ultimately will market it to the distributors and retail customers. We do not sell our products under any brand name. Following are our major products (manufacturing dosage forms):

- Oral Liquid (Syrups/Suspensions/Dry Powders (β eta & Non β eta-Lactam))
- Tablets & Capsules (β eta & Non β eta-Lactam).
- External Preparations

Opportunities, Threats and Outlook

Vilin Bio Med Limited will be able to place itself in a **strong position** by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization. The Company is looking at different opportunities in untapped markets and across a value chain. It plans for alliances with business associates in the Indian market, giving a huge boost to the selective products that it already deals in.

We are fully conscious of our responsibility toward our customers. Our efforts are directed toward the fulfillment of customer satisfaction through the quality of products. As the consolidation of this industry gains momentum, the need to develop a dedicated team of skilled manpower assumes urgency and importance.

We will continue to focus on training and motivation of manpower to develop teams of qualified and skilled personnel to effectively discharge their responsibilities in a number of projects and activities. It is, in this context, which we have been working towards promoting the skills and professionalism of our employees to cope with and focus on the challenges of change and growth.

Also, the majority of the new entrants in an already overcrowded market is the **major threat** to the Company. These can affect the profitability of established players in the short run. In the long run, however trusted players with strong brand equity will continue to prosper.

Internal control systems & their adequacy

The Company has strong and adequate internal control system suitable to its size and nature of business. We constantly upgrade our systems for incremental improvements. The Audit Committee of the Board regularly reviews our system. The systems ensure protection of assets and proper recording of transactions. Internal audit is carried out by an independent chartered accountants' firm on quarterly basis. The internal auditors' reports are regularly received by the Audit Committee. It is a regular practice to review the issues raised by statutory auditors by the Audit Committee.

“ANNEXURE D”

FORM NO. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014).

Form for disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in subsection (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

1. Details of contracts or arrangements or transactions **not at arm's length basis.**

Sl. No	Name(s) of the related party and nature of relationship	Nature of contracts / arrangements/ transactions	Duration of the contracts/ arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Justification for entering into such contracts or arrangements or transactions	Date(s) of approval by the Board	Amount paid as advances, if any	Date on which the special resolution was passed in general meeting as required under first proviso to section 188
There were no contracts or arrangements or transactions entered into during the year ended 31st March 2024, which were not at arm's length basis.								

2. Details of material contracts or arrangement or transactions **at arm's length basis.**

Sl No	Name of the related party and nature of relationship	Nature of Contracts/ arrangements/ transactions	Duration of Contracts/ arrangements/ transaction	Salient terms of the contracts or arrangements or transactions including the value; if any;	Date of approval by the Board/ Shareholders, if any.	Amount incurred in Rs. in lakhs
1.	Redizen Lifesciences Private Limited	Trade Receivables	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	220.88
2.	Spectrogen Pharmachem Limited	Advance to Customers	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	449.37
3.	Blue Nile Capital Advisory Limited	Inter Corporate Loans	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	274.14
4.	Viswa Prasad Sadhanala	Remuneration			F.Y 2023-24	20.50

Date: 22nd August, 2024
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-
Anuj Bajpai
Whole-Time Director
(DIN: 08939135)

ANNEXURE - E

CERTIFICATE OF COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE

To
The Members,
VILIN BIO MED LIMITED

We have examined the compliance of conditions of Corporate Governance by VILIN BIO MED LIMITED (“the Company”), for the year ended on March 31, 2024, as stipulated in Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) for the period 1st April 2023 to 31st March 2024.

The compliance of conditions of Corporate Governance is the responsibility of Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the Financial Statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us by the Directors, officers and the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the abovementioned Listing Regulations.

We further state that, such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Company Secretaries**

**Date August 17, 2024
Place: Hyderabad**

**Sd/-
Kashinath Sahu
Practicing Company Secretary
FCS: 4790 CP: 4807
UDIN: F004790F000996704
Peer Review No. 2957/2023**

ANNEXURE - F

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members,
VILIN BIO MED LIMITED

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of VILIN BIO MED LIMITED having **CIN: L24230TG2005PLC046689**, Registered Office at Sy.No.115, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Secunderabad, Telangana, 500009 (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V, Para-C, Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in, as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2024 have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sl No	Name of Director	DIN	Designation
1	Mr. Veerareddy Vallapureddy	08061781	Non-Executive Independent Director
2	Mr. Rakesh Kumar Chandak	09849680	Non-Executive Independent Director
3	Mr. Viswa Prasad Sadhanala	08068933	Managing Director
4	Mr. Anuj Bajpai	08939135	Whole-Time Director
5	Ms. Padmaja Kalyani Sadhanala	03096445	Non-Executive Non-Independent Director

Ensuring the eligibility for the appointment/continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is only to express an opinion on this as per our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Company Secretaries**

**Date August 17, 2024
Place: Hyderabad**

**Sd/-
Kashinath Sahu
Practicing Company Secretary
FCS: 4790 CP: 4807
UDIN: F004790F000996715
Peer Review No. 2957/2023**

INDEPENDENT AUDITORS' REPORT

**TO
THE MEMBERS OF
VILIN BIO MED LIMITED.
HYDERABAD**

Report on the Audit of the Financial Statements

Opinion

We have audited the Financial Statements of **VILIN BIO MED LIMITED** ("the Company"), which comprise the balance sheet as at 31st March 2024, and the statement of profit and loss, and statement of cash flows for the period ended, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information [hereinafter referred to as "the Financial Statements"].

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its Profits, (*changes in equity*) and its cash flows for the period ended on that date.

Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

"Information Other than the Financial Statements and Auditor's Report Thereon"

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report, but does not include the Financial Statements and our auditor's report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Key Audit Matters

Key Audit Matters are those matter that, in our professional judgement, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. During the year under consideration, we have no Key Audit Matters to report.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the financial position and financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in

- (i) Planning the scope of our audit work and in evaluating the results of our work; and
- (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure A statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
 - (c) The Balance Sheet, the Statement of Profit and Loss, (the Statement of Changes in Equity) & Cash Flow statements dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on 31st March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2024 from being appointed as a director in terms of Section 164(2) of the Act.
 - (f) According to information and explanations given to us together with our audit examination, reporting with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls we give in Annexure B to the extent applicable.
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv.
- (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- v. No Dividend has been declared or paid during the year by the company, hence provisions of section 123 of the Companies Act, 2013, are not applicable.
- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2024 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software's. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

for PPKG AND CO
Chartered
Accountants FRN No.
0009655S

Place : Hyderabad
Date : 29/05/2024

Sd/-
GIRDHARI LAL
TOSHNIWAL (PARTNER)
M No. 205140
UDIN: 24205140BKALIZ2286

Annexure – A to the Independent Auditor’s Report of even date to the Members of M/s Vilin Bio Med Limited, on the Financial Statements for the Year ended March 31, 2024

Based on the audit procedures performed for the purpose of reporting a true and fair view on the Financial Statements of the Company and taking into consideration the information and explanations given to us and the Books of Accounts and other records examined by us in the normal course of Audit, and to the best of our knowledge and belief, we report that:

- 1)
 - a. The Company has maintained proper records showing full particulars, including quantitative details and situation of Fixed Assets,
 - b. The Company has a regular program of physical verification of its Fixed Assets under which Fixed Assets are verified in a phased manner over a period for which we have received the certificate of confirmation from the Management.
 - c. The Title Deeds of all the Immovable Properties (which are included under the head (‘Property, Plant and Equipment’) are held in the name of the Company.
 - d. The Company has not revalued any of its Property, Plant and Equipment’s during the year.
 - e. As per the information given to us there are no proceedings initiated or pending against the Company for holding any Benami Property under the Benami Transactions (Prohibition) Act, 1988 and Rules made there under.
- 2)
 - a. In our opinion and according to the information and explanation given to us, the Management has conducted physical verification of Inventory at reasonable intervals during the year, and no material discrepancies were noticed on the aforesaid verification, for which we have received the certificate of confirmation from the Management.
 - b. The Company has availed Financial Assistance from Bank or Financial Institutions.
- 3) The Company has not granted any Loans, secured or unsecured, to any Companies, Firms, Limited Liability Partnerships or other parties.
- 4) In our opinion, the Company has complied with the provisions of Section 186 in respect of the Investments and Loans. Further, in our opinion, the Company has not entered into any transaction covered under Section 185 and Section 186 of the Act in respect of Guarantees and Security.
- 5) In our opinion, the Company has not accepted any Deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- 6) As informed to us that the provisions of Section 148 are not applicable to the Company.
- 7)
 - (a) In our opinion, the Company has been regular in depositing undisputed statutory dues, including Goods and Services Tax, Income Tax, Sales Tax, Duty of Custom, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service Tax, Income Tax, Sales Tax, duty of Custom, duty of Excise, Cess and other material statutory dues in arrears as at March 31, 2024 for a period of more than six months from the date they become payable. However as per the information provided by the management, Provident Fund and Employees’ State Insurance is not applicable to the company for the current year.
 - (b) There is no Dues outstanding in respect of Income Tax, Sales Tax, Service Tax, Duty of Customs on account of disputes, whereas the company has intimations and Outstanding demands under Income Tax Act, 1961.
 - (c) According to the information and explanations given to us, the dues in respect of Sales Tax, Income Tax, Custom Duties, Wealth Tax, Excise Duty and Cess that have been deposited with the appropriate authorities except in cases where there is a dispute.

- 8) All the transactions recorded in the books of account have been disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961). There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as Income during the year in the Tax Assessments under the Income Tax Act, 1961 (43 of 1961).
- 9) According to the records of the Company examined by us and as per the information and explanations given to us, we hereby report that:
 - a. The Company has not defaulted in repayment of Loans or Borrowings to any Bank during the Year under review. The Company has No Outstanding Debentures during the year.
 - b. The Company is not declared Willful Defaulter by any Bank or Financial Institution or other Lender.
 - c. The Company has raised Term Loan from any Bank or Financial Institution during the current year.
 - d. To the extent of our check, no funds raised by the Company for short-term has been utilized for long term purposes.
 - e. The Company has not taken any funds from any entity or person on account of or to meet the obligations of its Subsidiaries, Associates or Joint Ventures.
 - f. The Company has not raised loans during the Year on the Pledge of Securities held in its Subsidiaries, Joint Ventures or Associate Companies.
- 10) The Company has raised the funds by way of Initial Public Offer in the month June, 2023. The Company has made an Allotment of 40,00,000 Equity Shares of Face Value Rs. 10 each issued at Rs. 30/-
- 11)
 - a. According to the information and explanations given to us, no material fraud by the Company or by its officers or employees has been noticed or reported during the course of Audit.
 - b. No Report under sub-section (12) of section 143 of the Companies Act has been filed by the Auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - c. No Whistle Blowers Complaints were received during the year under review. As represented to us by the Management, no Whistle Blowers Complaints were received during the year under review.
- 12) In our opinion, the Company is not a Nidhi Company, and accordingly, provisions of Clause 3(xii) of the Order are not applicable.
- 13) In our opinion, the Company is in compliance with Sections 177 and 188 of the Companies Act, 2013, with respect to applicable transactions with related parties, and the requisite details have been disclosed in the Financial Statements.
- 14) As per the information provided to us, the company does not have an adequate Internal Audit System.
- 15) In our opinion, the Company has not entered in any non-cash transactions with the Directors or persons connected with them covered under Section 192 of the Act. Accordingly, the provisions of Clause 3(xv) of the order are not applicable.
- 16)
 - a. According to the information and explanation given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934 and the Company has not conducted any NBFC Company during the year.
 - b. The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.
- 17) The Company has not incurred cash losses in the Financial Year and in the immediately preceding Financial Year.
- 18) There has been no resignation of Statutory Auditors during the Financial year 2023-24.
- 19) On the basis of the Financial Ratios, ageing and expected dates of realization of Financial Assets and payment of Financial Liabilities, other information accompanying the Financial Statements, the Auditor's knowledge of the Board of Directors and the Management's plans, the Auditor is of the opinion that no material uncertainty exists as on the date of the Audit Report and that the Company is capable of meeting its Liabilities existing at the Date of Balance Sheet, as and when they fall due within a period of one year from the Balance Sheet Date. We however, state that this is not an assurance as to the future viability of the

Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- 20) The Company is not liable to contribute under Section 135 of the Companies Act, 2013. Accordingly, the provisions of Clause 3(xx) of the order are not applicable.
- 21) In our opinion and according to the information and explanations given to us, Company does not have any subsidiaries; associates and joint venture Therefore this clause is not applicable

For **PPKG & Co**
Chartered Accountants
Firm's Registration No. 009655S

Sd/-
Girdhari Lal Toshniwal
Partner
Membership No. 205140
UDIN: 24205140BKALIZ2286

Date: May 29, 2024
Place: Hyderabad

ANNEXURE - B TO THE AUDITORS' REPORT

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **VILIN BIO MED LIMITED**. ("The Company") as of 31 March, 2024 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company;

and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

for **PPKG AND CO**
Chartered Accountants

Place : **HYDERABAD**
Date : **29/05/2024**

Sd/-
GIRDHARI LAL TOSHNIWAL
5-8-352 ,701 7TH FLOOR, RAGHAVA RATNA TOWERS,
NEAR MEDWIN HOSPITAL, ABIDS, HYDERABAD-
500001 TELANGANA
UDIN: 24205140BKALIZ2286

BALANCE SHEET AS AT 31/03/2024

In ` Lakhs

Particulars	Note No.	as at 31/03/2024	as at 31/03/2023
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	1	1395.00	995.00
Reserves and surplus	2	889.00	72.76
Money received against share warrants		-	-
		2284.00	1067.76
Share application money pending allotment		-	-
Non-current liabilities			
Long-term borrowings	3	20.87	43.12
Deferred tax liabilities (Net)	4	8.16	7.00
Other Long term liabilities		-	-
Long-term provisions		-	-
		29.02	50.12
Current liabilities			
Short-term borrowings	5	662.12	450.00
Trade payables	6	-	-
Total outstanding dues of micro enterprises and small enterprises		-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises		195.34	118.94
Other current liabilities	7	11.89	26.43
Short-term provisions	8	58.01	54.33
		927.36	649.69
TOTAL		3240.38	1767.56
ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible Assets			
Property, Plant and Equipment	9	138.27	151.15
Intangible assets		-	-
Capital work-in-progress		-	-
Intangible assets under development		-	-
		138.27	151.15
Non-current investments		-	-
Deferred tax assets (net)		-	-
Long-term loans and advances	10	466.06	94.84
Other non-current assets	11	774.50	716.13
		1378.83	962.12
Current assets			
Current investments		-	-
Inventories	12	446.75	87.88
Trade receivables	13	568.41	560.05
Cash and cash equivalents	14	604.94	3.45
Short-term loans and advances	15	117.59	71.88
Other current assets	16	123.87	82.18
		1861.55	805.44
Accounting Policies and Notes on Accounts	1.0		
TOTAL		3240.38	1767.56

In terms of our attached report of even date

For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN: 009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI
LAL
TOSHNIWAL
(PARTNER)

Sd/-
ANAND LOHIA

(COMPANY
SECRETARY)

Sd/-
CHILLAM
SRIKANTH

(CHIEF
FINANCIAL
OFFICER)

Sd/-
ANUJ
BAJPAI

(WHOLE
TIME
DIRECTOR)
(DIN: 08939135)

Sd/-
VISWA PRASAD
SADHANALA

(MANAGING
DIRECTOR)
(DIN: 08068933)

Place : Hyderabad
Date : 29/05/2024
UDIN : 24205140BKALIZ2286

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31/03/2024

In ` Lakhs except earning per share

Particulars	Note No.	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Revenue from operations	17	1580.49	1231.30
Other income	18	32.43	2.44
Total Income		1612.92	1233.74
Expenses			
Cost of materials consumed	19	1279.55	709.53
Purchases of Stock-in-Trade		-	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	20	21.06	7.58
Employee benefits expense	21	80.38	77.74
Finance costs	22	78.58	64.84
Depreciation and amortization expense	23	13.01	16.76
Other expenses	24	117.83	179.12
Total expenses		1590.40	1055.58
Profit before exceptional and extraordinary items and tax		22.52	178.16
Exceptional items		-	-
Profit before extraordinary items and tax		22.52	178.16
Extraordinary Items		-	-
Profit before tax		22.52	178.16
Tax expense:	25		
Current tax		5.11	52.83
Deferred tax		1.16	0.84
Profit/(loss) for the period from continuing operations		16.24	124.50
Profit/(loss) from discontinuing operations		-	-
Tax expense of discontinuing operations		-	-
Profit/(loss) from Discontinuing operations (after tax)		-	-
Profit/(loss) for the period		16.24	124.50
Earnings per equity share:	26		
Basic		0.12	1.25
Diluted		0.12	1.25

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN: 009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI LAL TOSHNIWAL

Sd/-
ANAND
LOHIA

Sd/-
CHILLAM
SRIKANTH

Sd/-
ANUJ
BAJPAI

Sd/-
VISWA
PRASAD
SADHANALA

(PARTNER)

(COMPANY
SECRETARY)

(CHIEF
FINANCIAL
OFFICER)

(WHOLE
TIME
DIRECTOR)

(MANAGING
DIRECTOR)

(DIN:
08939135)

(DIN:
08068933)

Place : Hyderabad
Date : 29/05/2024
UDIN : 24205140BKALIZ2286

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2024

In ` Lakhs

Particulars	As at 31-Mar-2024	As at 31-Mar-2023
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	22.53	178.15
Adjustment For		
Depreciation	13.01	16.76
Foreign Exchange		
Gain or Loss on Sale of Fixed Assets		
Gain or Loss on Sale of Investment		
Finance Cost	78.58	
Dividend Income		
Other adjustment of Non-Cash Item		
Other adjustment to reconcile Profit		
	91.59	16.76
Adjustment For working Capital Change		
Adjustment for Increase/Decrease in Inventories	(358.87)	140.50
Adjustment for Increase/Decrease in Trade Receivables	(8.36)	(208.74)
Adjustment for Increase/Decrease in Other Current Assets	(41.69)	(59.36)
Adjustment for Increase/Decrease in Other Non Current Assets	(58.37)	(289.16)
Adjustment for Increase/Decrease in Short Term Borrowings	212.12	
Adjustment for Increase/Decrease in Long term Loans and Advances	(371.22)	
Adjustment for Increase/Decrease in Short Term Loans and advances	(45.71)	(10.36)
Adjustment for Increase/Decrease in Trade Payables	76.40	54.82
Adjustment for Increase/Decrease in Other Current Liabilities	(14.54)	14.87
Adjustment for Provisions	3.68	50.33
Total Adjustment For Working Capital (B)	(606.56)	(307.10)
Total Adjustment to reconcile Profit (A+B)	(514.97)	(290.34)
Net Cash Flow from (Used in) Operations	(492.44)	(112.19)
Dividend Received		
Interest Received	(32.43)	
Interest Paid	-	
Income Tax Paid / Refund	(5.11)	(53.67)
Net Cash Flow from (used in) operation before Extra-ordinary Items	(529.98)	(165.85)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from Operating Activities	(529.98)	(165.85)
Cash Flows from Investing Activities		
Proceeds from Fixed Assets		(2.95)
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets	0.13	
Purchase of Investments or Equity Instruments		
Interest Received	32.43	

Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash Flow from losing Control of Subsidiaries		
Cash Payment for acquiring Control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow / Outflow of Cash		
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	32.30	(2.95)
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (Used in) in Investing Activities	32.30	(2.95)
Cash Flows from Financial Activities		
Proceeds from Issue of Shares	400.00	204.00
Proceeds from Issuing shares for security premium	800.00	-
Proceeds from Issue of Debenture / Bonds / Notes		
Redemption of Preference Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Borrowing		(6.56)
Repayment of Borrowing	22.25	29.09
Dividend Paid		
Interest Paid	78.58	
Income Tax Paid / Refund		
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	1,099.17	168.35
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from (Used in) in Financial Activities	1,099.17	168.35
Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	601.49	(0.45)
Effect of Exchange Rate change on Cash and Cash Equivalents		
Net Increase (Decrease) in Cash and Cash Equivalents	601.49	(0.45)
Cash and Cash Equivalents at beginning of period	3.45	3.90
Cash and Cash Equivalents at end of period	604.94	3.45

In terms of our attached report of even date

For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN: 009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI LAL TOSHNIWAL

(PARTNER)

Sd/-
ANAND LOHIA

(COMPANY
SECRETARY)

Sd/-
CHILLAM
SRIKANTH
(CHIEF
FINANCIAL
OFFICER)

Sd/-
ANUJ BAJPAI

(WHOLE
TIME
DIRECTOR)
(DIN:
08939135)

Sd/-
VISWA PRASAD
SADHANALA
(MANAGING
DIRECTOR)

(DIN: 08068933)

Place : Hyderabad
Date : 29/05/2024
UDIN : 24205140BKALIZ2286

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2024

Note No. 1 Share Capital

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Authorised		
15000000 (9950000) Equity Shares of ` 10/- Par Value	1500.00	995.00
	1500.00	995.00
Issued		
13950000 (9950000) Equity Shares of ` 10/- Par Value	1395.00	995.00
	1395.00	995.00
Subscribed		
13950000 (9950000) Equity Shares of ` 10/- Par Value	1395.00	995.00
	1395.00	995.00
Paid-up		
13950000 (9950000) Equity Shares of ` 10/- Par Value Fully Paid-up	1395.00	995.00
	1395.00	995.00

Holding More Than 5%

Particulars	as at 31/03/2024		as at 31/03/2023	
	Number of Share	% Held	Number of Share	% Held
Sadhanala Venkata Rao	4589705	32.90	4589705	46.13
Srinivasa Reddy Devireddy	2012795	14.43	2012795	20.23
Viswa Prasad Sadhanala	1876140	13.45	1876140	18.86

Reconciliation of the number of Equity shares outstanding at the beginning and at the end of the reporting period

In ` Lakhs

Particulars	as at 31/03/2024		as at 31/03/2023	
	Number of Share	Amount	Number of Share	Amount
Number of shares at the beginning	9950000	995.00	3300000	330.00
Add : Issue	4000000	400.00	6650000	665.00
Less : Bought Back	0	0.00	0	0.00
Others	0	0.00	0	0.00
Number of shares at the end	13950000	1395.00	9950000	995.00

Shareholding of Promoters

Shares held by promoters as at 31/03/2023

Equity Shares of `10

Shares held by promoter at the end of year				% change during the year
SN	Promoters Name	No. of Shares	% of total shares	
1	Sadhanala Venkata Rao	4589705	46.13	32.31
2	Srinivasa Reddy Devireddy	2012795	20.23	14.04
3	Viswa Prasad Sadhanala	1876140	18.86	11.27
4	Ramesh Reddy Sama	463235	4.66	-0.96
5	Tanmayee Reddy Sama	21250	0.21	-18.53
6	Anuj Bajpai	15000	0.15	-20.64
7	Sama Ruchit Reddy	12500	0.13	-3.39
8	Sneha Bajpai	9375	0.09	-23.66

Note No. 2 Reserve and Surplus

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Capital Reserve - Opening	22.56	22.56
Addition	0.00	0.00
Deduction	0.00	0.00
	22.56	22.56
Securities Premium Opening	0.00	0.00
Additions	800.00	0.00
	800.00	0.00
Profit and Loss Opening	50.20	386.75
Amount Transferred From Statement of P&L	16.24	124.50
Amount Transferred From Sundries		
Others	0.00	(461.05)
	0.00	(461.05)
	66.44	50.20
	889.00	72.76

Note No. 3 Long Term Borrowings

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Term Loan		
Banks		
Secured		
Rupee		
PNB A/C 389800IL00000270 TERM LOAN A/C	20.87	43.12
	20.87	43.12

Note No. 4 Deferred Taxes

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Deferred Tax Liabilities		
Other	8.16	7.00
	8.16	7.00

Note No. 5 Short Term Borrowings

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Other loans and advances		
Secured		
PNB RAM NAGAR CC (16831 A/C)	474.22	450.00
KAPIL CHITS HYD PVT	43.18	0.00
MARGADARSI CHIT FUND PVT LTD	43.19	0.00
ICICI A/C NO.068005003833 A/C	101.53	0.00
	662.12	450.00

Note No. 6 Trade Payables

as at 31/03/2024

In ` Lakhs

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) MSME	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Others	80.65	114.69	0.00	0.00	0.00	195.34
(iii) Disputed dues-MSME	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed dues Others	0.00	0.00	0.00	0.00	0.00	0.00

as at 31/03/2023

In ` Lakhs

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) MSME	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Others	118.94	0.00	0.00	0.00	0.00	118.94
(iii) Disputed dues-MSME	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed dues Others	0.00	0.00	0.00	0.00	0.00	0.00

Note No. 7 Other Current Liabilities

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Other payables		
Other Current Liabilities		
SALARY PAYABLE	9.81	12.70
INTEREST PAYABLE	0.00	11.26
ESIC PAYABLE	0.03	0.03
E.P.F. PAYABLE	0.13	0.13
TDS PAYABLE	0.24	0.24
TDS 194Q@0.1% PURCHASES	0.05	0.05
POWER CHARGES PAYABLE	0.04	2.78
POWER PAYABLE FACTORY	1.50	0.00
CGST TAX	0.05	(0.38)
SGST TAX	0.05	(0.38)
DIRECTORS REMUNERATION PAYABLE	0.00	0.00
	11.89	26.43

Note No. 8 Short Term Provisions

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Tax Provision		
Current Tax		
INCOME TAX	56.94	52.83
Others		
AUDIT FEE PAYABLE	1.07	1.50
	58.01	54.33

No. 9 Property, Plant and Equipment

In ` Lakhs

Particulars	Gross					Depreciation					Impairment				Net	
	Openin g as at 01/04/ 2023	Addi tion	Dedu ction	Reval uatio n	Closin g as at 31/03 /2024	Openi ng as at 01/04 /2023	Duri ng Perio d	Dedu ction	Other Adj.	Closin g as at 31/03/ 2024	Open ing as at 01/0 4/20 23	Durin g Perio d	Rever sal	Closing as at 31/03/20 24	Closin g as at 31/03/ 2024	Closin g as at 31/03 /2023
Land																
Free Hold Land																
LAND	21.15				21.15										21.15	21.15
Total	21.15				21.15										21.15	21.15
Building																
Office Building																
BUILDING	39.86				39.86	25.68	1.45			27.13					12.73	14.18
BUILDING	19.15				19.15	13.19	0.62			13.81					5.34	5.96
BUILDING	22.36				22.36	15.87	0.68			16.54					5.81	6.49
BUILDING	34.10				34.10	28.65	0.45			29.10					5.00	5.45
BUILDING	37.44				37.44	30.99	0.51			31.50					5.94	6.45
BUILDING	129.76				129.76	103.16	2.74			105.91					23.85	26.60
BUILDING	43.68				43.68	36.12	0.74			36.86					6.82	7.56
BUILDING	22.65				22.65	11.05	1.15			12.20					10.46	11.60
Total	348.99				348.99	264.70	8.35			273.05					75.94	84.29
Plant and Machinery																
PLANT AND MACHINERY-1	201.15				201.15	188.76				188.76					12.39	12.39
PLANT AND MACHINERY-1	12.83				12.83	9.11	0.73			9.84					2.99	3.73
PLANT AND MACHINERY-1	0.92				0.92	0.65	0.05			0.70					0.22	0.27
PLANT AND MACHINERY-1	0.70				0.70	0.49	0.04			0.53					0.17	0.21
PLANT AND MACHINERY-1	8.00				8.00	5.69	0.46			6.15					1.85	2.31
PLANT AND MACHINERY-1	3.61				3.61	2.79	0.16			2.95					0.66	0.82
PLANT AND MACHINERY-1	2.85				2.85	0.10	0.18			0.28					2.57	2.75
PLANT AND MACHINERY-1	1.14				1.14	1.08				1.08					0.06	0.06
PLANT AND MACHINERY-1	0.18				0.18	0.17	0.00			0.17					0.01	0.01
PLANT AND MACHINERY-1	0.39				0.39	0.36	0.01			0.37					0.02	0.03
PLANT AND MACHINERY-1	0.40				0.40	0.35	0.01			0.36					0.04	0.05
PLANT AND MACHINERY-1	0.53				0.53	0.48	0.01			0.49					0.04	0.05
PLANT AND MACHINERY-1	4.16				4.16	3.48	0.14			3.62					0.54	0.68
PLANT AND MACHINERY-1	0.20				0.20	0.17	0.01			0.17					0.03	0.03
PLANT AND MACHINERY-1	0.34				0.34	0.22	0.02			0.24					0.10	0.13
PLANT AND MACHINERY-1	0.65				0.65	0.40	0.04			0.45					0.20	0.25
PLANT AND MACHINERY-1	0.34				0.34	0.22	0.02			0.24					0.10	0.12
PLANT AND MACHINERY-1	0.73				0.73	0.46	0.05			0.51					0.22	0.26
PLANT AND MACHINERY-1	0.35				0.35	0.23	0.02			0.25					0.10	0.12
PLANT AND MACHINERY-1	0.86				0.86	0.65	0.04			0.69					0.16	0.21
PLANT AND	88.16				88.16	83.75				83.75					4.41	4.41

MACHINERY-1																
PLANT AND MACHINERY-1	95.46				95.46	90.68				90.68				4.77	4.77	
PLANT AND MACHINERY-1	57.18				57.18	53.36	0.96			54.32				2.86	3.82	
PLANT AND MACHINERY-1	21.27				21.27	19.49	0.43			19.93				1.34	1.77	
PLANT AND MACHINERY-1	3.93				3.93	3.33	0.12			3.45				0.47	0.59	
PLANT AND MACHINERY-1	22.48				22.48	19.65	0.61			20.25				2.23	2.84	
PLANT AND MACHINERY-1	1.96				1.96	1.77	0.05			1.81				0.15	0.20	
PLANT AND MACHINERY-1	0.63				0.63	0.46	0.03			0.50				0.13	0.17	
PLANT AND MACHINERY-1	0.51				0.51	0.38	0.03			0.41				0.10	0.13	
PLANT AND MACHINERY-1	0.38				0.38	0.28	0.02			0.30				0.08	0.10	
Total	532.29				532.29	489.04	4.24			493.28				39.01	43.25	
Equipments																
Office Equipments																
OFFICE EQUIPMENT	0.29				0.29	0.28				0.28				0.01	0.01	
OFFICE EQUIPMENT	0.44				0.44	0.42				0.42				0.02	0.02	
OFFICE EQUIPMENT	2.93				2.93	2.78				2.78				0.15	0.15	
Total	3.67				3.67	3.48				3.48				0.19	0.19	
Computer Equipments																
COMPUTER	4.61				4.61	4.44				4.44				0.17	0.17	
Total	4.61				4.61	4.44				4.44				0.17	0.17	
Other Equipments																
PRINTER	0.11				0.11	0.00	0.06			0.07				0.04	0.10	
Total	0.11				0.11	0.00	0.06			0.07				0.04	0.10	
Furniture and Fixtures																
FURNITURE	0.15				0.15	0.11	0.01			0.13				0.03	0.04	
FURNITURE	0.48				0.48	0.40	0.02			0.43				0.05	0.07	
FURNITURE	2.46				2.46	2.33				2.33				0.12	0.12	
FURNITURE	2.82				2.82	2.59	0.08			2.66				0.16	0.24	
FURNITURE	6.55				6.55	5.83	0.22			6.05				0.49	0.72	
FURNITURE	3.51				3.51	3.32				3.32				0.19	0.19	
FURNITURE		0.13			0.13		0.01			0.01				0.12		
Total	15.96	0.13			16.09	14.59	0.34			14.93				1.16	1.38	
Vehicles																
Motor Vehicles																
VEHICLE	10.77				10.77	10.23				10.23				0.54	0.54	
VEHICLE	0.48				0.48	0.43	0.01			0.44				0.04	0.06	
VEHICLE	0.45				0.45	0.43				0.43				0.02	0.02	
Total	11.71				11.71	11.09	0.01			11.10				0.60	0.62	
Grand Total	938.49	0.13	0.00	0.00	938.62	787.34	13.01	0.00	0.00	800.35	0.00	0.00	0.00	0.00	138.27	151.15
Previous	935.53	2.96	0.00	0.00	938.49	770.58	16.76	0.00	0.00	787.34	0.00	0.00	0.00	0.00	151.15	164.96

Note No. 10 Long-term loans and advances

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Loans and advances to related parties	274.14	94.84
Loans and advances to others	191.92	0.00
	466.06	94.84

Note No. 11 Other non-current assets

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Trade Receivable		
Secured, Considered Good		
Exceeding Six Months		
REDIZEN LIFESCIENCES PVT LTD., TELANGANA	220.88	220.26
RECON LIFE SCIENCES-DEBTORS	133.44	127.37
NATIONAL PHARMA, SAHARNAPUR	50.45	0.00
MATHRA LIFE SCIENCES	102.97	97.26
MANSA MEDI IMPEX, TELANGANA	2.85	2.85
MANCOP REMEDIES, TELANGANA	64.70	65.70
CHEMIST PHARMACEUTICAL, NANAUTA, SAHARANPUR	21.67	24.83
B.R. MEDICALS, HYD, TELANGANA	50.47	50.47
ALRED HEALTH CARE, HYDERABAD TELANGANA	50.34	50.67
ALRED HEALTH CARE LTD., HYD.	37.51	37.51
ALRED HEALTH CARE LTD, BANGLORE	39.22	39.22
	774.50	716.13

Note No. 12 Inventories

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Raw Material	74.03	30.51
Finished Goods	297.91	21.06
Others		
Packing Material	74.80	36.31
	446.75	87.88

Note No. 13 Trade receivables

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Trade Receivable		
Secured, considered good		
Within Six Months		
ZOIC LIFE SCIENCES, DEHRADUN	0.04	0.04
WAVES BIOTECH PVT LTD.	4.60	4.88
VLN MEDICALS, TELANGANA	1.27	1.27
VENTO PHARMACEUTICALS, ROORKEE	38.96	38.96
VEDAM LIFE SCIENCE, ROORKEE	12.22	12.22
VAM PHARMA, HARIDWAR	1.09	1.09
SYMPAR LIFE SCIENCES, DEHRADUN	1.29	1.29
STERIS HEALTH CARE, JAIPUR	0.16	0.16
SRI ANNAPURNA PHARMA	0.28	0.28
SPARSH REMEDIES PRIVATE LIMITED, DELHI	4.18	2.17
SHREYASH BIO PHARMA PRIVATE LTD.	0.15	0.15
SHREE JI MEDICOSE, KHATAULI	0.05	0.02
SAKET KANSAL AC	0.50	0.00
SAI KIRAN MEDICALS, A/C	0.50	0.50
RAJNI SHANKAR MEDICALS, WARANGAL	4.59	4.59
ONEROUS PHARMA	0.06	0.06
NOSME PHARMACEUTICAL, KARNAL	0.01	0.01
NITRO ORGANICS PRIVATE LIMITED	0.66	0.66
MORA PHARMA PRIVATE LIMITED	297.41	0.00
MESTRA PHARMA PRIVATE LIMITED, ROORKEE	23.07	16.57
MEDISHINE PHARMACEUTICALS PVT LTD.	1.20	1.20
MAA ANJANA DISTRIBUTORS, RAJASTHAN	0.30	0.30
LEE HEALTH DOMAIN INDIA PVT LTD., HYDERABAD	0.09	0.09
LAHAR PHARMACEUTICALS, HYDERABAD	(4.06)	0.41
KAMRON LABORATORIES LTD., AHMEDABAD	1.22	1.22

JKG HEALTHCARE, SAHARANPUR	0.05	0.05
HARI PRIYA MEDICALS	0.46	0.46
HANS PHARMA -DEBTORS	(519.26)	5.06
HANS PHARMA, ANDHRA PARDESH	1129.59	200.42
GUEST HOUSE RKE (ANITA SAINI W/O KANVAR PAL)	1.60	0.00
EXCELLENT TRADERS, ROORKEE	0.00	0.00
EMPIRE HEALTH CARE, TELANGANA	12.38	12.38
C ZEN LIFESCIENCES, TELANGANA	(11.05)	0.55
BIOGENETICS HEALTH CARE(INDIA) PVT. LTD, KOLKATTA	0.81	0.81
BIOCLARIS DRUGS & PHARMACEUTICALS, ROORKEE	5.53	5.53
ANCONA PHARMACEUTICALS	4.43	4.43
ALRIC BIO MEDICS, OLD A/C TELANGANA	0.14	0.14
AARMED FORMULATION PVT. LTD., AHMEDABAD	3.24	3.24
SPECTROGEN INTERNATIONAL PRIVATE LIMITED	(449.37)	238.84
	568.41	560.05

Ageing Schedule as at 31/03/2024

Particulars	Outstanding for following periods from due date of payment						Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) Undisputed Trade receivables - considered good	477.28	91.13	0.00	0.00	0.00	0.00	568.41
(ii) Undisputed Trade Receivables - considered doubtful	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(iii) Disputed Trade Receivables considered good	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed Trade Receivables considered doubtful	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Ageing Schedule as at 31/03/2023

Particulars	Outstanding for following periods from due date of payment						Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) Undisputed Trade receivables - considered good	555.21	4.84	0.00	0.00	0.00	0.00	560.05
(ii) Undisputed Trade Receivables - considered doubtful	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(iii) Disputed Trade Receivables considered good	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed Trade Receivables considered doubtful	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Note No. 14 Cash and cash equivalents

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Cash in Hand	4.83	2.92
Balances With Banks		
Balance With Scheduled Banks		
Current Account		
ICICI BANK - 630805161779	0.11	0.00
PNB CURRENT AC NO-3898002100017782	0.00	0.02
PNB CURRENT ACCOUNT A/C NO.3898002100013041	0.00	0.00
P.N.B CURRENT A/C NO. - 3898002100013041	0.00	0.05
ICICI A/C NO.068005003833 A/C	0.00	0.46
Deposit Account		
FIXED DEPOSIT	600.00	0.00
	604.94	3.45

Note No. 15 Short-term loans and advances

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Security Deposits		
Secured, considered good		
DEPOSIT	2.00	2.00
ELECTRICITY SECURITY	2.85	2.85
RENT DEPOSIT	1.50	1.50
Loans and advances to related parties		
Loans and advances to others		
Secured, considered good		
A.S TRADING COMPANY	0.00	0.81
AASTHA MEDI SOLUTIONS, BHAGWANPUR, ROORKEE	0.00	0.51
AAY WON LAMITUBES & PACKING SOLUTION, H.P.	0.02	0.02
AIRCON ENGINEERS, DELHI	0.08	0.08
ANMOL CORRUPACK P LTD, BHAGWANPUR RKE	(0.29)	0.25
ASG PHARMA, ROORKEE	0.10	0.10
AYANSH ENTERPRISES, ROORKEE	0.01	0.01
BASHAR TRADERS, ROORKEE	0.02	0.02
FAIR COMMUNICATION & SERVICES, RKE	0.00	1.08
GAUR ENTERPRISES, GHAZIABAD	0.28	0.28
GUJRAT TRADING CORPORATION, ROORKEE	0.00	0.00
J K AARNA PRINTING & PACKERS, MANGLORE, ROORKEE	0.02	0.02
KOCHER PACKAGING INDUSTRIES, HARIDWAR	0.09	0.09
KUNDAN SALE COP.	(0.14)	0.11
LEROI PHARMACEUTICALS PVT. LTD, MANGLORE, RKE.	0.10	0.10
MAA LAXMI CHEMICALS, ROORKEE	0.00	0.00
MOHIT ARORA & CO. RKE	0.12	0.12
MONY CHEMICALS, GHAZIABAD	0.02	0.02
NEW AMBEY PACK, RKE.	0.12	0.12
PIYUSH TRADING CO.,	0.02	0.02
PRAGATI RAW PHARMA PVT. LTD, RKE.	0.07	0.07
PRECIOUS PHARMA, MUMBAI	0.00	0.50
R.S. ENTERPRISES, ROORKEE	0.05	0.05
RAJSHI FARMA PVT. LTD., HARIDWAR	0.01	0.01
SAINI PRINTING & PACKERS, ROORKEE	0.01	0.01
SEA SHELL CHEMICALS PVT. LTD.	0.06	0.06
SHREE BALAJI ENTERPRISES, ROORKEE	0.26	0.26
SHRI GANESH PRINTERS, ROORKEE	0.00	0.07
SHRI RADHEY PRINTERS, BHAGWANPUR	0.02	0.02
WINMARK GRAPHIX, SAHARANPUR	0.03	0.03
YACCA PHARMACEUTICALS PVT. LTD., RKE	0.01	0.01
DEVALAPALLI ARUNA	5.00	5.00

DHEERAJ MADAN A/C.	2.00	2.00
NANDINI MITTAL A/C	5.50	5.50
ROHIT KUMAR A/C	8.27	8.27
SREEKANTH REDDY SIR	35.95	35.95
INDO GERMAN REMEDIES, MEERUT	0.00	1.18
KAHAN PHARMACEUTICALS	0.00	0.50
MULTANI PHARMACEUTICALS LIMITED, RKE	(0.32)	0.03
SHRI LAXMI BHAWANI AGENCIES, ROORKEE	0.00	0.62
SINGH YUDHVEER & ASSOCIATES, RKE/	0.00	1.62
UP ENGINES SERVICES, HARIDWAR-ADVANCE	0.18	0.00
ANUPAMA AC	0.10	0.00
JADALA RAMESH	0.25	0.00
RAMBABU A/C	0.10	0.00
SUVARNA LATHA	0.10	0.00
POLLUTION SECUIRITY	0.04	0.00
PRADEEP REDDY SHARE ACCOUNT	25.00	0.00
SHREE GANESH PRINTERS, ROORKEE	0.07	0.00
SOURAV MATHUR A/C.	(1.08)	0.00
VISHWA PRASAD	25.00	0.00
ANUJ BAJPAI	4.00	0.00
	117.59	71.88

Note No. 16 Other current assets	In ` Lakhs	
Particulars	as at 31/03/2024	as at 31/03/2023
TDS RECEIVABLE	3.47	0.23
TCS 0.1% A/C	0.13	0.09
SALONI SHARMA ADVANCE	0.15	0.15
SALARY ADVANCES	0.12	0.12
REVERSE TAX CHARGES PAYABLE	0.00	0.16
REVERSE TAX CHARGES	0.00	0.82
PUBLIC ISSUE ACCOUNT	3.24	0.00
P. RAVIKIRAN A/C	0.08	0.08
NISHANT SHARMA A/C	0.05	0.05
NATIONAL SECURITY DDEPOSITORY LTD	(0.04)	0.02
MISC.EXPENDITURE	31.68	32.10
GUGULOTHU RAGHU A/C	0.35	0.35
G. MARUTI A/C	4.51	2.50
CHENNUR SAILOO	0.26	0.26
ARJUN DIXIT A/C.	0.10	0.10
AKHIL KM. ASS. CLPC HRW	0.28	0.28
AJAY KARANWAL	0.09	0.09
AARTI MATHUR A/C	0.15	0.15
IGST	0.00	44.66
CGST INPUT RECEIVABLE	7.92	0.00
SGST INPUT RECEIVABLE	71.36	0.00
	123.87	82.18

Note No. 17 Revenue from operations

Particulars	In ` Lakhs	
	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Sale of Products	1580.49	1231.30
	1580.49	1231.30

Note No. 18 Other income

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Miscellaneous	32.43	2.44
	32.43	2.44

Note No. 19 Cost of materials consumed

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Raw Material		
Opening	66.82	199.74
Purchase	1659.48	515.69
Adjustment	0.00	60.92
Closing	446.75	66.82
	1279.55	709.53
	1279.55	709.53

Details of Raw Material

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
RAW MATERIAL	1279.55	709.53
	1279.55	709.53

Note No. 20 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Opening		
Finished Goods	21.06	21.09
	21.06	28.64
Closing		
Finished Goods	0.00	21.06
	0.00	21.06
Increase/Decrease		
Finished Goods	21.06	0.03
	21.06	7.58

Details of Changes in Inventory

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Finished Goods		
FINISHED GOODS	21.06	0.03
Work in Progress		
WIP	0.00	7.55
	21.06	7.58

Note No. 21 Employee benefits expense

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Salary, Wages & Bonus	79.07	74.09
Staff Welfare Expenses	1.31	3.65
	80.38	77.74

Note No. 22 Finance costs

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Interest Expenses		
Interest Expenses	75.22	62.14
Bank Charges	2.82	2.71
Finance Charges		
Other Finance Charges	0.54	0.00
	78.58	64.84

Note No. 23 Depreciation and amortization expense

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Depreciation & Amortization		
Depreciation Tangible Assets	13.01	16.76
	13.01	16.76

Note No. 24 Other expenses

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Administrative and General Expenses		
Telephone Postage	0.61	0.40
Printing Stationery	0.65	0.38
Rent Rates And taxes	0.75	0.00
Auditors Remuneration	1.25	1.50
Repairs Maintenance Expenses	2.46	9.25
Travelling Conveyance	0.00	2.52
Legal and Professional Charges	0.81	14.18
Insurance Expenses	0.58	0.76
Vehicle Running Expenses	0.00	0.03
Safety and Security Expenses	5.54	6.74
Other Administrative and General Expenses	25.33	104.54
Selling Distribution Expenses		
Advertising Promotional Expenses	0.29	0.00
Other Selling Distribution Expenses	0.00	2.00
Write off Assets and Liabilities		
Other Write Offs	73.66	10.83
Other Expenses	5.90	26.01
	117.83	179.12

Note No. 25 Tax expense

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Current tax	5.11	52.83
Deferred tax	1.16	0.84
	6.27	53.67

Note No. 26 Earnings per equity share

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Earnings Per Equity Share		
Basic	0.12	1.25
Diluted	0.12	1.25
Number of Shares used in computing EPS		
Basic	139.5	99.5
Diluted	139.5	99.5

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN: 009655S

For VILIN BIO MED LIMITED

GIRDHARI LAL TOSHNIWAL

(PARTNER)

ANAND LOHIA	CHILLAM SRIKANTH	ANUJ BAJPAI	VISWA PRASAD SADHANALA (MANAGING DIRECTOR)
(COMPANY SECRETARY)	(CHIEF FINANCIAL OFFICER)	(WHOLE TIME DIRECTOR)	(DIN: 08068933)
		(DIN: 08939135)	

Place : Hyderabad
Date : 29/05/2024
UDIN: 24205140BKALIZ2286

Notes on Financial Statements for the Financial year ended on March 31, 2024

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

1. General information

Vilin Bio Med Limited ('the Company') is engaged in the business of manufacturing and selling pharmaceutical products.

The company is a public limited company incorporated under Companies Act, 2013 and domiciled in India bearing CIN No: L24230TG2005PLC046689 and has its registered office at Sy no 115, Hanumanji Colony, Opp Sub Register Office, Old Bowenpally, Secunderabad - 500003, Hyderabad, Telangana - India. Its share are listed on the NSE SME EMERGE.

2. Significant Accounting policies

(a) Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). These financial statements have been prepared to comply in all material respects with the Accounting Standards notified by Companies (Accounting Standards) Rules, 2006, (as amended) and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared under the historical cost convention on an accrual basis and going concern basis. The accounting policies have been consistently applied by the company are consistent with those used in the previous year.

(a) Use of estimates

The preparation of Financial Statements in conformity with the Generally Accepted Accounting Principles requires the Management to make estimates, judgements, and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period.

Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcome requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(b) Functional and Presentation Currency

The Financial Statements are prepared in Indian Rupees ("INR") which is the Company's Functional Currency for its Operations. All Financial Information presented in INR has been rounded to the nearest 'Lakhs' with two decimal places, unless stated otherwise.

(c) Recognition of Revenue and Expenditure

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria is ensured before revenue is recognized.

Income from services

Revenue from services contracts priced on time and material basis are recognized when services are rendered and related costs are incurred. The Company collects Goods and Services Tax on behalf of the government and therefore it is not an economic benefit flowing to the Company. Hence, it is excluded from revenue.

(d) Sale of goods

Revenue is measured at the transaction price of the consideration received or receivable. Revenue from Sale of products is recognized when the control on the Goods have been transferred to the Customer. The Performance Obligation in case of sale of product is satisfied at a point in time i.e., when the material is shipped to the customer or on delivery to the customer, as may be specified in the Contract.

(e) Interest income

Interest Income is recognized on a time proportion basis taking into account the amount outstanding and the effective interest rate method. Interest Income is included under the head "Other Income" in Statement of Profit and Loss.

(f) Property, Plant and Equipment (PPE)

i. Recognition and measurement

Property, Plant and Equipment are stated at Cost comprising of Purchase Price and any initial directly attributable cost of bringing the Asset to its working condition for its intended use less Accumulated Depreciation and Impairment Loss, if any

(a) Subsequent expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

(b) Depreciation

Depreciation on fixed assets is provided on Written Down Value method (WDV) as per Useful life of Asset and in the manner prescribed in Schedule II of the Companies Act, 2013.

(g) Intangible assets

Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortisation/depletion. All costs, including financing costs till commencement of commercial production, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets are capitalized.

The Company has elected to continue with the carrying value of all its intangible assets as recognized in the financial statements as at the date of transition, measured as per the previous GAAP and use that as the deemed cost as at the transition date.

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific to which it relates.

(h) Impairment of non-financial assets

Assets that have a definite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Management periodically assesses using, external and internal sources, whether there is an indication that an asset may be impaired.

The recoverable amount is higher of the asset's net selling price or value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss for an asset is reversed if, and only if, the reversal can be related objectively to an event occurring after the impairment loss was recognized. The carrying amount of an asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

(i) Borrowing cost

Borrowing costs attributable to the acquisition/construction of qualifying assets are capitalized and form part of the cost of the qualifying assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue as an expense.

(j) Income Tax

Provision for income tax is made for both current and deferred taxes. Provision for current income tax is made on the current tax rates based on the assessable income. The Company provides deferred tax based on the tax effect of timing differences resulting from the recognition of items in the financial statements and in estimating its current tax provision. Deferred tax assets are recognized where there is certainty that there will be sufficient future taxable income available against which such deferred tax assets can be realized.

(k) Inventories

Inventories are measured at lower of cost and net realisable value after providing for obsolescence, if any. Cost of inventories comprises of cost of purchase, cost of conversion and other cost including manufacturing overheads incurred in bringing them to their respective present location and condition. Cost of raw materials, work-in- progress, packing materials, trading and other products are determined on first-in-first-out basis.

(l) Research and development

Revenue expenditure on Research and Development is charged to Profit and Loss Account as incurred. Capital expenditure on assets acquired for Research and Development is added to Property, Plant and Equipment (PPE).

(m) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets Classification

The Company shall classify financial assets as subsequently measured at amortised cost and fair value through profit and loss (FVTPL) on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

Initial recognition and measurement

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date i.e., the date that the Company commits to purchase or sell the asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

(n) Cash and cash equivalents

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term deposits with banks with an original maturity of three months or less.

(o) Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost. Gains and losses are recognized in profit and loss when the liabilities are derecognized. This category generally applies to interest-bearing loans and borrowings.

(o) Foreign currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are retranslated using the exchange rate prevailing at the reporting date. Non-monetary items, which are measured in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency are translated using the exchange rate at the date when such value was determined.

Treatment of exchange differences

Exchange differences arising on settlement/restatement of foreign currency monetary assets and liabilities of the Company are recognized as income or expense in the statement of profit and loss.

(q) Leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the Statement of Profit and Loss on a Straight – line basis over the lease term.

(r) Employee benefits

All Employee Benefits payable for rendering the service such as Salaries, Wages etc. and the expected cost of ex-gratia are recognized in the period in which the employee renders the related service. A Liability is recognized for the amount expected to be paid when there is a present legal

or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

(s) Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognized when the Company has a Present Obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Contingent Liability is disclosed in case of a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognized in Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Entity. Contingent Assets are not recognized in Financial Statements and are disclosed in the Notes when it is virtually certain that economic benefits will inflow to the Company.

(t) Earnings per share (EPS)

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.

27. Related Party disclosure as required by Accounting standard (AS) 18 “Related Party Disclosure”

I) Related Party Disclosures with whom transaction have been taken place during the year.

a) Key Management Personnel (KMP)

Mr. S Viswa Prasad (Managing Director), Mr. Anuj Bajpai (Whole Time Director), Srikant Chilam (Chief Financial Officer) w.e.f. 17th December, 2022, Anand Lohia (Company Secretary and Compliance Officer) w.e.f. 04th May, 2024.

Significant Related Party Transaction with Related Parties during the year:

(In Lakhs)

Sr. No	Party Name	Relationship	Nature of Transactions	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023
1.	Viswa Prasad Sadhanala	Managing Director (w.e.f. 01.10.2022)	Advances	13.50	
2.	Viswa Prasad Sadhanala	Managing Director (w.e.f. 01.10.2022)	Remuneration	7.00	4.5
3.	Spectrogen International Private Limited	Enterprises-KMP having significant influence/owned by major shareholder	Trade Receivable	-	238.84
4.	Spectrogen International Private Limited	Enterprises-KMP having significant influence/owned by major shareholder	Advance to Customers	449.37	-
5.	Redizen Lifesciences Private Limited	Enterprises-KMP having significant influence/owned by major shareholder	Trade Receivable	220.88	220.26
6.	Blue Nile Capital Advisory Limited	Enterprises-KMP having significant influence/owned by major shareholder	Current Assets	274.14	94.84

28. Capital Management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital as well as the level of dividends to ordinary shareholders.

The Company monitors capital using a ratio of 'net debt' to 'equity'. For this purpose, net debt is defined as total debt, comprising loans and borrowings less cash and cash equivalents and current investments.

The Company's net debt to equity ratio as at 31st March 2024 and 31st March 2023 was as follows

Particulars	(` In Lakhs)	
	As at 31st March, 2024	As at 31st March, 2023
Current Borrowings	682.99	493.12
Gross Debt	682.99	493.12
Less - Cash and Cash Equivalents	604.95	3.45
Less - Current Investments	-	-
Net debt	78.04	489.67
Total equity	2284.00	1067.76
Net debt to Equity ratio*	0.034	0.46
*Since Net debt to Equity ratio result is negative, the same is shown as nil.		

29. Earning Per Share (EPS):

Basic EPS and Diluted EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the company by the weighted average number of Equity shares outstanding during the year.

Particulars	(` in Lakhs)	
	As at 31st March, 2024	As at 31st March, 2023
Profit attributable to equity holders	16.24	124.50
Weighted average number of shares outstanding during the year	139.5	99.5
Nominal Value of Equity Shares (in Rs.)	10	10
Earning Per Share Basic and Diluted (in Rs.)	0.12	1.25

30. As at 31st March, 2024, the Company has certain dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows:

	Year ended 31st March, 2024	Year ended 31st March,2023
a) The principal amount remaining unpaid to any supplier at the end of the year	0	0
b) Interest due remaining unpaid to any supplier at the end of the year	0	0
c) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during the year	0	0

d) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006	0	0
e) The amount of interest accrued and remaining unpaid at the end of each accounting year	0	0
f) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprises, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act, 2006	0	0

Disclosure of payable to vendors as defined under the “Micro, Small and Medium Enterprise Development Act, 2006” is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company. There are no overdue principal amounts / interest payable amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the year or for any earlier years and accordingly there is no interest paid or outstanding interest in this regard in respect of payment made during the year or on balance brought forward from previous year.

31. Trade Receivables Ageing Schedule:

Particulars	As at 31st March, 2024					
	Less than 6 Months	6 months - 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
i) Undisputed Trade Receivables - Consider Good	477.28	91.13	-	-	-	568.41
ii) Undisputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
iii) Undisputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
iv) Disputed Trade Receivables - Consider Good	-	-	-	-	-	-
v) Disputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
vi) Disputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
Total Debtors	477.28	91.13	-	-	-	568.41

Particulars	As at 31st March, 2023					
	Less than 6 Months	6 months - 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Undisputed Trade Receivables - Consider Good	555.21	4.84	-	-	-	560.05
(ii) Undisputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
(iv) disputed Trade Receivables - Consider Good	-	-	-	-	-	-
(v) disputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
(vi) disputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
Total Debtors	555.21	4.84	-	-	-	560.05
Less: Provision for Doubtful Debts					-	-
Net Debtors	555.21	4.84	-	-	-	560.05

32. Trade Payable Ageing Schedule:

Particulars	As at 31st March, 2024				
	Less than one year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Micro enterprises and small enterprises	80.65	114.69	-	-	195.34
(ii) Others					
(iii) Disputed dues -Micro enterprises and small enterprises	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-
Total	80.65	114.69			195.34

Particulars	As at 31st March, 2023				
	Less than one year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Micro enterprises and small enterprises	-	-	-	-	-
(ii) Others	54.82	64.12	-	-	118.94
(iii) Disputed dues -Micro enterprises and small enterprises	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-
Total	54.82	64.12	-	-	118.94

33. Capital commitment and contingent liabilities

a) Capital commitment

There are no capital commitment outstanding as at reporting date (as at March 31, 2024: NIL)

b) Contingent Liabilities and Commitments

There are no contingent liabilities

34. OTHER STATUTORY INFORMATION:

- (i) The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
- (ii) The Company has not granted Loans or Advances in the nature of loans to promoters, directors, KMPs and the related parties.
- (iii) The Company does not have any transactions with companies which are struck off.

35. The Company has considered the business segment as the primary reporting segment on the basis that the risk and returns of the Company is primarily determined by the nature of products and services. Consequently, the geographical segment has been considered as a secondary segment.

The business segment has been identified on the basis of the nature of products and services, the risks and returns, internal organization and management structure and the internal performance reporting systems. The business segment comprises of manufacturing and selling of pharmaceutical products. Geographical segment is considered based on sales within India and outside India.

36. Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN : 009655S

For VILIN BIO MED LIMITED

GIRDHARI LAL TOSHNIWAL

(PARTNER)

ANAND LOHIA	CHILLAM SRIKANTH	ANUJ BAJPAI	VISWA PRASAD SADHANALA (MANAGING D IRECTOR)
(COMPANY SECRETARY)	(CHIEF FINANCIAL OFFICER)	(WHOLE TIME DIRECTOR)	(DIN : 08068933)

Place : Hyderabad
Date : 29/05/2024
UDIN: 24205140BKALIZ2286

Vilin Bio Med Limited



VILIN BIO MED LTD.

Unit-II, Khasra No. 85, Madhopur Village, Hazaratpur, Roorkee, Dist : Haridwar (Uttarakhand)
E-mail : vilinbiomedltd@yahoo.co.in

August 25, 2023

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051
NSE Symbol- VILINBIO ISIN: INE0L4V01013

Subject: Submission of Annual Report for The Financial Year 2022-23

Ref: Disclosure under Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

In terms of Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit a copy of the Annual Report of the Company for the Financial Year 2022-23, including Notice of 17th Annual General Meeting (“AGM”) of the members of the Company, scheduled to be held on Saturday, September 23, 2023 at 12.00 P.M. (“IST”) through Video Conferencing /Other Audio-Visual Means (“VC/OAVM”).

Kindly take the same on record.

Thanking You

Yours Faithfully

For Vilin Bio Med Limited

Ashdeep Kaur
Company Secretary and Compliance Officer

Encl.: As above



Vilin Bio Med Limited



17th Annual Report 2022-23

CONTENTS

Corporate Information	04
Notice of the 17th Annual General Meeting	05-13
Board's Report	14-21
Annexures	22-28
Conservation of Energy, Technology Absorption and Foreign Exchange.....	22
Form MR-3: Secretarial Audit Report	23-25
Management Discussion and Analysis Report	26-27
Form AOC-2	28
Independent Auditor's Report	29-36
Standalone Financial Statement	37-56

CORPORATE INFORMATION

BOARD OF DIRECTORS:

Mr. Veerareddy Vallapureddy

Independent Director

Mr. Rakesh Kumar Chandak

Independent Director

Mr. Viswa Prasad Sadhanala

Managing Director

Mr. Anuj Bajpai

Whole Time Director

Ms. Padmaja Kalyani Sadhanala

Non-Executive Director

KEY MANAGERIAL PERSONNEL:

Mr. Chilam Srikanth

Chief Financial Officer

Ms. Ashdeep Kaur

Company Secretary & Compliance Officer

REGISTERED OFFICE:

Sy. No. 115, Hanumanji Colony,
Brig Sayeed Road, Bowenpally,
Secunderabad-500009 Telangana, India

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbiomed.co.in

TelNo.040-7961 8843

MANUFACTURING UNIT:

Unit-II, Khasra No. 85,
Madhopur Village, Roorkee,
Haridwar, Uttarakhand, India

STATUTORY AUDITORS:

M/s PPKG & Co

Chartered Accountants,

5-8-352, 701, 7th Floor,

Raghava Ratna Towers, Fateh Maidan Lane,

Chirag Ali Lane, Abids,

Hyderabad- 500001, Telangana

SECRETARIAL AUDITORS:

M/s Kashinath Sahu & Co

Company Secretaries,

Flat No. 101,

G K Arunodhaya Enclave Mallapur,

Hyderabad - 500076, Telangana

REGISTRAR & SHARE

TRANSFER AGENTS (RTA):

M/s Bigshare Services Private Ltd

306, 3rd floor, Right Wing, Amrutha Ville,

Somajiguda, Rajbhavan Road,

Hyderabad- 500082, Telangana

E-mail: bsshyd@bigshareonline.com

Website: www.bigshareonline.com

LISTING:

National Stock Exchange of India Limited

(EMERGE Platform) on June 30, 2023

BANKER TO THE COMPANY:

Punjab National Bank

NOTICE

NOTICE IS HEREBY GIVEN THAT THE 17TH ANNUAL GENERAL MEETING (AGM) OF THE MEMBERS OF VILIN BIO MED LIMITED (“THE COMPANY”) WILL BE HELD ON SATURDAY, SEPTEMBER 23, 2023 AT 12:00 P.M. IST THROUGH VIDEO CONFERENCING / OTHER AUDIO VISUAL MEANS (“VC/OAVM”) FACILITY TO TRANSACT FOLLOWING BUSINESS:

Ordinary Business:

1. To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March 2023 and the Reports of the Auditors and Board of Directors thereon.
2. To appoint a Director in place of Ms. Padmaja Kalyani Sadhanala (DIN: 03096445), who retires by rotation and being eligible offers herself for re-appointment.
3. Appointment of M/s. PPKG & Co. (Firm Registration No. 009655S), Chartered Accountants, as Statutory Auditors for a term of 5 (five) consecutive years and to fix their remuneration.

To consider and if thought fit, to pass with or without modifications the following resolution as an **Ordinary Resolution:**

“RESOLVED THAT pursuant to the provisions of Section 139, 141, 142 and other applicable provisions, if any, of the Companies Act, 2013 (“Act”) read with Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), and pursuant to the recommendations of the Audit Committee and the Board of Directors of the Company (the “Board”), approval of the Shareholders be and is hereby accorded for the appointment of M/s. PPKG & Co. (Firm Registration No. 009655S), Chartered Accountants, as the Statutory Auditors of the Company for a term of 5 (five) consecutive years from the conclusion of this 17th Annual General Meeting till the conclusion of 22nd Annual General Meeting of the Company. ”

“RESOLVED FURTHER THAT the approval of the shareholders be and is hereby accorded to authorise the Board of Directors to fix and pay the statutory audit fee and other charges as may be deemed fit for the Statutory Auditors plus applicable taxes and reimbursement of out of pocket expenses to M/s. PPKG & Co. Chartered Accountants.”

By Order of the Board
For **Vilin Bio Med Limited**

Sd/-
Ashdeep Kaur
Company Secretary and Compliance Officer

Place: Hyderabad

Date: August 24, 2023

NOTES:

1. In terms of Section 152 of the Companies Act, 2013, Ms. Padmaja Kalyani Sadhanala (DIN: 03096445) retires by rotation at the Meeting and being eligible, offers herself for re-appointment. The Nomination and Remuneration Committee and the Board of Directors of the Company recommends her re-appointment.
2. The Ministry of Corporate Affairs (MCA) vide General Circular No. 14/2020 dated 08.04.2020, General Circular No. 17/2020 dated 13.04.2020, General Circular No. 22/2020 dated 15.06.2020, General Circular No. 33/2020 dated 28.09.2020, General Circular No. 39/2020 dated 31.12.2020, General Circular No. 10/2021 dated 23.06.2021, General Circular No. 20/2021 dated 08.12.2021, General Circular No. 3/2022 dated 05.05.2022, and General Circular No. 10/2022 dated 28.12.2022 (collectively referred to as “MCA Circulars”) has permitted holding of AGM through Video Conferencing (VC) or Other Audio Visual Means (OAVM) on or before 30.09.2023. Hence, in compliance with the provisions of the Companies Act, 2013 (“Act”), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and MCA Circulars and SEBI Circulars, the 17th AGM of the Company is being held through VC / OAVM on Saturday, September 23, 2023 at 12:00 P.M. (IST).

In compliance of Section 20 of the Companies Act, 2013 and further to the aforesaid MCA Circulars and SEBI Circulars, Notice of the 17th AGM along with the Annual Report 2022-23 is being sent only through electronic mode to the Members whose e-mail addresses are registered with the Company/Depositories. Members may note that the Notice and the Annual Report 2022-23 will also be available on the Company's Website: <http://www.vilinbiomed.co.in/> and Website of the Stock Exchange i.e., National Stock Exchange Limited: <https://www.nseindia.com>, and on the Website of CDSL: <https://www.evotingindia.com>

3. Green Initiative: To support the Green Initiative, Members who have not registered their e-mail address are requested to register their e-mail address for receiving all the communications including Annual Report, Notices, Circulars etc. from the Company electronically.
4. A Member entitled to attend and vote at the AGM is entitled to appoint a Proxy to attend and vote on his / her behalf and the Proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars and SEBI Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of Proxies by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
5. Members of the Company under the category of Institutional Investors are encouraged to attend and vote at the AGM through VC/OAVM. Corporate Members intending to authorize their Representatives to participate and vote at the AGM are requested to upload a copy of the Board Resolution/Authorisation Letter on the E-Voting Portal or send to the Company at cs@vilinbiomed.co.in.
6. Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the Quorum under Section 103 of the Act. As per Regulation 40 of the SEBI Listing Regulations, as amended, Securities of Listed Entities can be transferred only in Dematerialised form with effect from April 1 2019, except in case of transmission or transposition of Securities. In view of this, Members holding Shares in Physical Form are requested to consider converting their holdings to Dematerialised form. Members can contact M/s Bigshare Services Private Limited, Registrar and Share Transfer Agents of the Company, ("RTA" or "Registrar") situated at 306, Right Wing, 3rd floor, Amrutha Ville, Opposite Yashoda Hospital, Somajiguda, Rajbhavan Road, Hyderabad- 500082, E-mail: bsshyd@bigshareonline.com and website of the Registrar: www.bigshareonline.com for assistance in this regard
7. Members are requested to intimate changes, if any, pertaining to their Name, Postal Address, E-mail Address, Telephone/Mobile Numbers, Permanent Account Number, Mandates, Nominations, Power of Attorney, Bank Details viz., Name of the Bank, Branch Details, Bank Account Number, MICR Code, IFSC Code etc., to their Depository Participants ("DPs") in case the Shares are held in Electronic Form and Registrar/RTA in case the Shares are held in Physical Form.
 - a. Registration of E-mail for Shareholders holding Physical Shares: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with the Registrar, by referring to their website: www.bigshareonline.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail and also upload the image of Share Certificate in PDF or JPEG format. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification. For Permanent Registration for Demat Shareholders: It is clarified that for permanent registration of E-mail address, Members are requested to register their E-mail address, in respect of Demat holdings with the respective Depository Participant (DP) by follow the procedure as prescribed by the Depository Participant.
 - b. For Temporary Registration for Demat Shareholders: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with the Registrar, by referring to their website: www.bigshareonline.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail.
 - c. Registration of Bank Details for Physical Shareholders: Members holding Shares in Physical Form and who have not registered their Bank details can get the same registered with the Registrar, by clicking the www.bigshareonline.com and follow the registration process as guided therein. Members are requested to provide details such as Name, Folio Number, Share Certificate Number, PAN, E-mail, along with the copy of the Cheque Leaf with the First named Member as mentioned on the Cheque Leaf containing Bank Name

and Branch, Type of Account, Bank Account Number, MICR Details and IFSC code in PDF or JPEG format. It is very important that the Member should submit the request letter duly signed. The Registrar will verify the documents upload and will only take on records for all valid cases. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification.

8. The Meeting shall be deemed to be held at the registered office of the Company at SY No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Secunderabad- 500 003, Telangana
9. Nomination: Pursuant to Section 72 of the Companies Act, 2013, Members holding Shares in Physical Form are advised to file Nomination in the prescribed Form SH-13 with the Company's Share Transfer Agent. In respect of the Shares held in Dematerialised form, Members may please contact their respective Depository Participant.
10. Consolidation of Physical Share Certificates: Members holding Shares in Physical Form, in identical order of Names, in more than One Folio are requested to send to the Company or Registrar, the details of such Folios together with the Share Certificates for consolidating their holdings in One Folio. A Consolidated Share Certificate will be issued to such Members after making requisite changes.
11. In compliance with the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI Listing Regulations, the Company has provided a facility to its Members to cast their vote electronically, through the E-Voting services provided by Central Depository Services (India) Limited ("CDSL") on all the Resolutions set forth in this Notice. Members who have cast their Votes by remote E-Voting prior to the AGM may also participate in the AGM through VC but shall not be entitled to cast their Vote on such Resolutions again. The manner and process of E-Voting remotely by Members is provided in the instructions for E-Voting which forms part of this Notice.
12. A Person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date for dispatch of Notice and Annual Report i.e. 25th August 2023 will only be entitled for receipt of Annual Report.
13. The Voting Rights of the Shareholders for voting through remote E-Voting at the AGM shall be in proportion to their share of the Paid-up Equity Share Capital of the Company as on **Saturday, 16th September, 2023 ('Cut-Off Date')**. A Person whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date, only shall be entitled to avail the facility of remote E-Voting or of voting at the AGM and who is not a Member as on the Cut-off Date shall treat this Notice for information purposes only.
14. The Remote E-Voting Period will commence on **Wednesday, 20th September, 2023 (IST 09:00 A.M.) and will end on Friday, 22nd September, 2023 (IST 05:00 P.M.)**. During this period, Members of the Company, holding Shares in Dematerialised form, as on the Cut-off Date i.e., on Saturday, 16th September, 2023 ('Cut-Off Date') shall be entitled to cast their vote by remote E-Voting. Once the Vote on a Resolution is cast by the Member, the Member shall not be allowed to change it subsequently.
15. The facility for Voting during the AGM will also be made available. Members present in the AGM through VC and who have not cast their Vote on the Resolutions through remote E-Voting and are otherwise not barred from doing so, shall be eligible to Vote through E-Voting system during the AGM.
16. Any person who becomes a Member of the Company after sending the Notice and holding Shares as on the **Cut-off date (Saturday, 16th September, 2023)** may obtain the Login-id and Password by sending a request at helpdesk.evoting@cdslindia.com. However, if a Member is already registered with CDSL for remote E-Voting then he/she can use his/her existing User-id and Password for casting the Vote.
17. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through remote E-Voting.
18. Members seeking any information with regard to the accounts or any matter to be placed at the AGM, are requested to write to the Company mentioning their Name, Demat Account Number/Folio Number, E-mail, Mobile Number at cs@vilinbiomed.co.in or vbml2005@gmail.com on or before **Saturday, 16th September, 2023**. The same will be replied by the Company suitably.
19. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through remote E-Voting.

20. The Board of Directors has appointed Mr. Kashinath Sahu, Practicing Company Secretary (Membership No. FCS 4790, COP No. 4807), Hyderabad as the Scrutinizer to scrutinize the remote E-Voting Process and voting during the AGM, in a fair and transparent manner.
21. The Scrutinizer shall immediately, after the conclusion of E-Voting at the AGM, first count the Votes Cast during the AGM, thereafter, unblock the Votes Cast through remote E-Voting and make, not later than 2 working dates of conclusion of the AGM, a consolidated Scrutinizer's Report of the Total Votes Cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same. The Results declared along with the Scrutinizer's Report shall be placed on the Website of the Company and on the Website of CDSL immediately. The results will also be communicated to NSE Limited, where the Shares of the Company are listed.
22. To prevent fraudulent transactions, Members are advised to exercise Due Diligence and notify the Company of any change in address or Demise of any Member as soon as possible. Members are also advised not to leave their Demat account(s) dormant for long. Periodic Statement of Holdings should be obtained from the concerned DPs and Holdings should be verified from time to time.
- 23. Instructions for attending the AGM through VC / OAVM:**
- a. Shareholder will be provided with a facility to attend the AGM through VC/OAVM through the CDSL E-Voting system. Shareholders may access the same at <https://www.evotingindia.com> under Shareholders / Members login by using the remote E-Voting credentials. The link for VC/OAVM will be available in Shareholder / Members login where the EVSN of the Company is displayed.
 - b. Members may join the Meeting through Laptops, Smartphones, Tablets and I-Pads for better experience. Further, Members will be required to use the Internet with a good speed to avoid any disturbance during the Meeting. Please note that participants connecting from Mobile Devices or Tablets or through Laptops connecting via mobile hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any glitches.
 - c. Shareholders who would like to express their views / ask questions during the Meeting may register themselves as a speaker by sending their request in advance between **17th September, 2023 (9:00 am) to 19th September, 2023 (5:00 pm)** from their registered E-mail address mentioning their names, DP-ID and ClientID / Folio Number, PAN and Mobile Number at cs@vilinbiomed.co.in. Only those Members who have pre-registered themselves as a speaker will be allowed to express their views / ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.
 - d. Members are encouraged to submit their questions in advance with regard to the Financial Statements or any other matter to be placed at the 17th AGM, from their registered E-mail address, mentioning their Name, DP-ID and Client-ID Number / Folio Number and Mobile Number, to reach the Company's E-mail address at cs@vilinbiomed.co.in before **5:00 P.M. (IST) on Tuesday, 19th September, 2023**. Such questions by the Members shall be suitably replied by the Company.
 - e. Those Shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the Meeting. If any votes are cast by the Shareholders through the E-Voting available during the AGM and if the same Shareholders have not participated in the Meeting through VC / OAVM facility, then the votes cast by such Shareholders shall be considered as invalid, as the facility of E-Voting during the Meeting is available only to the Shareholders attending the Meeting.
24. Subject to the receipt of Requisite number of Votes, the Resolutions forming part of the AGM Notice shall be deemed to be passed on the date of the AGM. Voting through Electronic Means: Pursuant to Section 108 of the Companies Act, 2013 and Rule 20 read with the Companies (Management and Administration) Rules, 2014 read with amendments or re-enactments made thereunder and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is pleased to provide the facility to exercise Members' Right to Vote at the 17th Annual General Meeting (AGM) by electronic means and the business may be transacted through E-Voting Services provided by Central Depository Services (India) Limited (CDSL). The Members attending the Meeting, who have not already cast their vote through Remote E-Voting shall be able to exercise their Voting Rights at the Meeting. The Members who have already cast their vote through Remote E-Voting may attend the Meeting but shall not be entitled to cast their vote again at the AGM.

25. The instructions for Shareholders for Voting Electronically are as under:

- (i) The **Voting Period commences on Wednesday, 20th September, 2023 (09:00 A.M.) and closes on Friday, 22nd September, 2023 (05:00 P.M.)** During this period, the Shareholders of the Company, holding Shares in Dematerialized Form, as on the Cut-off Date (Record Date), Saturday, 16th September, 2023 may cast their vote electronically. The E-Voting Module shall be disabled by CDSL for Voting thereafter.
- (ii) Shareholders who have already voted prior to the Meeting Date would not be entitled to vote at the Meeting.

Login method for E-Voting and Joining Virtual Meetings for Individual Shareholders holding Securities in Demat Mode:

Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/ CIR/P/2020/242 dated 9th December 2020 on “E-Voting Facility provided by Listed Companies”, Individual Shareholders holding Securities in Demat mode are allowed to cast their vote through their Demat Account maintained with the Depositories and Depository Participants. Shareholders are advised to update their Mobile Number and E-mail in their Demat Accounts in order to access the E-Voting Facility. Pursuant to the above said SEBI Circular, Login method for E-Voting and joining Virtual Meetings for Individual Shareholders holding Securities in Demat mode CDSL/NSDL is given below:

Type of Shareholders	Login Method
Individual Shareholders Holding Securities in Demat Mode with CDSL Depository	<ol style="list-style-type: none"> 1. Users who have opted for CDSL EASI/EASIEST facility, can login through their existing User-id and Password. Option will be made available to reach E-Voting page without any further authentication. The URL for Users to login to EASI/EASIEST are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System MYEASI. 2. After successful login to the EASI/EASIEST User will be able to see the E-Voting option for eligible Companies where the E-Voting is in progress as per the information provided by Company. On clicking the E-Voting option, the User will be able to see E-Voting page of the E-Voting Service Provider for casting your Vote during the remote E-Voting period or joining Virtual Meeting and Voting during the Meeting. Additionally, there are also links provided to access the system of all E-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME so that the User can visit the E-Voting Service Providers website directly. 3. If the user is not registered for EASI/ EASIEST, option to register is available at CDSL website www.cdslindia.com. To login click on login & New System MYEASI Tab and then click on registration option. 4. Alternatively, the User can directly access E-Voting Page by providing Demat Account Number and PAN on E-Voting link available on www.cdslindia.com homepage. The system will authenticate the User by sending OTP on the Registered Mobile and E-mail as recorded in the Demat Account. After successful authentication, the User will be able to see the E-Voting option where the E-Voting is in progress and also able to directly access the system of all the E-Voting Service Providers.
Individual Shareholders Holding Securities in Demat Mode with NSDL Depository	<ol style="list-style-type: none"> 1. If you are already registered for NSDL 'IDeAS' facility, please visit the E-services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a Mobile. Once the Homepage of E-services is launched Click on the “Beneficial Owner” icon under “Login” which is available under 'IDeAS' Section. A new screen will open. You will have to enter your User-id and Password. After successful authentication, you will be able to see E-Voting Services. Click on “Access to E-Voting” under E-Voting Services and you will be able to see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be re-directed to E-Voting Service Provider website for casting your vote during the remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.

	<p>2. If the User is not registered for IDeAS E-services, option to register is available at https://eservices.nsdl.com/ Select “Register Online for IDeAS” Portal or Click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</p> <p>3. Visit the E-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the homepage of E-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User-id(i.e. your sixteen digit Demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository Site wherein you can see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your Vote during the remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.</p>
Individual Shareholders Holding Securities in Demat Mode Login through their Depository Participants (DP)	You can also login using the login credentials of your Demat account through your Depository Participant registered with NSDL/CDSL for E-Voting facility. After Successful login, you will be able to see E-Voting option. Once you click on E-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see E-Voting feature. Click on Company Name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your vote during the remote E- Voting period or joining Virtual Meeting and voting during the Meeting

Important note: Members who are unable to retrieve User-id/ Password are advised to use Forgot User-id and Forgot Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding Securities in Demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders Holding Securities in Demat Mode with CDSL	Members facing any technical issue in login can contact CDSL Helpdesk by sending a request at the following e-mail: helpdesk.evoting@cdslindia.com or Contact at a toll free no.1800 22 5533
Individual Shareholders Holding Securities in Demat Mode with NSDL	Members facing any technical issue in login can contact NSDL Helpdesk by sending a request at evoting@nsdl.co.in or Call at Toll Free No. 1800 10 20990 and 1800 22 4430

Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode

- i. The Shareholders should log on to the E-Voting Website: www.evotingindia.com
- ii. Click on “SHAREHOLDERS” Module.
- iii. Now enter your User-id
 - i. For CDSL: 16 Digits Beneficiary ID
 - ii. For NSDL: 8 Character DP-ID followed by 8 Digits Client-ID
 - iii. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- iv. Next enter the ‘Image Verification’ as displayed and Click on Login.
- v. If you are holding Shares in Demat form and had logged on to www.evotingindia.com and had voted on an earlier E-Voting of any Company, then your existing password is to be used.

vi. If you are a first-time user follow the steps given below:

For Physical Shareholders and other than Individual Shareholders holding Shares in Demat Form

PAN	Enter your 10-digit alpha–numeric PAN issued by Income Tax Department (Applicable for both Demat Shareholders as well as Physical Shareholders) Shareholders who have not updated their PAN with the Company/ Depository Participant are requested to use the sequence number sent by Company /RTA or contact Company/ RTA
Dividend Bank Details or Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your Demat Account or in the Company Records in order to login. If both the details are not recorded with the Depository or Company, please enter the Member-id /Folio Number in the 'Dividend Bank Details' field.

vii. After entering these details appropriately, click on 'SUBMIT' tab.

viii. Shareholders holding Shares in Physical Form will then directly reach the Company selection screen. However, Shareholders holding Shares in Demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the 'New Password' field. Kindly note that this password is to be also used by the Demat Holders for Voting for Resolutions of any other Company on which they are eligible to vote, provided that the Company opts for E-Voting through CDSL Platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

ix. For Shareholders holding shares in Physical Form, the details can be used only for E-Voting on the Resolutions contained in this Notice.

x. Click on the EVSN of the relevant Company ('Vilin Bio Med Limited') on which you choose to vote.

xi. On the Voting Page, you will see 'RESOLUTION DESCRIPTION' and against the same the option 'YES/NO' for Voting. Select the option 'YES' or 'NO' as desired. The option 'YES' implies that you assent to the Resolution and option 'NO' implies that you dissent to the Resolution.

xii. Click on the 'RESOLUTIONS FILE LINK' if you wish to view the entire Resolution details.

xiii. After selecting the Resolution, you have decided to vote on, click on 'SUBMIT'. A Confirmation Box will be displayed. If you wish to confirm your vote, click on 'OK', else to change your vote, click on 'CANCEL' and accordingly modify your vote.

xiv. Once you 'CONFIRM' your vote on the resolution, you will not be allowed to modify your Vote.

xv. You can also take a print of the votes cast by clicking on 'Click here to Print' option on the Voting Page.

xvi. If a Demat Account Holder has forgotten the login password then enter the User-id and the 'Image Verification Code' and click on Forgot Password and enter the details as prompted by the system.

xvii. Additional Facility for Non – Individual Shareholders and Custodians – For Remote Voting:

- Non – Individual Shareholders (i.e. Other than Individuals, HUF, NRI etc.) and Custodians are required to log on to the website: www.evotingindia.com and register themselves in the 'CORPORATES' Module.
- A Scanned copy of the Registration Form bearing the Stamp and Sign of the Entity should be mailed to helpdesk.evoting@cdslindia.com
- After receiving the login details, a Compliance User should be created using the Admin login and Password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The List of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.

- It is Mandatory that a Scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the Scrutinizer to verify the same.
- Alternatively Non-Individual Shareholders are required to send the relevant Board Resolution/Authority Letter etc. together with the Attested Specimen Signature of the Duly Authorized Signatory who are authorized to vote, to the Scrutinizer and to the Company at the E-mail address: cs@vilinbiomed.co.in if they have voted from individual tab and not uploaded same in the CDSL E-Voting System for the Scrutinizer to verify the same.
- If you have any queries or issues regarding E-Voting from the CDSL E-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022-23058738 and 022-23058542/43.
- All grievances connected with the facility for Voting by electronic means may be addressed to Shri Rakesh Dalvi, Sr Manager, Central Depository Services (India) Limited (CDSL), Wing-A, 25th Floor.
- Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai-400013 or send an E-mail to helpdesk.evoting@cdslindia.com or call on 022-23058542/43.

Date: August 24, 2023
Place: Hyderabad

By Order of the Board of Directors

**Sd/-
Ashdeep Kaur
Company Secretary & Compliance Officer**

'ANNEXURE – A' TO THE NOTICE OF THE AGM

Details of Director seeking re-appointment at the forthcoming Annual General Meeting to be held on September 23, 2023 pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 for General Meetings (SS-2) are as mentioned below:

Particulars	Item No. 02 of the Notice
Name	Padmaja Kalyani Sadhanala
DIN	03096445
Date of Birth (Age in Years)	December 27, 1971, (52 Years)
Date of First Appointment to the Board	December 01, 2021
Designation	Non-Executive Director
Qualification	M.Sc (Micro Biology)
Brief Resume, Nature of Expertise and skill set in specific functional areas	Ms. Padmaja Kalyani is a Non-executive director of our Company having more than 20 years of vast experience in the Pharma Industry.
Shareholding (as on the date of this Notice) in the Company either directly or in form of beneficial interest for any other person	NIL
Relationship with other Directors & KMP's	Sister-in-Law of Viswa Prasad Sadhanala, Managing Director (DIN: 08068933)
No. of Meetings of the Board attended during the year 2022-23	Nine (9)
Directorships held in other Companies (Excluding Foreign Companies)	Managing Director in Blue Nile Capital Advisory Limited (CIN: U93000TG2007PLC054080)
Listed Companies from which the person has resigned from the directorship in the past three years	Resigned as WTD from Pharmaid's Pharmaceuticals Limited (BSE Scrip PHARMAID) w.e.f. 21.05.2022
Membership/ Chairmanship of Committees of other companies	Nil
Terms and conditions of appointment/ re-appointment and Remuneration sought to be paid/ last drawn	Appointed as a Non-Executive Director, liable to retire by rotation. Retiring by rotation at this AGM.

**By Order of the Board of Directors
For Vilin Bio med Limited**

**Sd/-
Ashdeep Kaur
Company Secretary & Compliance Officer**

**Date: August 24, 2023
Place: Hyderabad**

BOARD'S REPORT

Dear Members,

The Directors have pleasure in presenting the 17th Annual Report of the Company, together with the Audited accounts for the financial year ended 31st March'2023.

Financial Highlights

(Rs. In Lakhs)

Particulars	2022-2023	2021-2022
Sales	1,231.30	1,121.49
Other Income	2.44	0.42
Total Income	1,233.74	1,121.91
Total Expenses	1,055.58	1,117.44
Profit/(Loss)Before Tax	178.16	4.47
Current Year Tax	52.83	1.00
Deferred Tax	0.84	0.11
Profit/(Loss)After Tax	124.50	3.36

State of Company Affairs

The Company's Revenues stood at Rs. 1,231.30 Lakhs during the year under review, PAT at Rs. 124.50 Lakhs as against the corresponding Previous Year, there was Revenue of Rs. 1,121.49 Lakhs and the PAT was Rs. 3.36 Lakhs. Your Directors are giving their best efforts and are confident of exploring more business opportunities and growth and profitability of the Company, in the years ahead.

Dividend

The Board of Directors has not recommended any Dividend on the Equity Shares of the Company for the Financial Year ended March 31, 2023.

Transfer to Reserves

The Board of Directors has not proposed to transfer any amount to the General Reserve.

Changes in Share Capital

During the year under review, the **Authorized Share Capital** of the Company was **increased** from 3,30,00,000 to 15,00,00,000 (divided into 1,50,00,000 Equity Shares of Rs. 10/- each) and the Paid-up Share Capital has increased from 3,30,00,000 to 9,95,00,000/- (divided into 99,50,000 Equity Shares of Rs.10/- each).

The Company has issued 6,80,000 **Preferential Equity Shares** of Face Value Rs. 10 each issued at Rs. 30 and issued 59,70,000 equity shares of Face Value Rs. 10 each as **Bonus Shares** in the ratio of **1.5: 1** by Capitalization of its Reserves.

Material Changes and Commitments affecting the Financial Position of the Company which have occurred between 31st March'2023 and 24th August'2023 (Date of the Report)

a. Initial Public Offer

Subsequent to the year under review, the Company has successfully raised an amount of Rs. 1,200.00 lakhs by way of its Initial Public Offering ("**IPO**") by issue of 40,00,000 equity shares of face value of 10.00 each ("our company" or "the issuer") for cash at a price of ₹ 30.00 per equity share (including a share premium of ₹ 20.00 per equity share) ("issue price") in compliance with Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended. An overwhelming response was received on the Company's IPO as it was oversubscribed by 2.66 times.

The Company equity shares got Listed on the National Stock Exchange of India (**NSE**) SME EMERGE Platform on June 30, 2023.

b. Increase in the Paid Up share capital

The Company has issued 40,00,000 equity shares of face value of 10.00 each for cash at a price of `30.00 per equity share as the Initial Public offer (IPO). Hence the paid up share capital of the Company has increased from Rs. 9,95,00,000/- to Rs.13,95,00,000/-

Nature of Business

The Company is into the business of manufacturing pharmaceuticals products and there has been no change in the nature of Business of the Company.

Public Deposits

During the year under review, the company has not accepted any deposit pursuant to the provisions of Sections 73 and 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

Annual Return

A copy of the Annual Return as at March 31, 2023 pursuant to the sub-section (3) of Section 92 of the Companies Act, 2013 read with Rule 11(1) of the Companies (Management and Administration) Rules, 2014 and forming part of this Report is placed on the website of the Company as per provisions of Section 134(3)(a) and is available at the following link: <http://www.vilinbiomed.co.in/>

Director's Responsibility Statement

In terms of Section 134 (5) of the Companies Act, 2013, the Directors would like to state that:

- i) In the preparation of the Annual Accounts, the applicable Accounting Standards have been followed.
- ii) The Directors have selected such Accounting Policies and applied them consistently and made judgements and estimates that were prudent so as to give a true and fair view of the state of affairs of the Company at the end of the Financial Year and of the Profit or Loss of the Company for the Year under review.
- iii) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the Assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) The Directors have prepared the Annual Accounts on a Going Concern basis.
- v) The Directors had laid down Internal Financial Controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively.
- vi) The Directors had devised proper system to ensure compliance with the provisions of all the applicable laws and that such system were adequate and operating effectively.

Directors and Key Managerial Personnel**a. Retirement by Rotation:**

As per Section 152 of the Companies Act, 2013 and Articles of Association of the Company, Ms. Padmaja Kalyani Sadhanala (DIN: 03096445) who retires by rotation at the conclusion of this 17th AGM and offers herself for re-appointment in accordance with the provisions of the Companies Act, 2013. The Directors recommend her re- appointment.

b. Composition of Board of Directors of the Company:

As on March 31, 2023 the Board has the following directors:

Sl. No.	Name of Director	DIN	Designation
1	Mr. Rakesh Kumar Chandak	09849680	Independent Director
2	Mr. Veerareddy Vallapureddy	08061781	Independent Director
3	Mr. Viswa Prasad Sadhanala	08068933	Managing Director
4	Mr. Anuj Bajpai	08939135	Whole Time Director
5	Ms. Padmaja Kalyani Sadhanala	03096445	Non-Executive Director

c. Changes in the Composition:

During the period under review the following changes in the Board of Directors and KMP'S took place.

Sl. No	Name of Director/KMP	Nature of Change	Date of such Change
1	Ms. Padmaja Kalyani Sadhanala (DIN: 03096445), Non-Executive Director	Appointment as Non-Executive Director	27/08/2022
2	Mr. Viswa Prasad Sadhanala, Managing Director (DIN: 08068933)	Appointment as Managing Director	01/10/2022
3	Mr. Anuj Bajpai, Whole Time Director (DIN: 08939135)	Appointment as Whole Time Director	01/10/2022
4	Mr. Rakesh Kumar Chandak, (DIN: 09849680)	Appointment as Independent Director	04/01/2023
5	Mr. VeeraReddy Vallapureddy (DIN: 08061781)	Appointment as Independent Director	04/01/2023
6	Mr. Saket Kansal	Appointment as Company Secretary	17/12/2022
7	Mr. Chilam Srikant	Appointment as Chief Financial Officer	17/12/2022
8	Mr. Ashok Kumar Beniwal, Director (DIN: 08659902)	Resignation	01/01/2023
9	Mr. Addagunta Venu Gopal, Director (DIN: 01918868)	Resignation	01/01/2023
10	Mr. Anvesh Moola, Director (DIN: 08659891)	Resignation	01/01/2023

d. Changes after the year under review:

From the closure of the financial year (March 31, 2023) till the date of the Directors' Report (August 24, 2023), the following changes took place on the Board/KMP of the Company:

Sl. No	Name of KMP	Nature of Change	Date of such change
1	Mr. Saket Kansal	Resignation as Company Secretary & Compliance officer	02/08/2023
2	Ms. Ashdeep Kaur	Appointment as Company Secretary & Compliance officer	02/08/2023

Number of Meetings of the Board and Director's Attendance

During the year ended 31st March'2023 Nine (9) Board Meetings were held in accordance with the provisions of the Companies Act, 2013 and in compliance with the Secretarial Standards of the Institute of Company Secretaries of India (ICSI).

Sl. No.	Date of the Meeting	Number of Directors entitled to attend the meeting	Number of Directors who attended the meeting
1.	May 11, 2022	6	6
2.	August 27, 2022	6	6
3.	August 28, 2022	6	6
4.	December 02, 2022	6	6
5.	December 17, 2022	6	6
6.	January 01, 2023	3	3
7.	January 04, 2023	5	5
8.	February 04, 2023	5	5
9.	February 28, 2023	5	5

The following Annual/ Extra Ordinary General Meetings were held, during the year under review:

Sl. No.	Date of the Meeting	Purpose of the Meeting
1.	September 30, 2022 (AGM)	16 TH Annual General Meeting of the company
2.	January 12, 2023 (EGM)	For Increase in Authorized share capital of the Company from 3,30,00,000 to 15,00,00,000 (divided into 1,50,00,000 Equity Shares of Rs. 10/-each)
3.	February 27, 2023 (EGM)	For approval of the Bonus Issue
4.	March 06, 2023 (EGM)	For approval of Initial Public Offer

Formal Annual Evaluation

As per Section 149 of the Companies Act, 2013 the Independent Directors of the Company had a Meeting on February 28, 2023 without attendance of Non-Independent Directors and Members of the Management. In the Meeting, the following issues were taken up:

- Review of the performance of the Board as a whole;
- Review of the performance of the Chairperson of the Company, taking into account the views of Executive Directors and Non – Executive Directors;
- Assessing the Quality, Quantity and Timelines of flow of information between the Company Management and the Board, that is necessary for the Board to perform their duties effectively and reasonably.

The Meeting also reviewed and evaluated the performance of Non – Independent Directors.

The Meeting also reviewed and evaluated the performance the Board as whole in terms of the following aspects:

- Preparedness for Board / Committee Meetings
- Attendance at the Board / Committee Meetings
- Guidance on Corporate Strategy, Risk Policy, Corporate Performance and Overseeing Acquisitions and Disinvestments.
- Ensuring a Transparent Board Nomination Process with the diversity of Experience, Knowledge, Perspective in the Board.
- Ensuring the integrity of the Company's Accounting and Financial Reporting Systems, including the Independent Audit, and that appropriate systems of control are in place, in particular, systems for Financial and Operational Control and Compliance with the law and relevant Standards.

Declaration from Independent Directors on Annual Basis

The Company has received the Declarations from Mr. Rakesh Kumar Chandak, Mr. Veerareddy Vallapureddy, Independent Directors of the Company to the effect that they are Meeting the criteria of Independence as provided in sub-section (6) of section 149 of the Act and of sub-rule (1) and sub-rule (2) of the Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.

In the opinion of the Board, the Independent Directors possess the requisite integrity, expertise and experience (including the proficiency) of the independent directors.

Statutory Auditors

M/s. PPKG & Co, Chartered Accountants (Firm Registration No. 0096555) were appointed as the Statutory Auditors of the Company w.e.f December 02, 2022 to fill the casual vacancy caused due to resignation of the existing Statutory Auditor M/s Singh Yudhveer & Associates, Chartered Accountants (Firm Registration No: 011039C) to carry out the Statutory Audit for FY 2022-23. The said auditor will retire at the conclusion of the 17th AGM and gave their consent for appointment as the Statutory Auditor of the Company for a term of 5 consecutive years till the conclusion of 22nd Annual General Meeting. Your directors recommend their appointment.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

Pursuant to provisions of Section 134 of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 the details of Conservation of Energy, Technology Absorption is attached herewith as '**Annexure-A**'

Foreign Exchange Earnings and Outgo: During the period under review, there was no Foreign Exchange Earnings or Outflow.

Secretarial Audit

Pursuant to provisions of Section 204 of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the Company had appointed Mr. Kashinath Sahu, Company Secretary in Practice to undertake the Secretarial Audit of the Company. The Secretarial Audit Report is annexed herewith as '**Annexure-B**'

During the year under review, there were no qualifications, reservations or adverse remarks reported by Secretarial Auditor under Section 204 of the Companies Act, 2013 in the course of the performance of his duties as Secretarial Auditor.

Management Discussion and Analysis

Pursuant to Regulation 34(2)(e) of the SEBI (LODR) Regulations, 2015, Report on Management Discussion and Analysis, is herewith annexed as '**Annexure-C**'

Internal Control Systems and their Adequacy

The Company has an in house Internal Control System, commensurate with the Size, Scale and Complexity of its Operations. The Scope and Authority of the Internal Audit Function is defined in the Internal Audit Manual. To maintain its objectivity and independence, the Internal Audit Function reports to the Chairman of the Audit Committee of the Board and to the Chairman and Management.

The Internal Audit Department monitors and evaluates the efficacy and adequacy of Internal Control System in the Company, its compliance with Operating Systems, Accounting Procedures and Policies at all levels of the Company.

Based on the report of Internal Audit Function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant Audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

Audit Committee

The Audit Committee was constituted pursuant to a resolution of our Board dated February 28, 2023 in accordance with Section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI (LODR) Regulations with the following as members of the committee.

The Audit Committee comprises:

Name of Director	Status in Committee	Nature of Directorship
Veerareddy Vallapureddy	Chairman	Non-Executive Chairman and Independent Director
Rakesh Kumar Chandak	Member	Independent Director
Viswa Prasad Sadhanala	Member	Managing Director

The Company Secretary of the Company acts as the Secretary of the Audit Committee.

The terms of reference of our Audit Committee, in accordance with Section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI (LODR) Regulations.

Nomination and Remuneration Committee

The Nomination and Remuneration Committee was constituted by our Board on February 28, 2023. The scope and function of the Nomination and Remuneration Committee is in accordance with Section 178 of the Companies Act, 2013 and the SEBI (LODR) Regulations. The Nomination and Remuneration Committee include the following:

Name of Director	Status in Committee	Nature of Directorship
Veerareddy Vallapureddy	Chairman	Non-Executive Chairman and Independent Director
Rakesh Kumar Chandak	Member	Independent Director
Padmaja Kalyani Sadhanala	Member	Non-Executive Director

The scope, functions and the terms of reference of the Nomination and Remuneration Committee is in accordance with the Section 178 of the Companies Act, 2013 read with Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Stakeholders Relationship Committee

The Stakeholders' Relationship Committee was constituted by a resolution of our Board dated February 28, 2023. The Stakeholders' Relationship Committee comprises:

Name of Director	Status in Committee	Nature of Directorship
Veerareddy Vallapureddy	Chairman	Non-Executive Chairman and Independent Director
Rakesh Kumar Chandak	Member	Independent Director
Viswa Prasad Sadhanala	Member	Managing Director

The Company Secretary of the Company acts as the Secretary of the Stakeholders' Relationship Committee.

Risk Management Committee

The Regulation 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to forming of Risk Management Committee, is not applicable to the Company during the Financial Year under review.

Corporate Governance and Shareholders Information

Pursuant to Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is not required to comply with the provisions of filing Corporate Governance Report to the Stock Exchange as it is not applicable to the Companies listed on the SME platform.

Particulars of Loans, Guarantees or Investments under Section 186 of the Companies Act, 2013

The Company has not given any Loans nor provided Guarantee nor made any Investments during the Financial Year 2022-2023, which is beyond the limits as per Section 186 of the Companies Act, 2013.

Contracts or Arrangements with Related Parties under Section 188 (1) of the Companies Act, 2013

All the contracts/ arrangements/ transactions entered by the Company during the year under review with related parties were in the ordinary course of business and at arm's length basis. The particulars of such contracts or arrangements with related parties, pursuant to the provisions of section 134(3)(h) and Rule 8 of the Companies (Accounts) Rules, 2014, in the prescribed form AOC-2 is enclosed as '**Annexure D**' to this report.

All the related party transactions were placed before the Audit Committee and also before the Board for their respective approval. Omnibus approval of the Audit Committee is obtained as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the transactions which can be foreseen and are repetitive in nature. The Company has developed a Policy on Related Party Transactions including the latest amendments thereof for the purpose of identification and monitoring of such transactions.

Policy on Preservation of the Documents

The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 ("Regulations") on Preservation of the Documents of the following type:

- documents whose preservation shall be permanent in nature;
- documents with preservation period of not less than eight years after completion of the relevant transactions

Vigil Mechanism

The Vigil Mechanism/Whistle Blower Policy has been adopted to provide appropriate Avenues to the employees to bring to the attention of the management, the concerns about any unethical behaviour by using the mechanism provided in the Policy. In cases related to financial irregularities, including fraud or suspected fraud, the employees may directly approach the Chairman of the Audit Committee of the Company. No director or employee has been denied access to the Audit Committee. The web link for the policy is as follows: <http://www.vilinbiomed.co.in/>

Policy on criteria for determining materiality of events

The Company has adopted a Policy in accordance with the requirements of the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations). The Policy is authorizing the mentioned Key Managerial Personnel for the purpose of determining materiality of an event or information of the Company and to ensure that such information is adequately disseminated in pursuance with the Regulations and to provide an overall governance framework for such determination of materiality.

Policy on directors' appointment, remuneration & other details

The Company's remuneration policy is directed towards rewarding performance based on review of achievements periodically. The remuneration policy is in consonance with the existing industry practice.

The Company's shareholders may refer the Company's website for the detailed Nomination & Remuneration Policy of the Company on the appointment and remuneration of Directors including criteria for determining qualifications, positive attributes, independence of a Director; and other matters provided under sub-section (3) of section 178.

Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concerns Status and Company's Operations in future

The Company has not received any Significant or Material Orders passed by any Regulatory Authority, Court or Tribunal which shall impact the Going Concern Status and Company's Operations in future.

Details of Subsidiary Companies, Associates and Joint Venture Companies

The Company does not have any Subsidiary, Associate and Joint Venture Companies during the period under review.

Industrial Relations

Employee relations during the period under review continued to be healthy, cordial and harmonious at all levels and your Company is committed to maintain good relations with the employees. It has taken various steps to improve productivity across the organization.

Business Risk Management

Business Risk Evaluation and Management is an ongoing process within the Organization. The Company has a robust Risk Management Framework to identify, monitor and minimize risks as also identify business opportunities. At present, the Company has not identified any element of risk which may threaten the existence of the Company.

Transfer of Amounts to Investor Education and Protection Fund

Your Company does not have any Unpaid or Unclaimed amounts lying for a period of seven years. Therefore, there were no Funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

Particulars of Employees

In terms of Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company does not have any Employee who is employed throughout the Financial Year and in receipt of Remuneration of Rs.120 Lakhs or more, or Employees who are employed for part of the year and in receipt of Rs.8.50 Lakhs or more per month.

Corporate Social Responsibility

The Provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility are not applicable to our Company

Maintenance of Cost Records

The Provisions relating to maintenance of Cost Records under Section 148 of Companies Act, 2013 are not applicable to the Company.

Insider Trading Regulations

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992 read with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Code of Conduct for prevention of Insider Trading and the Code for Corporate Disclosures (“Code”), as approved by the Board from time to time, are in force by the Company. The objective of this Code is to protect the interest of Shareholders at large, to prevent misuse of any price sensitive information and to prevent any Insider Trading activity by dealing in Shares of the Company by its Directors, Designated Employees and other Employees. The Company also adopts the concept of Trading Window Closure, to prevent its Directors, Officers, Designated Employees and other Employees from Trading in the Securities of Vilin Bio Med Limited at the time, when there is Unpublished Price Sensitive Information.

Obligation of Company under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

In order to prevent Sexual Harassment of Women at Workplace as per “The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013” has been notified. Under the said Act, every Company is required to set up an Internal Complaints Committee to look into complaints relating to Sexual Harassment at workplace of any women employee. As required under law, an Internal Compliance Committee has been constituted for reporting and conducting inquiry into the complaints made by the victim on the harassments at the workplace. During the Year under review, no complaint of harassment at the workplace was received by the Committee.

Acknowledgement

Your Directors take this opportunity to place on record the valuable co-operation and continuous support extended by its valued business associates, Practicing Company Secretary, Auditors, Supplier, Customers, Banks / Financial Institutions, Government authorities and the shareholders for their continuously reposed confidence in the Company and look forward to having the same support in all its future endeavors.

Your Directors also wish to place on record their sincere appreciation for significant contribution made by the employees at all the levels through their dedication, hard work and commitment, thereby enabling the Company to boost its performance during the year under report.

By Order of the Board of Directors

Date: August 24, 2023
Place: Hyderabad

Sd/-
Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-
Anuj Bajpai
Whole Time Director
(DIN: 08939135)

“ANNEXURE–A”

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN .EXCHANGE

A. Conservation of Energy Power and Fuel Consumption

Particulars	Current Year (2022-23)	Previous Year (2021-22)
1. Electricity (Purchased) Units		
Total Amount (Rs.)	68,314	56,928
Rate Per Unit (Rs.)	5.58	5.58
2. Electricity (Generated) Units		
Total Amount (Rs.)	--	--
Rate Per Unit (Rs.)	--	--
3. Total Units Consumed		
Units Consumed in Per Lakh Production	13,64,000	11,91,000

- Company ensures that the Manufacturing Operations are conducted in the manner whereby optimum utilization and maximum possible savings of energy is achieved.
- No specific investment has been made in reduction in energy consumption.
- As the impact of measures taken for conservation and optimum utilization of energy are not quantitative, its impact on cost cannot be stated accurately.

B. Technology Absorption

Company's products are manufactured by using in-house knowhow and no outside technology is being used for manufacturing activities. Therefore, no technology absorption is required. The Company constantly strives for maintenance and improvement in quality of its products and entire activities are directed to achieve the aforesaid goal.

C. Foreign Exchange Earning and Outgo

Particulars	Current Year	Previous Years
Earnings	NIL	NIL
Outgo	NIL	NIL

By Order of the Board of Directors

Sd/-
Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-
Anuj Bajpai
Whole Time Director
(DIN: 08939135)

Date: August 24, 2023
Place: Hyderabad

“ANNEXURE–B”

FORM NO. MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2023

(Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014)

To

The Members

Vilin Bio Med Limited

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Vilin Bio Med Limited** having **CIN: U24230TG2005PLC046689** and having registered office at Sy. No. 115, Hanumanji Colony, Opp Sub Registrar Office, Bowenpally Hyderabad - 500 009, Telangana (hereinafter called the Company). Secretarial Audit was conducted in accordance with the guidance note issued by the Institute of Company Secretaries of India and in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information, confirmations, clarifications provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2023, complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2023, according to the provisions of:

- I. The Companies Act, 2013 (the Act) and the rules made there under;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- III. The Depositories Act, 1996 and the Regulations and Byelaws framed there under;
- IV. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings (Not applicable to company during the period of audit);
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and The Securities Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers (Amendment) Regulations, 2013; **(Not applicable to company during the period of audit);**
 - (b) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; **(Not applicable to company during the period of audit);**
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 - **(Not applicable to company during the period of audit);**
 - (d) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **(Not applicable to company during the period of audit);**
 - (e) Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; **(Not applicable to company during the period of audit);**
 - (f) Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021- **(Not applicable to company during the period of audit);**

- (g) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018- **(Not applicable to company during the period of audit);**
- (h) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; **(Not applicable to company during the period of audit)**
- (i) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021- **(Not applicable to company during the period of audit)** and
- (j) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. **(Not applicable to company during the period of audit)**

VI. Other laws **specifically** applicable to the Company as per the representations made by management include:

- a) Drugs & Cosmetics Act, 1940;
- b) Narcotic Drugs and Psychotropic Substances Act, 1985;
- c) Hazardous Waste Management Rules, 2016;
- d) The Factories Act, 1948;
- e) The Industrial disputes act, 1947;
- f) The Payment of Wages Act, 1936;
- g) The Minimum Wages Act, 1948;
- h) The Payment of Bonus Act, 1965;
- i) The Payment of Gratuity act, 1972.
- j) The Maternity Benefit Act, 1961.

We have relied on the representations made by the Company, its officers for systems and mechanism framed by the Company for compliances under other acts, laws and regulations applicable to the Company as mentioned above.

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India and notified under the Companies Act, 2013;
- (ii) The Listing Agreements entered by the Company with the Stock Exchange(s); **(Not applicable to the Company during the period of audit)**

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors/ Committees that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decisions are carried through while the dissenting member's views, if any, are captured and recorded as part of the minutes.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that the compliance by the Company of the applicable financial laws like direct and indirect tax laws and maintenance of financial records and books of accounts has not been reviewed in this audit since the same have been subject to review by statutory auditors and other designated professionals.

**For Kashinath Sahu & Co
Company Secretaries**

**Place: Hyderabad
Date: August 24, 2023**

**Sd/-
CS. Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN No: F004790E000854463
Peer Review No: 2957/2023**

This report is to be read with our letter of even date, which is annexed as **“Annexure – A”** and forms an integral part of this report.

“Annexure – (i) to the Secretarial Audit Report”

**To
The Members
Vilin Bio Med Limited**

Our report of even date is to be read along with this letter:

- Maintenance of secretarial records is the responsibility of the management of M/s Vilin Bio Med Limited (“the Company”). Our responsibility is to express an opinion on these secretarial records based on our audit.
- We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.
- We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
- Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
- The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
- The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Company Secretaries**

**Place: Hyderabad
Date: August 24, 2023**

**Sd/-
CS. Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN No: F004790E000854463
Peer Review No: 2957/2023**

“ANNEXURE–C”

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis present the Industry overview, opportunities and threats, the Company's initiatives and overall strategy of becoming a market-driven service provider with various offerings. The Company is optimistic about capturing a substantial share of the global and domestic market amid the threats faced due to the liberalisation and increased competition from well-established companies from India and abroad.

Global Economic Outlook

The estimated value of the global (Contract Research Organization) CRO services market in revenue for 2023 is \$76.6 billion, with a projected growth to reach \$127.3 billion by 2028, representing a compound annual growth rate (CAGR) of 10.7% from 2023 to 2028. This growth is primarily attributed to factors such as the continuous expansion of pharmaceutical, biopharmaceutical, and medical device R&D pipelines, as well as technological advancements in the clinical trials process. Additionally, the increasing demand for novel clinical trial designs to support cell and gene therapies is expected to create growth opportunities for companies operating in this market.

The global pharmaceutical market is now estimated to be over USD 1.6 trillion and expected to grow at CAGR of about 6%

Though the pharmaceutical industry is developing at rapid pace, the pharmaceutical manufacturing companies are confronted with enormous challenges such as:

Cost & Pricing, New Medicines & Therapy dosages, changing regulatory landscape & growing digitization.

Indian pharma market is expected to grow to USD 130 Billion by 2030 thereby emerging as the 6 largest pharmaceutical market globally by absolute size. The growth of the pharmaceutical industry is globally driven by ageing population as well as about 1% increase in the global population at the same time

Indian Economy

India's GDP growth rate was 6.4% during FY 2023 due to a combination of factors such as expected global economic slowdown, strict monetary policies, and high oil prices. Despite these obstacles, India's growth rate remains higher than that of comparable economies, primarily due to strong domestic consumption and lower dependence on global demand.

The Indian pharmaceutical industry has been experiencing steady growth with a focus on generic medicines. It is expected that spending on pharmaceuticals in India will continue to increase, with a CAGR of 7.5–10.5% between 2023-27 to reach US\$ 35-39 Billion annually. The industry's continued focus on generics is a key factor to its growth, as they are typically priced lower than branded medicines. The industry's low-cost structure and its ability to produce large quantities of medicines have also made it a key player in the global pharmaceutical market.

India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 Active Pharma Ingredients (API) producers that make for around 8% of the worldwide API market.

Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with a potential to steer the industry ahead to

greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the “pharmacy of the world” due to the low cost and high quality of its medicines.

Manufacturing

Our Sales Strategy is to sell our products in bulk to Pharmaceuticals Manufacturers, Marketers and Traders, who in turn provide the channel for sales to customers. Our products are primarily used by other pharmaceutical companies and traders, who ultimately will market it to the distributors and retail customers. We do not sell our products under any brand name. Following are our major products (manufacturing dosage forms):

- Oral Liquid (Syrups/Suspensions/Dry Powders (βeta & Non βeta-Lactam)
- Tablets & Capsules (βeta & Non βeta-Lactam)
- External Preparations

Opportunities, Threats and Outlook

Vilin Bio Med Limited will be able to place itself in a strong position by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization. The Company is looking at different opportunities in untapped markets and across a value chain. It plans for alliances with business associates in the Indian market, giving a huge boost to the selective products that it already deals in.

We are fully conscious of our responsibility toward our customers. Our efforts are directed toward the fulfillment of customer satisfaction through the quality of products. As the consolidation of this industry gains momentum, the need to develop a dedicated team of skilled manpower assumes urgency and importance.

We will continue to focus on training and motivation of manpower to develop teams of qualified and skilled personnel to effectively discharge their responsibilities in a number of projects and activities. It is, in this context, which we have been working towards promoting the skills and professionalism of our employees to cope with and focus on the challenges of change and growth.

Also the majority of the new entrants in an already overcrowded market is the major threat to the Company These can affect the profitability of established players in the short run. In the long run, however trusted players with strong brand equity will continue to prosper.

Internal control systems & their adequacy

The Company has strong and adequate internal control system suitable to its size and nature of business. We constantly upgrade our systems for incremental improvements. The Audit Committee of the Board regularly reviews our system. The systems ensure protection of assets and proper recording of transactions. Internal audit is carried out by an independent chartered accountants' firm on quarterly basis. The internal auditors' reports are regularly received by the Audit Committee. It is a regular practice to review the issues raised by statutory auditors by the Audit Committee.

“ANNEXURE D”

FORM NO. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014).

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in subsection (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

1. Details of contracts or arrangements or transactions **not at arm's length basis.**

Sl. No	Name(s) of the related party and nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of the contracts/ arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Justification for entering into such contracts or arrangements or transactions	Date(s) of approval by the Board	Amount paid as advances, if any	Date on which the special resolution was passed in general meeting as required under first proviso to section 188
There were no contracts or arrangements or transactions entered into during the year ended 31st March 2023, which were not at arm's length basis.								

2. Details of material contracts or arrangement or transactions **at arm's length basis.**

Sl. No.	Name of the related party and nature of relationship	Nature of Contracts/ arrangements/ transactions	Duration of Contracts/ arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value; if any;	Date of approval by the Board/ Shareholders, if any.	Amount incurred in rupees
1.	Redizen Lifesciences Private Limited	Sales	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	Rs. 2,20,26,000/-
2.	Spectrogen International Private Limited	Sales	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	Rs. 2,38,84,000/-
3.	Blue Nile Capital Advisory Limited	Sales	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	Rs. 94,84,000/-
4.	Mathra Lifesciences	Sales	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	Rs. 83,49,000/-

By Order of the Board of Directors

Sd/-

Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-

Anuj Bajpai
Whole Time Director
(DIN: 08939135)

Date: August 24, 2023
Place: Hyderabad

INDEPENDENT AUDITOR'S REPORT

To
The Members of
Vilin Bio Med Limited
Hyderabad

Report on the Financial Statements

Opinion

We have audited the accompanying Financial Statements of **M/s Vilin Bio Med Limited** ("the Company"), which comprises the Balance Sheet as of March 31, 2023, the Statement of Profit and Loss, Statement of Changes in Equity, Statement of Cash Flow for the year ended, and Notes to the Financial Statements, including a summary of Significant Accounting Policies and other explanatory information [hereinafter referred to as "Financial Statements"].

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under Section 133 of the Act and accounting principles generally accepted in India, of the State of Affairs of the Company as at March 31, 2023, and its Profit, Changes in Equity and its Cash Flows for the Year ended on that date.

Basis for Opinion

We conducted our Audit of the Financial Statements in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements Section of our Report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of Financial Statements under the provisions of the Act and the Rules defined thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the Audit Evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key Audit Matters are those matter that, in our professional judgement, were of most significance in our audit of the Financial Statements of the current period. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. During the year under consideration, we have no Key Audit Matters to report.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the Financial Position, State of Affairs, Profit (including Other Comprehensive Income) Changes in Equity and Cash Flows of the Company in accordance with the Accounting Principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Act, read with the Rules defined thereunder. This responsibility also includes maintenance of adequate Accounting Records in accordance with the provisions of the Act for safeguarding of the Assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate Accounting Policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate Internal Financial Controls that were operating effectively for ensuring the accuracy and completeness of the Accounting Records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a Going Concern, disclosing, as applicable, matters related to Going Concern and using the Going Concern Basis of Accounting unless the Board of Directors either intend to liquidate the Company or to cease the operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's Financial Reporting Process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements, as a whole, are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an Audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform Audit Procedures responsive to those risks, and obtain Audit Evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of Internal Controls.
- Obtain an understanding of Internal Controls relevant to the Audit in order to design Audit Procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Company has adequate Internal Financial Controls System with reference to the Financial Statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of the Accounting Policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Conclude on the appropriateness of the Management's use of the Going Concern Basis of Accounting and, based on the Audit Evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a Going Concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the Audit Evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as Going Concern.
- Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in:
 - (i) Planning the Scope of our audit work and in evaluating the results of our work; and
 - (ii) To evaluate the effect of any identified misstatements in the Financial Statements.
- We communicate with those charged with Governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in Internal Control that we identify during our audit.

We also provide those charged with Governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of Sub-section (11) of Section 143 of the Companies Act, 2013, we give in the "Annexure- A" statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper Books of Accounts as required by law have been kept by the Company, so far as it appears from our examination of those Books.

- c) The Balance Sheet, the Statement of Profit and Loss, the Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the Books of Account.
- d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the Written Representations received from the Directors as on March 31, 2023 taken on record by the Board of Directors, None of the Directors is disqualified as on March 31, 2023 from being appointed as a Director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the Internal Financial Controls with reference to the Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure-B”. Our Report expresses an Unmodified Opinion on the adequacy and operating effectiveness of the Company’s Internal Financial Controls Over Financial Reporting.
- g) With respect to other matters to be included in the Auditor’s Report in accordance with the requirements of Section 197(16) of the Act, as amended: In our opinion and to the best of our information and according to explanations given to us, the Remuneration paid by the Company to its Directors during the year, is in accordance with the provisions of Section 197 of the Act.
- h) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - a. The Company does not have any pending litigations which would impact its Financial Position.
 - b. The Company did not have any long-term contracts including Derivative Contracts for which there were any material foreseeable losses.
 - c. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - d. (i) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from Borrowed Funds or Share Premium or any other sources or kind of funds) by the Company to or in any other Person(s) or Entity(ies), including Foreign Entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (ii) The Management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any Person(s) or Entity(ies), including Foreign Entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (iii) Based on the Audit Procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) as provided under (a) and (b) above contain any material mis-statement.
- e. The Company has not declared any Dividend and nor paid during the year.

For **PPKG & Co**
Chartered Accountants
Firm’s Registration No. 009655S

Sd/-
Girdhari Lal Toshniwal
Partner
Membership No. 205140
UDIN: 23205140BGUNIT5030

Date: 19/07/2023
Place: Hyderabad

Annexure – A to the Independent Auditor’s Report of even date to the Members of M/s Vilin Bio Med Limited, on the Financial Statements for the Year ended March 31, 2023

Based on the audit procedures performed for the purpose of reporting a true and fair view on the Financial Statements of the Company and taking into consideration the information and explanations given to us and the Books of Accounts and other records examined by us in the normal course of Audit, and to the best of our knowledge and belief, we report that:

- (i) a. The Company has maintained proper records showing full particulars, including quantitative details and situation of Fixed Assets,
- b. The Company has a regular program of physical verification of its Fixed Assets under which Fixed Assets are verified in a phased manner over a period for which we have received the certificate of confirmation from the Management.
- c. The Title Deeds of all the Immovable Properties (which are included under the head ('Property, Plant and Equipment')) are held in the name of the Company.
- d. The Company has not revalued any of its Property, Plant and Equipment's during the year.
- e. As per the information given to us there are no proceedings initiated or pending against the Company for holding any Benami Property under the Benami Transactions (Prohibition) Act, 1988 and Rules made there under.
- (ii) a. In our opinion and according to the information and explanation give to us, the Management has conducted physical verification of Inventory at reasonable intervals during the year, and no material discrepancies were noticed on the aforesaid verification, for which we have received the certificate of confirmation from the Management.
- b. The Company has availed Financial Assistance from Bank or Financial Institutions against the hypothecation of stock and debtors.
- (iii) The Company has not granted any Loans, secured or unsecured, to any Companies, Firms, Limited Liability Partnerships or other parties.
- (iv) In our opinion, the Company has complied with the provisions of Section 186 in respect of the Investments and Loans. Further, in our opinion, the Company has not entered into any transaction covered under Section 185 and Section 186 of the Act in respect of Guarantees and Security.
- (v) In our opinion, the Company has not accepted any Deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- (vi) The provisions of Section 148(1) of the Companies Act, 2013 are not applicable to the Company.
- (vii) (a) In our opinion, the Company has been regular in depositing undisputed statutory dues, including Goods and Services Tax, Income Tax, Duty of Custom, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service Tax, Income Tax, duty of Custom, duty of Excise, Cess and other material statutory dues in arrears as at March 31, 2023 for a period of more than six months from the date they become payable. However as per the information provided by the management, Provident Fund and Employees' State Insurance is not applicable to the company for the current year.
- (b) There are Dues outstanding in respect of Income Tax, Sales Tax, Service Tax, Duty of Customs on account of disputes
- (c) According to the information and explanations given to us, the dues in respect of Sales Tax, Income Tax, Custom Duties, Wealth Tax, Excise Duty and Cess that have been deposited with the appropriate authorities except in cases where there is a dispute.
- (viii) All the transactions recorded in the books of account have been disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961). There were no transactions relating to previously

unrecorded income that have been surrendered or disclosed as Income during the year in the Tax Assessments under the Income Tax Act, 1961 (43 of 1961).

- (ix) According to the records of the Company examined by us and as per the information and explanations given to us, we hereby report that:
- a. The Company has not defaulted in repayment of Loans or Borrowings to any Bank during the Year under review. The Company has No Outstanding Debentures during the year.
 - b. The Company is not declared Wilful Defaulter by any Bank or Financial Institution or other Lender.
 - c. The Company has not raised any Term Loan from any Bank or Financial Institution during the current year.
 - d. To the extent of our check, no funds raised by the Company for short-term has been utilized for long term purposes.
 - e. The Company has not taken any funds from any entity or person on account of or to meet the obligations of its Subsidiaries, Associates or Joint Ventures.
 - f. The Company has not raised loans during the Year on the Pledge of Securities held in its Subsidiaries, Joint Ventures or Associate Companies.
- (x) The Company has raised the funds through by way of Initial Public Offer or Further Public Offer during the month June, 2023.
- a. The Company has made a Preferential Allotment of 6,80,000 Equity Shares of Face Value Rs. 10 each issued at Rs. 30.
 - b. During the year the Company has issued 59,70,000 bonus shares to all the shareholders in ratio of 1.5:1.
- (xi) a. In our opinion, no fraud by the Company or any fraud on the Company has been noticed or reported during the year under review. In our opinion and according to the information and explanation given to us, no fraud by the Company or any fraud on the Company has been noticed or reported during the year under review.
- b. No Report under sub-section (12) of section 143 of the Companies Act has been filed by the Auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - c. No Whistle Blowers Complaints were received during the year under review. As represented to us by the Management, no Whistle Blowers Complaints were received during the year under review.
- (xii) In our opinion, the Company is not a Nidhi Company, and accordingly, provisions of Clause 3(xii) of the Order are not applicable.
- (xiii) In our opinion, the Company is in compliance with Sections 177 and 188 of the Companies Act, 2013, with respect to applicable transactions with related parties, and the requisite details have been disclosed in the Financial Statements.
- (xiv) In our opinion, the Company has an adequate Internal Audit System commensurate with the size and nature of its business.
- (xv) In our opinion, the Company has not entered in any non-cash transactions with the Directors or persons connected with them covered under Section 192 of the Act. Accordingly, the provisions of Clause 3(xv) of the order are not applicable.
- (xvi) According to the information and explanation given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934 and the Company has not conducted any NBFC Company during the year.
- (xvii) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.
- (xviii) The Company has not incurred cash losses in the Financial Year and in the immediately preceding Financial Year.

- (xix) We, (M/s. PPKG & Co, Chartered Accountants, (Firm Registration No. 009655S) were appointed as the Statutory Auditors of the Company due to the casual vacancy of the M/s Singh Yudhveer & Associates, Chartered Accountants (Firm Registration No: 011039C) to carry out the Statutory Audit for FY 2022-23.
- (xx) The Company is not liable to contribute under Section 135 of the Companies Act, 2013. Accordingly, the provisions of Clause 3(xx) of the order are not applicable.
- (xxi) In our opinion and according to the information and explanations given to us, Company does not have any subsidiaries; associates and joint venture Therefore this clause is not applicable
- (xxii) There has been no qualifications and adverse remarks by the respective Auditors in the Companies (Auditor's Report) Order (CARO) Reports of the Companies to be included in the Standalone Financial Statements.
- (xxiii) The reporting under clause 3(xxiii) is not applicable in respect of Audit of Financial Statements of the Company. Accordingly, no comment has been included in respect of said Clause under this Report

For **PPKG & Co**

Chartered Accountants

Firm's Registration No. 009655S

Sd/-

Girdhari Lal Toshniwal

Partner

Membership No. 205140

UDIN: 23205140BGUNIT5030

Date: July 19, 2023

Place: Hyderabad

Annexure - B to the Independent Auditor's Report of even date to the Members of M/s Vilin Bio Med Limited, on the Financial Statements for the Year ended March 31, 2023

Independent Auditor's Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our Audit of the Financial Statements of M/s Vilin Bio Med Limited ('the Company') as at and for the year ended March 31, 2023, we have audited the Internal Financial Controls Over Financial Reporting ('IFCoFR') of the Company as at that date.

Management's Responsibility for Internal Financial Controls

The Company's Board of Directors is responsible for establishing and maintaining Internal Financial Controls based on the Internal Control Over Financial Reporting criteria established by the Company considering the essential components of Internal Control, as stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the Design, Implementation and Maintenance of adequate Internal Financial Controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's Business, including adherence to the Company's Policies, the Safeguarding of its Assets, the prevention and detection of frauds and errors, the accuracy and completeness of the Accounting Records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's IFCoFR based on our Audit. We conducted our Audit in accordance with the Standards on Auditing issued by the ICAI and deemed to be prescribed under Section 143(10) of the Act, to the extent applicable to an Audit of the IFCoFR, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate IFCoFR were established and maintained and if such controls operated effectively in all material respects.

Our Audit involves performing procedures to obtain Audit Evidence about the adequacy of the IFCoFR and their operating effectiveness. Our Audit of IFCoFR includes obtaining an understanding of IFCoFR, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of the Internal Controls based on the assessed risk. The procedures selected depend on the Auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error.

We believe that the Audit Evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Company's Internal Financial Controls Over Financial Reporting.

Meaning of Internal Financial Controls Over Financial Reporting

The Company's Internal Financial Controls Over Financial Reporting is a process designed to provide reasonable assurance regarding the reliability of Financial Reporting and the preparation of Financial Statements for external purposes in accordance with the Generally Accepted Accounting Principles. A Company's IFCoFR include those policies and procedures that:

- (i) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Assets of the Company;
- (ii) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the Financial Statements in accordance with the Generally Accepted Accounting Principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of Management and Directors of the Company; and
- (iii) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's Assets that could have a material effect on the Financial Statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the Inherent Limitations of the IFCoFR, including the possibility of collusion or improper Management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the IFCoFR to future periods are subject to the risk that the IFCoFR may become inadequate because of changes in conditions, or that the degree of compliance with the Policies or Procedures may deteriorate.

Opinion

In our opinion and to the best of information and according to the explanations given to us, the Company has maintained, in all material respects, adequate Internal Financial Controls Over Financial Reporting and such controls were operating effectively as of March 31, 2023, based on the 'Internal Control Over Financial Reporting criteria' established by the Company, considering the essential components of Internal Control as stated in the Guidance Note issued by the Institute of Chartered Accountants of India.

For **PPKG & Co**

Chartered Accountants

Firm's Registration No. 009655S

Sd/-

Girdhari Lal Toshniwal

Partner

Membership No. 205140

UDIN: 23205140BGUNIT5030

Date: July 19, 2023

Place: Hyderabad

Balance Sheet as at 31/03/2023

(Rs. In Lakhs)

Particulars	Note	31/03/2023	31/03/2022
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	1	995.00	330.00
Reserves and surplus	2	72.76	409.61
Money received against share warrants		-	-
		1,067.76	739.61
Share application money pending allotment		-	-
Non-current liabilities			
Long-term borrowings	3	43.12	73.40
Deferred tax liabilities (Net)	4	7.00	5.81
Other Long term liabilities		-	-
Long-term provisions		-	-
		50.12	79.21
Current liabilities			
Short-term borrowings	5	450.00	456.56
Trade payables	6		
Total outstanding dues of micro enterprises and small enterprises			-
Total outstanding dues of creditors other than micro enterprises and small enterprises		118.94	64.12
Other current liabilities	7	28.69	13.83
Short-term provisions	8	52.83	2.50
		650.46	537.01
TOTAL		1,768.34	1,355.83
ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible Assets			
Property, Plant and Equipment	9	151.15	164.96
Intangible assets		-	-
Capital work-in-progress		-	-
Intangible assets under development		-	-
		151.15	164.96
Non-current investments		-	-
Deferred tax assets (net)		-	-
Long-term loans and advances		-	-
Other non-current assets	10	288.80	-
		439.95	164.96
Current assets			
Current investments		-	-
Inventories	11	87.88	228.38
Trade receivables	12	987.38	778.65
Cash and cash equivalents	13	3.45	3.90
Short-term loans and advances	14	71.87	61.52
Other current assets	15	177.81	118.43
		1328.39	1190.88
TOTAL		1768.34	1355.83

In terms of our attached report of even date

For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN : 0009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI LAL TOSHNIWAL
(PARTNER)

Sd/-
VISWA PRASAD SADHANALA
(MANAGING DIRECTOR)
(DIN: 08068933)

Sd/-
ANUJ BAJPAI
(WHOLE TIME DIRECTOR)
(DIN: 08939135)

Place: Hyderabad
Date: 19-07-2023
Udin No: 23205140BGUNIT5030

Sd/-
SAKET KANSAL
(COMPANY SECRETARY)

Sd/-
CHILAM SRIKANTH
(CHIEF FINANCIAL OFFICER)

Statement of Profit and Loss for the year ended 31/03/2023

(Rs. In Lakhs)

Particulars	Note	31/03/2023	31/03/2022
Revenue from operations	16	1,231.30	1,121.49
Other income	17	2.44	0.42
Total Revenue		1,233.74	1,121.91
Expenses			
Cost of materials consumed	18	709.53	887.67
Purchases of Stock-in-Trade		-	-
Changes in inventories of finished goods	19	7.58	-0.87
work-in-progress and Stock-in-Trade			
Employee benefits expense	20	77.74	84.91
Finance costs	21	64.83	50.60
Depreciation and amortization expense	22	16.77	21.92
Other expenses	23	179.12	73.22
Total expenses		1,055.57	1,117.45
Profit before exceptional, extraordinary and prior period items and tax		178.17	4.47
Exceptional items		-	-
Profit before extraordinary and prior period items and tax		178.17	4.47
Extraordinary Items		-	-
Profit before prior period items and tax		178.17	4.47
Prior Period Items		-	-
Profit before tax		178.17	4.47
Tax expense:	24		
Current tax		52.83	1.00
Deferred tax		0.84	0.11
Profit/(loss) for the period from continuing operations		124.50	3.36
Profit/(loss) from discontinuing operations		-	-
Tax expense of discontinuing operations		-	-
Profit/(loss) from Discontinuing operations (after tax)		-	-
Profit/(loss) for the period		124.50	3.36
Earnings per equity share:	25		
Basic		1.25	0.10
Diluted		1.25	0.10

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN : 0009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI LAL TOSHNIWAL
(PARTNER)

Sd/-
VISWA PRASAD SADHANALA
(MANAGING DIRECTOR)
(DIN: 08068933)

Sd/-
ANUJ BAJPAI
(WHOLE TIME DIRECTOR)
(DIN: 08939135)

Place: Hyderabad
Date: 19-07-2023
Udin No: 23205140BGUNIT5030

Sd/-
SAKET KANSAL
(COMPANY SECRETARY)

Sd/-
CHILAM SRIKANTH
(CHIEF FINANCIAL OFFICER)

Cash Flow Statement for the year ended March 31, 2023

(Rs. In Lakhs)

Particulars	As at Mar-31-2023	As at Mar-31-2022
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	178.16	4.47
Adjustment For		
Depreciation	16.76	21.94
Provision for Doubtful debts	0.00	
Operating Profit before working capital changes	194.93	26.41
Adjustment For working Capital Change		
Adjustment for Increase/Decrease in Inventories	140.50	-21.96
Adjustment for Increase/Decrease in Trade Receivables	-208.74	-14.13
Adjustment for Increase/Decrease in Short term Loans and Advances	-10.36	43.61
Adjustment for Increase/Decrease in Non Current Assets	-289.16	
Adjustment for Increase/Decrease in Other Current Assets	-59.36	3.10
Adjustment for Increase/Decrease in Trade Payables	54.82	-17.56
Adjustment for Increase/Decrease in Other Current Liabilities	14.87	5.40
Adjustment for Provisions	50.33	-3.00
Total Adjustment For Working Capital (B)	-112.18	21.87
Less: Income Tax Paid / Provided	53.67	1.00
Net Cash Flow from (used in) operation before Extra-ordinary Items	-165.84	20.87
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from Operating Activities	-165.84	20.87
Cash Flows from Investing Activities		
Proceeds from Fixed Assets	-2.95	
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets		
Purchase of Investments or Equity Instruments		
Interest Received		
Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash Flow from loosing Control of Subsidiaries		
Cash Payment for acquiring Control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow / Outflow of Cash		
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items		
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (Used in) in Investing Activities	-2.95	
Cash Flows from Financial Activities		
Proceeds From Issuing Shares	204.00	
Proceeds from Issuing Debenture / Bonds / Notes	0.00	
Proceeds From Issuing Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Short term Borrowing	-6.56	6.56
Repayment of Long term Borrowing	-29.09	-28.18

Particulars	As at Mar-31-2023	As at Mar-31-2022
Dividend Paid		
Interest Paid	0.00	
Income Tax Paid / Refund		
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	168.35	-21.62
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from (Used in) in Financial Activities	168.35	-21.62
Net Increase (Decrease) in Cash and Cash Equivalents	-0.45	-0.75
Cash and Cash equivalents at beginning of period	3.90	4.65
Cash and Cash equivalents at end of period	3.45	3.90

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN : 0009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI LAL TOSHNIWAL
(PARTNER)

Sd/-
VISWA PRASAD SADHANALA
(MANAGING DIRECTOR)
(DIN: 08068933)

Sd/-
ANUJ BAJPAI
(WHOLE TIME DIRECTOR)
(DIN: 08939135)

Place: Hyderabad
Date: 19-07-2023
Udin No: 23205140BGUNIT5030

Sd/-
SAKET KANSAL
(COMPANY SECRETARY)

Sd/-
CHILAM SRIKANTH
(CHIEF FINANCIAL OFFICER)

(A) Authorised, Issued, Subscribed & Paid-up Share Capital:

PARTICULARS	AS AT	AS AT
	31st March 2023 (Rs.in Lakhs)	31st MARCH 2022 (Rs.in Lakhs)
Authorised Share Capital [1,50,00,000 Equity Shares of RS. 10/- Each]	1,500.00	330.00
Issued, Subscribed and Paid-up Capital [99,50,000 Equity Shares of RS. 10/- Each]	995.00	330.00
TOTAL	995.00	330.00

(B) Reconciliation of the Number of Share Outstanding:

PARTICULARS	AS AT	AS AT
	31st MARCH 2023 NUMBER	31st MARCH 2022 NUMBER
Equity Shares Outstanding at the beginning of the year	33,00,000	33,00,000
Add: Preferential Issue	6,80,000	-
Add: Bonus Issue	59,70,000	-
		-
Equity shares outstanding at the end of the year	99,50,000	33,00,000

(C) Shareholders Holding More than 5% Shares of the Company:

NAME OF SHAREHOLDERS	CLASS OF SHARES	AS AT 31st MARCH 2023		AS AT 31st MARCH 2022	
		NUMBER	%	NUMBER	%
Sadhanala Venkata Rao	Equity Shares	45,89,705	46.13	4,55,882	13.81
Srinivasa Reddy Devireddy	Equity Shares	20,12,795	20.23	2,04,118	6.19
Viswa Prasad Sadhanala	Equity Shares	18,76,140	18.86	2,50,456	7.59
Sneha Bajpayee	Equity Shares	-	-	7,83,750	23.75
Anuj Bajpayee	Equity Shares	-	-	6,86,000	20.79
S. Tanmayee	Equity Shares	-	-	6,18,500	18.74
S. Ramesh Reddy	Equity Shares	-	-	1,85,294	5.61

(D) Details of promoter's Shareholding:

NAME OF SHAREHOLDERS	CLASS OF SHARES	AS AT		AS AT	
		31st MARCH 2023		31st MARCH 2022	
		NUMBER	%	NUMBER	%
Sadhanala Venkata Rao	Equity Shares	45,89,705	46.13	4,55,882	13.81
Srinivasa Reddy Devireddy	Equity Shares	20,12,795	20.23	2,04,118	6.19
Viswa Prasad Sadhanala	Equity Shares	18,76,140	18.86	2,50,456	7.59
Ramesh Reddy Sama	Equity Shares	4,63,235	4.66	1,85,294	5.61
Tanmayee Reddy Sama	Equity Shares	21,250	0.21	6,18,500	18.74
Anuj Bajpai	Equity Shares	15,000	0.15	6,86,000	20.79
Sama Ruchit Reddy	Equity Shares	12,500	0.13	1,16,000	3.52
Sneha Bajpai	Equity Shares	9,375	0.09	7,83,750	23.75

Rights, Preferences and Restrictions attached to each class of Shares and Terms of redemption:-

- The company has only one class of shares referred as equity shares. The equity share are having a par value of Rs. 10/- each. Every holder of equity share is entitled to one vote per share in respect of all matters submitted to vote in the shareholders's meeting.
- In the event of liquidation of the company, the holder of equity shares will be entitled the receive the remaining assets of the company after distribution of preferential amounts. The distribution will be in the portion of the number of equity shares held by the shareholders.

Note: The company has allotted 6,80,000 Preferential Equity Shares, Face value Rs.10 with a premium of Rs. 20 & Bonus issue of 59,70,000 Equity shares, Face value Rs.10.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

1. General information

Vilin Bio Med Limited (“the Company”) is engaged in the business of manufacturing and selling pharmaceutical products.

The company is a public limited company incorporated under Companies Act, 1956 and domiciled in India bearing CIN No: U24230TG2005PLC046689 and has its registered office at Sy no 115, Hanumanji Colony, Opp Sub Register Office, Old Bowenpally, Secunderabad - 500009, Hyderabad, Telangana – India. The equity share of the Company are listed on the NSE SME EMERGE on June 30, 2023.

2. Significant Accounting policies

(a) Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). These financial statements have been prepared to comply in all material respects with the Accounting Standards notified by Companies (Accounting Standards) Rules, 2006, (as amended) and the relevant provisions of the Companies Act, 1956/2013. The financial statements have been prepared under the historical cost convention on an accrual basis and going concern basis. The accounting policies have been consistently applied by the company are consistent with those used in the previous year.

(b) Use of estimates

The preparation of Financial Statements in conformity with the Generally Accepted Accounting Principles requires the Management to make estimates, judgements, and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period.

Although these estimates are based on the management’s best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcome requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(c) Functional and Presentation Currency

The Financial Statements are prepared in Indian Rupees (“INR”) which is the Company’s Functional Currency for its Operations. All Financial Information presented in INR has been rounded to the nearest ‘Lakhs’ with two decimal places, unless stated otherwise.

(d) Recognition of Revenue and Expenditure

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria is ensured before revenue is recognized.

Income from services

Revenue from services contracts priced on time and material basis are recognized when services are rendered and related costs are incurred. The Company collects Goods and Services Tax on behalf of the government and therefore it is not an economic benefit flowing to the Company. Hence, it is excluded from revenue.

(e) Sale of goods

Revenue is measured at the transaction price of the consideration received or receivable. Revenue from Sale of products is recognized when the control on the Goods have been transferred to the Customer. The Performance Obligation in case of sale of product is satisfied at a point in time i.e., when the material is shipped to the customer or on delivery to the customer, as may be specified in the Contract.

(f) Interest income

Interest Income is recognized on a time proportion basis taking into account the amount outstanding and the effective interest rate method. Interest Income is included under the head “Other Income” in Statement of Profit and Loss.

(g) Property, Plant and Equipment (PPE)

i. Recognition and measurement

Property, Plant and Equipment are stated at Cost comprising of Purchase Price and any initial directly attributable cost of bringing the Asset to its working condition for its intended use less Accumulated Depreciation and Impairment Loss, if any

ii. Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

iii. Depreciation

Depreciation on fixed assets is provided on Written Down Value method (WDV) as per Useful life of Asset and in the manner prescribed in Schedule II of the Companies Act, 2013.

(h) Intangible assets

Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortisation/depletion. All costs, including financing costs till commencement of commercial production, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets are capitalized.

The Company has elected to continue with the carrying value of all its intangible assets as recognized in the financial statements as at the date of transition, measured as per the previous GAAP and use that as the deemed cost as at the transition date.

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific to which it relates.

(i) Impairment of non-financial assets

Assets that have a definite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Management periodically assesses using, external and internal sources, whether there is an indication that an asset may be impaired.

The recoverable amount is higher of the asset's net selling price or value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss for an asset is reversed if, and only if, the reversal can be related objectively to an event occurring after the impairment loss was recognized. The carrying amount of an asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

(j) Borrowing cost

Borrowing costs attributable to the acquisition/construction of qualifying assets are capitalized and form part of the cost of the qualifying assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue as an expense.

(k) Income Tax

Provision for income tax is made for both current and deferred taxes. Provision for current income tax is made on the current tax rates based on the assessable income. The Company provides deferred tax based on the tax effect of timing differences resulting from the recognition of items in the financial statements and in estimating its current tax provision. Deferred tax assets are recognized where there is certainty that there will be sufficient future taxable income available against which such deferred tax assets can be realized.

(l) Inventories

Inventories are measured at lower of cost and net realisable value after providing for obsolescence, if any. Cost of inventories comprises of cost of purchase, cost of conversion and other cost including manufacturing overheads incurred in bringing them to their respective present location and condition. Cost of raw materials, work-in-progress, packing materials, trading and other products are determined on first-in-first-out basis.

(m) Research and development

Revenue expenditure on Research and Development is charged to Profit and Loss Account as incurred. Capital expenditure on assets acquired for Research and Development is added to Property, Plant and Equipment (PPE).

(n) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets Classification

The Company shall classify financial assets as subsequently measured at amortised cost and fair value through profit and loss (FVTPL) on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date i.e., the date that the Company commits to purchase or sell the asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

(o) Cash and cash equivalents

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short term deposits with banks with an original maturity of three months or less.

(p) Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost. Gains and losses are recognised in profit and loss when the liabilities are derecognized. This category generally applies to interest-bearing loans and borrowings.

(q) Foreign currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are retranslated using the exchange rate prevailing at the reporting date. Non-monetary items, which are measured in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency are translated using the exchange rate at the date when such value was determined.

Treatment of exchange differences

Exchange differences arising on settlement/restatement of foreign currency monetary assets and liabilities of the Company are recognized as income or expense in the statement of profit and loss.

(r) Leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the Statement of Profit and Loss on a Straight – line basis over the lease term.

(s) Employee benefits

All Employee Benefits payable for rendering the service such as Salaries, Wages etc. and the expected cost of ex-gratia are recognised in the period in which the employee renders the related service. A Liability is recognised for the amount expected to be paid when there is a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

(t) Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognised when the Company has a Present Obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Contingent Liability is disclosed in case of a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognised in Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non- occurrence of one or more uncertain future events not wholly within the control of the Entity. Contingent Assets are not recognised in Financial Statements and are disclosed in the Notes when it is virtually certain that economic benefits will inflow to the Company.

(u) Earnings per share (EPS)

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2023

1. Share Capital

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Authorised 1,50,00,000 (3300000) Equity Shares of Rs. 10/- Par Value	1500	330
	1500	330
Issued 9950000 (3300000) Equity Shares of Rs. 10/- Par Value	995	330
	995	330
Subscribed 9950000 (3300000) Equity Shares of Rs. 10/- Par Value	995	330
	995	330
Paidup 9950000 (3300000) Equity Shares of Rs. 10/- Par Value Fully Paidup	995	330
	995	330

2. Reserve and Surplus

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Capital Reserve - Opening	22.56	22.56
Addition	0	0.00
Deduction	0	0.00
	22.56	22.56
Profit and Loss Opening	386.75	383.70
Amount Transferred From Statement of P&L	124.50	3.36
Amount Transferred From Sundries		
Others	-461.05	0.00
	-461.05	387.06
	72.76	409.62
	72.76	409.62

3. Long Term Borrowings

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Term Loan		
Banks		
Secured		
Rupee		
PNB A/C 389800IL00000270 TERM LOAN A/C	43.12	73.40
	43.12	73.40

NOTE: The bank has extended covid loan in the form of WCTL, which is payable in the next 12 months

4. Deferred tax Liabilities

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Deferred Tax Liabilities		
Other	7.00	5.81
	7.00	5.81

5. Short Term Borrowings

Particulars	31/03/2023	31/03/2022
Current maturities of long term borrowings		
P.N.B. RAM NAGAR, ROORKEE CC- A/C-16831	450.00	456.56
	450.00	456.56

NOTE: Cash Credit is taken against the hypothecation of stock and receivables.

6. Trade Payables

as at 31/03/2023

(Rs. In Lakhs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	118.94				118.94
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
					118.94

as at 31/03/2022

(Rs. In Lakhs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	64.12				64.12
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
					64.12

7. Other Current Liabilities

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Other payables		
Other Current Liabilities		
AUDIT FEE PAYABLE	1.50	-
DIRECTORS REMUNERATION PAYABLE	-	9.15
INTEREST PAYABLE	11.26	-
POWER CHARGES PAYABLE	2.78	1.22
TDS PAYABLE	0.24	-
TDS PAYABLE-194Q	0.05	-
SALARY PAYABLE	12.70	3.30
E.P.F.PAYABLE	0.13	0.13
ESIC PAYABLE	0.03	0.03
	28.69	13.83

8 Short Term Provisions

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Tax Provision		
Current Tax		
PROVISION OF INCOME TAX AY 23-24	52.83	2.50
	52.83	2.50

Note-9: FIXED ASSETS

(Rs in lakhs)

Block of Assets / Asset Group	Gross Block				Depreciation				Net Block	
	01-04-2022	Additions	Sale/Adj.	31-03-2023	01-04-2022	For the Year	Sale/Adj.	31-03-2023	31-03-2023	31-03-2022
	Rupees in Lakhs									
LAND										
LAND	21.15	0.00	0.00	21.15	0.00	0.00	0.00	0.00	21.15	21.15
BUILDINGS										
BUILDING	348.99	0.00	0.00	348.99	255.44	9.27	0.00	264.70	84.29	93.56
COMPUTERS AND DATA PROCESSING UNITS										
COMPUTER	4.61	0.00	0.00	4.61	4.44	0.00	0.00	4.44	0.17	0.17
PRINTER	0.00	0.11	0.00	0.11	0.00	0.00461	0.00	0.00	0.10	0
Total (Block)										0.17
FURNITURE AND FITTINGS										
FURNITURE	15.96	0.00	0.00	15.96	14.10	0.49	0.00	14.59	1.38	1.86
MOTOR VEHICLES										
VEHICLE	11.71	0.00	0.00	11.71	11.07	0.02	0.00	11.09	0.62	0.63
OFFICE EQUIPMENT										
OFFICE EQUIPMENT	3.67	0.00	0.00	3.67	3.48	0.00	0.00	3.48	0.19	0.19
PLANT AND MACHINERY										
PLANT AND MACHINERY	529.44	0.00	0.00	529.44	482.05	6.88	0.00	488.93	40.50	47.39
PLANT AND MACHINERY	0.00	2.85	0.00	2.85	0.00	0.10	0.00	0.10	2.75	0.00
Total (Block)										47.39
Grand Total	935.53	2.96	0.00	938.48	770.58	16.76	0.00	787.34	151.15	164.96

10. Non Current assets

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Secured, Considered good	288.80	
	288.80	

11. Inventories

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Raw Material	30.51	199.74
Work in Progress	-	7.55
Finished Goods	21.06	21.09
Others	-	-
Packing Material	36.31	-
	87.88	228.38

12. Trade receivables

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Trade Receivable		
Secured, considered good		
Less than six months	555.21	395.10
Exceeding Six Months	432.17	383.55
	987.38	778.65

13. Cash and cash equivalents

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Cash in Hand	2.92	3.08
Balances With Banks	-	
Balance With Scheduled Banks	-	
Current Account	-	
ICICI BANK	0.46	-
P.N.B CURRENT A/C NO. - 3898002100013041	0.05	0.82
P.N.B CURRENT A/C NO. - 3898002100017782	0.02	-
	3.45	3.90

14. Short-term loans and advances

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Security Deposits		
Secured, considered good	6.35	4.85
	-	-
Loans and advances to others	-	-
Secured, considered good	65.52	56.67
	71.87	61.52

15. Other current assets

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
CGST TAX	0.38	-
GST ITC	-	91.90
IGST	44.66	-
SGST TAX	0.38	-
MISC.assets	32.10	-
REVERSE TAX CHARGES PAYABLE	0.98	-
TCS 0.1% A/C	0.09	-
tds receivable 2022-2023	0.23	-
Advances - Others	94.84	26.53
Advances to Suppliers	4.13	-
Balances with Government Authorities	0.02	-
	177.81	118.43

16. Revenue from operations

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Sale of Products		
Other Goods		
SALES	1,231.30	1,121.49
	1,231.30	1,121.49

17. Other income

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Miscellaneous		
REBATE & DISCOUNT A/C	0.03	-
OTHER INCOME	2.41	0.42
	2.44	0.42

18. Cost of materials consumed

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Raw Material		
Opening	199.74	178.65
Purchase	576.61	908.75
Closing	66.82	199.74
	709.53	887.67

19. Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Opening		
Stock in Trade	-	-
Finished Goods	21.09	19.86
Work in Progress	7.55	7.91
	28.64	27.76
Closing		
Stock in Trade	-	-
Finished Goods	21.06	21.09
Work in Progress	-	7.55
	21.06	28.64
Increase/Decrease		
Stock in Trade	-	-
Finished Goods	0.03	-1.23
Work in Progress	7.55	0.36
	7.58	-0.87

20. Employee benefits expense

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Salary, Wages & Bonus	-	-
SALARIES A/C	74.09	80.16
DIRECTORS REMUNERATION	-	-
Contribution to Provident Fund	-	-
EPF ADMINISTRATION CHARGES	-	0.06
EPF CONTRIBUTION	-	0.80
Staff Welfare Expenses	-	-
STAFF WELFARE/ LABOUR UNIFORM	3.65	3.67
Employee Medical Insurance Expenses	-	-
ESIC CONTRIBUTION	-	0.22
	77.74	84.91

21. Finance costs

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Interest Expenses		
Interest Expenses		
BANK CHARGES CC A/C	2.58	-
BANK INTEREST - OTHER	-	-
BANK INTEREST A/C (13041 A/C)	-	-
BANK INTEREST T/L 270A/C	5.06	6.44
BANK INTEREST(CC 16831)A/C	57.07	-
INTEREST ON CC LIMIT	-	43.06
Bank Charges	-	-
BANK CHARGES	-	1.10
BANK CHARGES 13041 A/C	0.09	-
BANK TRANSCATION CHARGES	0.03	-
	64.83	50.60

22. Depreciation and amortisation expense

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Depreciation & Amortisation		
Depreciation Tangible Assets		
BUILDING	9.27	10.29
DEPRECIATION	-	-
FURNITURE	0.49	0.76
PLANT AND MACHINERY	6.99	10.80
PRINTER	-	0.04
VEHICLE	0.02	0.03
	16.77	21.92

23. Other expenses

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Manufacturing Service Costs Expenses		
Share in Manufacturing Service Cost of Joint Ventures	10.95	21.89
Administrative and General Expenses	-	-
Telephone Postage	0.40	0.75
Printing Stationery	0.38	0.42
Auditors Remuneration	1.50	1.50
Directors Remuneration	-	15.00
Repairs Maintenance Expenses	9.25	10.90
Travelling Conveyance	2.52	3.13
Legal and Professional Charges	14.18	3.82
Insurance Expenses	0.76	1.93
Vehicle Running Expenses	0.03	-
Safety and Security Expenses	6.74	6.80
Other Administrative and General Expenses	104.53	6.03
Selling Distribution Expenses	-	-
Advertising Promotional Expenses		0.83
Other Selling Distribution Expenses	2.00	-
Other Expenses	25.88	0.22
	179.12	73.22

24. Tax expense

(Rs. In Lakhs)

Particulars	31/03/2023	31/03/2022
Current tax		
INCOME TAX	52.83	1.00
DEFERRED TAX ASSET	0.84	0.11
	53.67	1.11

25. Earnings per equity share

Particulars	31/03/2023	31/03/2022
Basic and Diluted	1.25	0.10

26. Related Party disclosure as required by Accounting standard (AS) 18 “Related Party Disclosure”

I) Related Party Disclosures with whom transaction have been taken place during the year.

a) Key Management Personnel (KMP)

Mr. S Viswa Prasad (Managing Director), Mr. Anuj Bajpai (Whole Time Director), Mr. Srikant Chilam (Chief Financial Officer) w.e.f. 17th December, 2022, Saket Kansal (Company Secretary and Compliance Officer) w.e.f. 17th December, 2022.

Significant Related Party Transaction during the year:

(Rs. In Lakhs)

Sr. No	Party Name	Relationship	Nature of Transactions	For the Year Ended March 31, 2023	For the Year Ended March 31, 2022
1.	Venu Gopal	Director (ceased w.e.f.(01.01.2023)	Remuneration	0	15
2.	Viswa Prasad Sadhanala	Director(w.e.f.(01.10.2022)	Remuneration	4.5	0
3.	Spectrogen International Private Limited	One of the Director is common in the Companies	Trade Receivable	238.84	0
4.	Redizen Lifesciences Private Limited	On of the Director is common in the Companies	Trade Receivable	220.26	273.47
5.	Mathra Lifesciences	One of the Promoter is common in the Companies	Trade Receivable	83.49	0
6.	Blue Nile Capital Advisory Limited	On of the Director is common in the Companies major shareholder	Inter Corporate Loans	94.84	0

27. Capital Management

The Company’s policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital as well as the level of dividends to ordinary shareholders.

The Company monitors capital using a ratio of ‘net debt’ to ‘equity’. For this purpose, net debt is defined as total debt, comprising loans and borrowings less cash and cash equivalents and current investments.

The Company’s net debt to equity ratio as at 31st March 2023 and 31st March 2022 was as follows

(Rs. In Lakhs)

Particulars	As at 31st March, 2023	As at 31st March, 2022
Current Borrowings	493.12	529.96
Gross Debt	493.12	529.96
Less - Cash and Cash Equivalents	3.45	3.90
Less - Current Investments	-	-
Net debt	489.67	526.06
Total equity	1067.76	739.61
Net debt to Equity ratio*	0.46	0.71

*Since Net debt to Equity ratio result is negative, the same is shown as nil.

28. Earning Per Share (EPS):

Basic EPS and Diluted EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the company by the weighted average number of Equity shares outstanding during the year.

(Rs. In Lakhs)

Particulars	As at 31st March, 2023	As at 31st March, 2022
Profit attributable to equity holders	124.50	3.36
Weighted average number of shares outstanding during the year	99,50,000	33,00,000
Nominal Value of Equity Shares (in Rs.)	10	10
Earning Per Share Basic and Diluted (in Rs.)	1.25	0.10

29. As at 31st March, 2023, the Company has certain dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows:

Particulars	Year ended 31st March, 2023	Year ended 31st March, 2022
a) The principal amount remaining unpaid to any supplier at the end of the year	0	0
b) Interest due remaining unpaid to any supplier at the end of the year	0	0
c) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during the year	0	0
d) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006	0	0
e) The amount of interest accrued and remaining unpaid at the end of each accounting year	0	0
f) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprises, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act, 2006	0	0

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006" is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company. There are no overdue principal amounts / interest payable amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the year or for any earlier years and accordingly there is no interest paid or outstanding interest in this regard in respect of payment made during the year or on balance brought forward from previous year.

30. Trade Receivables Ageing Schedule:

Particulars	As at 31st March, 2023					
	Less than 6 Months	6 months - 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
i) Undisputed Trade Receivables - Consider Good	555.21	432.17	-	-	-	987.38
ii) Undisputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
iii) Undisputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
iv) Disputed Trade Receivables - Consider Good	-	-	-	-	-	-
v) Disputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
vi) Disputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
Total Debtors	555.21	432.17	-	-	-	987.38

Particulars	As at 31st March, 2022					
	Less than 6 Months	6 months - 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Undisputed Trade Receivables - Consider Good	395.10	383.55	-	-	-	778.65
(ii) Undisputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
(iv) disputed Trade Receivables - Consider Good	-	-	-	-	-	-
(v) disputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
(vi) disputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
Total Debtors	395.10	383.55	-	-	-	778.65
Less: Provision for Doubtful Debts					-	-
Net Debtors	395.10	383.55	-	-	-	778.65

Note - During the Current year there is an provision for doubtful debts as on 31st March, 2023 amounting to Rs 101.34 in lakhs and the amount has been written off or written back during the year in respect of debts due from/to them.

31. Trade Payable Ageing Schedule:

Particulars	As at 31st March, 2023				
	Less than one year	1-2 Years	2-3 Years	More than 3 Years	Total
(i) Micro enterprises and small enterprises	-	-	-	-	-
(ii) Others	54.82	64.12	-	-	118.84
(iii) Disputed dues -Micro enterprises and small enterprises	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-
Total	54.82	64.12	-	-	118.84

Particulars	As at 31st March, 2022				
	Less than one year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Micro enterprises and small enterprises	-	-	-	-	-
(ii) Others	44.83	19.29	-	-	64.12
(iii) Disputed dues -Micro enterprises and small enterprises	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-
Total	44.83	19.29	-	-	64.12

32. Capital commitment and contingent liabilities

a) Capital commitment

There are no capital commitment outstanding as at reporting date (as at March 31, 2023: NIL)

b) Contingent Liabilities and Commitments

There are no contingent liabilities

33. Other Statutory Information:

- (i) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (ii) The Company has not granted Loans or Advances in the nature of loans to promoters, directors, KMPs and the related parties.
- (iii) The Company does not have any transactions with companies which are struck off.

34. The Company has considered the business segment as the primary reporting segment on the basis that the risk and returns of the Company is primarily determined by the nature of products and services. Consequently, the geographical segment has been considered as a secondary segment.

The business segment have been identified on the basis of the nature of products and services, the risks and returns, internal organization and management structure and the internal performance reporting systems. The business segment comprises of manufacturing and selling of pharmaceutical products. Geographical segment is considered based on sales within India and outside India.

35. Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN : 0009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI LAL TOSHNIWAL
(PARTNER)

Sd/-
VISWA PRASAD SADHANALA
(MANAGING DIRECTOR)
(DIN: 08068933)

Sd/-
ANUJ BAJPAI
(WHOLE TIME DIRECTOR)
(DIN: 08939135)

Place: Hyderabad
Date: 19-07-2023
Udin No- 23205140BGUNIT5030

Sd/-
SAKET KANSAL
(COMPANY SECRETARY)

Sd/-
CHILAM SRIKANTH
(CHIEF FINANCIAL OFFICER)

Vilin Bio Med Limited

CIN: U24230TG2005PLC046689

Registered office: Survey No. 115/GF/J, Opposite Sub Registrar's Office,
Hanumanji Colony, Bowenpally, Secunderabad- 500009, Telangana

Email: cs@vilinbiomed.co.in; Telephone No: +91 40 7961 8843; website: www.vilinbiomed.co.in